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Abstract 
Due to the ageing population, the number of patients diagnosed with age-related 
diseases such as stroke and Parkinson’s disease are on the rise. In both post-stroke 
dementia (PSD) and mild cognitive impairment in Parkinson’s disease (PD-MCI), the 
mechanisms resulting in cognitive decline are unknown. This project aims to identify a 
biomarker which could predict those patients most at risk of developing cognitive 
decline, which would subsequently assist healthcare professionals in recommending 
early treatment and care.  
Epigenetics is an emerging field in which biomarkers have previously been useful in 
prognostication of cancers and prediction of cardiovascular disease. In this study, 30 
patients from a PSD cohort (COGFAST) and 48 patients from a PD-MCI cohort 
(ICICLE) were analysed using the Illumina HumanMethylation450 BeadChip to 
identify differentially methylated positions which could predict patients who would 
later develop cognitive decline. Top hits were validated using Pyrosequencing to 
confirm DNA methylation differences in a replication cohort.  
Individual CpG sites within APOB and NGF were identified as potential blood-based 
biomarkers for PSD and one CpG site within CHCHD5 was highlighted as a potential 
blood-based biomarker for PD-MCI. In addition, methylation at one CpG site within 
NGF and a CpG site (cg18837178) within a non-coding RNA, were found to be 
associated with Braak staging (degree of brain pathology) using DNA from two brain 
regions. NGF deregulation has previously been associated with Alzheimer’s disease, 
and this finding indicates it may also have a role in the development of PSD. 
These novel findings represent the first steps towards the identification of blood-based 
biomarkers to assist with diagnosis of PSD and PD-MCI, but require further validation 
in a larger independent cohort. The differentially methylated genes identified may also 
give insight into some of the mechanisms involved in these complex diseases, 
potentially leading to the future development of targeted preventative treatments. 
 
 
 
i 
 
 
 
Acknowledgements 
Firstly, I would like to thank my supervisors, Professor Caroline Relton, Professor John 
Mathers and Professor Raj Kalaria for their valuable support and guidance throughout 
the project. I would also like to thank Dr Louise Allan and Dr Alison Yarnall for their 
help and advice regarding the cohorts used in this thesis. Special thanks go to Dr 
Catherine Potter and Dr Hannah Elliott who provided much needed assistance in using 
R and analysing the HM450 data. Thanks are also given to Polly Usher for her help with 
the ICICLE Pyrosequencing work. Polly performed all primer optimisations, assay 
validations and the Pyrosequencing using the ICICLE samples, enabling me to spend 
more time completing other work. The University of Bristol allowed me to use their 
Illumina iScan to perform the HM450 arrays. Thank you to Dr Wendy McArdle for her 
help with the HM450 sample preparation and running the arrays. Thanks also go to the 
staff at the Newcastle Brain Tissue Resource for providing me with the tissue and 
information required to complete this work and all participants of COGFAST and 
ICICLE without whom this project would not have been possible. I would also like to 
thank my family and friends who all provided invaluable support and encouragement 
throughout my PhD. Finally, I would like to thank the Medical Research Council and 
Newcastle University for providing the funding which made this project possible.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ii 
 
 
 
Statement of Work Undertaken 
Study cohorts used in this project were established prior to the start of this project and 
all phenotypic data had already been collected. In ICICLE, all DNA had been extracted 
from whole blood samples prior to the start of this project. In COGFAST, the brain 
regions were sectioned by the Newcastle Brain Tissue Resource and I performed all 
subsequent DNA, RNA and protein extractions using both the baseline blood samples 
and two brain regions. All DNA samples (COGFAST and ICICLE) were then processed 
by myself and sent to the University of Bristol where Dr Wendy McArdle performed 
the HM450 BeadChip and sent the raw data back. I then performed all HM450 
normalisation, data analysis and selection of top hits. Using the COGFAST samples, I 
performed all the lab work for the Pyrosequencing and data analysis. Using the ICICLE 
samples, I designed the primers for the selected assays and all primer optimisations, 
validations and Pyrosequencing were performed by Polly Usher from Newcastle 
University. I then analysed the resulting Pyrosequencing data. All other lab work and 
data analysis were performed by myself.  
iii 
 
 
 
Table of Contents 
Chapter 1: Introduction  ........................................................................ 1 
1.1 Introduction to molecular epidemiology ................................................ 1 
1.1.1 Use of biomarkers in disease prediction and prognosis .............. 1 
1.1.2 Use of intermediate phenotypes to inform about disease 
mechanisms .......................................................................................... 2 
1.1.3 DNA methylation as a biomarker ............................................... 2 
1.2 Age-related diseases involving the loss of cognitive function ............... 4 
1.2.1 The ageing brain .......................................................................... 4 
1.2.2 Stroke .......................................................................................... 5 
1.2.2.1 Incidence ................................................................................ 5 
1.2.2.2 Types of stroke ....................................................................... 6 
1.2.2.3 Risk factors ............................................................................ 7 
1.2.2.4 Molecular mechanisms ........................................................ 10 
1.2.2.5 Stroke prevention and treatment .......................................... 11 
1.2.2.6 Consequences of stroke ...................................................... 12 
1.2.3 Post-stroke dementia ................................................................. 13 
1.2.3.1 Definition ............................................................................. 13 
1.2.3.2 Prevalence of post-stroke dementia ..................................... 13 
1.2.3.3 Risk factors .......................................................................... 14 
1.2.3.4. Consequences of post-stroke dementia ............................... 15 
1.2.3.5 Mechanisms ......................................................................... 16 
1.2.3.6 Prediction, prevention and treatment ................................... 18 
1.2.4 Parkinson’s disease ................................................................... 19 
1.2.4.1 Prevalence ............................................................................ 19 
1.2.4.2 Risk factors .......................................................................... 20 
1.2.4.3 Molecular mechanisms ........................................................ 20 
1.2.4.4 Prevention and treatment of Parkinson’s disease ................. 21 
1.2.4.5 Consequences of Parkinson’s disease ............................... 23 
1.3 Epigenetics .............................................................................................. 25 
1.3.1 Histones and chromatin ............................................................. 25 
1.3.2 MiRNAs .................................................................................... 26 
1.3.3 DNA methylation ...................................................................... 27 
1.3.3.1 Types of DNA methylation .................................................. 27 
1.3.3.2 Genomic content .................................................................. 27 
iv 
 
 
 
1.3.3.3 Key functions ....................................................................... 29 
1.3.3.3.1 Transcription ..................................................................... 29 
1.3.3.3.2 X-inactivation ................................................................... 29 
1.3.3.3.3 Genomic imprinting .......................................................... 29 
1.3.3.3.4 Genomic stability .............................................................. 30 
1.3.3.4 Regulation ............................................................................ 30 
1.3.3.4.1 DNA methyltransferases  .................................................. 30 
1.3.3.4.2 Environmental factors ....................................................... 31 
1.3.3.4.3 Genetic factors .................................................................. 32 
1.3.4 Epigenetics across the life course ............................................. 33 
1.3.4.1 Epigenetics in ageing and age-related disease ..................... 34 
1.3.5 The role of DNA methylation in the ageing brain .................... 34 
1.3.5.1 Normal development ............................................................ 34 
1.3.5.2 DNA methylation in diseased brains ................................... 36 
1.3.5.2.1 DNA methylation and stroke ............................................ 37 
1.3.5.2.2 DNA methylation and dementia ....................................... 39 
1.3.5.2.3 DNA methylation and post-stroke dementia ..................... 42 
1.3.5.2.4 DNA methylation and Parkinson’s disease ....................... 42 
1.3.5.3 DNA methylation as a candidate for prediction and prognosis in 
the ageing brain ................................................................................ 43 
1.4 Studying DNA methylation in the brain .............................................. 45 
1.4.1 Epidemiological approaches ..................................................... 45 
1.4.1.1 Study designs ....................................................................... 45 
1.4.1.2 The value of twin studies ..................................................... 47 
1.4.2 Methods to quantify DNA methylation..................................... 48 
1.4.2.1 Global DNA methylation ..................................................... 48 
1.4.2.2 Targeted DNA methylation.................................................. 49 
1.4.2.2.1 Genome-wide methylation ................................................ 49 
1.4.2.2.2 Locus-specific methylation ............................................... 49 
1.4.3 Considerations when designing an epigenetic study ................. 50 
1.4.3.1 Tissue specificity ................................................................. 50 
1.4.3.2 Temporality of epigenetic change ........................................ 51 
1.4.4 Approaches to studying the role of DNA methylation in the 
aetiology of post-stroke dementia and mild cognitive impairment in 
Parkinson’s disease ............................................................................ 52 
1.5 Exploring the functional importance of observational associations 
detected in epigenetic epidemiological studies ....................................................... 53 
v 
 
 
 
1.5.1 Biological function .................................................................... 53 
1.5.2 Gene expression ........................................................................ 54 
1.6 Study objectives, aims and hypotheses ................................................. 55 
1.7 Summary of thesis chapters .................................................................. 56 
Chapter 2: Methods .............................................................................. 57 
2.1 Study cohorts .......................................................................................... 57 
2.1.1 COGFAST ................................................................................ 57 
2.1.1.1 Sample selection .................................................................. 58 
2.1.1.2 Variables used in the analysis .............................................. 59 
2.1.1.2.1 Outcome measures ............................................................ 59 
2.1.1.2.2 Exposure measures ........................................................... 59 
2.1.1.2.3 Covariates ......................................................................... 60 
2.1.2 ICICLE ...................................................................................... 60 
2.1.2.1 Sample selection .................................................................. 61 
2.1.2.2 Variables used in the analysis .............................................. 61 
2.1.2.2.1 Outcome measures ............................................................ 62 
2.1.2.2.2 Exposure measures ........................................................... 62 
2.1.2.2.3 Covariates ......................................................................... 62 
2.2 DNA extraction and quantification ...................................................... 63 
2.2.1 Tissue DNA extraction .............................................................. 63 
2.2.2 Blood DNA extraction .............................................................. 63 
2.2.3 Quantification of DNA .............................................................. 64 
2.2.4 Precipitation of DNA ................................................................ 64 
2.3 Bisulphite modification of DNA ............................................................ 65 
2.3.1 Quality control .......................................................................... 65 
2.4 Illumina HumanMethylation450 BeadChip sample preparation ...... 67 
2.5 HM450 data pre-processing .................................................................. 69 
2.5.1 Sample quality control .............................................................. 69 
2.5.2 Probe quality control and normalisation ................................... 71 
2.5.3 Methods used for data summary, visualisation and diagnostics 73 
2.6 Pyrosequencing ....................................................................................... 75 
2.6.1 Selection of top hits ................................................................... 75 
2.6.2 Primer design ............................................................................ 75 
2.6.3 Primer optimisation ................................................................... 76 
2.6.4 Agarose gel ............................................................................... 77 
vi 
 
 
 
2.6.5 Assay validation ........................................................................ 77 
2.6.6 Pyrosequencing ......................................................................... 78 
2.6.7 Pyrosequencing quality control ................................................. 79 
2.7 Other laboratory techniques ................................................................. 80 
2.7.1 Tissue RNA extraction .............................................................. 80 
2.7.2 Blood RNA extraction .............................................................. 80 
2.7.3 Quantification of RNA .............................................................. 81 
2.7.4 Protein extraction ...................................................................... 81 
2.7.5 Protein quantification ................................................................ 82 
2.7.6 Western blots ............................................................................. 83 
2.7.6.1 Antibody optimisation ......................................................... 83 
2.7.6.2 Western blot ......................................................................... 83 
2.7.6.2.1 Acrylamide gel .................................................................. 83 
2.7.6.2.2 Activation of the membrane .............................................. 84 
2.7.6.2.3 Blotting ............................................................................. 84 
2.7.6.2.4 Blocking with 5% milk ..................................................... 84 
2.7.6.2.5 Blotting with antibodies .................................................... 84 
2.7.6.2.6 Imaging of membrane ....................................................... 84 
2.7.6.2.7 Loading standard ............................................................... 85 
2.8 Statistical methods ................................................................................. 86 
2.8.1 DNA methylation measures ...................................................... 86 
2.8.1.1 Methylation as a beta value.................................................. 86 
2.8.1.2 Methylation as a percentage ................................................. 86 
2.8.2 HM450 data analysis ................................................................. 86 
2.8.1.1 Cell type adjustment ............................................................ 87 
2.8.2.1.1 Blood ................................................................................. 87 
2.8.2.1.2 Brain ................................................................................. 87 
2.8.2.2 Calculating methylation scores to predict smoking status ... 87 
2.8.2.3 Predicting age using DNA methylation ............................... 88 
2.8.3 Pyrosequencing data analysis .................................................... 88 
2.8.4 Western blot analysis ................................................................ 88 
Chapter 3: Blood-based methylation signatures as a predictor of post-
stroke dementia ..................................................................................... 89 
3.1 Introduction ............................................................................................ 89 
3.2 Experimental design .............................................................................. 91 
vii 
 
 
 
3.2.1 Study cohort .............................................................................. 91 
3.2.2 Blood DNA extraction, quantification and precipitation .......... 91 
3.2.3 Illumina HumanMethylation450 BeadChip analysis ................ 92 
3.2.4 Analysis of HM450 data ........................................................... 92 
3.2.5 Selection of top HM450 hits ..................................................... 93 
3.2.6 Pyrosequencing ......................................................................... 94 
3.2.7 Statistical analyses .................................................................... 96 
3.3 Results ..................................................................................................... 97 
3.3.1 Discovery analysis using HM450 data .................................... 101 
3.3.1.1 Distribution of genome-wide methylation values .............. 102 
3.3.1.2 Cluster analysis .................................................................. 103 
3.3.1.3 Single-point analysis .......................................................... 106 
3.3.1.4 Selection of top hits – approach 1 ...................................... 106 
3.3.1.5 Selection of top hits – approach 2 ...................................... 116 
3.3.2 Primer optimisation and validation ......................................... 119 
3.3.3 Pyrosequencing analysis ......................................................... 122 
3.3.3.1 APOB and NGF ................................................................. 123 
3.3.3.1.1 Validation in discovery cohort  ....................................... 123 
3.3.3.1.2 Validation in Pyrosequencing cohort .............................. 129 
3.3.3.1.3 Neighbouring CpG sites .................................................. 129 
3.4 Discussion .............................................................................................. 133 
Chapter 4: Epigenetic mechanisms in post-stroke dementia .......... 140 
4.1 Introduction .......................................................................................... 140 
4.2 Experimental design ............................................................................ 141 
4.2.1 Study cohort ............................................................................ 141 
4.2.2 Tissue DNA extraction, quantification and precipitation ....... 141 
4.2.3 Illumina HumanMethylation450 BeadChip analysis .............. 141 
4.2.4 Analysis of HM450 data ......................................................... 142 
4.2.5 Selection of top HM450 hits ................................................... 142 
4.2.6 Pyrosequencing ....................................................................... 143 
4.2.7 Statistical analyses .................................................................. 144 
4.2.8 Protein extraction and quantification ...................................... 144 
4.2.9 Western blot optimisation ....................................................... 145 
4.2.10 Western blot .......................................................................... 145 
4.3 Results ................................................................................................... 147  
viii 
 
 
 
4.3.1 Discovery analysis .................................................................. 147 
4.3.1.1 Distribution of genome-wide methylation values .............. 150 
4.3.1.2 Cluster analysis .................................................................. 150 
4.3.1.3 Single-point analysis .......................................................... 155 
4.3.1.4 Selection of top hits – approach 1 ...................................... 155 
4.3.1.4.1 Dorsolateral prefrontal cortex ......................................... 155 
4.3.1.4.2 Hippocampus .................................................................. 159 
4.3.1.5 Summary of approach 1  .................................................... 166 
4.3.1.6 Selection of top hits – approach 2 ...................................... 169 
4.3.1.6.1 Dorsolateral prefrontal cortex ......................................... 169 
4.3.1.6.2 Hippocampus .................................................................. 171 
4.3.2 Primer optimisation and validation ......................................... 175 
4.3.3 Pyrosequencing analysis ......................................................... 177 
4.3.3.1 NGF and cg18837178 ........................................................ 178 
4.3.3.1.1 Validation in discovery cohort ........................................ 178 
4.3.3.1.2 Validation in Pyrosequencing cohort .............................. 184 
4.3.3.1.3 Neighbouring CpG sites .................................................. 184 
4.3.3.1.4 Further Braak staging analysis ........................................ 185 
4.3.3.2 cg18837178 in the dorsolateral prefrontal cortex .............. 187 
4.3.3.2.1 Validation in discovery cohort ........................................ 187 
4.3.3.2.2 Validation in Pyrosequencing cohort .............................. 189 
4.3.3.2.3 Neighbouring CpG sites .................................................. 189 
4.3.4 Protein analysis ....................................................................... 190 
4.3.4.1 NGF optimisation .............................................................. 190 
4.3.4.2 Western blots ..................................................................... 191 
4.3.5 APOB in the brain ................................................................... 194 
4.4 Discussion .............................................................................................. 196 
Chapter 5: Blood-based methylation signatures as a predictor of 
Parkinson’s disease  ............................................................................ 201 
5.1 Introduction .......................................................................................... 201 
5.2 Experimental design ............................................................................ 203 
5.2.1 Study cohort ............................................................................ 203 
5.2.2 Blood DNA extraction, quantification and precipitation ........ 203 
5.2.3 Illumina HumanMethylation450 BeadChip analysis .............. 203 
5.2.4 Analysis of HM450 data ......................................................... 204 
5.2.5 Selection of top HM450 hits ................................................... 204 
ix 
 
 
 
5.2.6 Pyrosequencing ....................................................................... 205 
5.2.7 Statistical analyses .................................................................. 206 
5.3 Results ................................................................................................... 208 
5.3.1 Discovery analysis .................................................................. 212 
5.3.1.1 Distribution of genome-wide methylation values .............. 213 
5.3.1.2 Cluster analysis .................................................................. 214 
5.3.1.3 Single-point analysis .......................................................... 217 
5.3.1.4 Selection of top hits ........................................................... 217 
5.3.2 Primer optimisation and validation ......................................... 224 
5.3.3 Pyrosequencing analysis ......................................................... 225 
5.3.3.1 CHCHD5 ........................................................................... 226 
5.3.3.1.1 Validation in discovery cohort ........................................ 226 
5.3.3.1.2 Validation in replication cohort ...................................... 228 
5.3.3.1.3 Comparison with healthy controls .................................. 228 
5.3.4 Further Pyrosequencing analysis............................................. 229 
5.3.5 RUNDC3A ............................................................................... 229 
5.3.6 MOGAT1 ................................................................................. 231 
5.3.7 PGS1 ....................................................................................... 232 
5.4 Discussion .............................................................................................. 233 
Chapter 6: DNA methylation signatures as exposure indicators in post-
stroke dementia and Parkinson’s disease ......................................... 237 
6.1 Introduction .......................................................................................... 237 
6.1.1 Exposures affecting post-stroke dementia .............................. 238 
6.1.2 Exposures affecting mild cognitive impairment in Parkinson’s 
disease .............................................................................................. 239 
6.2 Experimental design ............................................................................ 241 
6.2.1 COGFAST exposures.............................................................. 241 
6.2.2 ICICLE exposures ................................................................... 243 
6.2.3 Relationship between exposures and outcomes ...................... 244 
6.2.4 Associations between exposures and DNA methylation ........ 244 
6.2.5 Using methylation scores to predict smoking exposure status 245 
6.2.6 Identifying CpG sites associated with both an exposure and 
outcome ............................................................................................ 245 
6.2.7 Testing for interaction ............................................................. 245 
6.3 Results ................................................................................................... 246 
x 
 
 
 
6.3.1 Relationship between exposure and outcome ......................... 246 
6.3.1.1 Post-stroke dementia .......................................................... 246 
6.3.1.2 Mild cognitive impairment in Parkinson’s disease ............ 248 
6.3.2 Relationship between exposure and DNA methylation .......... 250 
6.3.2.1 Post-stroke dementia .......................................................... 250 
6.3.2.1.1 Baseline blood samples ................................................... 250 
6.3.2.1.2 Dorsolateral prefrontal cortex samples ........................... 253 
6.3.2.1.3 Hippocampus samples .................................................... 258 
6.3.2.2 Parkinson’s disease ............................................................ 262  
6.3.3 Is DNA methylation a good predictor of exposure status? ..... 267 
6.3.4 Is methylation associated with both an exposure and outcome? ...  
 ...................................................................................................................... 268 
6.3.4.1 Parkinson’s disease ............................................................ 268 
6.3.4.2 Post-stroke dementia .......................................................... 270 
6.4 Discussion .............................................................................................. 272 
Chapter 7: Methylation age as a risk factor for post-stroke dementia 
and Parkinson’s disease ...................................................................... 276 
7.1 Introduction .......................................................................................... 276 
7.2 Experimental design ............................................................................ 278 
7.3 Results ................................................................................................... 280 
7.3.1 DNA methylation age of COGFAST participants .................. 280 
7.3.2 DNA methylation age of ICICLE participants ........................ 282 
7.3.3 Does the methylation age of the brain differ from the blood? 284 
7.3.4 Does an older methylation age increase the risk of developing 
cognitive decline?............................................................................. 285  
7.4 Discussion .............................................................................................. 293 
Chapter 8: Discussion ......................................................................... 296 
8.1 Summary of aims and objectives ........................................................ 296 
8.1.1 To identify blood-based biomarkers of post-stroke dementia. 296 
8.1.2 To identify differentially methylated positions in the brain which 
are associated with impaired cognitive function in stroke patients .. 298 
8.1.3 To identify blood-based biomarkers of mild cognitive impairment 
in Parkinson’s disease ...................................................................... 301 
8.1.4 To assess whether DNA methylation can mediate the relationship 
between exposure and outcome ....................................................... 302 
xi 
 
 
 
8.1.5 To assess whether DNA methylation can be used as an indicator of 
exposure status ................................................................................. 303 
8.1.6 To assess whether age predicted from DNA methylation can 
identify individuals at risk of cognitive decline ............................... 304 
8.2 Strengths of the study .......................................................................... 307 
8.3 Limitations of the study ....................................................................... 309 
8.4 Future work .......................................................................................... 313 
8.5 Conclusion ............................................................................................. 317 
References ............................................................................................ 318 
Appendix A .......................................................................................... 345 
Appendix B .......................................................................................... 346 
Appendix C .......................................................................................... 347 
Appendix D .......................................................................................... 354 
 
 
 
 
 
 
 
xii 
 
 
 
List of Tables 
Table 1: A list of well-documented risk factors ................................................................ 7 
Table 2: Study designs used in epigenetic epidemiology and their applications ............ 47 
Table 3: Defined variables exported from GenomeStudio ............................................. 71 
Table 4: Pre-PCR mix ..................................................................................................... 78 
Table 5: Post-PCR mix ................................................................................................... 78 
Table 6: Components of each Pyrosequencing reagent .................................................. 79 
Table 7: Dilution factors for standards to be used in protein quantification ................... 82 
Table 8: Four different primary antibody conditions ...................................................... 83 
Table 9: Ingredients for all buffers used in Western blotting ......................................... 83 
Table 10: Optimal PCR conditions for each assay.......................................................... 95 
Table 11: Forward, reverse and sequencing primers for each successfully validated 
DMP Pyrosequencing assay ............................................................................................ 95 
Table 12: Summary statistics for variables relating to the stroke event ......................... 98 
Table 13: Summary statistics for variables relating to stroke/dementia risk factors and 
medical history ................................................................................................................ 99 
Table 14: Summary statistics for variables relating to both pathology and cognitive-
based outcomes ............................................................................................................. 100 
Table 15: Details about top 76 CpG sites selected based on genome wide significance
 ....................................................................................................................................... 114 
Table 16: CpG sites showing an effect when adjusted for cellular composition .......... 115 
Table 17: Number of CpG sites taken forward at each stage in the selection of top hits
 ....................................................................................................................................... 117 
Table 18: Description of 3 CpG sites showing expression differences in AD .............. 118 
Table 19: Observed mean methylation across all CpGs compared with reference 
expected methylation level ............................................................................................ 120 
Table 20: Number of samples in each cohort by Braak staging ................................... 125 
Table 21: ANOVA (and Kruskal Wallis) results for APOB and NGF Pyrosequencing
 ....................................................................................................................................... 130 
Table 22: Clinical features of COGFAST Braak stage VI individual .......................... 137 
Table 23: Optimal PCR conditions for each assay........................................................ 144 
Table 24: Forward, reverse and sequencing primer for each successfully validated DMP 
Pyrosequencing assay ................................................................................................... 144 
Table 25: Details about top 10 CpG sites based on genome wide significance ............ 157 
xiii 
 
 
 
Table 26: CpG sites showing an effect when adjusted for cellular composition .......... 158 
Table 27: Details about top 34 CpG sites based on genome wide significance in the 
hippocampus ................................................................................................................. 163 
Table 28: CpG sites showing an effect when adjusted for cellular composition .......... 165 
Table 29: Number of CpG sites taken forward at each stage in the selection of DLPFC 
top hits ........................................................................................................................... 170 
Table 30: Description of the 2 CpG sites showing differential expression in AD DLPFC 
samples .......................................................................................................................... 171 
Table 31: Number of CpG sites taken forward at each stage in the selection of 
hippocampus top hits .................................................................................................... 172 
Table 32: Description of the 21 CpG sites showing expression differences in AD 
hippocampus samples ................................................................................................... 174 
Table 33: Summary of assays designed for Pyrosequencing analysis in the brain ....... 175 
Table 34: Observed mean methylation across all CpGs significant in brain compared 
with reference expected methylation level .................................................................... 176 
Table 35: Number of hippocampal samples in each cohort by Braak staging .............. 179 
Table 36: ANOVA (and Kruskal Wallis) results for cg18837178 and NGF 
Pyrosequencing ............................................................................................................. 185 
Table 37: ANOVA (and Kruskal Wallis) results for cg18837178 Pyrosequencing ..... 190 
Table 38: Number of samples with each Braak stage pathology in each of the cohort 
groups ............................................................................................................................ 192 
Table 39: Optimal PCR conditions for each assay........................................................ 206 
Table 40: Forward, reverse and sequencing primers for each successfully validated 
DMP Pyrosequencing assay .......................................................................................... 206 
Table 41: Summary statistics for exposure variables .................................................... 209 
Table 42: Summary statistics for variables relating to cognitive-based outcomes ....... 210 
Table 43: Summary statistics for variables relating to motor-based outcomes ............ 211 
Table 44: Number of CpG sites significantly associated with cognition taken forward at 
each stage in the selection of top hits ............................................................................ 218 
Table 45: Number of CpG sites significantly associated with motor outcome taken 
forward at each stage in the selection of top hits .......................................................... 218 
Table 46: Description of 46 CpG sites associated with cognitive traits showing 
expression differences in PD, ranked in order of effect size ......................................... 222 
Table 47: CpG sites affected by cellular composition adjustment ................................ 222 
xiv 
 
 
 
Table 48: Description of 3 motor sites showing expression differences in PD ............ 223 
Table 49: Observed mean methylation across all CpGs compared with reference 
expected methylation level ............................................................................................ 224 
Table 50: Association between RUNDC3A methylation and language score ............... 230 
Table 51: Association between MOGAT1 methylation and MDS-UPDRS III ............. 232 
Table 52: Association between PGS1 methylation and tremor dominant phenotype ... 232 
Table 53: List of exposures measured in COGFAST ................................................... 243 
Table 54: List of exposures measured in ICICLE ......................................................... 243 
Table 55: Significant associations between exposures and outcomes in the COGFAST 
cohort ............................................................................................................................ 247 
Table 56: Significant associations between exposures and motor outcomes in the 
ICICLE cohort ............................................................................................................... 248 
Table 57: Significant associations between exposures and cognitive outcomes in the 
ICICLE cohort ............................................................................................................... 249 
Table 58: Summary and test statistics for the CpG site in blood associated with the side 
of the body affected by stroke ....................................................................................... 251 
Table 59: Summary and test statistics for the 4 CpG sites in blood associated with 
degree of weakness in leg ............................................................................................. 252 
Table 60: Summary and test statistics for the 21 CpG sites in DLPFC associated with 
the side of body affected by stroke ............................................................................... 254 
Table 61: Summary and test statistics for the 47 CpG sites in DLPFC associated with 
degree of weakness in leg ............................................................................................. 256 
Table 62: Summary and test statistics for the 5 CpG sites in DLPFC associated with 
intermittent claudication................................................................................................ 257 
Table 63: Summary and test statistics for the 2 CpG sites in the hippocampus associated 
with the side of body affected by stroke ....................................................................... 259 
Table 64: Summary and test statistics for the 58 CpG sites in the hippocampus 
associated with degree of weakness in leg .................................................................... 261 
Table 65: CpG sites affected by cellular composition .................................................. 263 
Table 66: Summary and test statistics for the CpG site associated with homocysteine…..
 ....................................................................................................................................... 263 
Table 67: Summary and test statistics for the 8 CpG sites associated with IHD .......... 264 
Table 68: Summary and test statistics of the 24 CpG sites associated with smoking 
status .............................................................................................................................. 265 
xv 
 
 
 
Table 69: Summary and test statistics for the 7 CpG sites associated with weight ...... 266 
Table 70: 9 CpG sites associated with both smoking and language ............................. 269 
Table 71: Methylation is associated with smoking at 9 CpG sites ............................... 269 
Table 72: Statistics for associations between exposures and outcomes identified in 
COGFAST samples ....................................................................................................... 271 
Table 73: Description of the output variables resulting from epigenetic clock analysis
 ....................................................................................................................................... 278 
Table 74: COGFAST blood DNA epigenetic clock data .............................................. 280 
Table 75: COGFAST DLPFC DNA epigenetic clock data .......................................... 281 
Table 76: COGFAST hippocampal DNA epigenetic clock data .................................. 282 
Table 77: ICICLE blood DNA epigenetic clock data ................................................... 283 
 
xvi 
 
 
 
List of Figures 
Figure 1: Types of stroke .................................................................................................. 6 
Figure 2: One unit of chromatin composed of DNA wrapped around an octamer of 
histones ............................................................................................................................ 26 
Figure 3: DNA methylation ............................................................................................ 28 
Figure 4: CpG islands, shores, shelves and open sea ...................................................... 28 
Figure 5: How can genetic control influence DNA methylation? ................................... 33 
Figure 6: Anatomy of the brain ....................................................................................... 59 
Figure 7: Description of CpG sites included on the HM450 BeadChip ......................... 68 
Figure 8: Number of probes dropped at each stage during probe filtering ..................... 72 
Figure 9: Two approaches used to select top hits for Pyrosequencing ........................... 75 
Figure 10A: Average detection p values in each blood sample .................................... 102 
Figure 11: A composite figure showing the distributions of methylation using raw and 
normalised data ............................................................................................................. 104 
Figure 12: Cluster dendrogram for all 29 blood samples coloured by diagnosis.......... 105 
Figure 13: Cluster dendrogram for all 29 blood samples coloured by sex ................... 105 
Figure 14: Cluster dendrogram for all 29 blood samples coloured by chip .................. 105 
Figure 15: Quantile-quantile (QQ) plot for association between methylation and Braak 
staging ........................................................................................................................... 107 
Figure 16: Manhattan plot for association between methylation and Braak staging .... 107 
Figure 17: QQ plot for association between methylation and memory remote ............ 108 
Figure 18: Manhattan plot for association between methylation and memory remote . 108 
Figure 19: QQ plot for association between methylation and total CAMCOG score .. 109 
Figure 20: Manhattan plot for association between methylation and total CAMCOG 
score .............................................................................................................................. 109 
Figure 21: Description of statistically significant CpG sites identified in blood samples
 ....................................................................................................................................... 111 
Figure 22: Flow diagram summarising the selection of top hits that reach genome wide 
significance ................................................................................................................... 115 
Figure 23: Quadrant plot of DMPs and associated expression levels ........................... 118 
Figure 24: Composite figure of 10 assay validation plots............................................. 122 
Figure 25: Correlation between methylation measured on the HM450 and 
Pyrosequencer at the APOB locus ................................................................................. 124 
xvii 
 
 
 
Figure 26: Correlation between methylation measured on the HM450 and 
Pyrosequencer at the NGF locus ................................................................................... 124 
Figure 27: QQ plot for association between methylation and Braak staging with the 
Braak stage VI individual removed ............................................................................... 125 
Figure 28: Manhattan plot for association between methylation and Braak staging with 
the Braak stage VI individual removed ......................................................................... 125 
Figure 29: Mean APOB locus methylation levels observed for each Braak stage 
measured on the HM450 and Pyrosequencer ................................................................ 126 
Figure 30: Mean NGF locus methylation levels observed for each Braak stage measured 
on the HM450 and Pyrosequencer ................................................................................ 127 
Figure 31: Box plot to show methylation levels measured using the HM450 and 
Pyrosequencing at the index CpG site in APOB ........................................................... 127 
Figure 32: Box plot to show methylation levels measured using the HM450 and 
Pyrosequencing at the index CpG site in NGF ............................................................. 128 
Figure 33: Methylation at APOB locus measured in COGFAST and demented Braak 
stage VI individuals ...................................................................................................... 131 
Figure 34: Methylation at NGF locus measured in COGFAST and demented Braak 
stage VI individuals ...................................................................................................... 132 
Figure 35A: Average detection p values in each DLPFC sample ................................. 148 
Figure 36A: Histogram to show the number of probes against the corresponding number 
of samples with p values greater than 0.01 across DLPFC samples ............................. 149 
Figure 37: A composite figure showing the distributions of methylation using raw and 
normalised DLPFC data ................................................................................................ 151 
Figure 38: A composite figure showing the distribution of methylation using raw and 
normalised hippocampus data ....................................................................................... 152 
Figure 39: Cluster dendrogram for all 24 DLPFC samples coloured by diagnosis ...... 153 
Figure 40: Cluster dendrogram for all 24 DLPFC samples coloured by sex ................ 153 
Figure 41: Cluster dendrogram for all 24 DLPFC samples coloured by chip .............. 153 
Figure 42: Cluster dendrogram for all 28 hippocampus samples coloured by diagnosis
 ....................................................................................................................................... 154 
Figure 43: Cluster dendrogram for all 28 hippocampus samples coloured by sex ....... 154 
Figure 44: Cluster dendrogram for all 28 hippocampus samples coloured by chip ...... 154 
Figure 45: QQ plot for association between methylation and Braak staging in the 
DLPFC .......................................................................................................................... 156 
xviii 
 
 
 
Figure 46: Manhattan plot for association between methylation and Braak staging in the 
DLPFC .......................................................................................................................... 156 
Figure 47: Flow diagram summarising the selection of top hits which reach genome 
wide significance in the DLPFC ................................................................................... 158 
Figure 48: QQ plot for association between methylation and Braak staging in the 
hippocampus ................................................................................................................. 160 
Figure 49: Manhattan plot for association between methylation and Braak staging in the 
hippocampus ................................................................................................................. 160 
Figure 50: QQ plot for association between methylation and memory remote in the 
hippocampus ................................................................................................................. 161 
Figure 51: Manhattan plot for association between methylation and memory remote in 
the hippocampus............................................................................................................ 161 
Figure 52: QQ plot for association between methylation and memory recent in the 
hippocampus ................................................................................................................. 162 
Figure 53: Manhattan plot for association between methylation and memory recent in 
the hippocampus............................................................................................................ 162 
Figure 54: Flow diagram summarising the selection of top hits which reach genome 
wide significance in the hippocampus .......................................................................... 164 
Figure 55: Description of statistically significant CpG sites identified in one or more 
brain region ................................................................................................................... 168 
Figure 56: Quadrant plot of DMPs and associated expression levels in the DLPFC ... 171 
Figure 57: Quadrant plot of DMPs and associated expression levels in the hippocampus
 ....................................................................................................................................... 173 
Figure 58: Composite figure of 5 assay validation plots............................................... 176 
Figure 59: Correlation between methylation measured on the HM450 and 
Pyrosequencer at the cg18837178 locus ....................................................................... 178 
Figure 60: Correlation between methylation measured on the HM450 and 
Pyrosequencer at the NGF locus ................................................................................... 179 
Figure 61: QQ plot for association between hippocampal methylation and Braak staging 
with the Braak stage VI individual removed................................................................. 180 
Figure 62: Manhattan plot for association between hippocampal methylation and Braak 
staging with the Braak stage VI individual removed .................................................... 180 
Figure 63: QQ plot for association between DLPFC methylation and Braak staging with 
the Braak stage VI individual removed ......................................................................... 181 
xix 
 
 
 
Figure 64: Manhattan plot f or association between DLPFC methylation and Braak 
staging with the Braak stage VI individual removed .................................................... 181 
Figure 65: Mean cg18837178 locus methylation levels observed for each Braak stage 
measured on the HM450 and Pyrosequencer ................................................................ 182 
Figure 66: Mean NGF locus methylation levels observed for each Braak stage measured 
on the HM450 and Pyrosequencer ................................................................................ 182 
Figure 67: Box plot to show methylation levels measured using the HM450 and 
Pyrosequencing at the CpG site cg18837178 ............................................................... 183 
Figure 68: Box plot to show methylation levels measured using the HM450 and 
Pyrosequencing at the index CpG site in NGF ............................................................. 183 
Figure 69: Methylation at cg18837178 locus measured in hippocampal DNA in 
COGFAST and demented Braak stage V and Braak stage VI individuals ................... 186 
Figure 70: Methylation at NGF locus measured in hippocampal DNA in COGFAST and 
demented Braak stage V and Braak stage VI individuals ............................................. 186 
Figure 71: Correlation between methylation measured on the HM450 and 
Pyrosequencer at the cg18837178 locus ....................................................................... 187 
Figure 72: Mean cg18837178 methylation levels observed for each Braak stage 
measured in the DLPFC on the HM450 and Pyrosequencer ........................................ 188 
Figure 73: Box plot to show methylation levels measured using the HM450 and 
Pyrosequencing at the CpG site cg18837178 ............................................................... 188 
Figure 74: Optimisation of anti-NGF ............................................................................ 191 
Figure 75: Western blot analysis ................................................................................... 193 
Figure 76: Correlation between hippocampal NGF methylation and NGF protein levels
 ....................................................................................................................................... 194 
Figure 77: Comparison of mean methylation levels by Braak staging in the blood and 
DLPFC using Pyrosequencing ...................................................................................... 194 
Figure 78: Comparison of mean methylation levels by Braak staging in the blood and 
hippocampus using Pyrosequencing ............................................................................. 195 
Figure 79A: Average detection p values in each blood sample .................................... 213 
Figure 80: A composite figure showing the distributions of methylation using raw and 
normalised data ............................................................................................................. 215 
Figure 81: Cluster dendrogram for all 46 blood samples coloured by diagnosis.......... 216 
Figure 82: Cluster dendrogram for all 46 blood samples coloured by sex ................... 216 
Figure 83: Cluster dendrogram for all 46 blood samples coloured by chip .................. 216 
xx 
 
 
 
Figure 84: Quadrant plot of DMPs and associated expression levels for cognition 
outcomes ....................................................................................................................... 220 
Figure 85: Quadrant plot of DMPs and associated expression levels for motor outcomes
 ....................................................................................................................................... 223 
Figure 86: Composite figure of 3 assay validation plots............................................... 225 
Figure 87: Correlation between methylation measured on the HM450 and 
Pyrosequencer at the CHCHD5 locus ........................................................................... 226 
Figure 88: Mean methylation levels for naming score measured at the CHCHD5 locus 
on the HM450 and Pyrosequencer ................................................................................ 227 
Figure 89: CHCHD5 DNA methylation analysis with language score in both PD cases 
and controls ................................................................................................................... 229 
Figure 90: Regional RUNDC3A DNA methylation analysis with language score in both 
PD cases and controls.................................................................................................... 231 
Figure 91: Associations tested in this thesis to assess the role of DNA methylation in the 
exposure-outcome association ...................................................................................... 238 
Figure 92: Manhattan plot for association between blood DNA methylation and the side 
of the body affected by stroke ....................................................................................... 251 
Figure 93: Manhattan plot for association between blood DNA methylation and degree 
of weakness in the leg ................................................................................................... 252 
Figure 94: Manhattan plot for association between DLPFC DNA methylation and the 
side of the body affected by stroke ............................................................................... 254 
Figure 95: Manhattan plot for association between DLPFC DNA methylation and the 
degree of weakness in the leg........................................................................................ 255 
Figure 96: Manhattan plot for association between DLPFC DNA methylation and 
intermittent claudication................................................................................................ 257 
Figure 97: Manhattan plot for association between hippocampal DNA methylation and 
the side of body affected by stroke ............................................................................... 259 
Figure 98: Manhattan plot for association between hippocampal DNA methylation and 
the degree of weakness in leg........................................................................................ 260 
Figure 99: Manhattan plot for association between blood DNA methylation and 
homocysteine ................................................................................................................ 263 
Figure 100: Manhattan plot for association between blood DNA methylation and IHD
 ....................................................................................................................................... 264 
xxi 
 
 
 
Figure 101: Manhattan plot for association between blood DNA methylation and 
smoking status ............................................................................................................... 265 
Figure 102: Manhattan plot for association between blood DNA methylation and weight
 ....................................................................................................................................... 266 
Figure 103: Smoking scores by reported smoking status ............................................. 268 
Figure 104: Graph of predicted values and linear fit lines from regression model for 
cg18045575 ................................................................................................................... 270 
Figure 105: Scatter plot of DNA methylation age against chronological age for each of 
the three tissues analysed in COGFAST ....................................................................... 284 
Figure 106: DNA methylation age against chronological age of the blood .................. 286 
Figure 107: Age acceleration residual of the blood by diagnosis of post-stroke dementia
 ....................................................................................................................................... 286 
Figure 108: Age acceleration residual of the blood by smoking status ........................ 287 
Figure 109: DNA methylation age against chronological age of the brain................... 288 
Figure 110: Age acceleration residual of the brain by diagnosis of post-stroke dementia
 ....................................................................................................................................... 289 
Figure 111: DNA methylation age against chronological age of the blood .................. 290 
Figure 112: Age acceleration residual of the blood by diagnosis of PD-MCI .............. 290 
Figure 113: Correlation between AAR and MDS-UPDRS II coded for diagnosis of MCI
 ....................................................................................................................................... 291 
Figure 114: Age acceleration residual of the blood by diabetes ................................... 291 
 
 
xxii 
 
 
 
Abbreviations 
5-aza   5-aza-2’-deoxycytidine 
5-hmC  5-hydroxy-methylcytosine 
5-mC   5-methylcytosine 
AAD   Age acceleration difference 
AAR   Age acceleration residual 
Aβ   Beta amyloid 
AD   Alzheimer’s disease 
APOB   Apolipoprotein B 
APOE4  Apolipoprotein E4 
APP   Amyloid precursor protein 
BLAT   BLAST-like alignment tool 
BM   Bisulphite modified 
bp   Base pairs 
BSA   Bovine serum albumin 
CA   Healthy controls 
CADASIL  Cerebral autosomal dominant arteriopathy with subcortical infarcts and 
leukoencephalopathy  
CAMCOG  Cambridge cognitive examination 
CANTAB Cambridge neuropsychological test automated battery 
CDR  Cognitive drug research battery 
CHCHD5  Coiled-coil-helix-coiled-coil-helix domain containing 5 
CN   Cognitively normal 
COGFAST  Cognitive function after stroke  
CpH   Non-CpG 
CRP   C-reactive protein 
CSF   Cerebrospinal fluid 
xxiii 
 
 
 
CVD   Cardiovascular disease 
D   Demented 
DBS   Deep brain stimulation 
ddNTPs  Dideoxynucleotide triphosphates 
DLB   Dementia with Lewy bodies 
DLPFC  Dorsolateral prefrontal cortex 
DMP   Differentially methylated positions 
DMR   Differentially methylated regions 
DNA   Deoxyribonucleic acid 
DNMT  DNA methyltransferases 
DS   Alzheimer’s disease, no stroke 
DSM   Diagnostic and statistical manual of mental disorders 
EDTA  Ethylenediaminetetraacetic acid 
EWAS  Epigenome-wide association study 
FACS   Fluorescence activated cell sorting 
FTD   Frontotemporal dementia 
FTD-ALS  Frontotemporal dementia-amyotrophic lateral sclerosis 
GDS-15  Geriatric depression scale 
GEoCoDE  Genomic and epigenomic complex disease epidemiology 
GWAS  Genome-wide association studies 
HM450  HumanMethylation450 
HPLP  High performance liquid chromatography 
HRP   Horseradish peroxidase 
ICD   International classification of diseases 
ICICLE  Incidence of cognitive impairments in cohorts with longitudinal 
evaluation 
IHD   Ischaemic heart disease 
xxiv 
 
 
 
IL-8   Interleukin-8 
IQ   Intelligence quotient 
IQR   Interquartile range 
LACS  Lacunar stroke 
LCM   Laser capture microdissection 
LDL   Low-density lipoprotein 
LINE-1  Long interspersed nucleotide element 1 
MAO-B  Monoamine oxidase B 
MCI   Mild cognitive impairment 
MDS-UPDRS  Movement disorder society-unified Parkinson’s disease rating scale 
MiRNA  Micro ribonucleic acid 
mmHg  millimetres of mercury 
MMSE  Mini mental state examination 
MoCA  Montreal cognitive assessment 
MR   Mendelian randomisation 
MRI   Magnetic resonance imaging 
mRNA  Messenger ribonucleic acid 
MTHFR  Methylenetetrahydrofolate reductase 
MZ   Monozygotic 
NBTR   Newcastle brain tissue resource 
NGF   Nerve growth factor 
NMS   Non-motor symptoms 
OCSP   Oxfordshire community stroke project 
PACS  Partial anterior circulation stroke 
PBS   Phosphate buffered saline 
PCR   Polymerase chain reaction 
PD   Parkinson’s disease 
xxv 
 
 
 
PDD   Parkinson’s disease dementia 
PD-MCI  Mild cognitive impairment in Parkinson’s disease 
PM   Post-mortem 
POCS  Posterior circulation stroke 
PROGRESS  Perindopril protection against recurrent stroke study  
PSD   Post-stroke dementia 
QC   Quality control 
RCF   Red cell folate 
RNA   Ribonucleic acid 
SAM   S-adenosylmethionine 
SCU   Stroke care unit 
SD   Standard deviation 
SES  Socio-economic status 
SMART  Simple modular architecture research tool 
SNCA   Alpha-synuclein 
SNP   Single nucleotide polymorphism 
SQN   Subset quantile normalisation 
ssDNA  Single stranded DNA 
TACS  Total anterior circulation stroke 
TBE   Tris-borate-ethylenediaminetetraacetic acid 
TBS  Tris buffered saline 
TBS-T  Tris buffered saline-tween 
TIA   Transient ischaemic attack 
TNF   Tumour necrosis factor 
UTR   Untranslated region 
VaD   Vascular dementia  
WHO   World health organisation 
xxvi 
 
 
 
Xist   X-inactive specific transcript 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xxvii 
 
 
 
Glossary of Variables 
Table 1. COGFAST Exposures 
Variable Abbreviation  Description 
Oxfordshire Community 
Stroke Project 
OCSP Classification of stroke type (TACS, LACS, 
PACS, TOCS) using clinical criteria.  
Side of body affected by 
stroke 
Side of body The side of the body (left/right), if any (none), 
affected by the stroke using clinical data. 
Degree of weakness in arm  The classification of the degree of weakness in the 
limb (no weakness, some weakness, no 
movement) on presentation of stroke using 
clinical notes. 
Degree of weakness in leg  The classification of degree of weakness in the 
limb (no weakness, some weakness, no 
movement) on presentation of stroke using 
clinical notes. 
Dysphasia  The presence or absence of dysphasia at stroke 
presentation as recorded by clinical notes. 
Number of CVD risk 
factors 
No CVD risk 
factors 
Number of Cardiovascular risk factors (Smoking, 
Diabetes, Hyperlipidaemia, Peripheral vascular 
disease, IHD, Atrial fibrillation, Hypertension). 
Hypertension  Present or absent, defined by blood pressure 
>140/90 mmHg. 
Atrial fibrillation  Present or absent, defined by WHO criteria. 
Ischaemic heart disease IHD Present or absent, defined by WHO criteria. 
Myocardial Infarction  Present or absent, defined by WHO criteria. 
Angina  Present or absent, defined by WHO criteria. 
Cardiac failure  Present or absent, defined by WHO criteria. 
Hypercholesterolemia  Present or absent, defined by WHO criteria. 
Diabetes  Present or absent, defined by WHO criteria. 
Intermittent claudication  Present or absent, defined by WHO criteria. 
Smoking  Smoking status (current, ex or never). 
Other COGFAST exposures included in this study were baseline CAMCOG scores. 
Definitions of these can be found in Table 2. COGFAST Outcomes.  
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Table 2. COGFAST Outcomes 
Variable Abbreviation Description 
Diagnosis  Diagnosis of post-stroke dementia based on 
neuropsychometric testing, agreement with DSM IIIR 
and IV criteria for dementia and post-mortem 
neuropathological examination. 
Braak staging  Degree of pathology (I-VI) assessed by post-mortem 
neuropathological examination (Braak and Braak, 
1995). 
Mini Mental State 
Examination 
MMSE Questionnaire test assessing various cognitive 
domains. ≤24/30 indicates some degree of cognitive 
impairment (Folstein et al., 1975). 
Orientation*  Score comprised of 10 items from the MMSE. 
Language 
comprehension* 
 Score out of 9 based on verbal and non-verbal 
responses to both spoken and written questions. 
Language 
expression* 
 A combination of naming, repetition, fluency and 
definitions. Scored out of 21.  
Memory remote*  Ability to recall famous historic events and people. 
Memory recent*  Ability to recall current news and recent events.  
Memory learning*  Ability to recall and recognise pictures and patterns.  
Memory total*  A combined score of the remote, recent and learning 
memory tests. Scored out of 27. 
Attention*  Assessed by counting backwards individually and in 
multiples of 7. Scored out of 7. 
Praxis*  Ability to copy, draw and write. Scored out of 12. 
Calculation*  The ability to perform addition and subtraction. 
Scored out of 2. 
Abstract thinking*  The ability to form links and similarities between two 
objects, e.g. apple/banana. Scored out of 8. 
Perception*  The ability to identify familiar objects and people. 
Scored out of 11. 
Executive function  An independent assessment of executive function 
assessing visual reasoning and verbal fluency. Scored 
out of 28 (Leeds et al., 2001). 
Total CAMCOG 
score* 
 The total combined score of all CAMCOG tests. 
Maximum score = 107. 
* represents a CAMCOG item (de Koning et al., 1998). 
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Table 3. ICICLE Exposures 
Variable Abbreviation Description 
Education  Number of years spent in education. 
National Adult Reading 
Test 
NART NART score used to predict premorbid IQ. 
Height  Height (m) at recruitment. 
Weight  Weight (kg) at recruitment. 
Body Mass Index BMI BMI (kg/m2) at recruitment. 
Ischaemic heart disease IHD Present or absent, defined by WHO criteria. 
Diabetes  Present or absent, defined by WHO criteria. 
Hypertension  Present or absent, defined by blood pressure 
>140/90 mmHg. 
Hypercholesterolaemia  Present or absent, defined by WHO criteria. 
Levodopa daily dose LEDD Daily dose of Levodopa or equivalent 
medication (mg/day). 
Geriatric Depression Scale GDS Geriatric Depression Scale score. A score ≥5 
indicates depression (Yesavage et al., 1982). 
Red cell folate RCF Red cell folate measurement (µg/L) at 
recruitment. 
Vitamin B12 B12 Vitamin B12 measurement (ng/L) at 
recruitment. 
Homocysteine  Homocysteine measurement (µmol/L) at 
recruitment. 
Alcohol  Average units of alcohol per week. 
Smoking  Smoking status (current, ex or never). 
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Table 4. ICICLE Outcomes 
Variable Abbreviation Description 
COGNITIVE   
Montreal Cognitive 
Assessment 
MoCA Test assessing global cognitive domains. 
<26/30 indicates some degree of cognitive 
impairment (Nasreddine et al., 2005). 
Mini Mental State 
Examination 
MMSE Questionnaire test assessing global cognitive 
domains. ≤24/30 indicates significant degree 
of cognitive impairment (Folstein et al., 
1975). 
Total FAS  Test of phonemic fluency (frontal/executive 
function) where participants have to list as 
many words beginning with F, A and S as 
they can in 60 seconds. 
Animals  Test of semantic fluency where participants 
have to list as many animals as they can in 
90 seconds.  
Non-motor symptoms 
questionnaire – memory 
NMSQ memory Self-completed questionnaire assessing 
participant’s memory disturbance as present 
or absent (Romenets et al., 2012). 
Non-motor symptoms 
questionnaire - 
concentration 
NMSQ 
concentration 
Self-completed questionnaire assessing 
participant’s concentration disturbance as 
present or absent (Romenets et al., 2012).  
Total number of non-
motor symptoms 
Total no NMS Total number of all non-motor symptoms 
experienced. 
Power of attention  A sum of reaction times (and measure of 
attention) measured using the Cognitive 
Drug Research (CDR) battery (Wesnes et al., 
2002). A higher score indicates more 
impairment.  
Digit vigilance accuracy  A domain of the CDR battery measuring 
attention (Wesnes et al., 2002).  
Pattern recognition 
memory 
PRM Part of the CANTAB and a test of visual 
memory where participants are tested on 
their ability to recognise previously seen 
patterns (Sahakian et al., 1988) (maximum 
score of 24). 
Spatial recognition 
memory 
SRM Part of the CANTAB and a test of visual 
memory where participants are tested on 
their ability to remember the spatial 
positioning of squares on the screen 
(Sahakian et al., 1988) (maximum score of 
20). 
Paired associates learning PAL Part of the CANTAB and test of visual 
memory where participants are tested on 
their ability to remember the location of 
patterns (Sahakian et al., 1988) (greater 
score indicates more impairment). 
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One touch stockings OTS Part of the CANTAB assessing spatial 
planning (executive function) where 
participants are tested on their ability to plan 
the movement of balls to match the pattern 
displayed on screen (Sahakian et al., 1988) 
(maximum score of 20). 
Pentagon copying  Part of the MMSE testing visuospatial 
function where participants have to copy 
pentagons (Folstein et al., 1975). 
Naming  Part of the MoCA where participants have to 
name pictured animals (Nasreddine et al., 
2005). 
Language  Part of the MoCA where participants have to 
verbally repeat sentences (Nasreddine et al., 
2005).  
Language total  The combined score of the naming and 
language tests above (Nasreddine et al., 
2005). 
Cognitive complaint  Presence or absence of a self-reported 
cognitive deficit. 
Mild cognitive impairment MCI Diagnosis of MCI was given if participants 
showed impairment (1-2 standard deviations 
below the normative values) on at least 2 
neuropsychological tests.  
MOTOR   
Hoehn and Yahr  Part 4 of the MDS-UPDRS. A broad scale 
assessing the level of disability ranging from 
1 (unilateral involvement) to 5 
(bedridden/wheelchair bound) (Hoehn and 
Yahr, 1967). 
Movement disorder society 
- unified Parkinson’s 
disease rating scale part II 
MDS-UPDRS II A self-reported evaluation of the activities of 
daily life such as cutting food and 
handwriting (Goetz et al., 2008) with a 
greater score indicating more perceived 
impairment in activities of daily living. 
Movement disorder society 
- unified Parkinson’s 
disease rating scale part II 
MDS-UPDRS 
III 
An evaluation of all aspects of motor ability 
assessed by a clinician (Goetz et al., 2008) 
with a greater score indicating more severe 
motor disease. 
Tremor dominant 
phenotype 
 A summed score for the assessment of 
tremor using the MDS-UPDRS III (Goetz et 
al., 2008) giving a specific phenotype. 
Postural instability gait 
difficulty phenotype 
PIGD A summed score for the assessment of gait 
using the MDS-UPDRS III (Goetz et al., 
2008), giving a specific phenotype. 
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Chapter 1. Introduction 
1.1 Introduction to molecular epidemiology 
Molecular epidemiology is a term referring to the study of the effect of potential 
exposures (both environmental and genetic), at a molecular level, on the aetiology, 
prediction or prevention of disease across populations. Molecular epidemiology can be 
useful in the identification of mechanisms culminating in disease but also in the 
identification of biomarkers of either exposure or disease which can be considered as 
indirect mechanisms or may even be unrelated to mechanisms. A biomarker has been 
defined as “a characteristic that is objectively measured and evaluated as an indicator of 
normal biological processes, pathogenic processes, or pharmacologic responses to a 
therapeutic intervention” (Biomarkers Definitions Working Group, 2001). 
 
1.1.1 Use of biomarkers in disease prediction and prognosis 
The term biomarker refers to a biological marker that can be quantified in a medical 
setting and is either associated with an exposure or disease phenotype. There are many 
different types of biomarkers and many ways in which they may be identified. Some 
possible techniques used in the identification of biomarkers include; genetic screening, 
imaging or immunohistochemistry techniques, metabolomics, proteomics, 
transcriptomics and more recently epigenomics. There are a number of ways in which 
biomarkers can be useful in disease prediction and prognosis.   
 
These include: 
• measuring exposures, 
• detecting early stages of disease/predicting individuals at-risk of disease,  
• aiding diagnosis of disease,  
• disease stratification/staging, and  
• treatment monitoring.  
 
Biomarkers used in disease prediction and prognosis are most useful when measured in 
a relatively non-invasive manner using a readily accessible tissue such as blood. 
However, this makes it less likely that the biomarker will be mechanistically involved in 
the pathogenesis of disease since many diseases are localised to specific tissues.  
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1.1.2 Use of intermediate phenotypes to inform about disease mechanisms 
Whilst biomarkers used in the prediction and to some extent the prognosis of disease do 
not need to be mechanistically linked to disease, some biomarkers can inform 
researchers as to the mechanisms involved in disease pathogenesis. These are 
particularly useful in the development of targeted treatments which target the cause of 
the disease rather than symptoms alone. However, the robust identification of 
biomarkers to inform about disease mechanisms is more complex than identifying 
biomarkers to predict disease. The main reason for this is that to reliably detect changes 
in biological measurements that are mechanistically linked to disease, the diseased 
tissue is most likely required (Foley et al., 2009; Talens et al., 2010). In diseases such as 
Alzheimer’s disease (AD) and Parkinson’s disease (PD) where the diseased tissue is the 
brain, prospective studies are impossible since the brain can only be sampled post-
mortem. It is therefore impossible to study and monitor the effects of treatment on these 
biological markers. However, for diseases such as autoimmune disease, which affect the 
blood, this can be an extremely useful function of mechanistic biomarkers.   
 
1.1.3 DNA methylation as a biomarker 
A current approach to identifying biomarkers is epigenetics, in particular 
deoxyribonucleic acid (DNA) methylation, both of which are explained in more detail 
in Section 1.3. DNA methylation has been described as a useful biomarker in several 
diseases. If DNA methylation changes are detected prior to disease onset they can be 
useful in informing disease prevention. Two examples of when DNA methylation 
changes have been detected prior to disease onset and are potential biomarkers of 
subsequent disease are outlined below.  
 
Kim et al., (2010) used a population-based prospective cohort to identify DNA 
methylation differences between participants with cardiovascular disease (CVD) 
(myocardial infarction and stroke) or a predisposing condition (diabetes and 
hypertension) and healthy individuals. Global methylation levels were measured and 
compared in three groups of participants; 1) in participants with CVD related traits at 
baseline, 2) in participants who were free of CVD related disease at baseline but 
developed a condition prior to follow up, and 3) in participants who remained free of 
CVD related disease at follow up. The authors found that participants who developed a 
CVD related disease during the study had elevated global methylation levels compared 
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to those who remained disease-free. However, those who presented with a disease at 
baseline had even higher global methylation levels. As methylation differences could be 
detected prior to the onset of disease this study suggests that global methylation levels 
could be used to detect those individuals who are at risk of developing CVD and related 
diseases (Kim et al., 2010). The findings would need to be replicated in an independent 
study before being evaluated for their clinical utility.  
 
DNA methylation has recently been identified as a possible predictive biomarker of 
preeclampsia. In a study by Anderson et al. (2013), maternal blood DNA was collected 
during the first trimester of pregnancy and mothers were followed up until birth. A 
genome-wide methylation array analysing methylation levels at over 480,000 CpG sites 
identified 207 loci which displayed differential methylation between women who 
developed preeclampsia compared with those with a normotensive pregnancy. In 
addition, they also discovered that many of the methylation differences were also 
present in placental DNA, highlighting the possible transgenerational effects in DNA 
methylation (Anderson et al., 2013). The study design used here does not allow one to 
draw conclusions about causality, as pre-existing hypertensive disorders may have been 
present in early pregnancy that could alter DNA methylation, rather than DNA 
methylation differences actually inducing preeclampsia.  
 
Nevertheless, despite limitations in study design, these two examples show that it is 
possible to identify epigenetic biomarkers to enable the early prediction of disease and 
provides an opportunity to intervene in disease prevention. The use of biomarkers may 
offer great benefits to the prediction of a range of diseases including neurodegenerative 
disorders.  
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1.2 Age-related diseases involving the loss of cognitive function 
1.2.1 The ageing brain 
There are a number of changes that occur in the human brain as part of the normal 
ageing process. The ageing brain undergoes structural, chemical and 
neuropsychological changes. Several normal brain changes are described below.  
 
Gross brain volume has been reported to decrease annually in old age (over 60 years of 
age), although changes are not uniform across all brain regions. The hippocampus has 
been widely studied and an average of 0.8 to 2% reduction in brain volume each year 
has been reported. Vast reductions in cortical volumes have been reported, especially in 
the frontal and temporal lobes. Brain atrophy is also a key feature of Alzheimer’s 
disease (AD), however studies have identified that atrophy rates are approximately 1% 
higher in AD affected brains (Fjell et al., 2009).  
 
A number of studies have reported changes in neuronal numbers, however due to the 
difficulty involved in performing these counts and the possibility that neurons shrink 
rather than disappear, many conflicting reports have been published. It is thought 
however, that in certain regions of the brain, such as the hippocampus, there is some 
neuronal loss with age (Anderton, 2002). 
 
The brain also experiences chemical changes with age, including levels of a number of 
neurotransmitters found within the brain. From early adulthood, levels of dopamine, 
which is a neurotransmitter with key roles in motor control and cognition, are found to 
reduce by 10% per decade. Levels of serotonin, which is an important neurotransmitter 
known to regulate learning and memory, are also seen to reduce in the adult ageing 
brain (Peters, 2006). Both dopamine and serotonin are associated with age-related 
disorders such as Parkinson’s disease (Morgan et al., 1987; Xu et al., 2012). 
 
Some degree of cognitive decline is also expected during normal ageing with the most 
commonly affected areas of cognition being attention and memory. The accumulation of 
oxidative damage caused by reactive oxygen species over the life course is also thought 
to contribute to this later life cognitive decline (Lovell and Markesbery, 2007). 
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Many of the brain changes described above, that occur as part of the normal ageing 
process could be used to explain why cognitive decline can be experienced in otherwise 
unaffected brains. However, the brain changes described above are also symptoms of 
many age-related diseases affecting the brain. The use of symptoms alone in the 
diagnosis of such diseases would therefore be inaccurate. The use of markers, such as 
molecular biomarkers, not seen in the normal ageing process, would therefore be 
beneficial in distinguishing between a normal aged and a diseased brain.   
 
A number of age-related diseases exist which affect cognitive function including AD 
and other dementias and Parkinson’s disease. This thesis will be restricted to 
consideration of post-stroke dementia and Parkinson’s disease.  
 
1.2.2 Stroke 
 
1.2.2.1 Incidence 
Approximately fifteen million incident strokes occur worldwide annually resulting in 
five million deaths and an additional five million survivors permanently unable to live 
independently (Redon et al., 2011). This accounts for a loss of 44 million disability-
adjusted life years (Mukherjee and Patil, 2011). The incidence rate for men is 1.25 times 
greater than for women, however more women die each year as a result of stroke, 
probably due to their extended lifespan (Sacco et al., 1997). Worryingly, due to the 
increasingly ageing population and the increasing prevalence of the major risk factors 
for stroke such as hypertension, the burden of stroke is set to rise over the coming 
decades. 
 
A stroke occurs due to a disruption of the cerebral blood supply resulting in a focal 
neurological deficit (Markus, 2011). The World Health Organisation (WHO) defines a 
stroke as “rapidly developing clinical signs of focal (at times global) disturbance of 
cerebral function, lasting more than 24 hours or leading to death with no apparent 
cause other than of vascular origin” (Sudlow and Warlow, 1996). Symptoms include 
sudden onset of impaired speech, loss of vision and paralysis, often only affecting one 
side of the body (Moskowitz et al., 2010).  
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1.2.2.2 Types of stroke 
Approximately 80% of all strokes are ischaemic whilst the remaining 20% are 
haemorrhagic (Figure 1). Ischaemic strokes occur when cerebral blood flow is 
obstructed. There are a number of causes for this. The most common cause, being 
responsible for approximately half of all ischaemic strokes, is atherothrombotic disease 
of the large extracranial or occasionally intracranial arteries supplying the brain. 
Lacunar infarcts, caused by the occlusion of a small, deep, perforating cerebral artery 
within the white and deep grey matter of the brain are responsible for about 25% of 
ischaemic strokes. 20% of ischaemic strokes arise when a clot (which usually forms in 
the heart) breaks off and embolises to the brain. This is known as cardioembolism. 
Atrial fibrillation is a common cause of embolism or blockage of an artery to the heart. 
The remaining 5% of ischaemic strokes have much rarer causes, including vasculitis, 
the inflammatory destruction of blood vessels (Sudlow and Warlow, 1996; Markus, 
2011). Haemorrhagic strokes can be split into two subtypes. 75% are primary 
intracerebral haemorrhages where a blood vessel inside the brain ruptures and 25% are 
subarachnoid haemorrhages with the burst vessel occurring in the subarachnoid space 
(Warlow et al., 2003). Some patients may also suffer from a mini stroke or a transient 
ischaemic attack (TIA). This is very similar to a stroke but has a better prognosis as 
symptoms dissipate within 24 hours (Warlow et al., 2003).  
 
 
Figure 1: Types of stroke. Adapted from http://www.webmd.com/stroke/ischemic-versus-hemorrhagic-
stroke. 
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1.2.2.3 Risk factors 
There are many risk factors for stroke, many of which are related to lifestyle and 
therefore could be modifiable. With the successful management of risk factors, it has 
been estimated that up to 75% of strokes can be prevented (Cumming and Brodtmann, 
2011). Table 1 shows a list of modifiable and non-modifiable risk factors. The key risk 
factors are explained in more detail below.  
 
Modifiable Potentially modifiable Non-modifiable 
Hypertension Diabetes mellitus Age 
Atrial fibrillation Hyperhomocysteinaemia Sex 
Infective endocarditis Left ventricular hypertrophy Hereditary/familial factors 
Mitral stenosis  Race/ethnicity 
Recent large myocardial 
infarction 
 Geographic location 
Cigarette smoking  Transient ischaemic attack 
Sickle cell disease   
Asymptomatic carotid 
stenosis 
  
Table 1: A list of well-documented risk factors. Adapted from Sacco et al. (1997). 
 
As we age, the risk of developing many diseases increases and this is true for stroke. 
Age is the single most important risk factor for stroke. It has been found that the risk of 
stroke doubles for every successive decade after the age of 55 in both men and women 
(Sacco et al., 1997). The brain changes with age. Studies using post-mortem brain tissue 
have suggested that between the ages of 20 and 60 years, brain weight decreases by 
approximately 0.1% each year, with the hippocampus and cerebral cortex being the 
most affected regions. Similar studies have also found brain volume to decrease 
between the ages of 30 and 50 by 0.1-0.2% per year and this decrease in brain volume 
increases to 0.3-0.5% each year in the over 70s. In addition to brain weight and brain 
volume changes with increasing age, there are also certain changes which occur in the 
brain which may also increase the risk of stroke. There are a number of changes which 
occur in the white matter that are thought to increase the susceptibility of axons to 
ischaemia (Chen et al., 2010). Rodent studies have been important in this area; most 
notably a study by Scavone et al. (2005), which found that white matter in ageing rats 
was more vulnerable to ischaemia, due to a reduced ability of ageing axons to maintain 
membrane properties. This compromised ability was found to be caused by reduced 
Na+-K+-ATPase performance found in the brains of ageing rats (Scavone et al., 2005). 
Another study suggesting ischaemia is more likely in aged brains, showed that in old 
mice there is a two-fold increase in the glial glutamate transporter, highlighting an 
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increase in glutamatergic signalling (Baltan et al., 2008). A consequence of high 
glutamate levels is an influx of calcium ions into cells leading to cell death 
(Brustovetsky et al., 2009). 
 
It has been suggested that genetic predisposition may also contribute to some cases of 
stroke. The heritability estimate for ischaemic stroke has been reported to be 37.9%, 
however there are variations between stroke subtypes (Bevan et al., 2012). Recent 
studies have identified several genes which may predispose an individual to stroke, 
including the area of Chromosome 9p21 surrounding the genes CDKN2A and CDKN2B 
(Gschwendtner et al., 2009) and genetic variants in PITX2 and ZFHX3 on Chromosome 
4q25 (Gudbjartsson et al., 2007; Gretarsdottir et al., 2008). Other inherited causes of 
stroke include disorders of imprinted genomic loci such as Prader-Willi syndrome and 
the X-linked disorder Fabry disease (Qureshi and Mehler, 2010). It is also thought that 
geographic location and ethnicity can increase the risk of a stroke although these may be 
due to underlying genetic differences.  
 
Another non-modifiable risk factor for a stroke is a previous stroke or TIA. A TIA often 
acts as a warning sign that the patient is at a high risk of stroke. As would be expected, 
the risk of recurrent stroke is much higher in the first week after TIA and reduces as 
time goes on. Within the first month after minor stroke or TIA, the risk of a recurrent 
stroke is as high as 30% in some subgroups (Donnan et al., 2008), this then reduces to 
17% after 90 days (Furie et al., 2011). 
 
Hypertension is the single most important modifiable risk factor for stroke. 
Hypertension is thought to play a key role in 54% of strokes worldwide. Hypertension is 
defined as a systolic blood pressure ≥140mmHg or diastolic blood pressure ≥90 mmHg. 
Increasing levels of hypertension are found throughout the world (Chobanian, 2009), 
but increases have been more notable in India and China, possibly as a result of the 
recent demographic change (Mukherjee and Patil, 2011).  This seems to have been 
translated into an increase in stroke incidence by over 100% in low-middle income 
countries reported by a systematic review of publications reporting stroke incidence 
between 1970 and 2008. This is likely due to increasing lifespan, westernised diets and 
decreasing levels of physical inactivity in developing countries, as well as more 
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effective healthcare and preventative treatments in high income countries, which have 
seen a 42% decrease in stroke incidence between 1970 and 2008 (Feigin et al., 2009). 
 
Atrial fibrillation is the most common cause of cardiac embolism and is most prevalent 
among the elderly (Iwasaki et al., 2011). It has been estimated that atrial fibrillation is 
present in almost half of all cardioembolic strokes (Furie et al., 2011). It therefore 
carries a high relative risk of stroke (Warlow et al., 2003). An early study into atrial 
fibrillation as a risk factor for stroke found that in subjects aged 50-59, 1.5% of strokes 
were attributable to atrial fibrillation compared to 23.5% in subjects aged 80-89. This 
shows that atrial fibrillation is much more common in the elderly with almost a quarter 
of strokes in the over 80s being attributable to atrial fibrillation (Furie et al., 2011). 
 
Other risk factors include those related to metabolism such as diabetes and 
hypercholesterolaemia. 15-33% of stroke patients in the USA have diabetes compared 
to just 8% of the overall adult population highlighting that diabetes is an important risk 
factor for stroke. This may be because of the increases in incidence of atherosclerosis, 
hypertension and obesity. Hypercholesterolaemia can also increase the risks of 
atherosclerosis and heart disease resulting in subsequent increases in risk for stroke 
(Furie et al., 2011).  
 
Other potential risk factors such as homocysteine levels are less well studied but recent 
studies have suggested there may be a causal relationship (Casas et al., 2005). However, 
data from several randomised controlled trials have shown no effect (Toole et al., 2004; 
Lee et al., 2010). Other lifestyle choices which result in poor health are also risk factors 
for stroke including smoking, alcohol consumption, obesity and a sedentary lifestyle 
(Furie et al., 2011). In Table 1, geographic location is listed as a non-modifiable risk 
factor, however the term ‘geography’ encompasses a number of risk factors. Different 
geographic locations are likely to have different genetic profiles and possibly even 
different ethnicities which may affect the risk of stroke. Geography may also reflect 
socio-economic status (SES) which encompasses factors such as smoking, education 
and profession, some of which are modifiable risk factors of stroke. Using geography to 
assess risk of stroke should be used with caution and should assess how (whether by 
genetics, SES or some other factor) geography has an effect on the risk of stroke.  
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Many of the established risk factors described above have been studied further to try 
and understand how they increase the risk of stroke. As mentioned above, many are 
associated with atherosclerosis or the stiffening of the arteries as well as the narrowing 
and thickening of arterioles and capillaries. In the brain, these changes in the vascular 
structure translate into a reduction in the cerebral blood flow meaning the brain is not 
adequately perfused. Risk factors which contribute to this failure of cerebral blood flow 
regulation include ageing, diabetes, hypertension and hypercholesterolaemia 
(Moskowitz et al., 2010). 
 
1.2.2.4 Molecular mechanisms 
Due to the wealth of information regarding risk factors it is thought that multiple 
systems contribute to stroke aetiology. Research into molecular mechanisms is now 
hoped to identify biomarkers of disease and also shed light into the molecular 
mechanisms involved.  
 
Expression studies including a recent publication by Zhang et al. (2014) have 
highlighted genes which are differentially expressed in ischaemic stroke cases compared 
to controls. Zhang et al. (2014) used a gene expression array to compare the expression 
profiles in peripheral blood mononuclear cells of 20 ischaemic stroke cases with 20 
controls and analysis revealed 37 differentially expressed genes. By producing an 
interaction network, they highlighted two genes – tumour necrosis factor (TNF) and 
interleukin 8 (IL-8) as having the highest level of interaction, suggesting they may have 
a critical role in ischaemic stroke.  These results are very interesting as both genes are 
known to be involved in the inflammation process, a mechanism widely implicated in 
the aetiology of ischaemic stroke (Zhang et al., 2014b). 
 
Proteomic studies have also been fruitful in the search for biomarkers.  Over a decade 
ago, C-reactive protein (CRP), an indicator of inflammation, was highlighted as a 
potential biomarker in the prediction of future stroke. Individuals in the highest quartile 
for CRP had between a 2-2.7 risk of ischaemic stroke, compared to those in the lowest 
quartile for CRP (Rost et al., 2001). More recently, using mass-spectrometry techniques 
Garcia-Berrocoso et al. (2013) highlighted 51 proteins that were altered in the area of 
the brain with an infarct. Five of these were analysed in 60 peripheral blood samples 
taken at stroke admission. Three of these proteins were also found to be differentially 
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translated in the blood of stroke patients early after onset. Increased levels of gelsolin, 
cystatin A and reduced levels of dihydropyrimidinase-related protein 2 were associated 
with a poor prognosis. This study highlighted three proteins which may be potential 
biomarkers for outcomes after stroke (Garcia-Berrocoso et al., 2013).  
 
Research into biomarkers for stroke is still a long way behind diseases such as diabetes 
and immunological disease, with limited studies particularly in the field of 
metabolomics, but recent research has been promising (Kim et al., 2013).  
 
1.2.2.5 Stroke prevention and treatment 
As a TIA often acts as a warning sign to patients that they are at high risk of suffering a 
stroke, this can encourage people to take action and change their lifestyles in order to 
prevent a stroke. Secondary preventative strategies include the ceasing of hormone 
replacement therapy in postmenopausal women (Warlow et al., 2003) and carotid 
endarterectomy which is effective in stroke patients with stenosis (narrowing of the 
symptomatic carotid artery) of at least 70% if carried out within twelve weeks of TIA or 
first stroke (Donnan et al., 2008). Other ways to prevent stroke either following a 
TIA/first stroke or if at high risk of a first stroke include lowering blood pressure, 
treatment with antiplatelet or anticoagulant drugs, reducing blood cholesterol levels, all 
of which are described in Section 1.2.3.6. 
 
It is vital that stroke patients receive treatment early after stroke symptoms appear. In 
addition to aspirin being an effective preventative treatment at daily doses of 75-150mg, 
if doses of 160-300mg are administered within 48 hours of stroke it can reduce the risk 
of early recurrent stroke and mortality within 14 days and increases the chance of 
disability-free survival (Warlow et al., 2003). Treatment with aspirin is attractive due to 
its low cost, ease of administration and low risk of side effects. However, the benefits of 
taking aspirin as a treatment are quite small with less than 1% of patients saved from 
death or disability (Donnan et al., 2008). 
 
A more effective method to reduce the risk of disability after stroke is early clot lysis 
with intravenous recombinant tissue-plasminogen activator (Chen et al., 2010). 
However, few patients are suitable to receive thrombolysis treatment due to the short 
therapeutic time window of just three hours post-stroke and the risk of symptomatic 
11 
 
 
 
intracerebral haemorrhage experienced by 6-7% of treated patients (Donnan et al., 
2008). It is thought that this method of treatment is effective across all age groups 
however; there has been a persistent underrepresentation of the oldest old in large-scale 
trials (Chen et al., 2010). 
 
Other potentially effective stroke treatments include intra-arterial fibrinolysis, 
fibrinogen-depleting agents and inhibitors of glycoprotein IIb/IIIa. Many drugs are 
being investigated for use in neuroprotection, however very few drugs make it through 
to clinical trials (Warlow et al., 2003; Chen et al., 2010). Due to the effectiveness of 
therapeutic hypothermia in cardiac arrest and neonatal ischaemia patients, investigations 
are underway into the translation of this technique for use in adult stroke victims 
(Moskowitz et al., 2010).  
 
Arguably the most successful advancement in recent decades is the introduction of 
stroke care units (SCUs) into routine practice. SCUs are suitable for all stroke patients 
regardless of age or subtype and involve specialised assessments by a multidisciplinary 
team. Patients admitted to SCUs have a 20% reduced risk of mortality and a 20% 
reduced risk of long-term disability (Donnan et al., 2008). Due to the effectiveness and 
widespread availability and accessibility of stroke care units, they are much more 
favourable than thrombolysis in the vast majority of cases (Warlow et al., 2003; Chen et 
al., 2010). It is unclear what makes SCUs so successful in reducing risk of recurrence, 
as well as mortality and dependency. It is most probably the combination of 
rehabilitating techniques including early mobilization and effective blood pressure 
monitoring, as well a general adherence to best practice (Donnan et al., 2008; Chen et 
al., 2010). Due to their effectiveness, the widespread introduction of SCUs across 
developing countries is recognised to be a priority to reduce stroke mortality (Warlow et 
al., 2003). 
 
1.2.2.6 Consequences of stroke 
Accountable for approximately 9.7% of all deaths worldwide (Mukherjee and Patil, 
2011), stroke is the third leading cause of death around the world and one of the leading 
causes of adult neurological disability. Though treatment and preventative measures do 
exist for stroke, about 30% of patients die within a year of a stroke and of those that 
survive, almost half of them are left dependent on others. Many of those who are able to 
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live independently, however, are not free of residual physical or cognitive deficits, so 
some are unable to continue with their normal daily family and working life. One 
consequence of stroke is the increased risk of late-onset epilepsy (Bevan and Markus, 
2011). There is approximately an 11.5% risk of at least one seizure in the five years 
following a stroke; however this may depend on the severity and location of the stroke 
(Burn et al., 1997). As well as age being a major risk factor for stroke, the elderly also 
recover much slower than younger stroke sufferers, meaning that the consequences of 
the stroke are often more severe in the elderly patients. This is partly due to other co-
morbidities increasing disability and needs (Chen et al., 2010). The main cause of 
dependency after a stroke is dementia. 
 
1.2.3 Post-stroke dementia 
 
1.2.3.1 Definition 
Post-stroke dementia (PSD) refers to any type of dementia present after a stroke, 
irrespective of its cause (Leys et al., 2005). Although vascular dementia (VaD) is a 
direct result of vascular changes such as cerebral infarcts and haemorrhages, not all 
patients who suffer from a stroke have VaD. PSD is most commonly diagnosed as VaD, 
Alzheimer’s disease (AD) or mixed dementia, as it may be the result of vascular lesions, 
Alzheimer pathology, white matter changes or a mixture of these (Leys et al., 2005). 
 
1.2.3.2 Prevalence of post-stroke dementia 
The prevalence of PSD is difficult to calculate accurately, as results vary depending on 
which classification system is used. A study by Pohjasvaara et al. (1998) utilised the 
Diagnostic and Statistical Manual of Mental Disorders, Third Edition (DSM-III) 
definition of dementia, in addition to a comprehensive neuropsychological examination, 
to determine the prevalence of PSD in a cohort of 337 stroke survivors. It was reported 
to be 31.8%. The authors observed that PSD patients were older, more frequent current 
smokers with a lower level of education and a previous history of cerebrovascular 
disease and stroke (Pohjasvaara et al., 1998). Similarly, Inzitari et al. (1998) adopted 
the International Classification of Diseases, 10th Revision (ICD-10) criteria to determine 
prevalence of PSD in a cohort of 339 stroke survivors. The ICD-10 has a lower 
sensitivity to dementia than the DSM-III and a prevalence of 16.8% was reported. They 
also found that those with PSD were older and more likely to suffer from atrial 
fibrillation (Inzitari et al., 1998). The prevalence of PSD is likely to increase over the 
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next few decades due to the ageing demographic of the population and decreasing 
mortality following a stroke (Leys et al., 2005). Though studies are not in agreement 
about the prevalence of dementia they do agree that stroke doubles the risk of dementia. 
Many stroke survivors who are not classed as having PSD do however have some 
degree of cognitive impairment. Previous studies using the Cognitive Function After 
Stroke (COGFAST) cohort (Section 2.1.1), which recruited cognitively normal stroke 
survivors three months post-stroke, found that 9.4% of participants developed dementia 
within between three months and fifteen months post-stroke, this increased to 21.4% at 
three years post-stroke and after seven years, the figure had reached 39.5% (Allan et al., 
2011).  These figures highlight that although some individuals regain cognitive function 
three months post-stroke, the risk of developing PSD remain high and increases with 
age.  
 
1.2.3.3 Risk factors 
Over and above the risk factors for stroke itself described in detail in previous sections, 
age remains a major risk factor for PSD. It is a disorder that most commonly affects the 
elderly, those with a low level of education and those who were dependent (unable to 
live independently) or cognitively impaired before the stroke (Leys et al., 2005). The 
Perindopril Protection Against Recurrent Stroke Study (PROGRESS) has identified 
high blood pressure as a possible risk factor for dementia. In this trial 6105 stroke 
patients were randomly assigned to either the active treatment (perindopril and 
indapamide) which reduces blood pressure or a placebo group. It was found that those 
taking the treatment were at a lower risk of developing dementia. 6.3% of the treatment 
group developed dementia compared with 7.1% in the placebo group. The risk of 
cognitive decline was also reduced by the treatment; 9.1% experienced cognitive 
decline following a stroke in the treatment group compared with 11.0% in the placebo 
group (Tzourio et al., 2003). 
 
It is now accepted that well-known vascular risk factors including diabetes, atrial 
fibrillation, smoking and depression not only increase the risk of cerebrovascular 
disease but also increase the likelihood of dementia (Leys et al., 2005). Vascular risk 
factors have been associated with changes in brain volume. Studies comparing brain 
volume and cognition in hypertensive patients have identified that those with higher 
blood pressure have significantly smaller whole brain, hippocampal and thalamic 
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volumes, more white matter hyperintensities and perform less well in memory and 
language tests than participants with normal blood pressure (Cumming and Brodtmann, 
2010). 
 
Neuroimaging following a stroke may also indicate which patients are at risk of PSD. 
The presence of silent infarcts, global cerebral and medial-temporal-lobe atrophy and 
white matter changes are all suggested risk factors. In addition to these factors, the 
location, cause and indeed the severity of the presenting stroke may affect the risk of 
PSD. A previous stroke and stroke recurrence are also likely to increase the risk of PSD 
(Leys et al., 2005).  
 
There can also be genetic contributors to post-stroke dementia. Cerebral autosomal 
dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is 
the most common form of hereditary stroke disorder which leads to the degeneration of 
smooth muscle cells in blood vessels and affects approximately 50 families in the UK. It 
occurs as a result of at least 60 mutations in the Notch3 gene and patients progress to 
dementia (Kalaria et al., 2004). 
 
The apolipoprotein E4 (APOE4) allele is a well-established genetic risk factor for AD 
but may also be considered a risk factor for PSD. Presence of APOE4 increases the risk 
of vascular disease through its effects on cholesterol transport and metabolism which 
accelerate atherogenesis. It is now thought that the APOE risk genotype is related to the 
progression of ischaemic white matter lesion load in addition to post-stroke cognitive 
decline (Cumming and Brodtmann, 2010). 
 
1.2.3.4 Consequences of post-stroke dementia 
Several studies have shown that patients with PSD have an increased mortality 
compared with stroke patients without dementia. This is true for all types of dementia 
which occur independently of stroke. It has been reported that only 39% of stroke 
patients with dementia will survive for five years post-stroke compared with 75% of 
cognitively normal stroke patients (Kalaria and Ballard, 2001). A reason for this may be 
that dementia patients may be less compliant with treatments to prevent new vascular 
events. Dementia may also worsen co-morbidities thus increasing the risk of mortality 
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(Leys et al., 2005). It has also been suggested that dementia could increase the risk of 
stroke recurrence by three times (Moroney et al., 1997). 
 
The brain is the major tissue affected by both stroke and dementia. As previously 
mentioned, the brain is the site of damage after both an ischaemic and haemorrhagic 
stroke. The brain also changes following the onset of dementia, one of the most 
common and obvious pathologies is brain atrophy which can be detected by magnetic 
resonance imaging. Studies into the pathophysiology of AD have revealed that the 
hippocampus and cortex are the most affected areas in this slow and progressive 
disease. It is characterised by senile plaques (extracellular aggregates of β-amyloid (Aβ) 
proteins) and neurofibrillary tangles (intracellular hyperphosphorylated Tau proteins) 
(Iraola-Guzman et al., 2011). Dementia with Lewy bodies (DLB) is characterised by the 
accumulation of Lewy bodies which are neuronal inclusions of alpha-synuclein that 
arise from neurofilaments and paired helical filament epitopes. A patient often presents 
with DLB before or with Parkinsonism. Whilst AD and DLB do have some distinctive 
characteristics, there is a considerable amount of overlap, making a definitive diagnosis 
difficult. One way to distinguish between AD and DLB is to perform a dopamine 
transporter scan (DaTscan) to look at the level of dopamine transporter uptake in the 
basal ganglia. A DLB patient would have a much lower uptake rate than an AD patient 
(McKeith, 2002; Cummings et al., 2011). As the name suggests, frontotemporal 
dementia (FTD) is characterised by the neurodegeneration and atrophy of the frontal 
and/or temporal lobe. Protein inclusions may also present in FTD. These can either be 
Tau, the microtubule-associated protein found in AD or TAR DNA-binding protein 43 
(Cardarelli et al., 2010). Vascular dementia is a term which has caused much debate 
among clinicians as approximately half of patients with vascular cognitive impairment 
have dementia. It is characterised by a rapid onset and stepwise progression. 
Neuroimaging detects infarcts, haemorrhages and/or white matter disease (Cumming 
and Brodtmann, 2011).  
 
1.2.3.5 Mechanisms 
For many years, it has been clear that there is a strong association between stroke and 
dementia, however, there is no clear evidence of a direct pathway linking the two. It is 
unknown whether PSD is due to vascular disease directly causing neuropathological 
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changes associated with dementia or whether there is any synergistic action between 
neuropathology and vascular disease to worsen cognition. 
 
To try and identify mechanisms involved, studies have begun to look into how the brain 
is affected pathophysiologically by PSD. Sachdev et al. (2009) carried out a study on 
104 post-stroke patients, 45 of whom had mild cognitive impairment and 59 who were 
cognitively intact. They found that those with some cognitive impairment had more 
white matter hyperintensities but did not differ in the number or volume of infarctions, 
or brain and hippocampal volume. Most of the cognitive deficits were frontal and were 
most likely a result of the white and grey matter atrophy caused by ischaemia (Sachdev 
et al., 2009). A similar study by Stebbins et al. (2008) which assessed grey matter 
atrophy found that in stroke patients with cognitive impairment, there was a greater 
reduction in grey matter volume compared with cognitively normal stroke survivors, 
predominantly in the thalamus (Stebbins et al., 2008). The thalamus is regarded as an 
important brain region for long-term memory attention and executive function 
(Cumming and Brodtmann, 2010). 
 
Previous studies using the Cognitive Function after Stroke (COGFAST) study, which is 
comprised of a cohort of >75 year old stroke survivors who are cognitively functional 
three months post-stroke, have found that even those who are cognitively normal 
following a stroke still often experience deficits in attention and executive function. 
These deficits then worsen in those patients who develop dementia and a number of 
other brain function impairments including orientation and memory arise (Stephens et 
al., 2004). However, improvement in cognition can occur (Ballard et al., 2003). A 
recent study looked at hippocampal neuronal density and volume using COGFAST 
participants. Whilst hippocampal neuronal density did not differ between demented and 
non-demented post-stroke patients, differences were observed in the volumes of 
hippocampal cornu ammonis 1 (CA1) and CA2 neurones in PSD patients when 
compared with cognitively intact stroke survivors. Neuronal volume was positively 
correlated with cognitive function (Gemmell et al., 2012). 
 
Although vascular risk factors have been associated with both stroke and dementia risk, 
they cannot fully explain the relationship between stroke and subsequent cognitive 
decline. Studies have still found associations between white matter hyperintensities and 
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increased risk of cognitive decline, independent of vascular risk factors (Cumming and 
Brodtmann, 2010). 
 
There are a number of suggested mechanistic links. One possible link is that ischaemia 
may be a catalyst for amyloid deposition. Another suggestion is that there may be a 
leakage of serum components through the blood-brain barrier as a result of the stroke 
that could cause neuronal damage. Or the disruption is cerebral blood supply may not 
only lead to a stroke but also to secondary neuronal degeneration (Cumming and 
Brodtmann, 2010). 
 
Due to this uncertainty there is an urgent need to elucidate the mechanistic link between 
stroke and dementia and develop better treatment and preventative measures.  
 
1.2.3.6 Prediction, prevention and treatment 
As there is currently no effective cure for dementia, research has aimed to find ways to 
prevent dementia onset. As there are many parallels between stroke risk factors and 
dementia risk factors, many of the ways to prevent stroke mentioned in 1.2.2.5 are also 
adopted in the prevention of post stroke dementia and are considered below.  
 
As hypertension is one of the main risk factors for stroke, finding strategies to reduce 
the risk has been a priority in the Western world for many years. Since the 1950s 
strategies to lower blood pressure have been used to reduce the risk of a first stroke.  
Lowering blood pressure has also been shown to be effective in reducing the risk of a 
secondary stroke (Donnan et al., 2008). Meta-analyses of randomised controlled trials 
found lowering blood pressure accounted for 30-40% reductions in secondary stroke 
risk across all age groups (Furie et al., 2011). 
 
Aspirin is a widely prescribed antiplatelet drug which reduces the risk of all vascular 
events, including primary and secondary stroke, by 22% (Donnan et al., 2008). It is 
recommended to be taken by healthy women over the age of 65 to reduce risk of 
ischaemic stroke as well in the very old who have atherosclerosis or other conditions 
placing them at a high risk of cardiovascular event (Chen et al., 2010).  
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In patients with atrial fibrillation, warfarin reduces the relative risk of a recurrent stroke 
by 68% (Chen et al., 2010). However, there are serious risks in taking warfarin – major 
bleeding including intracerebral haemorrhage may occur (risk of 0.3-0.6% per year). 
The risks of major bleeding increase with age, hypertension and more severe 
anticoagulation. Warfarin should not be taken in combination with aspirin as this may 
increase the risk of suffering a haemorrhage and as warfarin is the most biologically 
effective secondary preventative treatment (Donnan et al., 2008), warfarin should be 
prescribed over aspirin (Warlow et al., 2003). 
 
Although there is no strong evidence that high blood cholesterol levels increase the risk 
of stroke, treatment with statins to reduce the concentration of cholesterol in plasma 
have proven effective in reducing stroke risk in both patients with or without coronary 
disease. Meta-analyses have found a 22% reduction in relative risk in patients younger 
than 65 years of age and a 19% reduction in those over 65 years of age (Chen et al., 
2010). 
 
Due to the mechanisms resulting in post-stroke dementia being currently unknown, the 
ability to predict stroke survivors who are likely to develop dementia would be 
extremely valuable in the targeting of preventative treatments. A biomarker identifying 
these patients at high risk of developing dementia may help to identify mechanisms 
involved and lead to more suitable treatments as well as helping to target which patients 
and their families require more support following the stroke.   
 
Finding methods to treat PSD is difficult as not only does the clinician have to treat the 
stroke but they also have to treat the dementia. AD and VaD patients have shown 
improvements when treated with cholinesterase inhibitors so these provide potential 
treatment options for PSD however they have not been trialled in PSD cases (Leys et 
al., 2005). Similar to the treatment of strokes, rehabilitation such as physiotherapy and 
speech therapy are currently used in the treatment of PSD. 
 
1.2.4 Parkinson’s disease 
 
1.2.4.1 Prevalence 
Idiopathic Parkinson’s disease (PD) is the second most common neurodegenerative 
disorder affecting approximately 1% of the over-65 population (Saracchi et al., 2014). 
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The mean age of onset is 62 years of age, although young-onset PD can affect 
individuals under 45 although these only account for a small proportion (<10%) of PD 
cases. The disorder is more common in males than females. Parkinson’s disease is 
characterised by a series of motor symptoms although symptoms can differ between 
individuals. Clinical criteria state that bradykinesia plus at least one other motor 
symptom (tremor, rigidity, postural instability) should be present for diagnosis (Hughes 
et al., 1992). A number of non-motor symptoms such as cognitive impairment, 
gastrointestinal disturbance and disturbed sleep are also found in Parkinson’s disease 
which often can precede motor symptoms, making the diagnosis of early stage PD 
difficult. The diagnosis of PD, as already described, is currently clinically derived and 
can only be confirmed by neuropathological examination post-mortem (Saracchi et al., 
2014).   
 
1.2.4.2 Risk factors 
There are several known risk factors for PD, both genetic and environmental. As PD is 
an age-related disease, age is the greatest risk factor for PD. The prevalence increases 
from 1% in a population of 60 year olds to 3% in those over 80. Less than 10% of PD 
cases are caused by genetic factors. There are around 28 chromosomal locations that 
have been implicated with PD. The most studied genes related to PD include parkin, α-
synuclein (SNCA) and LRRK2, which is the commonest genetic abnormality in Western 
populations (Gilks et al., 2005). In addition to family history, PD is also more common 
in males and those who work in the agriculture sector or live in rural areas, a link that 
has been tentatively linked to exposure to pesticides (Gillies et al., 2014). It has been 
suggested that several factors are protective against PD including tobacco smoking and 
caffeine intake (Schapira and Jenner, 2011). Other factors associated with an increased 
risk of PD include head trauma (Marques et al., 2011). 
 
1.2.4.3 Molecular mechanisms 
As diagnosis is based on clinical symptoms, the earliest of which are often non-motor 
making the early diagnosis of PD difficult, research into the molecular mechanisms of 
disease and identification of biomarkers to aid diagnosis and prediction of disease is 
important. There have been a number of “omics” techniques employed to try to achieve 
this.  
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Gene expression profiles have been performed in numerous PD cohorts although many 
of the findings are inconsistent. A seemingly promising study highlighted 22 genes with 
differential expression in PD cases. The most interesting gene highlighted was that of 
ST13, the expression of which was significantly reduced in PD cases; this was an 
interesting finding since ST13 is involved in the misfolding of SNCA, which may be of 
particular relevance to PD (Scherzer et al., 2007). However, a study targeting ST13 
using real-time polymerase chain reaction (PCR) in a cohort of early-stage PD cases did 
not support these findings and it concluded that ST13 was not a suitable biomarker for 
early PD (Shadrina et al., 2010).  
 
Protein studies have been performed to quantify the protein content of a biological 
sample.  Using this approach a number of proteins including APOE and IL-8 have been 
identified as potential biomarkers for diagnosis and disease progression with altered 
levels found in PD patients. The choice of tissue for biomarker identification, 
cerebrospinal fluid (CSF) or blood, has been the focus of some debate. The proteome of 
the substantia nigra has also recently been characterised (Saracchi et al., 2014).  
 
Compared to stroke, many more metabolomics studies have been performed in PD 
research. A recent study that compared the metabolomics profiles of PD cases and 
controls identified different levels of uric acid and glutathione, both of which are 
antioxidants, in the plasma of PD cases compared to healthy controls (Bogdanov et al., 
2008). A study has also highlighted increased pyruvate levels in PD cases again using 
plasma (Ahmed et al., 2009). Metabolomic studies have therefore proved fruitful in the 
study of biomarkers for PD however, replication is required using an alternative 
platform and larger cohorts.   
 
In conclusion, further research is required in this field to identify biomarkers which are 
able to detect at-risk individuals to offer the best help possible whether that be disease-
modifying therapeutic strategies or just psychological support (Saracchi et al., 2014).  
 
1.2.4.4 Prevention and treatment of Parkinson’s disease 
Due to the key risk factors for PD being linked to demographics it is a disease with little 
scope for onset prevention. Research into the molecular mechanisms that cause PD will 
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hopefully shed some light on possible prediction and prevention targets in coming 
years.  
 
There are a number of different treatments for PD. A range of pharmacotherapies are 
available although all focus on the symptomatic features of disease, rather than 
preventing disease progression. In PD, levels of dopamine, a neurotransmitter usually 
found in abundance in the central nervous system, are significantly reduced compared to 
controls. Levodopa, which has the ability to cross the blood brain barrier and is 
converted into dopamine, is currently the gold standard, however there are a number of 
side effects associated with long-term administration. The most significant limitation of 
Levodopa is that after each dose there is an attenuation effect where symptoms of PD 
are no longer under control. Dyskinesia (involuntary muscle movements) is another 
common complication associated with long-term Levodopa usage. To help combat the 
attenuation effect Levodopa can be administered with catechol-O-methyltransferase 
inhibitors, which acts by extending the time Levodopa is available in the brain. Other 
treatments currently used to reduce PD symptoms include dopamine agonists which act 
directly on dopamine receptors within the central nervous system and monoamine 
oxidase B (MAO-B) inhibitors, which block the degradation of dopamine (Tarazi et al., 
2014).  
 
Since all the current treatments are associated with significant side-effects, new 
treatments currently in development are hoped to overcome some of the problems 
described above. The dyskinesias which may result from extended Levodopa use may 
be helped by treatment with glutamate receptor antagonists which are currently in 
development. Another type of treatment currently undergoing research are adenosine 
A2A receptor antagonists; the early data on which suggests they may improve the 
mobility of PD patients. Due to the hypothesis that oxidative stress plays an important 
role in neurodegeneration, it has been suggested that antioxidants may have 
instrumental therapeutic effects. It is hoped that the removal of free radicals by 
antioxidants will prevent apoptosis and neuronal degeneration (Tarazi et al., 2014).  
 
In addition to pharmacotherapies, surgery provides a number of treatment options. Deep 
brain stimulation (DBS) is a possible option for patients whose motor symptoms persist 
and/or in those with refractory dyskinesias despite receiving medical treatment. A 
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combination of DBS and medical treatments can greatly increase the quality of life of 
patients compared with pharmacotherapies alone. However, due to the invasive nature 
of the surgery there is the risk of a number of potentially serious complications 
including infection, intracranial haemorrhage and seizures. Problems with cognition and 
psychological symptoms such as anxiety and depression may also arise (Tarazi et al., 
2014). 
 
1.2.4.5 Consequences of Parkinson’s disease 
Following onset of disease, PD patients often experience a decrease in quality of life 
which can be attributed to increased risk of depression, falls, gait instability and 
cognitive impairment (Schrag et al., 2000). Following PD onset, approximately 18.3% 
of patients are unable to live independently and require some level of care (Riedel et al., 
2012).  
 
Cognitive impairment is a common complication of Parkinson’s disease. Parkinson’s 
disease dementia (PDD) affects almost 80% of PD patients when followed 
longitudinally in community studies (Hely et al., 2008). In addition, mild cognitive 
impairment in Parkinson’s disease (PD-MCI) is increasingly recognised. This definition 
has largely been borne out of the literature on Alzheimer’s disease and is thought to 
represent a transitional state between normal cognition and dementia (Petersen, 2004). 
Although not everyone with PD-MCI will develop PDD, it is a recognised risk factor 
for the disorder. MCI is diagnosed in a PD patient who suffers from cognitive deficits 
not solely attributed to age but is still able to live independently (Litvan et al., 2012). 
Cross-sectionally, approximately one in four PD patients without dementia are 
diagnosed as having PD-MCI (Aarsland and Kurz, 2010). A longitudinal study by 
Janvin et al., (2006) found that after four years, 62% of PD-MCI patients had developed 
PDD compared with 20% of those who were cognitively normal prior to dementia 
diagnosis (Janvin et al., 2006). This suggests that PD-MCI may be an early 
manifestation of PDD (Mufson et al., 2012a). However, since not all PD-MCI cases 
develop dementia there are likely to be multiple mechanisms involved in the 
progression to dementia. Research into biomarkers would help elucidate mechanisms of 
cognitive impairment in PD.  A number of risk factors have been described for PDD 
including older age, lower education level, a faster progression of motor symptoms, 
depression and sleep disorders. In addition, there have been a few genetic risk factors 
defined including carrying the APOE allele, the HI haplotype in the MAPT gene and 
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mutations in the SNCA gene although some studies have reported inconsistent findings 
(Pagonabarraga and Kulisevsky, 2012).  
 
There are several suggested mechanisms for the development of PDD. It is thought that 
most of these mechanisms may apply to PD-MCI although to a lesser degree and 
evidence is severely limited. Widespread cortical Lewy body deposition was one of the 
earliest recognised neuropathological correlates. Additional potential mechanisms 
include abnormal β-amyloid (Aβ) deposition, a result of abnormal amyloid precursor 
protein (APP) processing. PD-MCI and PDD patients have been found to have reduced 
levels of Aβ-42 (a marker of amyloid aggregation) in the CSF compared to cognitively 
normal cases. Aβ levels have also been associated with memory function in early PD 
patients (Yarnall et al., 2013). However, there is very little evidence of any biomarkers 
that are able to predict PD-MCI or PDD in a cohort of PD-MCI cases highlighting that 
research in this area is still in its infancy. Much larger studies, especially involving post-
mortem information, are required for further validation.  
 
Prevention and treatment options for PD-MCI are very limited. Current treatments focus 
on the symptoms of PD. There have been no randomised control trials in PD-MCI to 
date (Yarnall et al., 2013). Since the mechanisms resulting in PD-MCI are largely not 
understood, this makes finding suitable treatment options challenging. Research into 
possible biomarkers would be beneficial to help predict at-risk individuals, monitor 
disease progression and help find treatment targets.  
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1.3 Epigenetics 
Each cell in a multicellular organism is genotypically identical. However, the various 
cell types are phenotypically different. These differences are due to differences in gene 
expression between the various cell types. Differences in gene expression are 
maintained by epigenetic control (Reik, 2007). Phenotypic differences are not only 
observed at the single-cell level. Monozygotic twins have the same genotype yet are 
phenotypically different, with variable differences in their appearances as well as 
disease discordance (Fraga et al., 2005). The term epigenetics refers to the mechanisms 
which cause mitotically heritable but reversible changes to gene expression and 
phenotype, without modifying the DNA sequence.  
 
Epigenetic mechanisms are important regulators of all biological processes throughout 
the life course from conception to death. Although epigenetic marks are established 
early in life, they are dynamic and receptive to internal and environmental stimuli, 
which may increase disease risk in later life (Delcuve et al., 2009). Epigenetics is a very 
rapidly expanding field, with new discoveries aiding our understanding of the 
mechanisms and involvement in both development and disease. Histone modifications, 
microRNAs (miRNAs) and DNA methylation are all common types of epigenetic 
mechanisms and are described in further detail below. 
 
1.3.1 Histones and chromatin 
In eukaryotic organisms, genomic DNA is condensed as chromatin in the nucleus. Each 
unit of chromatin consists of DNA, at a length of 140-150 base pairs wrapped around 
the nucleosome, which is the core of chromatin, composed of an octamer of four 
different histones (H2A, H2B, H3 and H4). Another component of chromatin is histone 
H1 which keeps the DNA in place (Figure 2). All histones are composed of a globular 
C-terminal domain and are flanked by a highly variable N-terminal tail (Kim et al., 
2009). Histones, particularly the N-terminal tails of H3 and H4, can be modified by a 
number of post-translational mechanisms. Histone modifications act by changing the 
structure of chromatin into either euchromatin (“active”); in which the DNA is 
accessible for transcription or heterochromatin (“inactive”); where the DNA is 
inaccessible for transcription. Histones can be modified at different sites simultaneously 
and each histone can have several modifications instigating cross-talk between the 
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different marks. There are currently many types of known modifications including 
phosphorylation, methylation and acetylation (Lorenzen et al., 2012).  
 
 
Figure 2: One unit of chromatin composed of DNA wrapped around an octamer of histones. Histone H1 
keeps the structure in place. 
 
1.3.2 MiRNAs 
Recent high-throughput analysis of the transcriptome has revealed that the majority of 
DNA is transcribed as non-coding ribonucleic acid (RNA). A total of 90% of the 
genome is transcribed with only 1-2% transcribed as proteins – this shows that the vast 
majority of transcribed DNA is non-coding RNA. In recent years it has become 
apparent that they may play a role in epigenetic control. To date, over 800 different 
miRNAs have been identified in humans. miRNAs are small (22 nucleotides in length) 
non-coding RNAs which can bind to target mRNA transcripts that are complimentary in 
sequence. Many miRNAs have gene regulatory functions and are important in the 
control of mRNA stability. Due to having only been discovered in humans in 2001 
(Sato et al., 2011), they have been less widely studied than other epigenetic mechanisms 
and the majority of studies have focussed on cancer. However in recent years, it has 
been shown that they are involved in the post-transcriptional degradation of mRNA 
leading to the repression of translation and silencing of genes (Lorenzen et al., 2012). In 
tumours, many miRNAs are aberrantly expressed suggesting that they may have a role 
in the development of cancer (Portela and Esteller, 2010; Kasinski and Slack, 2011). 
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1.3.3 DNA methylation 
DNA methylation is by far the most commonly studied epigenetic mechanism. There 
are a number of reasons for this including it being found at high levels across the 
genome (Shenker and Flanagan, 2012), having  key roles in a number of important 
developmental functions (Huh et al., 2013) and, more importantly, being the most stable 
epigenetic modification (Talens et al., 2010). DNA methylation involves the addition of 
a methyl group to the 5-carbon of the pyrimidine ring of a cytosine residue to form 5-
methylcytosine (5-mC) (Figure 3A). In mammalian genomes, this cytosine residue is 
usually 5’ adjacent to a guanine residue, forming a CpG site (Figure 3B) (Pearce et al., 
2012).  
 
1.3.3.1 Types of DNA modification 
Whilst most DNA methylation occurs within CpG sites and most commonly forms 5-
mC, there are some exceptions. Cytosine residues can also be converted to 5-hydroxy-
methylcytosine (5-hmC), formed by the addition of a hydroxyl group to 5-mC by the 
ten-eleven translocation (TET) enzymes (Figure 3A) (Booth et al., 2012). 5-hmC has 
been implicated in embryonic stem cell differentiation. Recently, non-CpG methylation 
has been described. This refers to methylation occurring at cytosine residues not within 
CpG sites, known as non-CpG (CpH) sites. These occurrences are rare, found only in 
embryonic stem cells and are thought to be involved in the maintenance of the 
pluripotent state (Portela and Esteller, 2010). 
 
1.3.3.2 Genomic content 
CpG dinucleotides are found within the mammalian genome at a much lower frequency 
than expected by random assortment, accounting for 1% of the genome (Kim et al., 
2009). This CpG site deficiency is thought to be due to the high mutation rate or 
deamination of methylated cytosine residues to thymine (Duret and Galtier, 2000). 
Furthermore, CpG sites are not distributed evenly throughout the genome but instead 
commonly found in dense clusters referred to as CpG islands (Kim et al., 2009). CpG 
islands are usually located within gene promoters (approximately 70%) and are most 
commonly unmethylated or display very low levels of methylation (Bell and Spector, 
2011). CpG islands are defined as regions of 200-300 base pairs in length which have a 
CG content of approximately 50% (Lorenzen et al., 2012). In addition to CpG islands, 
CpG shores, shelves and open seas have now been described. Shores are defined as 
regions up to 2kb from CpG islands, shelves are considered regions 2-4kb from CpG 
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islands and open sea regions are isolated CpG sites with no specific designation (Figure 
4). CpG islands are the most CpG dense region within the genome with decreasing 
numbers found in shores, shelves and open seas (Rechache et al., 2012).  
 
Figure 3: DNA methylation. A. Biochemical structure of cytosine and 5-methylcytosine. B. CpG site; in 
humans DNA methylation usually occurs at cytosine residues located 5’ adjacent to guanine residues 
forming the commonly denoted CpG site. Red lollipop highlights presence of methyl group. 
 
Figure 4: CpG islands, shores, shelves and open sea. Lollipops indicate CpG density within each region. 
Red lollipops show methylated CpG sites and white lollipops show unmethylated CpG sites.  
 
For many years it was believed that the most functionally important DNA methylation 
occurred in promoters and that most DNA methylation changes occur in CpG islands. 
Promoter methylation has been associated with an inverse relationship with gene 
expression in the majority of cases, although there are several exceptions. Methylation 
has been found to be more strongly related to gene expression in the CpG island shores. 
This suggests that methylation in the CpG island shores may have more functional 
importance than the CpG islands (Irizarry et al., 2009; Bell and Spector, 2011). 
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1.3.3.3 Key functions 
 
1.3.3.3.1 Transcription 
DNA methylation has often been associated with an inhibition of transcription and gene 
silencing. There are two main mechanisms by which DNA methylation may inhibit 
transcription and subsequent gene expression. DNA methylation may repress 
transcription by impeding transcription factors binding to their target sites (Boyes and 
Bird, 1991). More recently, methyl-CpG binding proteins which bind to methylation 
marks and repress transcription by recruiting histone-modifying proteins have been 
discovered (Iraola-Guzman et al., 2011; Lorenzen et al., 2012). Whilst an inverse 
relationship between DNA methylation and gene expression has been reported in many 
cases, it is now thought that this relationship is not strictly true. This inverse 
relationship is still expected at promoter regions, however, the opposite has been found 
within gene bodies with increased gene body methylation being associated with 
increased transcription (Wagner et al., 2014). DNA methylation has also been 
associated with the regulation of splicing without necessarily affecting the overall 
transcript levels of the given gene (Gelfman et al., 2013).  
 
1.3.3.3.2 X-inactivation 
DNA methylation has a key role in X inactivation, the silencing of one X chromosome 
to ensure equal sex-linked gene dosage between males (XY) and females (XX). X 
inactivation genes are silenced by a non-coding RNA gene called X-inactive specific 
transcript (Xist) which coats the entire length of the X chromosome. Xist is only 
expressed on the inactive X chromosome. The Xist gene is hypermethylated and 
therefore silenced on the active X chromosome whilst the active Xist gene is 
hypomethylated on the silenced X chromosome. This suggests that DNA methylation 
may control the expression of Xist and therefore have an important role in X 
inactivation (Panning and Jaenisch, 1996). 
 
1.3.3.3.3 Genomic imprinting 
DNA methylation has an important role in genomic imprinting. Genomic imprinting 
occurs in only 1% of autosomal genes (Jirtle and Skinner, 2007) and involves one 
parental allele of the gene (from either parent) being hypermethylated affecting the 
expression of that allele resulting in monoallelic expression (Delcuve et al., 2009). 
Imprinted genes show both parent-of-origin specific differential methylation and parent-
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of-origin specific differential expression. This means that genes are differentially 
methylated and expressed depending on which parent they originated from (Bartolomei, 
2009). There are several developmental disorders that are associated with deregulation 
of genomic imprinting including Prader-Willi and Beckwith-Wiedermann syndrome 
(Jirtle and Skinner, 2007). 
 
1.3.3.3.4 Genomic stability 
DNA methylation is also important in preventing the translocation of repetitive and 
transposable elements thereby preventing insertional mutagenesis. Over 99% of 
transposable elements are heavily methylated and therefore transcriptionally silent 
highlighting that DNA methylation plays a key role in maintaining genomic stability 
(Delcuve et al., 2009). Repetitive elements account for 45% of the human genome and 
it is thought that the loss of methylation in these repetitive elements may account for a 
large portion of the characteristic global hypomethylation that is seen in a number of 
cancers (Weisenberger et al., 2005). 
 
1.3.3.4 Regulation 
 
1.3.3.4.1 DNA methyltransferases 
The enzymatic transfer of methyl groups to DNA is catalysed by DNA 
methyltransferases (DNMTs). DNMT3a and DNMT3b are important in establishing 
methylation profiles in early development but are expressed throughout the life course 
(Siegmund et al., 2007) and are responsible for de novo methylation whereas DNMT1 is 
involved in the maintenance of methylation patterns during replication (Qureshi and 
Mehler, 2010). The DNMTs transfer a methyl group from the methyl donor SAM, to a 
cytosine in the DNA sequence to produce 5-mC (Figure 3) (Gravina and Vijg, 2010). 
DNMTs are vital in the establishment of methylation profiles in early development. 
Knockout experiments have identified DNMTs as fundamental proteins for a successful 
mammalian development. The homozygous deletion of Dnmt1 or Dnmt3b has been 
found to result in embryonic lethality (Wu and Zhang, 2011). DNMT expression is 
abundant in the brain, implicating these enzymes in brain development and 
neurodegeneration (Endres et al., 2000). Until recent years, DNA methylation patterns 
in post-mitotic tissue such as the brain were believed to be fixed. However, the recent 
discovery of DNA methyltransferases in brain tissue have pointed to the possibility that 
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methylation patterns are labile and responsive to endogenous and exogenous stimuli 
(Miller and Sweatt, 2007). 
 
1.3.3.4.2 Environmental factors 
Due to the labile nature of epigenetics, environmental factors can cause epigenetic 
modifications which may contribute to the development of abnormal diseased 
phenotypes. Since epigenetic modifications present a plausible link between 
environmental exposures and effects on gene expression, research has focussed on 
identifying the effects of the environment on DNA methylation to help identify possible 
mechanisms in diseases with an established environmental component (Jaenisch and 
Bird, 2003; Jirtle and Skinner, 2007). 
 
Research has identified many associations between environmental exposures and 
changes in DNA methylation. Some of these environmental exposures include 
nutritional (folate intake (Jaenisch and Bird, 2003)), chemical (tobacco smoking 
(Breitling et al., 2011) and lead exposure (Bakulski et al., 2012b)) and physical factors 
(age – see Sections 1.3.4.1) 
 
Folate and other dietary supplements such as vitamins can influence disease 
susceptibility and have been shown to have marked effects in the incidence of various 
cancers such as of the colon and liver. This is due to the effect folate and other vitamins 
have on the availability of methyl groups and the subsequent effect on DNA 
methylation levels. Low folate levels have been associated with genomic instability and 
genomic hypomethylation (Jaenisch and Bird, 2003) as well as neural tube defects 
(Crider et al., 2012). This hypomethylation which occurs as a result of low folate can 
also affect expression levels of oncogenes, increasing the susceptibility to colon and 
liver cancers (Jaenisch and Bird, 2003). Lead exposure has been linked with altered 
DNA methylation which may influence cognition. This is described in more detail in 
Section 1.3.5.2.2.  
 
In recent years, smoking has been a very well-researched environmental exposure. 
Tobacco smoking has long been known to be harmful to health and it is possible that the 
effects of smoking are mediated through DNA methylation. Smoking has previously 
been associated with changes in global methylation and altered methylation of several 
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cancer-related genes. Breitling et al. (2011) performed one of the first genome-wide 
methylation arrays analysing methylation levels in DNA from peripheral whole blood in 
smokers and non-smokers aged between 50 and 60 years. Of 27,000 CpG sites 
interrogated, only one CpG site was significantly associated with smoking and 
replicable in a larger, non-overlapping cohort. The F2RL3 locus was significantly less 
methylated in smokers than non-smokers (Breitling et al., 2011). This finding has been 
supported by other studies including the study by Shenker et al. (2013) which 
performed a HumanMethylation450 (HM450) array to identify loci differentially 
methylated in smoking. This study also identified other differentially methylated loci 
including aryl-hydrocarbon receptor repressor (AHRR) (Shenker et al., 2013). Both of 
these genes have been implicated in disease; AHRR has been associated with breast and 
colon cancer whilst F2RL3 is involved in inflammation pointing to a possible role in 
cardiovascular related diseases (Breitling et al., 2011). Recent research has pointed to a 
possible mechanistic link between smoking and premature death through the altered 
methylation of F2RL3. This association between F2RL3 is strongest in men (Zhang et 
al., 2014a).  
 
1.3.3.4.3 Genetic factors 
In addition to being mitotically heritable (i.e. passed on during cell division) epigenetic 
marks have also been shown to be phenotypically heritable to some degree (i.e. 
regulated by genetic variants passed on from parent to offspring). There are a number of 
ways a single nucleotide polymorphism (SNP) can influence DNA methylation at 
specific CpG sites. These are shown in Figure 5.  
 
Firstly (Figure 5A), if either the cytosine or guanine residue of the CpG site itself is a 
SNP this will have a direct impact on the methylation status of that site. For instance, if 
the alternative allele of either residue is inherited the CpG site will be disrupted and 
methylation will not occur. Secondly, (Figure 5B) SNPs or other genetic variants may 
influence the methylation status of local (cis) or distant (trans) CpG sites.  Finally, 
(Figure 5C) the presence of a SNP at one CpG site may also alter co-methylation at 
neighbouring CpG sites. A combination of these various scenarios may also be 
observed.  
 
The proportion of locus-specific methylation variance caused by genetic variation is 
known as DNA methylation heritability. Twin studies have been valuable in genetic 
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heritability studies due to their shared genetic variants and almost identical 
environmental exposures (Bell and Spector, 2011). An example of DNA methylation 
heritability can be seen in the H19/IGF2 region whereby SNPs in the H19/IGF2 region 
have been associated with methylation status of both IGF2 and H19 indicating that this 
methylation change may be under genetic control (Zhang et al., 2010).  
 
 
Figure 5: How can genetic control influence DNA methylation? A. CpG site is a SNP. B. SNPs may 
influence methylation status of cis or trans CpG sites. C. A SNP may result in co-methylation of 
neighbouring SNPs. Red bases indicate SNP.  
 
1.3.4 Epigenetics across the life course 
Epigenetic mechanisms are important regulators of all biological processes throughout 
the life course from conception to death. Although epigenetic marks are established 
early in life, they are dynamic and receptive to internal and environmental stimuli, 
which may increase disease risk in later life (Delcuve et al., 2009). The Developmental 
Origins of Health and Disease hypothesis postulates that early life exposures can 
influence health in later life (Barker, 2006). Studies have found exposures in utero can 
have effects on DNA methylation later in life. The Dutch Hunger Winter of 1944-45 is a 
well-documented example of how diet in utero can affect methylation decades later. 
Individuals who were exposed to the famine prenatally had a much lower methylation at 
the imprinted IGF2 locus compared with their same-sex unexposed siblings (Heijmans 
et al., 2008). Studies like this indicate how exposures in early life can affect the 
epigenome which can have an effect on health on later life.  
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1.3.4.1 Epigenetics in ageing and age-related disease 
Epigenetic mechanisms are known to have an important role in development (Reik et 
al., 2001) but in recent years it has been suggested that they may also be a feature of the 
ageing process. Epigenetic patterns change throughout the ageing process. Twin studies 
have identified epigenetic drift occurring as individuals age with greater differences 
seen in twins in later life than in their early years (Fraga et al., 2005). This could be due 
to the normal ageing process or it could be due to environmental exposures experienced 
throughout the life course or potentially as a result of disease (Bakulski and Fallin, 
2014).  
 
A healthy development relies on the successful regulation of DNA methylation. Many 
age-related diseases such as cancer, result from a fault in the epigenetic regulation of 
gene expression (Yang et al., 2004). DNA methylation usually acts to silence gene 
expression. In general, DNA methylation globally (across the genome) decreases with 
age resulting in the expression of genes which should usually be silenced by 
methylation (although this straightforward relationship is far from clear in many 
instances). This may explain why many diseases are more commonly found among 
elderly populations. However, several genes are hypermethylated during ageing, an 
example of which is the oestrogen receptor (Kahn and Fraga, 2009) which has 
previously been associated with increased risk of atherosclerosis (Post et al., 1999). 
However, it is difficult to distinguish between normal changes in methylation in line 
with ageing and changes causally linked with disease.  
 
1.3.5 The role of DNA methylation in the ageing brain 
 
1.3.5.1 Normal development 
Genome-wide methylation analysis has been carried out in mammalian brains at 
multiple stages of life from early development to adult brains, the results of which 
suggest a key role for DNA methylation in the function and development of mammalian 
brains. Expression of DNMT3A was found to be critical for establishing a normal brain 
DNA methylation pattern and a subsequent normal brain development (Nguyen et al., 
2007). Another finding was that methylation at CpH sites was found to accumulate in 
neurons, but not glia, through early childhood to adolescence (Lister et al., 2013). 
Furthermore, an inverse relationship between DNA methylation and gene function was 
observed. Genes known to be upregulated during development and associated with 
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neuronal function were found to be associated with an increased promoter methylation 
in glia and a hypomethylation in neurons. The reverse was seen in genes downregulated 
during brain development, with decreased methylation levels in glia, but 
hypermethylation in neurons. These highlight the functional role of DNA methylation in 
brain development (Lister et al., 2013). 
 
Epigenetic research has also identified differences in DNA methylation between 
neuronal and non-neuronal nuclei obtained from human prefrontal cortex. The study by 
Iwamoto et al. (2011) showed that promoters of neuronal nuclei had lower global DNA 
methylation and also showed higher inter-individual variation when compared to non-
neuronal nuclei. These findings suggest that neuronal cells have a greater ability to alter 
their epigenetic status in response to developmental and environmental conditions 
(Iwamoto et al., 2011). 
 
Studies have investigated the effect of ageing on DNA methylation across brain regions. 
A key study in this field is by Hernandez et al. (2011) in which DNA methylation was 
analysed at over 27,000 CpG sites throughout the human genome in multiple brain 
regions; pons, frontal cortex, temporal cortex and cerebellum, extracted from 
individuals aged between 1 and 102 years. 589 CpG sites were found to be associated 
with age in at least one brain region. Increased methylation at ten CpG sites was 
associated with age in all four brain regions. Further investigation of the associated sites 
revealed that many were in close proximity to genes associated with DNA binding and 
regulated transcription, suggesting that specific age-related changes in DNA 
methylation might be important in the maintenance of transcription and gene expression 
in ageing tissues (Hernandez et al., 2011). 
 
A similar study looked at genome-wide DNA methylation signatures in the human 
prefrontal cortex across the lifespan with samples taken from the second trimester of 
gestation to old age. This study by Numata et al. (2012) identified the vast temporal 
patterns in DNA methylation across the life course. The prenatal period displayed the 
fastest changes in DNA methylation with the rate slowing during childhood and later 
life. The ten genes identified as being positively correlated with age in Hernandez et al. 
(2011) were also confirmed in this study. The age-related changes were predominantly 
found in CpG island shores, rather than in the islands themselves highlighting that CpG 
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island shores may have a more important functional role in ageing and disease than 
previously thought (Numata et al., 2012).  
 
It is largely known that the formation of long-term memory is dependent on gene 
expression and a number of studies have now highlighted a pivotal role for epigenetics 
in learning. Histone modifications have previously been associated with learning and 
memory formation and more recent research points to a role for DNA methylation 
(Lubin et al., 2011). This evidence includes; the finding that DNA methylation changes 
are triggered by learning in the adult hippocampus; DNA methylation changes have 
been found to occur at both memory-permissive and memory-suppressive gene 
promoters when treated with DNMT inhibitors, suggesting a critical role for DNA 
methylation in memory formation (Lubin et al., 2011). Furthermore, a study 
investigating the effect of DNMT inhibitors on memory found that when hippocampal 
slices were treated with DNMT inhibitors, there was a reduction in long-term 
potentiation, the cellular mechanism behind long term memory formation (Nelson and 
Monteggia, 2011). The potential role of DNA methylation in memory formation 
suggests epigenetics may also be involved in disorders affecting memory and cognitive 
decline including PSD and PD.  
 
1.3.5.2 DNA methylation in diseased brains 
There is growing evidence to suggest that epigenetic mechanisms are involved in many 
diseases affecting the brain in old age. Epigenetic modifications have been implicated in 
several neurological, neurodegenerative and psychiatric disorders. Epigenetic 
mechanisms are known to be involved in the aetiologies of many neurological disorders. 
Mutations in the methyl-CpG-binding protein 2 gene on the X chromosome which 
codes for a protein involved in both DNA methylation and histone acetylation causes 
Rett syndrome; a neurodevelopmental disorder of the grey matter of the brain. Fragile X 
syndrome results from the hypermethylation of a CGG trinucleotide repeat on the X 
chromosome which results in the failure to express the fragile X mental retardation 
protein (FMRP), which is required for normal neural development. DNA methylation 
has also been associated with neurodegenerative disorders such as Alzheimer’s disease 
and Huntington’s disease and psychiatric disorders such as depression and 
schizophrenia (Nelson and Monteggia, 2011). Due to so many associations between 
epigenetic regulation and neurological disease, it is hypothesised that DNA methylation 
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may have a role in the regulation of neuronal function and cognition, both during 
development and in the mature brain (Nelson and Monteggia, 2011). Many epigenetic 
studies have looked into DNA methylation patterns in the brain throughout the lifespan 
to try and identify the function of epigenetics in both brain development and disease. 
Here the discussion is limited to stroke, PSD and PD.  
 
1.3.5.2.1 DNA methylation and stroke   
Recent literature reports a number of associations between aberrant DNA methylation 
and several diseases including obesity, cancer and stroke. A number of studies have 
been performed in recent years to establish the relationship between DNA methylation 
and stroke. There is a delay between stroke and neuronal death and it is thought that this 
delay is due to transcriptional changes causing cell death (Hwang et al., 2013). 
 
It is recognised that DNA hypomethylation is associated with cardiovascular related 
diseases such as atherosclerosis and stroke. Baccarelli et al. (2010) used DNA samples 
extracted from the blood of 712 elderly male participants of the Normative Aging Study 
to measure DNA methylation levels of Long Interspersed Nucleotide Element 1 (LINE-
1) which, being a repetitive element found throughout the genome is representative of 
global genomic methylation levels. Medical records and physician examinations were 
used to diagnose pre-existing CVD. The remaining participants who were free of CVD 
at baseline were followed up for approximately three years and the onset of any 
cardiovascular related disease was noted. Baccarelli et al. (2010) found that those with 
ischaemic heart disease (IHD) and/or stroke had lower levels of LINE-1 methylation 
and also reported that low LINE-1 methylation levels are associated with an increased 
risk of IHD and stroke. In addition, 24 participants who were disease-free at baseline 
but developed either IHD or stroke during follow-up had a second blood sample taken 
after IHD/stroke diagnosis. No difference in methylation levels were detected between 
the two samples. These results suggest that the decrease in LINE-1 methylation seen in 
the diseased participants precedes disease onset and might be useful in predicting 
disease risk (Baccarelli et al., 2010). Another study by Castillo-Diaz et al. (2010) also 
reported DNA hypomethylation in patients at risk of stroke. They conducted array-
based analysis of DNA methylation in both atherosclerotic and control arteries and 
found decreased levels of DNA methylation in the CpG islands of diseased arteries. 
Genes showing differential methylation were found to be in close proximity to known 
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genes involved in atherogenesis suggesting DNA methylation may increase the risk of 
stroke by promoting atherogenesis (Castillo-Diaz et al., 2010). 
 
It is hypothesised that these methylation changes may be due to environmental factors 
such as diet, smoking behaviour and environmental pollutants (Mathers et al., 2010) 
which then increase the risk of diseases such as stroke.  
 
Using a mouse model for focal cerebral ischaemia, Endres et al. (2000) found that DNA 
methylation levels increased following a brain ischaemic injury. In addition, Endres et 
al. (2000) found that both treatment with 5-aza-2’-deoxycytidine (5-aza), an inhibitor of 
DNA methylation, and decreased expression of Dnmt1 significantly reduced the extent 
of the ischaemic injury (Endres et al., 2000; Qureshi and Mehler, 2010).  
 
DNA methylation may play a role in the regulation of certain genes such as 
thrombospondin 1 in response to cerebral ischaemia (Qureshi and Mehler, 2010). The 
effect of DNA methylation on the vulnerability of the brain to ischaemic injury has also 
been suggested to be a likely candidate for the mechanism by which 
methylenetetrahydrofolate reductase (MTHFR) deficiency causes an increased risk of 
stroke, but this has not yet been proven (Qureshi and Mehler, 2010). MTHFR is the 
catalyst for the synthesis of 5-methyltetrahydrofolate, the precursor of SAM, and is 
therefore an important factor for DNA methylation (Stern et al., 2000). Both MTHFR 
deficiency and certain MTHFR gene polymorphisms, notably C677T, have been 
implicated in hyperhomocysteinaemia and consequently in an increased risk of several 
diseases including stroke. Similarly, it was found that patients with high levels of 
plasma homocysteine, a common biomarker for vascular disease, had a significant 
decrease in leukocyte global DNA methylation when compared to a control group. It is 
thought that this alteration in DNA methylation may promote the vulnerability of the 
brain to ischaemic injury (Castro et al., 2003). 
 
The epigenetic effects of a stroke are not only detectable in peripheral blood and the 
affected brain tissue. It is thought that other somatic tissues may be affected by the 
insult through an epigenetic bystander-effect. Bystander-effects have previously been 
documented in radiation and chemotherapy exposure, where neighbouring cells can be 
affected. Kovalchuk et al. (2012) investigated levels of DNMTs in heart, liver and 
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kidney tissues taken from rodents with an ischaemic insult. They reported slight 
changes in DNMT1 levels in the heart (p<0.1) but significant increases (p<0.05) in 
DNMT3a in the kidneys of stroke rodents. They also investigated levels of histone 
modifications in each of the tissues and found significant increases of 16% in the levels 
of H3K4 trimethylation, a 15% increase in acetylated H3K9 and 15% decrease in 
methylated H3K9 in the kidney tissue from stroke rats only. Gene expression analysis 
highlighted 22 genes which were up-regulated in the kidney tissue of the rats with 
stroke.  These subtle yet significant findings are of great interest in the investigation into 
the role of epigenetics in stroke. As kidney damage and acute kidney failure are well-
described post-stroke complications it is interesting to note the sensitivity of kidney 
tissue to ischaemic insult at the molecular level. The results of this study suggest that 
DNA methylation may play a role in the aetiology of stroke as well as having a role in 
the consequences post-stroke (Kovalchuk et al., 2012). Antecedents of stroke may also 
be relevant to post-stroke dementia.  
 
1.3.5.2.2 DNA methylation and dementia 
Environmental and nutritional factors along with their actions through epigenetic 
mechanisms may contribute to the high prevalence of dementia in older populations. 
Reduced folate and vitamin B6 and B12 levels lead to increased levels of homocysteine, 
which is not only a known risk factor for AD but also, reduced DNA methylation 
(Leszek et al., 2012). There is now a wealth of evidence to suggest DNA methylation is 
associated with dementia. The vast majority of studies have focussed on AD; however, 
there are a slow growing number of publications investigating the role of epigenetics in 
other dementias.  
 
Most studies have compared methylation and expression levels of AD cases and 
controls. A global hypomethylation has been reported in the majority of studies with 
increasing age; however gene-specific DNA methylation analysis has revealed both 
hypomethylation and hypermethylation. Some studies have used easily accessible 
peripheral blood (Bollati et al., 2011) to identify methylation and gene expression 
differences whilst others have used the most relevant target tissue; the post-mortem 
brain (Wang et al., 2008; Bakulski et al., 2012a; Chouliaras et al., 2013). Methylation is 
tissue-specific; therefore the most suitable tissue to interrogate DNA methylation in 
dementia patients is the brain. This topic is explored in more detail in Section 1.4.3.1.  
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An interesting study by Chouliaras et al. (2013) compared levels of 5-mC and 5-hmC in 
the hippocampus of AD patients and age-matched controls. Both 5-mC and 5-hmC were 
found at reduced levels in the AD hippocampal tissues. Neuropathological 
investigations of the hippocampus revealed a negative correlation between levels of 5-
mC and 5-hmC and amyloid plaque load, suggesting that DNA methylation is indeed 
associated with AD pathology (Chouliaras et al., 2013). 
 
Several genes implicated in early onset AD, including PSEN1 and APP have been found 
to be hypomethylated in the brains of AD patients. This hypomethylation results in the 
aberrant upregulation of these genes which could be causal in the accumulation of β-
amyloid (Aβ) (Sung et al., 2011). In other genes, including APOE and MTHFR 
hypermethylation has been identified in the prefrontal cortex of AD brains and 
peripheral lymphocytes (Wang et al., 2008). This highlights that the pathogenesis of AD 
may be caused by both the hypomethylation and hypermethylation of certain genes 
(Sung et al., 2011). Further studies have highlighted that both hypomethylation and 
hypermethylation may be involved in disease pathogenesis. These include the finding 
that CREB5 is hypomethylated in AD patients when compared to controls (Graff and 
Mansuy, 2009; Chouliaras et al., 2010) and the study by Siegmund et al. (2007) which 
reported higher methylation of the SORBS3 locus in the cerebral cortex of AD cases 
than in controls. SORBS3 has previously been detected in the neuronal synapse 
indicating a possible function for SORBS3 in AD progression (Siegmund et al., 2007; 
Urdinguio et al., 2009).  
 
Recent DNA methylation studies have identified a number of loci differentially 
methylated in AD, some of which, e.g. ANK1 have previously been associated with AD 
(De Jager et al., 2014; Lunnon et al., 2014). This indicates that DNA methylation 
analysis may highlight potential mechanisms of disease aetiology. Another recent study 
has highlighted differences in global DNA methylation using peripheral blood 
mononuclear cells between Alzheimer’s disease cases and healthy controls, with global 
hypermethylation identified in the Alzheimer’s cases. This hypermethylation was also 
associated with the presence of the APOE4 allele. This study suggests that global DNA 
methylation could be a useful biomarker of Alzheimer’s disease (Di Francesco et al., 
2014). Another recent study by Yu et al. (2015) looked at genome-wide DNA 
methylation levels in the dorsolateral prefrontal cortex and identified a number of loci 
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associated with AD pathology further implicating DNA methylation in the 
pathophysiology of AD (Yu et al., 2015).  
 
One of the larger more recent studies comparing methylation in brain tissue between 
AD cases and controls was conducted by Bakulski et al. (2012). Genome-wide analysis 
quantifying methylation at over 27,000 CpG sites across the genome was performed on 
twelve AD and twelve age and sex matched controls. They found 948 CpG sites that 
were associated with AD. The mean methylation difference was only subtle at 2.9%. 
Interestingly, one of those CpG sites, located in the promoter of TMEM59 was 7.9% 
hypomethylated in cases when compared to controls. They extended their investigations 
to include gene expression and reported a negative correlation between DNA 
methylation and expression of TMEM59. As this gene has previously been implicated in 
the post-translational processing of APP, this study strengthens the suggestion that 
DNA methylation has a role in AD pathology (Bakulski et al., 2012a). 
 
Studies have also looked at early life exposures and their risk of AD in later life. One 
recent mouse study has identified that early life exposure to lead disrupts the normal 
methylation and expression patterns of AD-related genes in later life (Alashwal et al., 
2012). Studies of lead exposure in rats has identified dose-dependent decreases in the 
methylation of the promoter region of amyloid precursor protein (APP), indicating a 
possible link between lead exposure and AD (Li et al., 2012). Lead exposure has also 
been well studied in humans. As it is a known neurotoxicant in children, associated with 
an increased risk of reduced intelligence quotient (IQ) and behavioural problems, it was 
hypothesised that lead exposure may influence cognitive function in later life. Lead 
exposure has also been suggested as a possible risk factor for AD and other dementias 
in epidemiological human studies.  Cumulative lifetime lead exposure has been 
associated with accelerated cognitive decline and lead exposure has been associated 
with increased levels of homocysteine further supporting the evidence that lead 
exposure increases risk of AD by disrupting regulatory epigenetic mechanisms 
(Bakulski et al., 2012b). 
 
Desplats et al. (2011) studied the role of epigenetics in dementia with Lewy bodies and 
identified depleted levels of DNMT1 protein in the cell nuclei of diseased brains. This 
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infers that DNA methylation may be involved in the mechanisms resulting in disease 
progression (Desplats et al., 2011). 
 
All reported changes in DNA methylation have been relatively small when compared to 
age-matched controls. However, it could be that these subtle changes in DNA 
methylation, when in combination with other predisposing factors such as APOE 
genotype, could augment the susceptibility to neurodegeneration (Leszek et al., 2012). 
 
1.3.5.2.3 DNA methylation and post-stroke dementia 
Whilst there have been methylation studies in both stroke and dementia cohorts DNA 
methylation studies have never been performed in a post-stroke dementia cohort. 
Although little is known about methylation patterns in PSD it is likely that since 
methylation is involved in both stroke and dementia, as described in 1.3.5.2.1 and 
1.3.5.2.2, DNA methylation may also have a role in PSD. Antecedents of stroke may 
also be relevant to post stroke dementia. Literature searches in September 2014 using 
the search terms “DNA methylation” AND “post-stroke dementia” and “DNA 
methylation” AND “stroke” AND “cognitive impairment” yielded no publications in 
PubMed (NCBI) highlighting a gap in current research.  
 
1.3.5.2.4 DNA methylation and Parkinson’s disease 
The role of DNA methylation in PD is not as well studied as in AD. However, there are 
a limited number of studies which suggest DNA methylation may have a mechanistic 
role in PD progression.  
 
Arguably the main finding to date is that methylation is reduced in the first intron of α-
synuclein (SNCA) and is associated with increased expression in the substantia nigra of 
PD cases (Jowaed et al., 2010). Methylation of SNCA has also been studied in white 
blood cell DNA but no differences between PD cases and controls have been identified 
(Richter et al., 2012), possibly due to the localisation of SNCA to neurons (Lu et al., 
2013). The finding that SNCA methylation levels differ in PD cases compared to 
controls is of great interest since α-synuclein is a major component of Lewy bodies, a 
feature of PD. Levels of DNMT1 have also been found to be reduced in PD brains 
indicating a possible cause of decreased SNCA methylation levels (Lu et al., 2013).  
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Other studies have focussed on inflammation related genes such as tumour necrosis 
factor α (TNFα) which is hypothesised to promote dopaminergic cell death, possibly 
through the action of DNA methylation. TNFα is detected at much higher levels in the 
CSF of PD cases which suggests that DNA methylation may be reduced thereby causing 
TNF-α to be over expressed in PD. This, however, is just speculation and requires 
further study (Lu et al., 2013).  
 
The methylation status of cytochrome P450 2E1 (CYP2E1) has also been analysed. 
CYP2E1 was found to be hypomethylated in the brains of PD cases which may suggest 
a role for detoxifying enzymes in PD pathobiology, however more research is required 
(Lu et al 2013).  
 
An increased plasma homocysteine concentration has been associated with PD. Mouse 
models have shown that increased levels of homocysteine are detrimental to 
dopaminergic neurons (Lu et al., 2013). Increased levels of homocysteine are also 
associated with hypomethylation further indicating that methylation may have a role in 
PD.   
 
Very few studies have looked at the methylation profiles of PD-MCI cases compared to 
controls. One study that has found associations between methylation and cognitive 
function measured levels of a number of biochemical markers in the plasma of PD 
patients. They identified those with increased levels of SAM and Vitamin B6 were less 
likely to be cognitively impaired. Increased levels of SAM were also associated with 
lower levels of APP and SNCA. It has been speculated that Vitamin B6 may influence 
the degradation of APP which in turn affects α-synuclein levels, however the effect of 
Vitamin B6 on α-synuclein needs to be investigated further before any conclusions can 
be drawn (Obeid et al., 2009).  
 
1.3.5.3 DNA methylation as a candidate for prediction and prognosis in the ageing brain  
Epigenetics is one such possible mechanism that has not yet been researched in a post-
stroke dementia cohort. Previous studies have successfully identified differential 
methylation in both stroke patients and dementia patients when compared to healthy 
age-matched controls. As epigenetic marks are affected in both of these diseases it is 
hypothesised that DNA methylation changes will be detected in PSD patients. As 
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epigenetics is important in both stroke and dementia, it may also be a key factor in 
contributing to the risk of developing PSD. As described in Section 1.3.5.2.1, LINE-1 
hypomethylation was detected prior to stroke suggesting that this epigenetic marker 
could be used as a biomarker for stroke. Like PSD, DNA methylation studies have not 
been carried out in a PD-MCI cohort. The possibility of using DNA methylation as a 
biomarker for PSD would be extremely beneficial to both patients and health care 
services. The early detection of patients at-risk of developing PD-MCI would be of 
great benefit to PD patients. The earlier detection may allow more specific disease-
modifying treatments to be administered earlier which could prevent the development of 
disease. In both diseases the identification of biomarkers could be useful in a number of 
ways. A biomarker can aid the early diagnosis of disease and repeated measures can 
help monitor disease progression. Biomarkers could also be used to monitor treatment 
success and to indicate exposure status. Finally, a biomarker detected in the affected 
tissue (in PSD and PD-MCI this is the brain) can be used to help understand the 
mechanisms involved in the disease pathway. These mechanistic markers could then 
help to target treatment options such as the inhibition of the involved pathways. 
Therefore, in both PSD and PD-MCI, the identification of biomarkers can have great 
utility for a variety of appplications.  
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1.4 Studying DNA methylation in the brain 
 
1.4.1 Epidemiological approaches 
Epigenetic epidemiology is the term used to describe the study of epigenetic variation 
within populations by combining well established epidemiological approaches with 
epigenomic technologies (Mill and Heijmans, 2013). Large-scale population-based 
studies are becoming increasingly common in studies investigating the associations 
between epigenetics and disease phenotype, due to the recent advances in genomic 
technologies (Ng et al., 2012). Epigenetic epidemiology aims to add to the 
understanding of mechanisms involved in the associations between exposures and 
human disease phenotypes (Heijmans and Mill, 2012). A number of considerations need 
to be explored when designing suitable epidemiological studies for the effective 
interrogation of epigenetic mechanisms. A few of these are described below. 
 
1.4.1.1 Study designs 
There are many different study designs available for use in an epigenetic epidemiology 
context each with their own advantages and disadvantages. It is important to select the 
correct type of study design to use in each study; this depends on the exposures and 
outcomes of interest and the effect of any confounding. The types of study design used 
in this thesis are described below. 
 
Cross-sectional study 
A cross-sectional study measures all exposures and phenotypic measures at one time-
point only. They are suitable for studies wishing to determine the prevalence rate of a 
phenotype or disease. They can also be used to assess differences between different 
sample sets, such as different sexes or ethnicities at that one time-point. Cross-sectional 
studies take a snapshot of the epigenome at the specific point in time, and when 
combined with data on exposures and phenotypic measures, can be used to assess the 
relationship between exposure and the epigenome and/or the epigenome and disease.  
Cross-sectional studies are advantageous as they are cheap to carry out and maintain as 
they do not require too much effort on the study participants behalf. However, results 
are only representative of the study sample and due to only one time-point used it is 
impossible to assess the temporal nature of epigenetics or investigate causality.  
 
45 
 
 
 
Cohort studies 
In a cohort study, participants are usually recruited for a specific time period, however 
many cohort studies are open-ended and participants are followed up throughout their 
life. Studies including prospectively collected data and biological samples at multiple 
time points are known as longitudinal studies. Prospectively collected data is of more 
value than retrospectively collected data as it is more accurate due to the risk of recall 
bias arising in many retrospective studies.  These studies are much more valuable for 
epigenetic studies hoping to establish temporal relationships and biological relevance of 
epigenetic changes associated with exposures and/or disease. At recruitment, baseline 
measurements and phenotypic information including detailed exposure information is 
collected and at each follow-up throughout the study further biological and phenotypic 
measurements are collected. This allows any changes in DNA methylation or disease 
state to be assessed over time. A cohort study is usually made up of hundreds or even 
thousands of participants. As clinical and epigenetic measurements are collected before 
disease onset, cohort studies can be used to infer temporal relationships and strengthen 
causality as well as remove the problem of reverse causation. Although being more 
expensive, studies utilising multiple time points are increasingly being recognised as the 
most suitable study design to investigate the epigenetics of common complex diseases. 
Several research collaborations involving cohort studies such as Genomic and 
Epigenomic Complex Disease Epidemiology (GEoCoDE) 
(http://www.bristol.ac.uk/caite/geocode/) have been formed which increase sample sizes 
and power in the investigations of disease risk factors throughout the life course. 
Collaborations such as GEoCoDE have also enabled findings from individual studies to 
be replicated in a much larger cohort (Ng et al., 2012). Nested case-control studies can 
also be created from existing cohort studies. Participants who develop the disease 
phenotype of interest during the cohort study period are recruited into the nested case-
control study as cases and matched individuals free of disease are taken from the cohort 
to be used as controls.  
 
A summary of the different study designs used in epidemiological studies and their 
applications is found in Table 2. 
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Study Design Application 
Cross-sectional study Prevalence of an epigenetic mark in a well-defined 
population subgroup 
Retrospective case-control 
study 
Permanent epigenetic marks among individuals with 
and without disease 
Cohort study Epigenetic mechanisms underlying a risk factor-
disease association 
Nested (prospective) case-
control study 
Epigenetic marks predisposing to disease 
Biomarkers for early disease detection 
Biomarkers for disease risk 
Intervention study Effect of intervention on epigenetic pattern 
Effect of epigenetic therapies on disease 
Family-based study Transgenerational inheritance of epigenetic traits 
Birth cohort Influence of preconceptional and prenatal factors on 
establishment of the genome 
Table 2: Study designs used in epigenetic epidemiology and their applications. (Taken from Michels, 
2012). 
 
1.4.1.2 The value of twin studies 
Cases of discordance in monozygotic (MZ) twins, where one twin developed a disease 
whilst the other did not, have been extremely valuable in the study of epigenetics and 
the ageing process. Due to MZ twins having the same genetic profiles, DNA 
methylation changes over the life course appear to be a credible explanation for this 
discordance between MZ twin pairs (Gilbert, 2009). More divergence in DNA 
methylation patterns has been observed between elderly twin pairs when compared to 
younger twin pairs. This suggests that epigenetic control may be more stringent during 
early life (Fraga et al., 2005). These findings were replicated in a larger study by Talens 
et al. (2012) which assessed methylation in MZ twins of a wider age range. This study 
found more discordance in methylation between the older twin-pairs compared with 
younger twin-pairs in a number of common disease associated genes (Talens et al., 
2012). 
 
Significant differences in DNA methylation have been identified in twins discordant for 
breast cancer. The Infinium HumanMethylation450 (HM450) BeadChip (Illumina, 
USA) has been performed on peripheral blood taken from fifteen twin pairs; one of 
whom had been diagnosed with the breast cancer whilst the other remained healthy. 403 
CpG sites were found to be differentially methylated, 97% of which were 
hypomethylated in the twin with cancer. In addition to identifying differentially 
methylated genes after cancer diagnosis, blood samples taken prior to breast cancer 
diagnosis were also analysed and this analysis identified potential biomarkers for breast 
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cancer. DOK7 was identified as the most likely candidate for a biomarker as it displayed 
the most significant change in DNA methylation and these changes were detectable 
three years prior to breast cancer diagnosis. This study shows the value of using MZ 
twins in epigenetic studies. They are the most efficient study design due to factors 
which would usually add variability such as age, genetic factors and other 
environmental factors being controlled for (Heyn et al., 2013). 
 
Twin studies have also been important in the study of epigenetics and 
neurodegenerative disorders. Mastroeni et al. (2009) analysed DNA methylation levels 
in the cortical neurons of one pair of MZ twins discordant for AD. Both twins were 
male and died between ages 76-79. The neuropathology of the twins differed greatly 
with the AD twin having Braak stage VI pathology whilst the unaffected twin had 
Braak stage II pathology. Immunochemistry of the temporal cortex revealed lower 
levels of 5-methylcytosine in the AD twin compared to the unaffected twin. When the 
test was repeated using tissue from the cerebellum (largely unaffected by AD) no 
difference in levels of 5-methylcytosine were identified. This indicates that the temporal 
cortex differences in 5-methylcytosine were not due to tissue handling differences or 
other human error, but may suggest a role for epigenetic mechanisms in the 
pathophysiology of AD (Mastroeni et al., 2009). 
 
1.4.2 Methods to quantify DNA methylation 
Quantification of DNA methylation can be either global or gene-specific. The different 
methods of quantifying DNA methylation are explored below.  
 
1.4.2.1 Global DNA methylation 
The quantification of DNA methylation on a global scale takes advantage of repetitive 
elements that are found throughout the genome. Repetitive elements are transposable 
elements of DNA found repeated throughout the genome. Quantifying the methylation 
levels of these repetitive elements measures the average methylation level found 
throughout the genome, making it a good surrogate for global methylation analysis. 
Repetitive elements can be categorised into several categories, the most commonly used 
being long interspersed nucleotide elements and short interspersed nucleotide elements. 
Sat2 and Alu are also commonly used measures of global DNA methylation levels 
(Weisenberger et al., 2005). Measuring DNA methylation levels of repetitive elements 
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usually requires PCR primers specific to a particular repeated sequence such as LINE-1 
(Yang et al., 2004). A more sensitive way of assessing global methylation uses High 
Performance Liquid Chromatography (HPLC) which separates nucleotides according to 
size and quantifies unmethylated and methylated cytosine residues. Whilst this 
technique is more sensitive, it requires larger amounts of DNA compared to the PCR-
based techniques using repetitive elements and therefore limits its use (Lisanti et al., 
2013). Quantification of global DNA methylation levels was not used in this thesis but 
many important studies in the field of epigenetics and ageing have performed global 
methylation analysis.  
 
1.4.2.2 Targeted DNA methylation 
Whilst global methylation is an average measure of methylation levels throughout the 
genome, DNA methylation can also be measured at the level of individual CpG sites 
using either genome-wide or candidate gene (locus-specific) approaches.  
 
1.4.2.2.1 Genome-wide methylation 
Studies analysing genome-wide methylation are becoming increasingly popular as 
technological advances are increasing the number of CpG sites that can be interrogated 
per sample, simultaneously. Microarray techniques are the most commonly used 
method to measure genome-wide methylation (although only a small fraction of CpG 
sites are included in the microarrays). The HM450 has, in recent years, replaced the 
27K as the most commonly used BeadChip. The HM450 BeadChip assesses the 
methylation status at over 480,000 CpG sites which are spread throughout the genome. 
CpG sites included in the array are not only found in CpG islands, but CpG shores, gene 
bodies and 3’-and 5’-untranslated regions (UTRs), to name a few (Bibikova et al., 
2011). Microarray platforms use BeadChips which have probes able to discriminate 
between methylated and unmethylated DNA, so when bisulphite modified DNA (see 
Sections 1.4.2.2.2 and 2.3) is hybridised to the BeadChips the methylation status at each 
CpG site captured on the array can be analysed (Beck and Rakyan, 2008). The HM450 
array was used in this thesis and is described in more detail in Section 2.4. 
 
1.4.2.2.2 Locus-specific methylation 
For many years, the gold standard for measuring DNA methylation at a specific locus 
has been bisulphite sequencing (Beck and Rakyan, 2008). This involves treating 
genomic DNA with sodium bisulphite which deaminates unmethylated cytosine 
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residues into uracil. As methylated cytosines are resistant to this modification, they 
remain as cytosine residues. On PCR amplification the uracil residues are amplified as 
thymine bases and subsequent sequencing of DNA calculates DNA methylation levels 
of each CpG site by comparing the relative abundance of cytosine to thymine residues 
(Yang et al., 2004).  
 
A relatively recent development and a more cost effective approach is Pyrosequencing, 
which was initially developed for SNP analysis of DNA, but when preceded by 
bisulphite modification, can quantify the methylation of specific CpG sites in the DNA 
sequence. Pyrosequencing adopts a “sequence by synthesis” strategy whereby one 
nucleotide is incorporated into the single stranded sequence at a time. When a 
nucleotide complementary to the target template is added, pyrophosphate is released 
which initiates an enzyme cascade during which luciferase converts luciferin into 
oxyluciferin generating visible light which can be detected by a camera. The amount of 
light generated when each nucleotide is added determines the DNA sequence. When a 
bisulphite modified DNA sequence is run on the Pyrosequencer the methylation status 
of each CpG site can be read as a C/T SNP. The amount of light generated when 
cytosine and thymine residues are incorporated is compared to quantify DNA 
methylation (Dupont et al., 2004; Reed et al., 2010). In essence, Pyrosequencing is a 
form of targeted bisulphite sequencing which allows short fragments of DNA to be 
analysed rather than the whole genome. A limitation of bisulphite sequencing 
techniques is the inability to distinguish between 5-mC and 5-hmC. Using these 
techniques, all methylation marks (5-mC and 5-hmC) are presumed to be 5-mC. Studies 
using these techniques are therefore unable to detect whether differences in DNA 
methylation between groups are due to differences in 5-mC or 5-hmC (Huang et al., 
2010). Pyrosequencing has been used in this thesis and is described in Section 2.6.6. 
 
1.4.3 Considerations when designing an epigenetic study 
There are a number of factors that need to be considered when designing an epigenetic 
study. The two issues pertinent to this thesis are described below. 
 
1.4.3.1 Tissue specificity 
In multicellular organisms, different cells have different gene expression profiles which 
determine the function of each cell. Each organ in the human body, therefore, is made of 
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a number of different cells; each cell type with a different expression, and therefore a 
different epigenetic profile. DNA methylation patterns are highly tissue-specific with 
greater variation found between tissues within individuals than between individuals 
themselves (Byun et al., 2009). For this reason, it is important to use the 
affected/diseased tissue as the target tissue in epigenetic studies. However, this can 
cause problems for epigenetic studies especially since, in the majority of cases, to 
extract a sample of affected tissue from a living cohort requires an invasive procedure 
such as a biopsy. Animal models are useful in the study of ‘hard to reach’ tissues as 
these can be obtained post-mortem. Additionally, studies of the human brain are only 
possible using post-mortem tissue. For this reason, many studies resort to using easily 
accessible such as buccal cells or most commonly peripheral blood as a source of DNA. 
However, it is not well established whether or not blood is a useful surrogate for each 
human tissue – investigations into this are still on-going (Davies et al., 2012; Masliah et 
al., 2013). In the search for a clinical biomarker however, DNA methylation changes 
that are mechanistic are not required, making blood an ideal, easily accessible source of 
DNA. Cell heterogeneity is also an important consideration. Blood and other tissues 
such as brain are made up of different cellular compositions which could bias epigenetic 
measurements (Ng et al., 2012).  
 
1.4.3.2 Temporality of epigenetic change 
Epigenetic changes are dynamic. Studies have shown epigenetic profiles to alter with 
age (Fraga et al., 2005) and other environmental stimuli such as smoking (Breitling et 
al., 2011). Some epigenetic changes may be due to the disease in question whereas 
others may be due to certain exposures experienced either before or after disease onset. 
To establish whether epigenetic changes are causal in disease onset or progression the 
timing of epigenetic changes needs to be known. This requires epigenetic signatures to 
be profiled immediately before and after any exposures of interest to be able to 
determine whether any later life changes in phenotype such as disease onset are as a 
result of the exposure and not just a result of reverse causation. This is often not 
practical in human populations due to not knowing when certain exposures will be 
experienced in advance. Studies investigating exposures which result in a rapid and 
temporary change in epigenetic profiles may be best suited to experimental approaches.  
 
51 
 
 
 
1.4.4 Approaches to studying the role of DNA methylation in the aetiology of 
post-stroke dementia and mild cognitive impairment in Parkinson’s disease  
A longitudinal study design which measures DNA methylation at two or more time 
points is particularly useful in epigenetic studies when causality is to be established. 
Longitudinal studies are able to track methylation changes over time enabling the 
temporal relationship (Section 1.4.3.2) between exposure and disease to be established. 
In contrast, cross-sectional studies which measure methylation at only one time point 
are unable to capture the dynamic nature of epigenetic mechanisms and, therefore 
cannot be used to establish causality (Ng et al., 2012). 
   
In the study of both PSD and PD-MCI, the most affected organ is the brain which 
makes longitudinal studies difficult, as the brain can only be extracted following death. 
The use of peripheral blood as a surrogate for the target tissue must therefore be used as 
it is an easily accessible DNA source, however, tissue-specific methylation differences, 
as mentioned in Section 1.4.3.1, do exist (Yang et al., 2010; McKay et al., 2011). DNA 
methylation in peripheral blood has been a successful predictor of other diseases 
(Brennan et al., 2012) so the possibility that peripheral blood could be used to identify 
patients at risk of PSD and PD-MCI is feasible and exciting. Brain tissue can be used to 
assess the methylation status at death but to identify at-risk individuals a DNA sample 
collected before the onset of dementia is required. Peripheral blood may therefore be a 
suitable choice.  
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1.5 Exploring the functional importance of observational associations 
detected in epigenetic epidemiological studies 
Observational studies which highlight an association between an epigenetic alteration 
and phenotype are not able to establish either causality or functional relevance.  
Establishing causality and functional relevance is an important part of epigenetic 
studies. Identifying differences in DNA methylation does not mean that epigenetic 
mechanisms are mechanistically involved in disease; DNA methylation may instead be 
a consequence of disease or may be entirely unrelated. Identifying functional pathways 
offers the greatest chance for disease prevention. There are a number of ways we can 
elucidate functional pathways and disease mechanisms involved in disease pathogenesis 
in DNA methylation studies and these will be outlined below.  
 
1.5.1 Biological function 
The simplest approach that may be taken to assess whether an alteration in DNA 
methylation may have functional importance is to look at the biological function of the 
gene in question.  
 
Since the human genome has been fully sequenced we can predict the likely protein 
structure that will be produced by gene transcripts. One of the resources available for 
predicting protein structure is Simple Modular Architecture Research Tool (SMART) 
(http://smart.embl-heidelberg.de/). SMART looks for conserved domains that have been 
previously characterised in a range of proteins. An example of this would be if a protein 
contains a transmembrane domain, it is likely to have a function at the cell membrane 
such as in a cell signalling pathway.  
 
Gene ontology aggregates known gene attributes into a single database 
(http://www.geneontology.org/).  The data collected comes from a range of organisms 
so data from one organism can be used to infer function of a homologous gene in 
another organism. The database contains information on biological processes, molecular 
function and cellular component. This is especially useful when looking at multiple 
genes to see if they act on the same pathways or have a shared function. By using these 
resources it allows us to prioritise only the most functionally relevant hits for more 
detailed analysis.  
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1.5.2 Gene expression 
DNA methylation is commonly inversely correlated with gene expression. When CpG 
sites, particularly those close to the transcription start site, are methylated this impedes 
transcription factor binding thereby repressing gene expression (Boyes and Bird, 1991). 
This relationship, as previously mentioned, is not expected within gene bodies where an 
increase in methylation has been associated with an increase in transcription levels 
(Wagner et al., 2014). It is possible to test whether DNA methylation impacts upon 
transcription, gene expression analyses by interrogating publicly available data or by 
experimental studies where RNA samples are available. To assess the expression levels 
of a number of genes an expression microarray or RNA sequencing could be performed. 
For validation of array or RNA sequencing data, or if analysis is targeted to just a few 
genes, quantitative PCR can be used. Using cell culture, the effects of DNA methylation 
on gene expression can be directly monitored using de-methylating agents such as 5-aza 
(Hitchins et al., 2011).  
 
In addition, quantification of protein levels could also determine whether differential 
gene expression is also detectable at the protein level. This could be achieved using 
either a proteomic (array or 2 dimensional gel electrophoresis) approach or the more 
targeted method of Western blotting or enzyme-linked immunosorbent assay.  If 
methylation differences were found to alter gene expression and protein levels then this 
would provide compelling evidence that the alteration in DNA methylation is exerting a 
biological effect and could be involved in disease causation.  
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1.6 Study objectives, aims and hypotheses 
The main aims of this thesis were to identify epigenetic biomarkers present in the blood 
of stroke survivors and Parkinson’s disease patients which could be used to predict 
those patients at risk of developing post-stroke dementia and mild cognitive impairment 
in Parkinson’s disease.  
 
The objectives of this work were: 
1. To identify blood-based differentially methylated positions (DMPs) which could 
be potential biomarkers of post-stroke dementia; 
2. To identify DMPs in the brain that are associated with impaired cognitive 
function in stroke patients; 
3. To identify blood-based DMPs which could be potential biomarkers of mild 
cognitive impairment in Parkinson’s disease; 
4. To assess whether DNA methylation can mediate the relationship between 
exposure and outcome; 
5. To assess whether DNA methylation can be used as an indicator of exposure 
status; 
6. To assess whether biological age predicted from DNA methylation data can 
identify individuals at risk of cognitive decline. 
 
The following hypotheses were tested: 
1. Specific changes in blood DNA methylation measured prior to onset of dementia 
predict later cognitive impairment; 
2. Patients suffering from post-stroke dementia exhibit different DNA methylation 
signatures in their blood and brain tissue when compared with cognitively 
normal post-stroke patients; 
3. Patients suffering from PD-MCI exhibit different DNA methylation signatures 
in peripheral blood when compared with cognitively normal Parkinson’s cases; 
4. Specific changes in DNA methylation measured at diagnosis of Parkinson’s 
disease predict later cognitive and motor impairment; 
5. DNA methylation may mediate the relationship between exposure and outcome; 
6. DNA methylation can be used as an indicator of exposure status; 
7. Biological age predicted from DNA methylation data may predict participants at 
increased risk of cognitive decline.  
55 
 
 
 
1.7 Summary of thesis chapters 
This thesis is structured as described below. Chapter 2 contains a summary of the 
methods and equipment used throughout this thesis. Chapters 3-7 contain the results of 
this thesis. In more detail, Chapter 3 addresses the possibility of using DNA methylation 
data to identify a biomarker of post-stroke dementia. Chapter 4 investigates whether 
DNA methylation data can inform about disease mechanisms involved in post-stroke 
dementia. Chapter 5 addresses the possibility of using DNA methylation data to identify 
a biomarker of mild cognitive impairment in Parkinson’s disease. Chapter 6 investigates 
the relationship between exposures and DNA methylation and whether DNA 
methylation data can be used as a surrogate for exposure status. Chapter 7 explores the 
epigenetic clock method and assesses whether age predicted using DNA methylation 
data can predict those more likely to suffer from age-related cognitive impairment. 
Finally, Chapter 8 discusses the main findings of this thesis, the strengths and 
limitations of this work and explores possible next steps in this field.  
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Chapter 2. Methods 
 
2.1 Study cohorts 
Two cohorts were utilised throughout the course of this project to investigate the role of 
DNA methylation in post-stroke dementia and Parkinson’s disease and to assess the 
utility of epigenetic biomarkers in predicting disease outcome. The cohorts are 
described in the following sections.  
 
2.1.1 COGFAST 
The Cognitive Function After Stroke (COGFAST) cohort (Allan et al., 2011) is a 
prospective observational study initiated in 1999 with the aim of understanding the risk 
factors and mechanisms that contribute to post-stroke dementia in elderly stroke 
survivors.   
Recruitment: Hospital-based stroke registers were utilised to recruit cognitively normal 
(non-demented) stroke survivors three months post-stroke. Patients were excluded from 
the study if they; i) were under the age of 75 years; ii) had a significant physical illness 
or disability; iii) had a Mini-Mental State Examination (MMSE) (Folstein et al., 1975) 
score of <24 and iv) were diagnosed with dementia according to the DSM-IIIR.  Of the 
706 older stroke survivors originally screened consecutively from six hospital-based 
stroke registers in Tyneside and Wearside in the North East of England, a total of 355 
individuals were eligible to be recruited at baseline for the follow up COGFAST study.  
Clinical assessment: At baseline (three months after stroke) all potential participants 
had their cognitive function assessed by a series of neuropsychological assessments 
including the Cambridge Cognitive Examination (CAMCOG) (de Koning et al., 1998); 
a battery of tests which aids dementia diagnosis by assessing a range of cognitive 
functions affected by dementia and is able to detect mild cognitive impairment, and the 
MMSE; a series of questions and tests with a total score of 30, used to assess a person’s 
language, attention and memory, useful for diagnosis of dementia as well as progression 
and severity. Participants’ medical history and information relating to lifestyle was also 
recorded. Information relating to the index stroke was also collected at baseline.  
Follow-up: The neuropsychological assessments were repeated each year to assess 
whether the participant’s cognitive function had deteriorated and whether they were 
clinically demented.  
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Biological sampling: At baseline, a peripheral whole blood sample was collected and 
stored in vacutainer tubes at -80°C. On death, the brain was extracted and the 
neuropathology of the brain was assessed. Each brain was given a Braak Staging score 
to inform in the final diagnosis of dementia. Braak staging is a method used to 
determine the degree of AD pathology through the assessment of the location of 
neurofibrillary tangles (Braak and Braak, 1995). It is commonly used in both 
Parkinson’s disease and Alzheimer’s disease. A final diagnosis of dementia as well as 
the Braak staging of the brain was given at autopsy and brains were frozen at -80°C to 
preserve tissue integrity (Allan et al., 2011). 
Ethical approval: Approval for use of samples and data for research was obtained from 
the Joint Ethics Committee of Newcastle and North Tyneside Health Authority, the 
University of Newcastle upon Tyne and the University of Northumbria at Newcastle. 
Participants gave written informed consent in accordance with the Declaration of 
Helsinki. 
 
2.1.1.1 Sample selection 
All COGFAST study members were eligible for inclusion in the epigenetic studies 
reported in this thesis. Participants were selected based upon the availability of 
biological samples. Participant samples were included if they had donated both a 
baseline blood sample and a post-mortem brain sample. As both the hippocampus and 
dorsolateral prefrontal cortex (DLPFC) are regions of the brain associated with ageing 
and dementia, these regions were selected for epigenetic analysis. The DLPFC has a 
functional role in working memory and executive function. Studies assessing the effects 
of DLPFC damage have reported a worsening of spatial and verbal reasoning (Barbey et 
al., 2013). The hippocampus is a widely studied region of the brain and has been 
strongly implicated in long-term, and to a lesser extent, short-term memory formation. 
Damage to the hippocampus has been found to affect the ability to form new memories 
(Abrahams et al., 1997; King et al., 2004).  Specific regions were requested from 
COGFAST samples collected by the Newcastle Brain Tissue Resource (NBTR). These 
regions were: hippocampus, Level 18-19 according to the Newcastle Brain Map and 
dorsolateral prefrontal cortex, Levels 5-7 according to the Newcastle Brain Map (BA 
9+46) (Perry and Oakley, 1993). Figure 6 shows the locations of the regions of interest 
in relation to the brain. 
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Figure 6: Anatomy of the brain. (Taken from Wickelgren, 2012). 
 
2.1.1.2 Variables used in the analysis  
Hippocampus and DLPFC tissue and corresponding baseline blood samples were made 
available from the NBTR for the current project. A range of variables were used as 
outcome measures, exposure measures and covariates. Definitions for all variables can 
be found in the Glossary (Tables 1 and 2).  
 
2.1.1.2.1 Outcome measures 
The following variables were used as outcome measures in the analysis:  - Cognitive scores - MMSE (Folstein et al., 1975) and a number of CAMCOG (de 
Koning et al., 1998) scores (abstract thinking, attention, calculation, executive 
function, language comprehension, language expression, memory learning, 
memory recent, memory remote, memory total, orientation, perception, praxis, 
total CAMCOG score).  - Neuropathological information – Braak Staging, diagnosis. 
 
2.1.1.2.2 Exposure measures 
The following variables were used as exposure measures in the analysis:  
- Medical history - hypertension, angina, atrial fibrillation, cardiac failure, 
intermittent claudication and ischaemic heart disease. 
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- Stroke-related factors – degree of weakness in arm/leg, side of the body affected, 
dysphasia and the Oxfordshire Community Stroke Project (OCSP) class 
(Bamford et al., 1991). 
- Risk factors – Smoking status and total number of cardiovascular risk factors. 
- Baseline cognition scores – MMSE, abstract thinking, attention, calculation, 
executive function, language comprehension, language expression, memory 
learning, memory recent, memory remote, memory total, orientation, perception, 
praxis, total CAMCOG score. 
 
2.1.1.2.3 Covariates 
The following variables were used as covariates in the analysis: Baseline age, Sex and 
Chip on which the samples were scanned.  
 
2.1.2 ICICLE 
The Incidence of Cognitive Impairments in Cohorts with Longitudinal Evaluation or 
ICICLE study (Yarnall et al., 2014) aimed to recruit all newly diagnosed Parkinson’s 
disease (PD) patients in the Newcastle and Gateshead area.  
Recruitment: The recruitment period ran from June 2009 to December 2011 and all 
primary care practices as well as secondary care health workers such as neurologists, 
geriatricians and PD nurse specialists were encouraged to refer all patients with 
suspected Parkinsonism. Participants were also excluded from the study if they i) were 
diagnosed with PD prior to the study recruitment window; ii) lacked the English skills 
required to complete questionnaires or assessments; and iii) showed signs of significant 
cognitive impairment scoring <24 on the MMSE. Age-matched healthy control subjects 
were recruited through local advertising and other community sources ensuring they 
were representative of the North East population. In total, 158 cases and 99 controls 
were recruited onto the project.  
Clinical assessment: All patients recruited onto the study were diagnosed with 
idiopathic Parkinson’s disease by a movement disorder specialist. Patients diagnosed 
with vascular, drug-induced or atypical forms of Parkinsonism were excluded from the 
ICICLE study. After consenting to participate in the study all PD cases underwent a 
clinical assessment by a physician. This assessment included education level, biometric 
measurements and other lifestyle factors such as smoking status. Symptom history, 
other co morbid diseases and medication use were also recorded. A number of cognitive 
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tests were utilised including the MMSE (Folstein et al., 1975), Montreal Cognitive 
Assessment (MoCA) (Nasreddine et al., 2005), CDR (Wesnes et al., 2002) and 
CANTAB (Sahakian et al., 1988) to assess global cognitive function, the Geriatric 
Depression Scale (GDS-15) (Yesavage et al., 1982) to assess depression, Hoehn and 
Yahr (Hoehn and Yahr, 1967) to rate the severity of disease (score 1-5; with higher 
score indicating more severe disease) and The Movement Disorder Society-Unified 
Parkinson’s Disease Rating Scale (MDS-UPDRS) parts II and III (Goetz et al., 2008) to 
assess motor disability. A diagnosis of MCI was given if participants showed 
impairment (1-2 standard deviations below normative values) on at least two 
neuropsychological tests. 
Follow-up: All cases and controls were invited to take part in a follow up at 18 months. 
All assessments were repeated at follow up to check for any alterations in disease 
phenotype (Khoo et al., 2013).  
Biological sampling: A peripheral blood sample was taken from both cases and controls 
at baseline. The blood sample was collected in a vacutainer containing 
ethylenediaminetetraacetic acid (EDTA) and stored at -80°C. DNA extracted from 
baseline blood samples was provided for epigenetic analysis. 
Ethical approval: Approval for use of samples and data for research was obtained from 
the Newcastle and North Tyneside Research Ethics Committee (REC:08/H0906/147) 
and the study was performed according to the Declaration of Helsinki. All subjects 
provided written informed consent.  
 
2.1.2.1 Sample selection 
150 PD cases and 90 controls donated a baseline blood sample. From these baseline 
blood DNA samples, 48 were selected for inclusion in the discovery phase of this 
project. 24 samples were from Parkinson’s disease participants with mild cognitive 
impairment (MCI) and 24 Parkinson’s disease participants without MCI. Initial sample 
selection was based on phenotype, with the selected PD-MCI cases displaying the most 
impaired cognition (at 2SD below normative levels). All other samples (with normal 
cognition) selected for inclusion in the discovery phase were age and sex matched. All 
other ICICLE DNA samples were available for use in the validation phase of this study. 
 
2.1.2.2 Variables used in the analysis 
A range of variables were used as outcome measures, exposure measures and 
covariates. Definitions for all variables can be found in the Glossary (Tables 3 and 4).  
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2.1.2.2.1 Outcome variables 
The following variables were used as outcome measures in the analysis:  
- Cognition- MCI, animals, cognitive complaint, language, language total, 
MMSE, MoCA, naming, NMSQ concentration, NMSQ memory, one touch 
stockings, paired associates learning, pentagon copying, power of attention, 
pattern recognition memory, spatial recognition memory and total FAS. 
- Motor: digit vigilance accuracy, Hoehn and Yahr, MDS UPDRS Parts II and III, 
PIGD phenotype and tremor dominant phenotype.  
 
2.1.2.2.2 Exposure variables 
The following variables were used as exposure measures in the analysis: 
- Lifestyle factors – alcohol, smoking status, weight, BMI, height. 
- Risk factors – B12, homocysteine, red cell folate (RCF), education, NART.  
- Medical history – IHD, hypertension, hypercholesterolaemia, diabetes, 
depression. 
 
2.1.2.2.3 Covariates 
Age, sex and chip (on which the samples were scanned) were used as covariates in all 
analyses.  
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2.2 DNA extraction and quantification 
 
2.2.1 Tissue DNA extraction 
Sections from the DLPFC and hippocampus were provided by the NBTR for DNA 
extraction. To extract DNA from the brain tissue the E.Z.N.A.® Tissue DNA Kit 
(OMEGA bio-tek, USA) was used and the standard Tissue DNA Spin protocol was 
followed. The extraction protocol was performed on DLPFC pieces weighing 
approximately 30mg and hippocampus sections weighing approximately 10mg. Each 
tissue section (30mg/10mg) was added to 200µl TL Buffer and 25µl OB protease. 
Tubes were then vortexed and incubated at 55°C on a thermoshaker (Grant Instruments, 
UK) until all tissue had lysed. Samples were centrifuged for 5 minutes at 13000xg and 
the supernatant was transferred to a new sterile tube. 220µl BL Buffer was added, 
vortexed and incubated at 70°C for 10 minutes on a thermoshaker (Grant Instruments, 
UK). Following the addition of 220µl absolute ethanol, the entire sample was 
transferred to a HiBind DNA Mini Column and centrifuged at 10000xg for 30 seconds. 
In a new collection tube, 500µl HB Buffer was added to the column and centrifuged at 
10000xg for 30 seconds. Two wash steps with 700µl Wash Buffer followed, each 
punctuated with a centrifugation step. A final centrifugation step was performed at 
13000xg for 2 minutes to completely dry the column. The HiBind DNA Mini Column 
was inserted into a 1.5ml microcentrifuge tube and 100µl of preheated (70°C) Elution 
Buffer was added, left to stand at room temperature for 2 minutes and centrifuged at 
13000xg for 1 minute to elute the DNA. Following elution, all DLPFC DNA extracted 
from the same brain section were pooled. Similarly, all hippocampal DNA samples 
extracted from the same individual were pooled. All DNA samples were stored at -
70°C. 
 
2.2.2 Blood DNA extraction 
DNA was extracted from frozen blood using the standard Blood and Body Fluid 
Protocol as outlined in the E.Z.N.A.® Blood DNA Kit (OMEGA bio-tek, USA). This 
protocol involved the addition of 25µl reconstituted OB protease and 250µl Buffer BL 
to 250µl whole blood. After vortexing for 15 seconds, the tubes were incubated at 65°C 
for 10 minutes on a thermoshaker (Grant Instruments, UK) and 260µl absolute ethanol 
was added. The lysate was transferred to a HiBind DNA column, previously treated 
with 100µl Equilibration Buffer, and was centrifuged at 10000xg for 1 minute to bind 
the DNA. In a new collection tube, 500µl HB Buffer was added to the column and 
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centrifuged as above. Two wash steps with 700µl Wash Buffer then followed each 
punctuated by a centrifugation step. Columns were then centrifuged at 13000xg for 2 
minutes to completely dry the column. DNA samples were then eluted in 100µl 
preheated (65°C) Elution Buffer and left to stand at room temperature for 5 minutes 
before being centrifuged at 13000xg for 1 minute. DNA samples extracted from the 
same blood sample were then pooled and DNA samples were stored at -70°C. 
 
2.2.3 Quantification of DNA 
DNA samples were quantified using a ND1000 Spectrophotometer (Labtech 
International Ltd, UK). The ND1000 was first initialised with 1.5µl of distilled H2O and 
a blank measurement was taken using 1.5µl of Elution buffer. 1.5µl of each sample was 
then loaded onto the ND1000 and was measured. Extracted DNA samples with a 
concentration lower than 50ng/µl were precipitated following the method described 
below. 
 
2.2.4 Precipitation of DNA 
Where low concentrations of extracted DNA were obtained, DNA was precipitated to 
give a higher concentration. This involved the addition of 2x volume of ice cold 100% 
ethanol, 1/8x volume of 5M NaCl and 1µl glycogen. Samples were incubated overnight 
at -70°C. Samples were then centrifuged at 14000xg for 30 minutes and 200µl of ice 
cold 70% ethanol was added to the supernatant. A 5 minute spin step then followed and 
after the supernatant was removed, the pellet was left to air dry for 30 minutes. The 
samples were then re-suspended in 30µl DEPC-treated water and were quantified on the 
ND1000 Spectrophotometer (Labtech International Ltd, UK).  
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2.3 Bisulphite modification of DNA 
Two distinct methods were utilised within this project to quantify DNA methylation, 
namely Illumina HumanMethylation450 BeadChip (Section 2.4) and Pyrosequencing 
(Section 2.5). Both methods require a prior modification of the DNA samples to enable 
the distinction of methylated from unmethylated cytosine bases, which was achieved by 
bisulphite conversion.  
The Zymo EZ DNA Methylation Gold TM Kit (Cambridge Biosciences, UK) which 
uses sodium bisulphite to convert unmethylated cytosine residues to uracil and 
subsequently allows the detection of methylated cytosines was used to bisulphite 
modify the DNA samples. 500ng of DNA was added to 130µl CT reagent and the 
following temperature steps were run on a thermocycler (SensoQuest GmnH, 
Germany): 98°C for 10 minutes, 64°C for 2.5 hours and held at 4°C for up to 20 hours.  
The DNA samples were added to Zymo-Spin TM IC columns (Cambridge Biosciences, 
UK) each containing 600µl of M-binding buffer. After a centrifugation step, 100µl of 
M-Wash Buffer was added to the columns followed by 200µl of M-Desulphonation 
Buffer, and 2x 200µl M-Wash Buffer. Each addition was punctuated with a 
centrifugation step. Bisulphite modified DNA was eluted in 15µl of M-Elution Buffer.  
2.3.1 Quality control 
To check that the bisulphite modification had proceeded to completion i.e. all 
unmethylated cytosines had been converted to uracil, a PCR specific for converted 
DNA and a PCR which amplifies unconverted DNA was performed.   
 
The following primers were used:  
Unconverted: B2M - Forward: CACTGAAAAAGATGAGTATGCC 
            Reverse: AACATTCCCTGACAATCCC 
Converted: IGSF9 - Forward: 5Biosg/TTAAGGTAGTTTTGGTA 
           Reverse: CATAAATCCAATAAATAATCTT 
 
The PCR mastermixes and PCR conditions used were as follows:  
The B2M mastermix was made as follows: 12.5µl 2x Hotstar TAQ Mastermix (Qiagen, 
UK), 5.5µl dH2O, 0.5µl of 100pmol/µl forward primer, 0.5µl of 100pmol/µl reverse 
primer and 1.0µl BM DNA. The following temperature steps were performed on a 
thermocycler (SensoQuest GmbH, Germany): 95°C for 15 minutes, then 30 cycles of 
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95°C for 15 seconds, 62°C for 30 seconds and 72°C for 15 seconds, followed by 72°C 
for 5 minutes and held at 6°C. 
 
The IGSF9 mastermix was made as follows: 12.5µl 2x Hotstar TAQ Mastermix 
(Qiagen, UK), 3.0µl of 25mM MgCl2 (Qiagen, UK), 1.5µl dH2O, 1.0µl of 100pmol/µl 
forward primer (biotin labelled) and 1.0µl of 100pmol/µl reverse primer and 1.0µl BM 
DNA. The following temperature steps were performed on a thermocycler (SensoQuest 
GmbH, Germany): 95°C for 15 minutes, then 45 cycles of 95°C for 15 seconds, 53°C 
for 30 seconds and 72°C for 15 seconds, followed by 72°C for 5 minutes and held at 
6°C. 
 
The PCR products were then run on a 1% agarose gel to confirm the bisulphite 
modification was complete in all samples. In the B2M reaction, only the unconverted 
DNA should be amplified whereas in the IGSF9 reaction, only the converted DNA 
should be amplified.  
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2.4 Illumina HumanMethylation450 BeadChip sample preparation 
Epigenome wide discovery analyses were performed in the first instance using the 
Illumina HumanMethylation450 (HM450) BeadChip. This microarray system 
simultaneously quantifies DNA methylation levels at 485,577 single base (cytosine) 
positions across the genome, covering 98.9% of UCSC RefGenes with multiple probes 
per gene (Bibikova et al., 2011). Even though such a large number of CpG sites are 
included in the array this equates to only 1.7% of all CpG sites within the human 
genome (Kim et al., 2012b). The vast majority (99.3%) of these cytosine loci are in 
CpG sites. 200,339 CpGs are located within gene promoters. 150,254 of these CpG sites 
are found within CpG islands. An even greater proportion of CpG sites are found within 
the open sea. 361,766 CpGs correspond to coding messenger RNA genes, only 4,168 
CpG sites included in the array are non-coding and 119,830 and intergenic. The HM450 
includes CpG sites from all 22 autosomal chromosomes as well as the two sex 
chromosomes. Chromosome 1 has the most CpG sites included in the array with 46,867 
and unsurprisingly the Y chromosome has the fewest with only 416. Figure 7 shows an 
overview of CpG sites in relation to functional region, genomic location, associated 
RNA transcripts and chromosome location (Sandoval et al., 2011). 
 
The HM450 analyses twelve human DNA samples on each BeadChip. Each BeadChip 
consists of a number of beads with long target-specific probes to interrogate individual 
CpG sites. The HM450 uses two different Infinium probe chemistries. 135,501 Infinium 
I probes are present alongside 350,076 Infinium II probes. Infinium I probes have two 
separate beads per CpG locus; one which binds and extends along methylated DNA and 
the other which binds and extends along unmethylated DNA. Hence, they are tagged by 
and scanned using the same fluorescent dyes. The methylation status is deduced by the 
ratio of the signal intensities between them. Infinium II probes require just one bead 
type which can bind and extend along either methylated or unmethylated DNA. The 
distinction between them is made by different fluorescent dye tags. For instance, when 
bound to methylated DNA the primer is extended with the use of a green labelled 
dideoxynucleotide triphosphates (ddNTP) compared to a red labelled ddNTP for 
unmethylated DNA. Infinium II probes, due to the reduced space they require enable the 
HM450 platform to interrogate more CpG sites, however the use of two colour channels 
gives rise to the possibility of dye bias which needs to be adjusted for in data 
normalisation (Section 2.5.2). 
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Figure 7: Description of CpG sites included on the HM450 BeadChip. A. Functional genomic distribution 
(FGD) and number of CpGs within each group. B. CpG content within genomic location. C. Associated 
RNA transcripts and number of CpGs. D. Number of CpGs within each chromosome. (Figure taken from 
Sandoval et al., 2011). 
 
Aliquots of 5µl bisulphite modified DNA were sent to the University of Bristol for 
processing and analysis using the Illumina HM450 BeadChip. The samples were first 
treated with a whole genome amplification step followed by the enzymatic 
fragmentation. The fragmented and re-suspended DNA samples were loaded onto the 
BeadChips which were then incubated at 48°C in the Illumina Hybridization Oven for 
16-24 hours. Any unhybridised fragments were washed away and a TEM reagent used 
to extend the primers hybridised to DNA on the BeadChip, which was then stained. The 
BeadChips were then imaged on an Illumina iScan; a confocal laser scanning system 
(Illumina, USA). Data were output as raw intensity (.idat) files. Each DNA sample has 
two .idat files – one red and one green. Data were then taken forward for normalisation 
and analysis. 
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2.5 HM450 data pre-processing 
 
2.5.1 Sample quality control 
Data were exported from the iScan System in .sdf and .idat files and uploaded into the 
manufacturer’s GenomeStudio software for quality control (QC) assessment. The 
HM450 BeadChip uses several types of controls for quality assurances including both 
sample-independent and sample-dependent controls. Sample-independent controls 
evaluate the quality of specific steps in the process. These include staining controls, 
extension controls, target removal controls and hybridisation controls. Sample-
dependent controls allow the performance across samples to be evaluated. These include 
bisulphite conversion, specificity controls, non-polymorphic controls and negative 
controls. These controls are described in more detail below (Illumina User Guide v1.8). 
 
The most basic are the staining and extension controls. Staining controls are used to 
examine the efficiency of the staining step, independent of the hybridisation and 
extension step. Extension controls are used to test the extension efficiency of A, T, C 
and G nucleotides from a hairpin probe. 
 
Synthetic targets are present in the hybridisation buffer and complement the sequence 
on the array perfectly, thereby allowing the probe to extend on the synthetic target 
producing a signal. The synthetic targets are present at various concentrations – high, 
medium and low and therefore the beads should give off signals at various intensities. 
Signal intensity should increase as the synthetic target concentration increases. The 
hybridisation controls use these synthetic targets to test the overall performance of the 
entire assay.  
 
The hybridisation buffer also contains target removal probes which test the efficiency of 
the stripping step after the extension reaction. Compared to the hybridisation controls, 
the signal of the target removal probes should be much lower, indicating that the targets 
were successfully removed following extension.  
 
Two sets of controls are present to assess the efficiency of the bisulphite conversion 
step; one based on the Infinium I probe design and the other based on the Infinium II 
probe design. For the Infinium I probe design there are two probes. One binds to 
unconverted DNA and the other to converted DNA. Both are subsequently extended and 
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signals detected using the same colour channel. For Infinium II, the converted and 
unconverted probes are extended and detected by distinct signals i.e. red and green. 
Ultimately, extension of either type of unconverted probe indicates the presence of 
unconverted DNA and an incomplete bisulphite conversion step.   
 
There are also two types of specificity controls. The first, designed for Infinium I 
probes. Each chip includes a number of randomly permutated sequences or negative 
controls that should not hybridise to the DNA template. They are used to define system 
background.  
 
Non-polymorphic controls are also included to test the overall performance of the assay. 
Assay performance is assessed across different samples with a particular base being 
queried in a non-polymorphic region of the bisulphite modified genome.   
 
These controls can be visualised in the Controls Dashboard in GenomeStudio and those 
sample positions that do not meet the quality standard, as recommended by the 
manufacturer, were excluded from any further analysis. 
 
Two data files were exported from GenomeStudio. The first included the methylation 
data as raw signal intensities (red and green) with no background correction or data 
normalisation, along with other measures relating to QC and probe design. The 
variables included are defined in Table 3. The second data file included the control data.   
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Variable Definition 
Detection PVal The chance that the target sequence signal was 
distinguishable from the negative control 
Avg_NBEADS Average number of beads per probe for gene 
TargetID Probe name identifier 
CHR Chromosome on which target is found 
Color_Channel Colour channel 
INFINIUM_DESIGN_TYPE Assay type – Infinium I or Infinium II 
Probe_SNPs Assays with SNPs present within probe >10bp from 
query site 
Probe_SNPs_10 Assays with SNPs present within probe<10bp from 
query site 
UCSC_Refgene_Name UCSC gene name 
UCSC_Refgene_Accession UCSC accession number 
USCS_Refgene_Group UCSC gene region category 
Relation_to_UCSC_CPG_Island Relationship to CpG island: shore or shelf 
Mapinfo Probe position for hg19 
COORDINATE_36 Probe position for hg18 
STRAND Design strand 
Table 3: Defined variables exported from GenomeStudio. (Adapted from Illumina User Guide v1.8). 
 
2.5.2 Probe quality control and normalisation 
In addition to assessing the quality of data at the sample level, HM450 data QC was also 
assessed at the probe level. In each of the following probe filtering steps, the default 
parameters set by Touleimat and Tost (2012) were used. Firstly, a detection p value 
threshold of 0.01 was set and individual samples were dropped if more than 20% of 
probes reported detection p values greater than this. Secondly, it is expected that on 
average fifteen beads per probe will be hybridised to the BeadChip in any given 
experiment. The greater the number, the more reliable the data becomes, as it is taken as 
an average across the beads. Consequently, if for any reason only a small number of 
beads hybridise to the chip, the resulting data could be considered less robust. For this 
reason, probes with less than three beads were dropped from the analysis. Finally, a 
number of probes were dropped due to analytical concerns. These include; allosomal 
probes, which due to sex biases require separate analysis (Touleimat and Tost, 2012); 
65 probes that were included on the array to genotype SNPs rather than measure 
methylation but can be used for sample QC and mix-up detection; probes spanning 
genetic variants (minor allele frequency>5% in the Caucasian population) that may 
influence probe hybridization and thus methylation levels detected (Touleimat and Tost, 
2012). Figure 8 reveals the number of probes dropped from analysis during the filtering 
steps. 
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Figure 8: Number of probes dropped at each stage during probe filtering. 
 
As with all microarray data, data resulting from the HM450 BeadChip are susceptible to 
technical artefacts and batch effects. Technical variation refers to variation resulting 
from technical factors rather than biological differences between samples. A number of 
technical factors as well as batch effects (differences seen between groups of samples 
processed at different times or in separate sets) can affect HM450 data. Some of these 
effects may arise from differences in the handling of samples, such as DNA extraction 
or bisulphite modifications done in batches. Similarly, differences arising in the 
processing of DNA samples prior to being scanned, such as labelling and hybridisation 
can cause a batch effect. The location of the samples on the chip may also affect the 
level of staining experienced by each sample. Background noise can vary between 
different scans as well as other technical variation that arises due to the two probe 
chemistries included in the array and the use of two colour channels giving rise to probe 
type bias and colour dye bias, respectively (Sun et al., 2011). Hence, a three step 
normalisation process was performed on the data following filtering and QC. Firstly, the 
signal intensities measured by negative controls were used to correct for background 
noise. Secondly, as the HM450 uses two colour channels, the intensities measured in the 
two colour channels might be imbalanced due to biases in labelling and scanning so 
colour correction was required to make these data comparable. Finally, an adjustment 
for probe type bias was performed, which is described below. 
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 A number of normalisation packages have been developed for use with the HM450 
data. Some of these methods only adjust for colour, others only for probe type and most 
do not enable any pre-filtering steps to be carried out. However, the HM450 analysis 
pipeline proposed by Touleimat and Tost (2012) which encompassed all of these steps 
was applied to the data analysed in this thesis. Following sample and probe filtering (as 
described above), background and colour correction, this package performs a probe type 
correction based on subset quantile normalisation (SQN). SQN is a method used to 
adjust for the two different probe types being used and enables data generated from 
them to be more comparable. There are two reasons SQN is performed. The first reason 
is that the probes capture CpG sites located randomly across the genome and, for 
biological reasons (1.3.3.2), sites mapping to similar genomic regions demonstrate 
distinct levels of methylation. For example, sites in CpG islands are generally 
unmethylated; sites in non-CpG islands are generally highly methylated. Secondly, the 
numbers of type I and type II probes mapping to these distinct regions vary greatly. This 
specific SQN process takes these genomic regions into account by performing quantile 
normalisation on subsets of probes based on their genomic location (e.g. CpG island or 
shore) rather than across the full 450K probes as a whole. Infinium I probes are used as 
anchor probes to estimate the reference quartiles to which the Infinium II probes are 
normalised. There are a group of anchor probes for each type of genomic region 
(Touleimat and Tost, 2012).    
 
As a final step of pre-processing, any data points with a corresponding detection p value 
greater than 0.01 and not removed via sample filtering were dropped (i.e. converted to 
missing) in the data set. Any probes in which more than 90% of samples had missing 
data were dropped.  
 
2.5.3 Methods used for data summary, visualisation and diagnostics 
Graphs showing data before and after normalisation were plotted in R (version 2.15.0).  
 
Density plots are similar to histograms but are presented as a continuous line rather than 
adjacent bars. These show the proportion of probes on the y-axis with a methylation 
value measured at the corresponding point on the x-axis. The shape of the line gives a 
representation of the methylation values across all >450K probes for each individual. 
Each sample is represented on the graph with a separate line. By overlaying the lines in 
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this way it is easier to visualise and compare the methylation distributions across 
samples. If any samples stand out particularly, it suggests their distribution is somewhat 
different to the others. There may be a biological reason for this but this approach can 
also help to detect poor assays. Density plots were plotted in R. 
 
Hierarchical cluster analysis was performed using the complete-linkage method which 
compares the most distant samples within each group to find and cluster with the closest 
group. The complete-linkage method was chosen over single-linkage due to the number 
of samples used in the analysis and the shape of the dendrogram produced. Cluster 
analysis was performed to identify natural groupings (either phenotypic or technical) 
amongst the samples based on the methylation data. All cluster analysis was performed 
in R. 
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2.6 Pyrosequencing  
 
2.6.1 Selection of top hits 
To select which CpG sites from the HM450 analysis to follow up, a ranking system was 
put in place to prioritise the sites most likely to be real associations and which could be 
selected for follow up. CpG sites showing differential methylation between the outcome 
measures were ordered by p value with the most statistically significant difference being 
ranked number one. Figure 9 outlines two different approaches taken to select top hits 
for further interrogation.    
 
 
Figure 9: Two approaches used to select top hits for Pyrosequencing. Step 3 refers to the expected 
relationship between DNA methylation and gene expression in promoter regions (i.e. an inverse 
relationship) however it is recognised that this relationship is not true within gene bodies. Although this 
step has its limitations it was successful at reducing the number of top hits suitable for Pyrosequencing.   
 
2.6.2 Primer design 
Using the “View DNA” feature on the BLAST-like alignment tool (BLAT) genome 
browser, the 400bp upstream of the CpG site’s sequence and the 400bp downstream of 
the CpG site’s sequence were acquired. This 922bp genomic sequence was then copied 
and pasted into Microsoft Word to undergo in silico bisulphite modification. In many 
laboratory methods assessing DNA methylation, bisulphite modification is a key step. 
This treatment results in the deamination of unmethylated cytosine residues to uracil, 
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whilst 5-methylcytosines remain unchanged. This effectively induces a SNP at 
unmethylated cytosines thereby fixing the methylation pattern allowing detection. For 
this reason, most downstream methylation assays require bisulphite modified DNA as 
the input material. The in silico bisulphite modification step is a simple but important 
step of the process as it is bisulphite modified DNA which is required to design primers 
for subsequent PCRs. The aim of this step is to replace all unmethylated cytosines with 
uracil but leave methylated cytosines unchanged. By merely looking at a genomic DNA 
sequence it is impossible to know which CpG sites are methylated so the first step is to 
protect all potentially methylated CpG sites from undergoing deamination by replacing 
the CG in the sequence with XG. As methylation only occurs at CpG sites, all other 
cytosine residues in the DNA sequence are deaminated, meaning all C residues are 
replaced with T, depicting the real base change occurring when genomic DNA is treated 
with sodium bisulphite. The final step is to replace all XG residues (the CpG sites) with 
C/TG. This change represents the two possible alleles (C or T) which may be present 
depending on the methylation status of each CpG site in the sequence. These bisulphite 
modified sequences which encompass the CpG site of interest were then analysed using 
the PSQ Assay Design software (Qiagen, UK). The entire sequence was inputted into 
the software and the target region was manually set as the CpG site included on the 
HM450 array. The software then tried to find suitable forward, reverse and sequencing 
primers for each CpG site. Wherever possible, primers were designed not only for the 
CpG site included on the array but for at least one additional CpG site either side of the 
target CpG site. All default parameters were used. The software gives a score ranging 
from 0 to 100 for each primer set. A score of 0 means that no primers were available for 
the selected CpG site/s. A score close to 100 means that the primers are very likely to be 
successful in amplifying the DNA and providing a robust Pyrosequencing assay. In this 
study, no primers were taken forward that had a score of less than 70. The success rate 
in finding suitable primers was around 50%. All suitable primers generated by the assay 
design software were ordered for synthesis by Integrated DNA Technologies (IDT, 
USA). 
 
2.6.3 Primer optimisation   
To test for the optimum PCR conditions, two Pyrosequencing PCR Mastermixes were 
made up for each assay; one containing MgCl2 and one excluding MgCl2. The 
Mastermix including MgCl2 was made as follows: 6.25µl Hotstar TAQ Mastermix 
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(Qiagen, UK), 1.5µl of 25mM MgCl2 (Qiagen, UK), 2.75µl dH2O, 0.5µl of 100pmol/µl 
forward primer and 0.5µl of 100pmol/µl reverse primer (one of which is biotin 
labelled). The Mastermix excluding MgCl2 was made as follows: 12.5µl Hotstar TAQ 
Mastermix (Qiagen, UK), 4.25µl dH2O, 0.5µl forward primer and 0.5µl reverse primer 
(one of which is biotin labelled). 1µl of pooled BM DNA was added to 11.5µl of 
Mastermix in each well. A gradient PCR spanning 50-60°C was also run to determine 
the optimum annealing temperature (Tm).  The PCR was run on a thermocycler 
(SensoQuest GmbH, Germany) under the following conditions: 95°C for 15 minutes, 
then 45 cycles of 95°C for 15 seconds, gradient for 30 seconds and 72°C for 15 seconds, 
followed by 72°C for 5 minutes and held at 6°C. The composition (with/without 
MgCl2) and temperature which produced the strongest band on a 1% agarose gel was 
selected for subsequent PCRs.  
 
2.6.4 Agarose gel 
0.7g agarose was dissolved in 70ml Tris-Borate-EDTA (TBE) buffer to make a 1% 
agarose gel. 4µl of SafeView (NBS Biologicals, UK) was added and poured into a gel 
tray, combs inserted and left to set. 5µl loading buffer and 5µl of BM DNA was loaded 
into each well, with 4µl of Gene RulerTM 100bp DNA Ladder (Fermentas, International) 
loaded at either side of the gel. 
 
2.6.5 Assay validation 
Epitect PCR controls (Qiagen, UK) containing a 100% methylated DNA sample and a 
0% methylated DNA sample were used to make a range of reference methylation levels 
ranging from 0% to 100%. To provide an accurate validation and confirmation of no 
preferential amplification of either methylated or unmethylated DNA, samples were 
mixed both pre-PCR and post-PCR. The following tables show how the samples were 
produced for the pre-PCR mix (Table 4) and post-PCR mix (Table 5). All samples were 
run in duplicate. 
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Methylation (%) Amount of methylated 
(100%) Epitect control (µl) 
Amount of unmethylated (0%) 
Epitect control  (µl) 
95 34.9 of 100% 1.9 
90 26.8 of 95% 1.5 
75 18.3 of 90% 3.7 
50 12 of 75% 6 
25 8 of 50% 8 
10 6 of 25% 9 
5 5 of 10% 5 
Table 4: Pre-PCR mix. 
 
The same conditions were used for the PCR mastermix and Pyrosequencing PCR as 
previously described. 
 
Methylation (%) Amount of methylated 
(100%) Epitect control (µl) 
Amount of unmethylated (0%) 
Epitect control (µl) 
95 87.4 of 100% 4.6 
90 67 of 95% 3.75 
75 45.75 of 90% 9.25 
50 30 of 75% 15 
25 20 of 50% 20 
10 15 of 25% 22.5 
5 12.5 of 10% 12.5 
Table 5: Post-PCR mix. 
 
2.6.6 Pyrosequencing 
In each well of a PCR plate, 2µl of Streptavidin Sepharose beads (GE Healthcare Life 
Sciences, UK), 38µl of binding buffer (Qiagen, UK) and 20µl of H2O were added along 
with 10µl of BM PCR product. The plate was mixed on a plate shaker (Grant 
Instruments, UK) vigorously for at least 5 minutes. To each well on the Pyrosequencing 
plate, 0.5µl 10uM sequencing primer and 11.5µl annealing buffer were added. Samples 
were then cleaned up to single stranded DNA using the Vacuum Prep Workstation 
(Qiagen, UK). The vacuum block tool was used to remove the PCR product and bead 
mix (biotin labelled primer bound to bead) from the PCR plate, before a rinse with 
ethanol to remove any unwanted soluble PCR components. Double stranded DNA was 
then denatured to single stranded DNA (ssDNA) by aspirating denature buffer and the 
probe block was then placed in a wash buffer to clean the ssDNA. The vacuum was then 
switched off and DNA bound to beads was then deposited in the Pyrosequencing plate 
containing the annealing buffer and sequencing primer. The Pyrosequencing plate was 
then incubated at 80°C for 2 minutes to allow the primers to anneal and then placed in 
the Pyrosequencer, which had previously been equipped with appropriate amounts of an 
78 
 
 
 
enzyme mix, a mixture of substrates and deoxynucleotide triphosphates. Components of 
each reagent are listed in Table 6. By using a series of algorithms to calculate the most 
efficient use of bases to complete the sequence, the Pyrosequencing software generates 
a nucleotide dispensation sequence. This dispensation order includes a number of 'spike' 
nucleotides which are randomly placed to ensure the sequence being assayed conforms 
to the input sequence. The samples were then run in duplicate on a Pyromark MD 
Pyrosequencer (Qiagen, UK). A negative control (containing no DNA) along with a 
100% and 0% methylation control were included in every run. Methylation values are 
displayed as percentage methylation. The Pyrosequencer cannot accurately detect 
methylation differences less than 5% (Mikeska et al., 2011), therefore the duplicate 
pairs must be within 5% of one another. Any pairs discordant by 5% were repeated. The 
dispensation order for each validated assay is provided in Appendix A. 
 
Pyrosequencing Reagents Components 
Binding buffer 10mM Tris-HCL;2M NaCl, 1mM EDTA, 0.1% TweenTM 20 
Denaturation solution 0.2M NaOH 
Wash buffer 10mM Tris-Acetate 
Annealing buffer 20mM Tris-Acetate, 2mM Mg-Acetate 
Enzyme Mixture DNA polymerase, sulfurylase, luciferase, apyrase 
Substrate Mixture Adenosine 5’phosphosulfate, luciferin 
Table 6: Components of each Pyrosequencing reagent. 
 
2.6.7 Pyrosequencing quality control 
In addition to running samples in duplicate, repeating any samples that exceeded the 5% 
discordance threshold and running a negative control (containing no DNA) as already 
mentioned, an additional QC step was taken. As Pyrosequencing measures DNA 
methylation using bisulphite modified DNA sequences, it was essential to ensure that 
the bisulphite conversion step proceeded to completion. Where possible, each assay 
included at least one bisulphite treatment control in the dispensation sequence. As 
cytosines which are not part of a CpG site should be converted to thymine residues 
following bisulphite treatment, there should be no non-CpG site cytosine residues in the 
dispensation sequence. By inserting a cytosine residue into the dispensation sequence, it 
is possible to check whether any unconverted cytosines are still present in the bisulphite 
modified DNA as a result of an unsuccessful/incomplete bisulphite conversion. 
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2.7 Other laboratory techniques 
A number of experiments were performed to assess the functional significance of any 
top hits successfully validated via Pyrosequencing. These include quantification of 
RNA and protein and subsequent western blots. 
 
2.7.1 Tissue RNA extraction 
Sections of DLPFC and hippocampus were provided from the NBTR for RNA 
extraction. To extract RNA from the brain tissue the E.Z.N.A.® Tissue RNA Kit 
(OMEGA bio-tek, USA) was used and the standard Tissue RNA Spin protocol was 
followed. The extraction protocol was performed on DLPFC pieces weighing 
approximately 30mg and hippocampus sections weighing approximately 15mg. In a 
containment level 2 tissue culture facility, each tissue section (30mg/15mg) was added 
to 300µl TRK Lysis Buffer which contained 20µl 2-mercaptoethanol per 1ml TRK. 
Samples were mixed on a thermoshaker (Grant Instruments, UK) until all tissue had 
lysed. Following lysis, 590µl RNase-free water and 10µl OB protease was added and 
samples were incubated at 55°C for 10 minutes on a thermoshaker (Grant Instruments, 
UK). Following a 5 minute centrifugation step at 14000xg, the supernatant was 
transferred to a clean 1.5ml microcentrifuge tube and was mixed with 450µl absolute 
ethanol. 700µl sample was transferred into a HiBind RNA Spin Column and was 
centrifuged at 10000xg for 1 minute. This centrifugation step was repeated until the 
entire sample had been transferred to the column. A series of three wash steps then 
followed; 1x 700µl of RNA wash buffer I, 2x 500µl RNA wash buffer II. Each wash 
step was punctuated by a centrifugation step. The column was then centrifuged at 
13000xg for 2 minutes to completely dry the membrane. Samples were eluted in 40µl 
DEPC-treated water and stored at -70°C. 
 
2.7.2 Blood RNA extraction 
RNA was extracted from frozen blood using the standard Isolation of Total RNA from 
Blood Protocol as outlined in the E.Z.N.A.® Blood RNA Kit (OMEGA bio-tek, USA). 
To 150µl of whole blood, 750µl ERL buffer was added and incubated on ice for 15 
minutes or until lysis of red blood cells was complete and the solution became 
translucent. Samples were then centrifuged at 400xg at 4°C for 10 minutes to pellet the 
leukocytes and the supernatant was removed and discarded. Cells were then re-
suspended in 300µl ERL buffer. Samples then underwent a second centrifugation step at 
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400xg at 4°C for 10 minutes and again the supernatant was discarded. White blood cells 
were lysed in 400µl NTL lysis buffer, containing 20µl 2-mercaptoethanol per 1ml NTL 
and the entire sample was transferred to a Homogeniser column. After a centrifugation 
step at 13000xg for 2 minutes, the filtrate was added to 400µl 70% ethanol. 700µl of 
sample was transferred to a HiBind RNA column and centrifuged at 10000xg for 30 
seconds. This centrifugation step was repeated until the entire sample had been 
transferred to the column. A series of wash steps followed. First, 500µl RWF wash 
buffer and 2x 700µl of Wash buffer II, each step punctuated by a centrifugation step at 
10000xg for 30 seconds. Columns were then centrifuged at 13000xg for 2 minutes to 
completely dry the column membrane. Samples were eluted in 50µl DEPC-treated 
water and stored at -70°C. 
 
2.7.3 Quantification of RNA 
RNA samples were quantified using a ND1000 Spectrophotometer (Labtech 
International Ltd, UK). The ND1000 was first initialised with 1.5µl of distilled H2O and 
a blank measurement was taken using 1.5µl of DEPC-treated water. RNA samples were 
also analysed using an Agilent 2100 Bioanalyser. 36 samples were analysed across 3 
chips. The RNA samples were heat denatured for 2 minutes at 70°C and immediately 
snap-frozen along with the RNA ladder. 1µl of dye concentrate was added to 65µl of 
filtered gel matrix. After decontaminating the electrodes with both RNaseZap and 
RNase-free water, the chip was loaded into the chip priming station. 9µl of gel dye mix 
was loaded into the well marked G. The plunger was then compressed and held for 30 
seconds. After releasing the plunger, 9µl of the gel-dye mix was loaded into wells. 5µl 
of the NanoMarker was added into each of the 12 sample wells as well as the ladder 
well. In addition, 1µl of ladder was loaded into the ladder well and 1µl of each sample 
was loaded into each of the samples wells. After vortexing the chip to ensure thorough 
mixing, the chip was loaded into the Agilent 2100 Bioanalyser and the run was initiated. 
This process was repeated for each chip and was cleaned with RNaseZap and distilled 
water after the last run was complete.  
 
2.7.4 Protein extraction 
100µg DLPFC and 4x100µM sections of hippocampus were homogenised in 400µl 
extraction buffer (50mM Tris-HCl, 5mM EGTA, 10mM EDTA, pH 7.4) (Kirvell et al., 
2010), containing a protease and phosphatase inhibitor (Thermo Scientific, USA), in a 
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Precellys 24 homogeniser (Bertin Technologies, France). After 3 x 20 second cycles in 
the Precellys 24, samples were then spun in a centrifuge at 13000rpm for 30 minutes 
and the supernatant was carefully removed and stored at -20°C.  
 
2.7.5 Protein quantification 
Proteins were quantified using the Thermo Scientific™ Pierce™ BCA™ Protein Assay 
(Thermo Scientific, USA). Standards (n=9) were made by mixing Bovine Serum 
Albumin (BSA) of a known concentration with Phosphate Buffered Saline (PBS) as 
shown in Table 7.  
 
Vial Volume of diluent 
(µL) 
Volume and source of BSA 
(µL) 
Final BSA Concentration 
(µg/mL) 
1 0 30 of stock 2000 
2 12.5 37.5 of stock 1500 
3 32.5 32.5 of stock 1000 
4 17.5 17.5 of vial 2 750 
5 32.5 32.5 of vial 3 500 
6 32.5 32.5 of vial 5 250 
7 32.5 32.5 of vial 6 125 
8 40.0 10 of vial 7 25 
9 40.0 0 0 
Table 7: Dilution factors for standards to be used in protein quantification. 
 
25µl of each standard and 5µl of protein sample were placed into a well of a clear 96 
well microwell plate (Beckman Coulter, USA). 200µl of WR (50 parts BCA Reagent A: 
1 part BCA Reagent B) was added into each well containing standard or protein sample. 
In addition 200µl of WR was added into a blank well containing 25µl of PBS.  The 
plate was mixed for 30 seconds, covered and incubated at 37°C for 30 minutes. Once 
cooled, the plate was placed in a FLUOstar Omega plate reader (BMG Labtech, 
Germany) and absorbance was measured at 562nm. The absorbance of the blank well 
was subtracted from all wells and a standard curve was calculated which was then used 
to calculate the concentrations of the unknown protein samples using the Omega Mars 
software (BMG Labtech, Germany). Protein samples were then standardised to 25µg 
and made up to 15µl using the extraction buffer described in Section 2.7.4. An equal 
mix of all DLPFC samples and hippocampal samples were made to be used as standards 
in each Western blot.  
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2.7.6 Western blots 
 
2.7.6.1 Antibody optimisation 
To assess the optimal blotting conditions for the primary antibodies, four different 
conditions were tested shown in Table 8. 
 
Conditions tested Blocking Agent Primary Antibody 
Diluent 
1 5% milk 5% milk 
2 5% milk 1% milk 
3 5% BSA 5% BSA 
4 5% BSA 1% BSA 
Table 8: Four different primary antibody conditions. 
 
The conditions which resulted in a strong band with little background were selected as 
the optimum conditions for the primary antibody.  
 
2.7.6.2 Western blot 
 
Firstly, all the buffers required for the Western blot were made, as outlined in Table 9.   
 
Buffer Ingredients 
1L 10X Running Buffer 30.3g Tris base, 144g glycine and 10g SDS 
1L 10X Transfer Buffer 144g glycine and 30.3g Tris base 
1L 10X TBS Tween 20 (TBST) 12.11g Tris base, 29.22g NaCl and 10ml Tween 20 
Table 9: Ingredients for all buffers used in Western blotting. 
 
2.7.6.2.1 Acrylamide gel 
90ml 1X running buffer was added to each Amersham ECL Gel Box System (GE 
Healthcare Life Sciences, UK) and the precast Amersham ECL 12% gel (GE Healthcare 
Life Sciences, UK) was rinsed, inserted into the gel tank and pre-run at 160V for 12 
minutes. Meanwhile, 15µl protein sample was mixed with 15µl Laemmli sample buffer 
(Sigma-Aldrich, USA) and heated to 96°C for 5 minutes using a thermocycler 
(SensoQuest GmbH, Germany). Once the pre-run was complete, the well comb was 
removed and 6ml 1x Running buffer was added into the wells. 25µl of the protein and 
loading buffer mix was then added into each well. On each gel, 10µl SpectraBr ladder 
(Fermentas, International) was added in one of the wells along with 25µl of the two 
standards described in Section 2.7.5. The gel was then run at 160V for 60 minutes.  
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2.7.6.2.2 Activation of the membrane 
The membrane was cut to size and covered in 100% methanol for 1 minute. The 
membrane was then equilibrated in 1X Transfer buffer until required. 
 
2.7.6.2.3 Blotting 
All equipment (transfer tank, cassette, sponges and filter paper) used in the protein 
transfer were soaked in 1X transfer buffer. Once the acrylamide gel was run, the 
blotting cassette was opened and a sponge placed on one side. Blotting paper was then 
added onto this sponge.  The gel was removed from the cast and the stacking gel was 
cut off. The gel was then added onto the filter paper and the membrane placed on top of 
the gel. An additional piece of filter paper and a sponge was added onto the transfer 
sandwich and a glass rod was used to remove any air bubbles that may impede the 
transfer of proteins from the gel onto the membrane. The cassette was then closed and 
added into the transfer tank. The tank was filled with 1X transfer buffer and covered in 
ice to ensure the transfer buffer was kept as cold as possible. The transfer was run at 
100V for 1 hour.  
 
2.7.6.2.4 Blocking with 5% milk 
5% milk (low-fat skimmed milk powder) was made up in 1X TBS-tween and the 
membrane was incubated in the 5% milk solution for 1 hour.  
 
2.7.6.2.5 Blotting with antibodies 
The membrane was then incubated with anti-NGF antibody (1:200 in 5% milk, rabbit 
polyclonal IgG) (SantaCruz Biotechnology) for 1 hour. The membrane was then washed 
in TBST 3x 5 minutes. The membrane was then incubated with anti-rabbit IgG antibody 
conjugated with horseradish peroxidase (HRP) (1:1000 in 1% milk) (Cell Signalling 
Technology, USA) for 1 hour, followed by 3x 5 minute washes in TBST.  
 
2.7.6.2.6 Imaging of membrane 
Equal parts of A and B taken from the Amersham ECL Prime Western Blotting 
Detection Reagent (GE Healthcare Life Sciences, UK) were mixed and washed over the 
membrane. The membrane was then covered in a thin plastic sheet and imaged using a 
Syngene G:Box camera (Syngene, UK) and Genesys software (Syngene, UK). 
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2.7.6.2.7 Loading standard 
To strip the membrane of the anti-NGF antibody the membrane was covered with 
Restore Western Blot Stripping Buffer (Thermo Scientific, USA) for 15 minutes. The 
membrane was then blocked with 5% milk and left at 4°C overnight. The membrane 
was then incubated with anti-alpha-tubulin (α-tubulin) antibody (which is used as a 
loading standard) (1:1000 in 1% milk, mouse monoclonal IgG) (Sigma-Aldrich, USA) 
for 1 hour. 3x 5 minute washes in TBST then followed. The membrane was then 
incubated in the secondary anti-mouse IgG antibody conjugated with HRP (1:1000 in 
1% milk) (Dako, Denmark) for 1 hour and washed 3 times for 5 minutes each in TBST. 
Again equal parts of A and B from the Amersham ECL Prime Western Blotting 
Detection Reagent (GE Healthcare Life Sciences, UK) were mixed and used to cover 
the membrane. A plastic film was used to cover the membrane and imaged using a 
Syngene G:Box camera (Syngene, UK) and Genesys software (Syngene, UK). 
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2.8 Statistical methods 
 
2.8.1 DNA methylation measures 
 
2.8.1.1 Methylation as a beta value 
Following normalisation of the Illumina HM450 data, a measure of methylation was 
given as a beta value, ranging from 0 to 1.  The beta value is the ratio of methylated 
probe intensity over the sum of the methylated and unmethylated probe intensities. The 
equation is shown below.  
 
𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵 𝑣𝑣𝐵𝐵𝑣𝑣𝑣𝑣𝐵𝐵 =  𝑚𝑚𝐵𝐵𝐵𝐵ℎ𝑦𝑦𝑣𝑣𝐵𝐵𝐵𝐵𝑦𝑦𝑦𝑦𝑦𝑦 𝑝𝑝𝑝𝑝𝑦𝑦𝑝𝑝𝐵𝐵 𝑦𝑦𝑦𝑦𝐵𝐵𝐵𝐵𝑦𝑦𝑖𝑖𝑦𝑦𝐵𝐵𝑦𝑦
𝑚𝑚𝐵𝐵𝐵𝐵ℎ𝑦𝑦𝑣𝑣𝐵𝐵𝐵𝐵𝑦𝑦𝑦𝑦𝑦𝑦 𝑝𝑝𝑝𝑝𝑦𝑦𝑝𝑝𝐵𝐵 𝑦𝑦𝑦𝑦𝐵𝐵𝐵𝐵𝑦𝑦𝑖𝑖𝑦𝑦𝐵𝐵𝑦𝑦 + 𝑣𝑣𝑦𝑦𝑚𝑚𝐵𝐵𝐵𝐵ℎ𝑦𝑦𝑣𝑣𝐵𝐵𝐵𝐵𝐵𝐵𝑦𝑦 𝑝𝑝𝑝𝑝𝑦𝑦𝑝𝑝𝐵𝐵 𝑦𝑦𝑦𝑦𝐵𝐵𝐵𝐵𝑦𝑦𝑖𝑖𝑦𝑦𝐵𝐵𝑦𝑦 
 
 
A beta value of 0 suggests that every copy of the CpG site is unmethylated (this can be 
interpreted as 0% methylated) and a value of 1 suggests that every copy of the CpG site 
is methylated (often interpreted as 100% methylation) (Du et al 2010).  
 
2.8.1.2 Methylation as a percentage 
The Pyrosequencer generates methylation values as percentage methylation ranging 
from 0% to 100%. 0% indicates that none of the copies of the CpG site are methylated 
whilst a value of 100% indicates that all copies of the CpG site are methylated. A value 
of 50% indicates that half of all copies of the CpG site are methylated whilst the other 
half of copies are unmethylated.  
 
2.8.2 HM450 data analysis 
The CpGassoc package (Barfield et al., 2012) which performs multiple linear regression 
analyses with continuous predictor variables and ANOVA for categorical predictor 
variables was implemented in R (version 2.15.0). For all analyses, age, sex and chip (i.e. 
the microarray chip upon which the samples were scanned) were included in the 
analysis model as covariates. The outcome variables for COGFAST and ICICLE are 
outlined in Glossary Tables 2 and 4, respectively.  
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2.8.2.1 Cell type adjustment 
 
2.8.2.1.1 Blood 
HM450 data were adjusted for cell composition using an algorithm described by 
Houseman et al. (2012). This algorithm is able to estimate the proportion of immune 
cells in unfractionated whole blood samples without the need to directly count 
proportions within fresh samples. The authors first identified the DNA profiles of each 
of the principal immune components of blood (B cells, granulocytes, monocytes, NK 
cells, T cell subtypes), then developed a regression calibration tool, which can be used 
to estimate cell distributions and act as a surrogate for cell distribution in subsequent 
analyses (Houseman et al., 2012). HM450 data analyses (i.e. CpGassoc) were repeated 
after adjustment for cell type to assess whether the DNA methylation differences were 
immunologically mediated.  
 
2.8.2.1.2 Brain 
HM450 data were adjusted for cell composition using CETS, an R package described 
by Guintivano et al. (2013). This package is able to estimate the proportion of neurons 
and glia in bulk brain tissue without the need to directly count proportions within fresh 
samples using Fluorescence Activated Cell Sorting (FACS) or laser capture 
microdissection. The authors first identified the DNA profiles of neurons and glia using 
prefrontal cortical tissue and then developed an algorithm, which can be used to 
estimate cell distributions and act as a surrogate for cell distribution in subsequent 
analyses (Guintivano et al., 2013). To best match the COGFAST cohort, the CETS 
package was modified to only include cell proportion data from healthy Caucasians. 
HM450 data analyses (i.e. CpGassoc) were repeated after adjustment for cell type to 
assess whether the DNA methylation differences were associated with cellular 
composition.  
 
2.8.2.2 Calculating methylation scores to predict smoking status 
Methylation values published by Zeilinger et al. (2013) were used as a reference data 
set (Zeilinger et al., 2013). Methylation at 183 CpG sites was used to calculate weighted 
methylation scores for each DNA sample. Median methylation values of never smokers 
identified by Zeilinger et al. (2013) were used as the reference values and the associated 
effect sizes were used as weights. The difference between the ICICLE beta value and 
reference beta value was calculated for each CpG site. The sum of all CpG site scores 
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was calculated to give a final weighted score. The threshold score able to distinguish 
current from never smokers was calculated using random forests (Breiman, 2001) in R 
(Version 3.1.0). 
 
2.8.2.3 Predicting age using DNA methylation 
The age of each blood and brain sample was predicted using the algorithm described by 
Horvath (2013). This script uses the methylation values at 353 CpG sites (measured on 
the HM450) to predict the age of each sample. In addition to predicted age, the 
algorithm also provides the age acceleration difference (difference between DNA 
methylation age and chronological age) and the age acceleration residual (residual from 
regressing DNA methylation age on chronological age, i.e. DNA methylation age 
corrected for chronological age).  
 
2.8.3 Pyrosequencing data analysis 
For all data passing QC, a mean methylation value for the duplicates was calculated and 
was used for all Pyrosequencing analyses. Pyrosequencing data were analysed using 
ANOVA with age and sex as covariates. All analysis was performed in Stata (Version 
11.2). 
 
2.8.4 Western blot analysis 
Band densitometry was utilised to calculate relative protein levels across multiple blots. 
The ImageJ software (National Institutes of Health, USA) is able to generate values for 
band intensity in gel lanes. For each gel, the NGF and α-tubulin blots were aligned and 
opened in ImageJ software (National Institutes of Health, USA). The rectangular 
selections tool was used to define lanes and these were opened in the profile plot 
analysis. Background was eliminated using the straight line tool and the wand tool was 
used to calculate the area under curve. The results were exported into Microsoft Excel. 
The values calculated for each antibody exposure were normalised to the mean of the 
standards loaded onto the gel.  
The relative value for NGF was calculated using the following: 
 
𝑅𝑅𝐵𝐵𝑣𝑣𝐵𝐵𝐵𝐵𝑦𝑦𝑣𝑣𝐵𝐵 𝑁𝑁𝑁𝑁𝑁𝑁 =  𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁 𝑁𝑁𝑁𝑁𝑁𝑁
𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁 𝛼𝛼−𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑁𝑁𝑁𝑁𝑡𝑡  
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Chapter 3. Blood-based methylation signatures as a predictor of post-
stroke dementia 
 
3.1 Introduction 
Post-stroke dementia (PSD) is a disabling consequence of a stroke, affecting 
approximately a third of stroke survivors (Pohjasvaara et al., 1998; Allan et al., 2011). 
Due to the increasingly ageing population and consequent rising prevalence of PSD, the 
associated healthcare costs are becoming a substantial burden to public healthcare 
services. In 2010, dementia cost the UK National Health Service over €22 billion and 
this figure is likely to be higher today (Fineberg et al., 2013). A key hurdle in the 
treatment of PSD is that we do not yet understand the mechanisms that follow stroke 
and which culminate in this disease. It is unclear why some stroke survivors develop 
dementia whilst others remain cognitively normal. It would therefore be beneficial to 
develop a method of predicting which stroke survivors are likely to develop dementia, 
so that early preventative treatments could be implemented for those individuals at 
highest risk.  
 
DNA methylation is an epigenetic mark closely involved in gene regulation and 
variation in DNA methylation is known to be associated with an array of complex 
phenotypic traits and common human diseases including cancer (Teschendorff et al., 
2009), cardiovascular disease (Baccarelli et al., 2010) and metabolic disorders 
(Grundberg et al., 2013). Epigenetic mechanisms, including altered DNA methylation 
patterns, have also been implicated in increased risk of both stroke (Endres et al., 2000; 
Castillo-Diaz et al., 2010) and dementia (Wang et al., 2008; Bollati et al., 2011; 
Bakulski et al., 2012a; Chouliaras et al., 2013). Although there are several reliable 
associations between DNA methylation and disease, a causal role of DNA methylation 
has not been demonstrated in many instances. It is conceivable that DNA methylation 
patterns, either pre-existing or resulting from the stroke itself, may contribute towards 
the long term prognosis in stroke survivors, including the variable and unpredictable 
pathogenesis of PSD in some survivors but not others. This mechanistic link requires 
the analysis of the diseased tissue (in this case the brain) (see Chapter 4 for further 
exploration of this issue). An alternative, complementary potential use of DNA 
methylation information is as a robust biomarker to predict disease or to aid prognosis. 
This does not require a causal relationship to be established, nor does it require the 
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target disease tissue to be studied. A surrogate, more readily accessible source of DNA, 
such as peripheral blood, can be used for this application. This is explored within this 
Chapter.  
  
DNA methylation marks, measured in both a global and gene-specific manner are 
beginning to emerge as biomarkers of disease risk and prognosis, particularly within the 
field of cancer. For instance, distinct DNA methylation profiles in tissue-specific and 
peripheral blood samples have been shown to be predictive of bladder (Marsit et al., 
2011), ovarian (Teschendorff et al., 2009) and lung cancer (Dietrich et al., 2012) as well 
as disease subtype in patients with medulloblastoma (Schwalbe et al., 2013). DNA 
methylation patterns have not only been associated with risk of disease development but 
also have been found to have prognostic value in cancer. In oesophageal 
adenocarcinoma patients, increased methylation of seven cancer-related genes was 
associated with reduced survival and tumour recurrence (Brock et al., 2003). The 
hypomethylation of one CpG site within ZAP-70 has been identified as a reproducible 
biomarker for poor prognosis in chronic lymphocytic leukaemia (Claus et al., 2012).  
 
This approach has yet to be applied in PSD. In this Chapter I have postulated that DNA 
methylation signatures, detectable in peripheral blood drawn after a stroke, will be 
predictive of subsequent cognitive decline and possibly overt dementia. To test this 
hypothesis, the prospectively collected COGFAST study is used (Section 2.1.1). This is 
a prospective study composed of individuals who have suffered a stroke, had biological 
samples collected and stored at this time and that have been followed up over several 
years with cognitive assessments undertaken at multiple intervals.  
 
 
 
 
 
 
 
 
90 
 
 
 
3.2 Experimental design 
General methods are described in Chapter 2, with additional details relevant to this 
investigation described in detail here.  
 
3.2.1 Study cohort 
The COGFAST study recruited 355 stroke survivors. A subset of 46 blood samples 
from the cohort (Section 2.1.1), all of whom were stroke survivors over the age of 75 at 
the time of stroke were utilised for this study. A diagnosis of dementia was made based 
on neuropsychometric testing and agreement with DSM IIIR and IV criteria for 
dementia, and confirmed by post-mortem (PM) neuropathological examination. To date, 
31 COGFAST subjects who came to autopsy have been diagnosed with dementia, with 
a similar number of individuals who were not demented at death. Data relating to 
clinical history, including details of stroke severity as well as stroke risk factors were 
available for analysis. Variables relating to the stroke event such as Oxfordshire 
Community Stroke Project score (OCSP), side of body affected and degree of weakness 
were collected at the time of stroke. Age at death, PM delay, Braak staging and years 
between stroke and death were collected at death. All other variables were collected at 
baseline (recruitment into study) and are described in the Glossary (Table 2). Samples 
used for the discovery analysis were selected from deceased participants, to enable 
neuropathological information to be utilised in the analysis. Blood samples were 
collected three months post-stroke, when all participants were cognitively normal, with 
a mini mental state examination (MMSE) score >24. Samples were divided into a 
‘discovery’ sample (n=30) and ‘Pyrosequencing’ sample (n=46), the latter consisting of 
the discovery sample and an additional sixteen samples all drawn from the same cohort.  
 
3.2.2 Blood DNA extraction, quantification and precipitation 
Blood samples were held in long-term storage at -80°C and were selected and removed 
from storage for the purposes of this study. DNA was extracted from 3ml blood using 
the standard Blood and Body Fluid Protocol as outlined in the EZNA Blood DNA Kit 
(OMEGA bio-tek, USA) (Section 2.2.2). DNA samples were quantified using a 
ND1000 Spectrophotometer (Labtech International Ltd, UK) (Section 2.2.3). Samples 
with a concentration lower than 50ng/µl were ethanol precipitated and re-suspended in 
30µl DEPC-treated water (Section 2.2.4) before requantification.  
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3.2.3 Illumina HumanMethylation450 BeadChip analysis 
Epigenome wide discovery analysis was performed using the Illumina 
HumanMethylation450 (HM450) BeadChip.  Thirty individuals with >1µg blood 
derived DNA were selected for discovery phase DNA methylation analysis. These 30 
samples included 17 participants diagnosed with dementia (D) and 13 cognitively 
normal (CN) participants, who were matched on sex and age within three years.  500ng 
of DNA from each sample was treated with sodium bisulphite, to convert unmethylated 
cytosine residues to uracil and subsequently allow the detection of methylated 
cytosines, using the Zymo EZ DNA Methylation GoldTM Kit (Cambridge Biosciences, 
UK). Bisulphite modified (BM) DNA was eluted in 15µl of M-Elution Buffer (Section 
2.3). To check that the bisulphite modification had been successful, a PCR specific for 
BM DNA and a PCR which amplifies unconverted DNA was performed (Section 2.3.1).  
The PCR products were run on a 1% agarose gel to confirm that the BM conversion was 
successful. Aliquots of 5µl BM-DNA were analysed using the Illumina HM450 
BeadChip (Section 2.4) at the MRC Integrative Epidemiology Unit, University of 
Bristol. Data were returned as .idat files containing raw signal intensity values from the 
array. These files were uploaded into GenomeStudio (Illumina, USA) for sample QC. A 
number of controls included on each BeadChip were used to assess the quality of the 
samples (Section 2.5.1). Methylation data were extracted as beta values, with no 
background correction or data normalisation. Beta values are methylation scores for 
each CpG, ranging from 0 (unmethylated) to 1 (methylated) and calculated as the ratio 
of methylated probe intensity over the sum of the methylated and unmethylated probe 
intensities.  
 
The analysis pipeline proposed by Touleimat and Tost (Touleimat and Tost, 2012) was 
implemented in R (version 2.15.0) to filter probes and samples and to normalise the beta 
values. The details of the normalisation are provided in Section 2.5.2.  
 
3.2.4 Analysis of HM450 data 
A total of 455,173 probes and 29 samples were included in the final dataset. 
Exploratory analyses were performed across the methylation data, by considering 
distribution density plots, mean-sd plots and hierarchical clustering with heat plots. The 
CpGassoc package (Barfield et al., 2012), which performs multiple linear regression 
analyses with a continuous predictor variable and ANOVA for categorical predictor 
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variables, was implemented in R (version 2.15.0). CpGassoc was performed to test for 
associations between methylation and diagnosis (D/CN), the last MMSE and CAMCOG 
scores before death and Braak staging as PSD outcome variables. For all analyses, 
baseline age, sex and chip (i.e. the microarray chip upon which the samples were 
scanned) were included in the analysis model as covariates. Data generated provided a 
beta value difference between the comparison groups (for categorical variables) and a 
beta value per unit change in the predictor variable (for ordinal and continuous 
variables). The beta values had an associated p-value denoting the strength of statistical 
significance with standard errors denoting the confidence around the statistical estimate 
of association. To test for sensitivity to cellular composition, HM450 data were adjusted 
for cellular composition using the method described by Houseman et al. (2012). 
Statistical analyses were then repeated to assess whether cell composition accounted for 
any significance observed between methylation and the outcome variable.  
 
3.2.5 Selection of top HM450 hits 
To select which CpG sites were the most promising candidates to validate, two 
approaches were taken. CpG sites showing differential methylation between the 
outcome measures were ordered by p-value with the most significant differences being 
ranked first. In the first approach, p values above the cut off imposed for multiple test 
correction (0.05/455,173) were not considered. The second approach included all CpG 
sites with a p value <1x10-5 (to include more hits) and compared methylation data with 
publicly available expression data. The Gene Expression Omnibus (GEO) website 
(NCBI) (http://www.ncbi.nlm.nih.gov/geo/) was searched for an appropriate expression 
dataset with which to compare the methylation data generated in this project. The 
closest expression dataset was GSE4229, a study which compared expression levels in 
blood between AD patients and healthy controls (Maes et al., 2009).  Each of the 
methylation hits was categorised into either hypomethylated or hypermethylated in PSD 
and hits were searched within the expression dataset. Any locus differentially expressed 
in AD was categorised into either over or under expressed in AD. Those hits which 
showed the expected inverse relationship between methylation and expression (i.e. 
hypermethylated and under expressed, hypomethylated and over expressed) were taken 
forward to the next step. This inverse relationship between methylation and expression 
is only expected in promoter regions, it is less clear that it is always the case in other 
regions, such as gene bodies. The next criterion in both approaches was that the effect 
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size (difference between the outcome groups) was more than 5%. This criterion is based 
upon the technical limitations of validating any observed differences using 
Pyrosequencing, which is suggested to be unable to robustly detect differences of less 
than 5% (Mikeska et al., 2011). Finally, a BLAT search was performed to test for the 
presence of a SNP within the CpG site. This step was implemented as the list of CpGs 
used in the filtering step was found to be incomplete. If the CpG site was indeed a SNP, 
or if there was a SNP in the probe sequence, this site was removed from consideration. 
This step removed any CpG sites likely to be directly under genetic influence.  
 
The HM450 data were processed and analysed as described to generate a priority list of 
target differentially methylated positions (DMPs). The Illumina gene ID was used to 
assign a gene name to the probe; where this was not possible, the HM450 probe ID was 
retained. These DMPs were then taken forward for validation using Pyrosequencing. 
 
3.2.6 Pyrosequencing 
Primers for amplicons covering DMPs were designed using the PSQ Assay Design 
software (Section 2.6.2) and synthesised by Integrated DNA Technologies (IDT, USA). 
Where possible, primers were designed, not only to cover the target DMP, but also any 
neighbouring CpG sites that could be captured within a reasonable amplicon size (50-
250bp).  Primers were first optimised (Section 2.6.3) and then validated on the 
Pyrosequencer using Epitect PCR controls (Qiagen, UK) (Section 2.6.5), prior to being 
run on COGFAST samples. PCR controls containing a 100% methylated DNA sample 
and a 0% methylated DNA sample were used to make reference methylation levels 
ranging from 0% to 100%. These validation mixes were created both pre-PCR and post-
PCR. Ten of the 22 DMP primer sets were successfully validated. All COGFAST 
samples were run in duplicate and repeated if duplicate discordance was >5%. 
 
Pyrosequencing assays (n=10) were performed on the “discovery” sample (n=29) along 
with blood derived DNA samples from an additional sixteen individuals drawn from the 
same cohort. 500ng of DNA was first bisulphite modified, amplified using the 
optimised Pyrosequencing PCR conditions in Table 10 and finally sequenced on a 
PyroMark MD Pyrosequencer (Qiagen, UK) following the standard protocol (Section 
2.6.6). Details of all Pyrosequencing primers are provided in Table 11.  
 
94 
 
 
 
 
Gene/DMP HM450 
probe ID 
Tm(°C) MgCl2 
+/- 
Size of 
product(bp) 
No. 
CpGs 
Successfully 
validated 
using 
Epitect 
controls 
LIMK2 cg02055988 52.7 + 113 1 Yes 
CTRL cg02126424 50.9 - 155 3  
CTRC cg03096785 50.9 - 144 1  
cg20583640 cg20583640 54.5 - 168 6  
cg18837178 cg18837178 54.5 + 143 2 Yes 
C17orf101 cg02973735 50.9 - 272 6 Yes 
PCDHGA1/2 cg06742719 52.7 + 102 2  
cg11349123 cg11349123 54.5 + 129 2  
APOB cg23603877 50.9 + 105 2 Yes 
cg21463981 cg21463981 52.7 + 126 1 Yes 
EIF4E3 cg01228342 50.9 - 118 1 Yes 
FAXC cg05621516 56.4 + 345 3  
HSPB3 cg11391732 50.9 - 171 3 Yes 
CISD1 cg17324161 53.6 - 330 3 Yes 
NGF cg00794813 53.6 - 305 4 Yes 
DSCAM cg19477942 53.6 - 398 3  
NNMT cg09632136 53.6 - 346 2  
COX16 cg23562388 53.6 - 378 2  
cg24902278 cg24902278 50.9 - 375 7  
cg08758568 cg08758568 53.6 - 416 2  
cg02925831 cg02925831 50.7 - 291 2  
cg02490189 cg02490189 50.4 - 373 5 Yes 
Table 10: Optimal PCR conditions for each assay. Tm = Annealing temperature.  
 
Gene Forward primer  
(5’>3’) 
Reverse primer  
(5’>3’) 
Sequencing primer 
(5’>3’) 
LIMK2 5Biosg/GGAAAAATTTGAA
TATTTATA 
CATTTCCCTTATATTTACTAT
C 
CTTCCTATTTATCATTTTT
A 
cg18837178 5Biosg/TATGGTGATTTGT
GATTAG 
CCATCTTCTCAAATTACT AAATAAACCTACTTTCTT
CC 
C17orf101 GTTTTAGTAATGGTGAGT
TG 
5Biosg/CCCCAATCCTACTAC
TAT 
TTTTTTGTAGAGGATATA
AT 
APOB TGGAGAAATTAGGTATG
T 
5Biosg/AATACACTATTCCAA
TTATC 
TTGTTTTTGGGAATATAT
AG 
cg21463981 GATGTTAGTGGGTTTAAT 5Biosg/AACCCAAATTAACTA
AATAC 
TTTATTAGAAGGAATTG
AGA 
HSPB3 AGGTTGGTTGTTGATAA
A 
5Biosg/CCAACTAAATCCTTT
ACTTC 
GTTGTTGATAAAAGTAT
AAT 
EIF4E3 TGTTTATAGGGTGTGATA
TT 
5Biosg/ACACTAAAAACTACC
ATCTAAT 
TGTTTTTTATGTGGGAAT 
NGF GGAATTATATTTAGAGA
GTAA 
5Biosg/TACTCCTATAAATCCT
ATTAA 
ATTTTAGGTTGTTTAAAA
AG 
CISD1 5Biosg/TTTTAGTATTATT
GGAGGTTAT 
CCAACTACTCAAAAATCTAA  
 
ATTTAAAATACAAATAT
CCC 
cg02490189 GGGTATTTTGAAATATA
GTA 
5Biosg/CACATCATCCATATC
TATA 
TGTTGGATTTGTAGGAG
A 
Table 11: Forward, reverse and sequencing primers for each successfully validated DMP Pyrosequencing 
assay. 5Biosg = Biotin label. 
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3.2.7 Statistical analyses 
Summary statistics of sub-samples used from the COGFAST cohort were calculated 
using Chi squared tests, t-tests or Wilcoxon rank sum tests. Within each cohort, 
differences between D and CN participants were investigated. Following correction for 
multiple testing, a p value <3.79x10-4 was considered significant. Tests were also 
performed to look for differences between the discovery cohort and entire COGFAST 
cohort, as well as the Pyrosequencing cohort and the entire COGFAST cohort. This was 
to investigate whether the sample subsets were representative of the entire COGFAST 
cohort. To reduce the risk of false positives, the p value was adjusted for the number of 
independent tests performed and a p value <2.84x10-4 was considered significant.  
 
Associations between methylation and the outcome variables (diagnosis (D/CN), last 
MMSE, Braak staging, abstract thinking, attention, calculation, executive function, 
language comprehension, language expression, memory learning, memory recent, 
memory remote, memory total, orientation, perception, praxis and total CAMCOG 
score) were first assessed in the initial “discovery” set (n=29) using regression analyses, 
adjusted for baseline age and sex. Subsequently, association analyses were repeated 
including data from the additional samples (“Pyrosequencing” cohort). Given the non-
normally distributed nature of methylation data, sensitivity analyses were also 
performed by comparing differences in the distribution of methylation between sample 
groups using non-parametric Wilcoxon rank-sum or Kruskal-Wallis tests. In addition to 
assessing individual DMPs for methylation levels using Pyrosequencing, for those loci 
containing multiple CpG sites, regional methylation levels were also investigated using 
the average methylation value across all CpG sites. These validation analyses were 
performed in Stata. 
 
Correlations between estimates of methylation at each CpG site measured by the 
HM450 array and by Pyrosequencing were assessed using Spearman’s rank in Stata, 
due to the non-normal distribution of the methylation data. 
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3.3 Results 
Summary statistics for clinical variables of COGFAST participants and sub-groups 
utilised in this study are summarised in Table 12, Table 13 and Table 14. A number of 
participants had a large amount of missing data relating to a number of variables. For 
each variable, the total number of data points used is equal to the number of participants 
with the relevant information recorded. 
 
Within group comparisons between D and CN demonstrate very similar characteristics 
relating to stroke and general characteristic variables in each of the 3 cohorts used 
(Table 12). Participants with dementia were found to be older at both time of stroke and 
time of death in the Pyrosequencing cohort however these differences were not 
significant. Both the discovery and Pyrosequencing cohort were considered 
representative of the entire COGFAST cohort as no significant differences were 
observed between cohorts in any variable.   
 
No differences were observed between D and CN in any cohort group in relation to 
medical history or known stroke risk factors (Table 13). No differences were observed 
in either D or CN participants between any of the cohort groups, indicating that the 
discovery and Pyrosequencing cohorts were representative of the entire COGFAST 
cohort.  
 
The within group comparisons between D and CN demonstrate robust differences in the 
majority of cognitive tests as expected (Table 14). In the entire COGFAST cohort, D 
and CN had significantly different results in all cognitive tests. There were no 
significant differences in cognitive test scores in either D or CN participants between 
the discovery/Pyrosequencing cohort and the entire COGFAST cohort.   
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 Entire COGFAST Discovery Cohort Pyrosequencing Cohort 
Variables D CN p value D CN p value D CN p value 
Baseline Age (Yrs) mean(SD) 81.18 (4.71) 80.36 (4.19) 0.314‡ 82.53 (5.25) 80.62 (4.35) 0.296§ 83.08 (5.32) 80.04 (3.79) 0.024§ 
Death Age (Yrs) mean(SD) 85.03 (5.31) 83.81 (4.01) 0.060‡ 88.18 (5.94) 86.23 (5.15) 0.355§ 88.42 (5.26) 85.32 (4.59) 0.030§ 
Sex (%males) 54.41 60.16 0.391† 47.06 46.15 0.961† 50.00 56.00 0.781† 
PM delay (Hrs) mean(SD) 50.64 (27.20) 54.53 (22.70) 0.940§ 40.82 (23.11) 32.46 (15.41) 0.335‡ 40.82 (23.11) 38.93 (22.26) 0.762‡ 
Survival post stroke (Yrs) 
mean(SD) 
4.01 (2.49) 3.46 (2.20) 0.169‡ 6.0 (2.87) 6.00 (2.66) 0.976§ 5.335 (2.68) 5.28 (2.94) 0.933§ 
OCSP class n(%)   0.638†   0.632†   0.571† 
LACS 20 (43.48) 42 (38.18)  4 (30.77) 3 (23.08)  7 (31.82) 7 (28.00)  
PACS 20 (43.48) 47 (42.73)  5 (38.46) 6 (46.15)  10 (45.45) 12 (48.00)  
TACS 3 (6.52) 6 (5.45)  3 (23.08) 1 (7.69)  3 (13.64) 1 (4.00)  
POCS 3 (6.52) 15 (13.64)  1 (7.69) 3 (23.08)  2 (9.09) 5 (20.00)  
Side of body n(%)   0.647†   1.00†   0.517† 
No lateralising signs 8 (17.02) 16 (13.91)  2 (13.33) 1 (7.69)  2 (8.33) 2 (8.00)  
Right 16 (34.04) 48 (41.74)  8 (53.33) 7 (53.85)  16 (66.67) 13 (52.00)  
Left 23 (48.94) 51 (44.35)  5 (33.33) 5 (38.46)  6 (25.00) 10 (40.00)  
Deg weakness arm n(%)   1.00†   0.505†   0.456† 
No deficit 13 (27.66) 33 (28.70)  5 (33.33) 3 (23.08)  10 (41.67) 7 (28.00)  
Weakness 33 (70.21) 78 (67.83)  8 (53.33) 10 (76.92)  12 (41.38) 17 (68.00)  
No movement 1 (2.13) 4 (3.48)  2 (13.33) 0  2 (8.33) 1 (4.00)  
Deg weakness leg n(%)   0.429†   0.607†   0.401† 
No deficit 20 (42.55) 46 (40.00)  7 (46.67) 6 (46.15)  10 (41.67) 13 (52.00)  
Weakness 27 (57.45) 65 (56.52)  6 (40.00) 7 (53.85)  12 (50.00) 12 (48.00)  
No movement 0 4 (3.48)  2 (13.33) 0  2 (8.33) 0  
Dysphasia n(%) 8/47 (17.02) 23/115 
(20.00) 
0.662† 6/15 (40.00) 3 (23.08) 0.435† 9 (37.50) 7/25 (28.00) 0.478† 
Table 12: Summary statistics for variables relating to the stroke event. Data are presented for the entire COGFAST cohort, the initial discovery sample set and the Pyrosequencing cohort. D = 
Participants with dementia. CN = Cognitively normal. † = chi squared, ‡ = Wilcoxon rank sum, §= t test. LACS=lacunar stroke, PACS=partial anterior circulation stroke, TACS=total anterior circulation 
stroke, POCS=posterior circulation stroke. Deg=degree. 
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 Entire COGFAST Discovery Cohort Pyrosequencing Cohort 
Variables D CN P value D CN p value D CN p value 
Antihypertensive 
therapy 
23/46 (50.00) 61/114 (53.51) 0.687† 6/15 (40.00) 7/13 (53.85) 0.464† 10/24 (41.67) 13/25 (52.00) 0.469† 
Antiplatelet therapy 25/46 (54.35) 57/114 (50.00) 0.619† 7/15 (46.67) 5/13 (38.46) 0.662† 10/24 (41.67) 12/25 (48.00) 0.656† 
Anticoagulant 
therapy 
1/46 (2.17) 12/114 (10.53) 0.111† 2/15 (13.33) 0 0.484† 3/24 (12.50) 0 0.110† 
Lipid lowering 
therapy 
1/46 (2.17) 10/114 (8.77) 0.180† 0 1/13 (7.69) 0.464† 0 1/25 (4.00) 1.00† 
Heart failure therapy 
loop diuretics 
7/46 (15.22) 21/114 (18.42) 0.629† 4/15 (26.67) 3/13 (23.08) 1.00† 5/24 (20.83) 7/25 (28.00) 0.742† 
Antidepressants 8/46 (17.39) 12/114 (10.53) 0.235† 3/15 (20.00) 1/13 (7.69) 0.60† 5/24 (20.83) 2/25 (8.00) 0.247† 
No of CVD risk 
factors 
(mode(range)) 
2 (0-4) 1 (0-6) 0.440‡ 2 (0-4) 1 (0-4) 0.314§ 2 (0-4) 1 (0-4) 0.394§ 
Hypertension 31/48 (64.58) 63/115 (54.78) 0.248† 8/15 (53.33) 7/13 (53.85) 0.978† 13/24 (54.17) 15/25 (56.00) 1.00† 
Atrial fibrillation 4/48 (8.33) 18/113 (15.93) 0.315† 5/15 (33.33) 3/13 (23.08) 0.686† 6/24 (25.00) 5/25 (20.00) 0.742† 
IHD 22/48 (45.83) 39/114 (34.21) 0.163† 4/15 (26.67) 2/13 (15.38) 0.655† 8/24 (33.33) 5/25 (20.00) 0.345† 
Angina 21/48 (43.75) 35/114 (30.70) 0.111† 4/15 (26.67) 2/13 (15.38) 0.655† 7/24 (48.98) 5/25 (20.00) 0.52† 
Cardiac failure 7/48(14.58) 21/115 (18.26) 0.570† 3/15 (20.00) 3/13 (23.08) 1.00† 4/24 (16.67) 8/25 (32.00) 0.321† 
Hyperchol 2/47 (4.26) 16/115 (13.91) 0.099† 1/15 (6.67) 0 1.00† 2/24 (8.33) 1/25 (4.00) 0.609† 
Diabetes 6/48 (12.50) 8/115 (6.96) 0.250† 1/15 (6.67) 1/13 (7.69) 1.00† 2/24 (8.33) 1/25 (4.00) 0.609† 
Intermittent 
claudication 
4/48 (8.33) 11/115 (9.57) 1.00† 2/15 (13.33) 1/13 (7.69) 1.00† 2/24 (8.33) 4/25 (16.00) 0.667† 
Smoking   0.563†   0.292†   0.300† 
Current 6 (9.23) 16 (13.91)  3 (20.00) 0  4/23 (17.39) 1/23 (4.35)  
Ex-smoker 3 (4.62) 8 (6.96)  1 (6.67) 1 (7.69)  1/23 (4.35) 3/23 (13.04)  
Non-smoker 56 (86.15) 91 (79.13)  11 (73.33) 12 (92.31)  18/23 (78.26) 19/23 (82.61)  
Table 13: Summary statistics for variables relating to stroke/dementia risk factors and medical history. Data are presented for the entire COGFAST cohort, the initial discovery sample set and 
the Pyrosequencing cohort. D = Participants with dementia. CN = Cognitively normal. † = chi squared, ‡ = Wilcoxon rank sum, §= t test. Hyperchol=hypercholesterolaemia. Unless stated, data 
for n(%) are displayed. 
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 Entire COGFAST Discovery Cohort Pyrosequencing Cohort 
Variables D CN p value D CN p value D CN p value 
Braak Staging n(%)   0.586†   0.987†   0.814† 
I 4 (12.9) 6 (20.00)  2 (11.76) 2 (15.38)  2 (9.09) 3 (15.79)  
II 9 (29.03) 9 (30.00)  3 (17.65) 4 (30.77)  6 (27.27) 8 (42.11)  
III 9 (29.03) 9 (30.00)  6 (35.29) 4 (30.77)  8 (36.36) 4 (21.05)  
IV 5 (16.13) 4 (13.33)  3 (17.65) 2 (15.38)  3 (13.64) 2 (10.53)  
V 3 (9.68) 2 (6.67)  2 (11.76) 1 (7.69)  2 (9.09) 2 (10.53)  
VI 1 (3.23) 0  1 (5.88) 0  1 (4.55) 0  
Last MMSE before 
death 
16.15 (6.29) 25.84 (2.59) 1.65E-23‡ 15.82 (5.49) 26.38 (3.07) 1.89E-05‡ 17.88 (6.16) 23.32 (5.99) 7.00E-04‡ 
Orientation 5.61 (2.81) 9.25 (1.04) 1.80E-20‡ 4.65 (2.60) 9.15 (1.21) 2.163E-05‡ 5.89 (3.00) 8.4 (1.85) 0.001‡ 
Language 
comprehension 
7.00 (1.83) 8.22 (1.25) 2.05E-08‡ 6.65 (2.32) 8.69 (0.48) 0.0005§ 6.96 (2.01) 8.24 (0.88) 0.007‡ 
Language expression 13.19 (3.48) 16.85 (1.94) 2.26E-15‡ 12.59 (3.52) 17.54 (1.13) 0.0001§ 13.42 (3.31) 16.36 (2.29) 0.001‡ 
Memory remote 3.69 (1.66) 5.14 (1.01) 7.79E-10‡ 3.88 (1.58) 5.00 (0.58) 0.036‡ 4.00 (1.39) 4.64 (1.22) 0.058‡ 
Memory recent 2.00 (1.40) 3.67 (0.67) 9.50E-18‡ 2.06 (1.34) 3.38 (0.77) 0.004‡ 2.35 (1.35) 3.08 (1.00) 0.048‡ 
Memory learning 7.31 (3.92) 12.50 (2.62) 4.13E-17‡ 7.53 (3.74) 13.23 (1.83) 0.0001‡ 8.5 (4.19) 11.24 (3.55) 0.014§ 
Attention 2.96 (2.16) 5.68 (1.48) 5.92E-15‡ 2.88 (1.96) 6.31 (0.85) 4.077E-05‡ 3.35 (2.23) 5.28 (1.81) 0.002‡ 
Praxis 6.88 (2.23) 9.69 (1.97) 9.93E-14‡ 6.94 (2.38) 10.69 (1.03) 2.214E-05‡ 7.31 (2.78) 9.08 (2.61) 0.013‡ 
Calculation 0.88 (0.75) 1.76 (0.48) 1.18E-15‡ 0.88 (0.86) 1.69 (0.48) 0.009‡ 1.08 (0.89) 1.48 (0.59) 0.111‡ 
Abstract thinking 4.12 (2.30) 5.94 (1.64) 9.24E-08‡ 4.12 (2.74) 6.23 (1.64) 0.030§ 4.62 (2.38) 5.64 (1.96) 0.117§ 
Perception 5.33 (2.08) 6.77 (1.61) 1.29E-06‡ 4.94 (2.73) 7.38 (1.56) 0.009§ 5.42 (2.76) 7.12 (1.56) 0.020§ 
Total CAMCOG 58.78 (17.52) 85.45 (8.61) 1.48E-23‡ 57.76 (18.68) 89.31 (6.18) 4.54E-06§ 63.31 (19.68) 80.56 (14.15) 0.001‡ 
Executive function 9.61 (4.10) 15.42 (4.34) 1.07E-14§ 9.29 (5.03) 17.38 (3.04) 0.0001§ 10.92 (5.16) 14.88 (4.6) 0.007§ 
Memory total 12.90 (5.86) 21.30 (3.19) 1.44E-19‡ 13.41 (5.80) 21.46 (2.90) 0.0001§ 14.81 (6.03) 18.6 (5.28) 0.014‡ 
Table 14: Summary statistics for variables relating to both pathology and cognitive-based outcomes. Data are presented for the entire COGAST cohort, the initial discovery sample set and the 
Pyrosequencing cohort. D = Participants with dementia. CN = Cognitively normal. † = chi squared, ‡ = Wilcoxon rank sum, §=t test. Unless stated, mean (SD) are presented for each variable.
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3.3.1 Discovery analysis using HM450 data 
Of the 30 blood samples that underwent HM450 analysis, 29 samples passed the quality 
control assessment of the inbuilt microarray controls assessed in GenomeStudio. One 
sample (from the dementia group) failed due to incomplete bisulphite modification and 
was dropped from further analysis. 
 
Low failure rates were observed on both a sample and probe by probe basis, assessed 
using detection p values generated from the array scanner. As described in Section 
2.5.2, samples were only removed if ≥20% of probes had a detection p value >0.01. 
Probes were removed if ≥10% of samples had a detection p value >0.01. No samples 
were removed from analysis using these criteria. 1665 probes were removed. 
Summaries of the detection p values observed for samples and probes are shown in 
Figure 10A and 10B.  
 
Following data filtering and normalisation, as described in Section 2.5.2, 455,173 CpG 
sites were taken forward for analysis measured in baseline blood samples from 29 
individuals; 16 D vs 13 CN.   
 
The small sample size of this study limited the power to detect methylation differences. 
This study had 2.6% power to detect a mean difference of 5% methylation between 
groups, with a standard deviation of 3 and alpha=1.1x10-7. 
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Figure 10A: Average detection p values in each blood sample. For each sample the average detection p 
value is very low and samples are of approximately equal quality.  
Figure 10B: Histogram to show the number of probes against the corresponding number of samples with 
p values greater than 0.01. The red line indicates 10%. 465939 probes had no missing data and for space 
reasons, this data is not shown on the histogram. 
 
3.3.1.1 Distribution of genome-wide methylation values 
Figure 11 (A-F) shows the distribution of methylation values using both raw (A-C) and 
normalised (D-F) data. Figure 11A is a density plot showing the distribution of raw 
methylation beta values for each blood sample. This shows a commonly observed 
bimodal distribution; the majority of CpG sites are very lowly or very highly methylated 
with much fewer CpG sites exhibiting intermediate methylation levels. The distribution 
for each individual can be more easily seen in a box plot (Figure 11B). This shows that 
there is some variability in the methylation levels of each blood sample, particularly 
with regard to the median methylation and interquartile range (IQR). Each sample has a 
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minimum methylation level of 0% and a maximum of 100% with a median around 60-
70% methylated. Some of this variation could be due to batch effects and sample 
processing. The position of the sample on the chip is also thought to have an effect on 
methylation values (Dedeurwaerder et al., 2013) but this variation should be removed 
after normalisation.  Mean and standard deviation (SD) methylation beta values across 
all probes, prior to normalisation and QC, are depicted in Figure 11C to show 
heteroskedasticity. Heteroskedasticity refers to the phenomenon whereby the variance in 
a measure such as methylation beta values is not constant across all levels of that 
measure. As can be seen, there is a wide range of variance across the probes. In 
particular, probes with a mid-range methylation value between 30-80% show greater 
variability compared to those at the extreme ends of the methylation spectrum. 
Figure 11 (D-F) shows the distribution of methylation after normalisation. All plots 
using normalised data show that there is much less variation between samples. All 
samples have a median methylation value of around 50%. This suggests that most of the 
variation was removed during normalisation and is therefore likely to be due to 
technical variation.  
 
3.3.1.2 Cluster analysis 
Hierarchical cluster analysis, using the complete-linkage method, was performed on the 
normalised data to look for natural groupings (either phenotypic or technical) amongst 
the samples based on the methylation data.  No clear clusters were observed for 
diagnosis of dementia, indicating that global DNA methylation signatures are not 
sufficiently distinct in blood samples drawn from stroke patients who subsequently go 
on to develop dementia (Figure 12). 
 
However, as shown in Figure 13, even after normalisation and removal of probes 
mapping to the sex chromosomes, there remained some subtle groupings amongst 
samples based on sex. Due to these results, sex was included as a covariate in 
subsequent analyses of single-point CpG sites. In contrast, there were no apparent 
clusters based on experimental chip (Figure 14), suggesting that any batch effects were 
removed. Nonetheless, to fully account for any remaining, albeit subtle, batch effects, 
chip was also included as a covariate in the single-point analysis model. The cluster 
plots show that the data is clustered into two main groups, however this clustering was 
not due to diagnosis, sex, chip or any other batch effect measured.  
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Figure 11: A composite figure showing the distributions of methylation using raw and normalised data. A. Density plot showing methylation distribution in 29 blood samples using 
raw data. B. Box plot showing mean methylation raw beta values across all blood samples. C. Mean vs SD plot showing heteroskedasticity using raw data. D. Density plot showing 
methylation distribution in 29 blood samples using normalised data. E. Box plot showing mean methylation normalised beta values across all blood samples. F. Mean vs SD plot 
showing heteroskedasticity using normalised data.  
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Figure 12: Cluster dendrogram for all 29 blood samples coloured by diagnosis. 
 
 
Figure 13: Cluster dendrogram for all 29 blood samples coloured by sex. 
 
 
Figure 14: Cluster dendrogram for all 29 blood samples coloured by chip. 
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3.3.1.3 Single-point analysis 
ANOVA was performed on all beta values across 455,173 CpG sites against the 
following outcome measures: diagnosis (D/CN), last MMSE result before death, Braak 
staging and a number of CAMCOG scores (abstract thinking, attention, calculation, 
executive function, language comprehension, language expression, memory learning, 
memory recent, memory remote, memory total, orientation, perception, praxis and total 
CAMCOG score). Baseline age, sex and chip were included in the analysis model as 
covariates. Results from this step were exported as a table in Microsoft Excel and 
ordered by ascending p value.  
 
Two approaches were employed when selecting top hits.  
 
3.3.1.4 Selection of top hits – approach 1 
The first approach selects hits which reach genome wide significance. When testing for 
association between methylation and both diagnosis and last MMSE, no CpG sites were 
highlighted as significant at the conservative genome wide correction threshold of 
p<1.10x10-7. Likewise, a number of CAMCOG scores (abstract thinking, attention, 
calculation, executive function, language comprehension, language expression, memory 
learning, memory recent, memory total, orientation, perception and praxis) were not 
associated with methylation at any of the 455,173 CpG sites included in the analysis. 
However, when Braak staging was included in the model as the outcome variable, 
methylation was significantly different at 74 CpG sites (DMPs) (Figure 15 and Figure 
16). One CpG site was found to be associated with the CAMCOG variable “memory 
remote” (Figure 17 and Figure 18) and another with the total CAMCOG score (Figure 
19 and Figure 20). These 76 DMPs were then considered as targets for validation by 
Pyrosequencing.  
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Figure 15: Quantile-quantile (QQ) plot for association between methylation and Braak staging. The QQ 
plot shows the expected against the observed p values. Data points plotted in red reach the Bonferroni 
corrected significance threshold. 
 
 
Figure 16: Manhattan plot for association between methylation and Braak staging. Each circle represents 
an individual CpG site. The continuous line marks the p<1.1x10-7 significance threshold. CpG sites with p 
values below the threshold are labelled with their Illumina ID.  
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Figure 17: QQ plot for association between methylation and memory remote. The QQ plot shows the 
expected against the observed p values. Data points plotted in red reach the Bonferroni corrected 
significance threshold. 
 
 
Figure 18: Manhattan plot for association between methylation and memory remote. Each circle 
represents an individual CpG site. The continuous line marks the p<1.1x10-7 significance threshold. CpG 
sites with p values below the threshold are labelled with their Illumina ID. 
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Figure 19: QQ plot for association between methylation and total CAMCOG score. The QQ plot shows 
the expected against the observed p values. Data points plotted in red reach the Bonferroni corrected 
significance threshold. 
 
 
Figure 20: Manhattan plot for association between methylation and total CAMCOG score. Each circle 
represents an individual CpG site. The continuous line marks the p<1.1x10-7 significance threshold. CpG 
sites with p values below the threshold are labelled with their Illumina ID. 
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Figure 21 (A-D) shows the distribution of the most significant 76 CpG sites (when 
tested with Braak staging, memory remote and total CAMCOG score as outcome 
variables) across the different probe chemistries and genomic region (chromosome, 
position relative to nearby CpG island and regions within gene).  
 
A chi squared goodness of fit test was performed to test whether the distributions of hits 
observed were as expected. A significantly lower number of significant CpG sites were 
measured using probe type I chemistry than expected (16% vs 27%, p=0.01) (Figure 
21A). The majority of significant CpG sites are unannotated on the Illumina technical 
information sheet and have no information on genomic location or relation to CpG 
islands. 21% of all CpG sites are located within CpG islands (Figure 21B). Differences 
in the position of the CpG site in relation to CpG islands were also not as expected, with 
fewer significant CpG sites being observed in the CpG islands (p=9.12x10-4). 21% of all 
significant CpG sites are located within gene promoters (Figure 21C); this indicates that 
some of these CpG sites may have functional relevance. In addition, differences in 
functional genomic location (eg. promoter, gene body) were also identified between the 
number of CpG sites observed and expected in each region (p=0.01). Significant CpG 
sites do not appear to be more likely to appear on one chromosome than any other as 
hits are spread across the genome. No differences were observed in the distribution of 
CpG sites across the chromosomes (p=0.74) (Figure 21D). 
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Figure 21: Description of statistically significant CpG sites identified in blood samples. A. Distribution of CpG sites measured using different probe types. B. position relative to 
nearby CpG island. C. Functional genomic location. D. Proportion of statistically significant CpGs located on each chromosome. 
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Of the 76 top hits, 30 primer pairs were successfully designed (Table 15). Four CpG 
sites dropped out of the selection due to having small (<5%) effect sizes, i.e. the 
difference between the lowest and highest measure (e.g. the mean methylation of Braak 
stage I individuals minus the mean methylation of Braak stage VI individuals). 5% was 
chosen as the minimum effect size due to the technical sensitivity of the Pyrosequencer 
and to limit the validation phase to those CpG sites most likely to exhibit a methylation 
difference. Although a number of SNPs were removed during the HM450 filtering step 
(Section 2.5.2), an additional SNP search was incorporated into the work flow. A BLAT 
search (NCBI) of the probe sequence highlighted that 18 of the remaining 72 CpG sites 
were in fact SNPs and these were removed from the selection. A search on the National 
Human Genome Research Institute (NHGRI) Genome-Wide Association Studies 
(GWAS) Catalog (www.genome.gov/gwastudies) revealed that none of these 18 SNPs 
had previously been associated with post-stroke dementia or any related disease. The 
remaining 54 loci were taken forward for primer design.  
 
Thirty assays were successfully designed, with PSQ design software quality scores > 70 
and no other warnings. Therefore, the limiting factors at this stage of the study design, 
were the technical requirements for successful assay design using the Pyrosequencing 
platform. Figure 22 shows the selection of top hits. 
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Variable CpG site P value Gene Test 
statistic 
Effect 
size 
SNP Primers 
Braak Staging cg17324161 1.43E-16 CISD1 771.70 0.815 No Yes 
Braak Staging cg03771731 9.63E-11 SLC6A5 110.62 0.604 No No 
Braak Staging cg05498041 8.53E-10  80.10 0.599 No No 
Braak Staging cg00794813 2.29E-16 NGF 721.32 0.599 No Yes 
Braak Staging cg02055988 5.43E-15 LIMK2 457.68 0.590 No Yes 
Braak Staging cg02126424 3.29E-14 CTRL 353.07 0.570 No Yes 
Braak Staging cg03096785 1.56E-09 CTRC 73.18 0.550 No Yes 
Braak Staging cg07438999 3.94E-08  44.92 0.539 No No 
Braak Staging cg09632136 6.02E-11 NNMT 118.54 0.496 No Yes 
Braak Staging cg18837178 8.63E-13  220.13 0.465 No Yes 
Braak Staging cg20583640 4.67E-10  87.60 0.457 No Yes 
Braak Staging cg16765928 1.05E-10 NRXN3 109.15 0.449 No No 
Braak Staging cg02973735 1.58E-11 C17orf101 144.25 0.427 No Yes 
Braak Staging cg19477942 3.08E-13 DSCAM 255.57 0.426 No Yes 
Braak Staging cg02788798 3.49E-09  64.90 0.403 No No 
Braak Staging cg09454882 1.06E-07 FAM189A1 38.56 0.398 No No 
Braak Staging cg11349123 2.13E-10  98.44 0.365 No Yes 
Braak Staging cg13118849 7.02E-08 NCAN 47.17 0.348 No No 
Braak Staging cg05475277 7.91E-08 FOXRED2 40.34 0.346 No Yes 
Braak Staging cg02925831 6.28E-09  59.40 0.316 No Yes 
Braak Staging cg20609274 6.90E-08 PPP2R2C 41.21 0.313 No Yes 
Braak Staging cg08872013 2.51E-12 OPCML 188.56 0.311 No No 
Braak Staging cg23603877 1.20E-12 APOB 209.81 0.311 No Yes 
Braak Staging cg05314310 1.68E-08 LHFPL5 51.15 0.295 No Yes 
Braak Staging cg04131792 3.81E-08  45.15 0.295 No No 
Braak Staging cg19901421 2.64E-08  47.75 0.276 No No 
Braak Staging cg21164813 3.06E-09  66.18 0.271 No No 
Braak Staging cg06700494 5.02E-08  43.27 0.264 No Yes 
Braak Staging cg11235712 2.15E-08  49.30 0.242 No Yes 
Braak Staging cg08758568 3.64E-09  64.49 0.241 No Yes 
Braak Staging cg05621516 2.01E-09 FAXC 70.47 0.227 No Yes 
Braak Staging cg17997207 4.40E-08 FAM184B 44.16 0.215 No No 
Braak Staging cg24239992 9.86E-08  38.99 0.201 No No 
Braak Staging cg11617965 4.52E-12 PKD1L1 173.08 0.184 No No 
Braak Staging cg21991616 1.09E-07 HGC6.3 38.39 0.165 No No 
Braak Staging cg11391732 4.15E-09 HSPB3 63.24 0.159 No Yes 
Braak Staging cg01486145 7.96E-09  57.31 0.154 No Yes 
Braak Staging cg03211388 3.39E-08  45.97 0.150 No Yes 
Memory 
remote 
cg08787268 6.73E-08  -8.75 0.059 No No 
Total 
CAMCOG 
cg02490189 6.33E-08 NUAK1 8.78 -0.050 No Yes 
Braak Staging cg00519463 8.40E-08 KIF11 39.97 -0.093 No No 
Braak Staging cg07959491 8.73E-09  56.51 -0.098 No No 
Braak Staging cg09475324 1.11E-10 FICD 108.26 -0.099 No No 
Braak Staging cg23562388 5.26E-10 COX16 103.70 -0.214 No Yes 
113 
 
 
 
Braak Staging cg09257092 1.43E-14 ITPR2 397.96 -0.225 No No 
Braak Staging cg01228342 3.85E-17  931.54 -0.236 No Yes 
Braak Staging cg23814365 2.37E-08 DCLK1 48.55 -0.242 No Yes 
Braak Staging cg21463981 4.63E-10  87.71 -0.288 No Yes 
Braak Staging cg22686854 2.18E-10  98.05 -0.331 No No 
Braak Staging cg22367678 3.17E-08  46.43 -0.347 No No 
Braak Staging cg06742719 2.30E-08 PCDHGA2 48.78 -0.352 No Yes 
Braak Staging cg14099398 1.04E-07 PLD6 38.67 -0.381 No No 
Braak Staging cg24902278 2.46E-09  68.39 -0.385 No Yes 
Braak Staging cg16482324 6.12E-08 AUTS2 41.97 -0.435 No No 
Braak Staging cg21446655 5.43E-09 UBE2E3 71.45 0.764 Yes  
Braak Staging cg23404610 3.27E-17  953.62 0.623 Yes  
Braak Staging cg27157669 3.30E-19 KLHD5C 1841.79 0.575 Yes  
Braak Staging cg01624571 4.45E-09 SMAD3 62.56 0.573 Yes  
Braak Staging cg17378686 8.49E-10 PTH1R 80.16 0.561 Yes  
Braak Staging cg16529007 1.91E-08  50.19 0.559 Yes  
Braak Staging cg20862860 1.28E-16 TSSC1 784.32 0.537 Yes  
Braak Staging cg08220028 1.36E-09 GALNT9 74.75 0.529 Yes  
Braak Staging cg20095669 3.92E-10 PPFIBP1 108.62 0.524 Yes  
Braak Staging cg04698472 5.84E-11 SIGLEC12 119.05 0.514 Yes  
Braak Staging cg00991192 3.96E-10  89.78 0.474 Yes  
Braak Staging cg24185649 4.03E-08 ZNF354B 44.76 0.432 Yes  
Braak Staging cg22375320 7.13E-09  58.27 0.397 Yes  
Braak Staging cg07370274 4.70E-08  43.71 0.319 Yes  
Braak Staging cg18854398 1.28E-08 C1orf66 53.31 -0.100 Yes  
Braak Staging cg04459585 7.94E-10  80.97 -0.125 Yes  
Braak Staging cg18627179 1.20E-10 RPL18A 131.04 -0.202 Yes  
Braak Staging cg13723217 3.57E-15  486.12 -0.359 Yes  
Braak Staging cg01289352 7.05E-08  41.07 0.048   
Braak Staging cg10701801 1.06E-16  805.80 0.027   
Braak Staging cg15703790 7.97E-08  40.29 0.022   
Braak Staging cg00630420 8.06E-08  40.23 0.018   
Table 15: Details about top 76 CpG sites selected based on genome wide significance. 
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Figure 22: Flow diagram summarising the selection of top hits that reach genome wide significance. 
 
The HM450 data were then adjusted for cellular composition using the method 
described by Houseman et al. (2012) and the CpGassoc analyses were repeated. The 
before and after cell adjustment analyses were compared to look for differences. At the 
majority of CpG sites, cell adjustment did not alter the results at all (p value or F/t 
statistic). The effect, however, was altered slightly in only three of the 76 selected CpG 
sites (Table 16). 
 
Variable CpG site Pre-adjustment Post-adjustment 
F/t statistic P value F/t statistic P value 
Braak 
Staging 
cg15703790 40.29 (F) 7.97E-08 23.14 (F) 2.62E-06 
Braak 
Staging 
cg00630420 40.23 (F) 8.06E-08 52.39 (F) 1.44E-08 
Total 
CAMCOG  
cg02490189 8.78 (t) 6.33E-08 9.24 (t) 2.97E-08 
Table 16: CpG sites showing an effect when adjusted for cellular composition. 
  
Since the effects of cellular composition are very small and in some cases strengthen the 
intensity of the effect, all three sites were still considered to be largely unaffected by 
cellular composition and were still considered to be potential biomarkers. As seen in 
Table 15, one of these CpG sites (cg02490189) was taken forward for validation 
analyses on the Pyrosequencer. These results suggest that differences in cellular 
composition have very little effect on the methylation differences observed between 
outcome groups in this Chapter.   
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3.3.1.5 Selection of top hits – approach 2 
The second approach utilised for selecting top hits from the HM450 analysis using 
ANOVA involved lowering the significance threshold to p<1x10-5 and comparing 
methylation data with publicly available expression data (Maes et al., 2009). The 
expression data set used is described in Section 3.2.5.  
 
Table 17 shows the number of hits that were selected for Pyrosequencing consideration 
using the second selection approach. Lowering the significance threshold from p<10-7 to 
p<10-5 greatly increased the number of top hits in the selection pool, i.e. the number of 
significant hits increased from 76 to 224. Of these 224 hits, 44 had expression data 
available and five of these were differentially expressed in AD. The five remaining hits 
were then considered in terms of the direction of effect, i.e. whether the CpG sites were 
hyper or hypo methylated in AD and whether they were up or down regulated in AD. 
Three CpG sites were found to have the expected methylation-expression relationship 
(hypermethylated and downregulated in AD or hypomethylated and upregulated in AD).  
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Variable Hits 
significant to 
<1x10-5 (n) 
Hits 
represented 
on the 
expression 
array (n) 
Hits 
differentially 
expressed (n) 
Hits with the expected 
methylation-expression 
relationship (n) 
Diagnosis 9 4 1 1 
Braak staging 147 26 4 2 
MMSE 4 0 0 0 
Orientation 4 2 0 0 
Language 
comprehension 
11 2 0 0 
Language 
expression 
3 1 0 0 
Memory 
remote 
6 0 0 0 
Memory recent 6 2 0 0 
Memory 
learning 
5 2 0 0 
Memory total 3 1 0 0 
Attention 3 1 0 0 
Praxis 4 0 0 0 
Calculation 4 1 0 0 
Abstract 
thinking 
3 1 0 0 
Perception 6 1 0 0 
Executive 
function 
3 0 0 0 
Total 
CAMCOG 
score 
3 0 0 0 
Total number 
of hits 
224 44 5 3 
Table 17: Number of CpG sites taken forward at each stage in the selection of top hits. 
 
Figure 23 shows the relationship between methylation and expression in each of the 
significant CpG sites that had both methylation and expression data. Sites (n=3) within 
the shaded regions showed the expected methylation-expression relationship at the 
significance threshold imposed. Two loci were identified as being hypomethylated in 
post-stroke dementia and upregulated in AD. One locus was identified as having the 
reverse relationship with hypermethylation of a site within the gene in post-stroke 
dementia and down regulation of the gene in AD. These three sites were taken forwards 
for further investigation (Table 18).  
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Figure 23: Quadrant plot of DMPs and associated expression levels. DNA methylation (x axis) and gene 
expression (y axis) are graphically presented as log10 p values. Significance is defined as <1x10-5 for 
methylation and <1.13 for expression (as indicated by the vertical and horizontal dashed lines). The 
direction of effect is indicated by the red text. The shaded areas represent sites with the expected inverse 
relationship between methylation and expression. Sites within these shaded areas were taken forward for 
further analysis.  
 
 
 
Only one (cg02055988) of the three CpG sites had an effect size >5%. Since 
cg02055988 reached genome wide significance it has already been selected using the 
first approach and is included in Table 18.  The other two CpG sites (cg17633463 and 
cg22963863) were dropped due to a small effect size.  
 
3.3.2 Primer optimisation and validation 
Using both approaches to select top hits, primer pairs for 30 loci were successfully 
designed as in Table 15. All 30 primer pairs targeted at least the index CpG (CpG 
included on the HM450). Where possible, amplicons were designed to capture 
neighbouring CpG sites.  
Variable CpG site Gene Methylation 
p value 
Methylation 
effect size 
Expression 
p value 
SNP Primers 
Braak 
staging 
cg02055988 LIMK2 5.43E-15 0.590 0.049 No Yes 
Braak 
staging 
cg22963863 SNF8 4.29E-07 -0.031 0.032   
Diagnosis 
(D/CN) 
cg17633463 UBTD1 8.47E-06 -0.013 0.041   
Table 18: Description of 3 CpG sites showing expression differences in AD. 
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Primer pairs for eight loci could not be optimised and were removed from further 
analysis. The primer pairs for the remaining 22 successfully optimised assays were used 
to amplify, by PCR, a range of methylation concentrations spanning 0% to 100% to 
ensure the assay was able to measure the full range of possible methylation values. An 
assay was considered to be validated if three conditions were reached; 1) the observed 
methylation value for 100% was above 80%; 2) the observed methylation value for 0% 
was below 10% and 3) there was a linear relationship with an R2 value above 0.99. Ten 
assays were successfully validated. Concordance of observed and reference methylation 
values are shown in Table 19, using the mean methylation value across all CpG sites in 
each amplicon. The validation results for both the pre-PCR and post-PCR mixes were 
plotted as a scatter graph with a trend line and R2 values presented (Figure 24).  
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Expected 
Meth (%) 
Observed Methylation (%) 
C17orf101 APOB cg18837178 NGF CISD1 cg21463981 LIMK2 HSPB3 EIF4E3 cg02490189 
Pre Post Pre Post Pre Post Pre Post Pre Post Pre Post Pre Post Pre Post Pre Post Pre Post 
100 92.8 92.8 92.9 92.9 85.7 85.7 93.8 93.8 81.0 81.5 94.0 94.0 84.9 84.9 91.8 91.8 99.3 99.3 92.3 92.3 
95 88.5 89.3 89.3 88.0 81.6 81.3 91.1 91.9 78.7 78.2 91.2 93.4 83.5 81.3 91.4 87.3 93.5 94.9 84.2 86.5 
90 87.1 83.4 85.1 82.8 75.3 78.0 85.1 87.0 72.3 72.8 83.0 91.0 77.1 76.0 88.4 86.3 92.3 89.5 82.4 81.9 
75 77.3 67.7 72.2 68.8 61.5 65.4 75.9 83.0 60.0 59.8 71.8 79.2 68.2 61.7 75.3 70.2 78.0 73.5 69.4 66.2 
50 54.6 45.9 54.3 46.9 36.8 43.7 62.0 57.5 43.8 43.9 49.2 52.2 45.2 39.6 57.8 49.8 55.3 47.7 50.2 50.7 
25 29.7 23.4 28.2 24.7 26.0 23.6 27.7 29.9 27.6 26.5 24.6 25.7 23.2 20.5 32.1 26.4 28.1 25.2 25.8 25.6 
10 11.3 15.6 15.5 11.6 12.7 11.2 15.7 14.3 14.4 13.4 11.7 11.5 11.4 9.4 15.3 13.8 13.9 12.8 16.0 15.5 
5 9.1 11.3 9.6 7.8 7.6 7.9 7.5 8.0 12.6 11.0 6.9 6.3 4.4 7.8 10.1 11.2 5.7 7.8 10.7 11.2 
0 3.8 3.8 3.4 3.4 3.4 3.4 5.3 5.3 8.0 8.0 0.8 0.8 2.3 2.3 5.4 5.4 3.7 3.7 4.3 4.3 
Table 19: Observed mean methylation across all CpGs compared with reference expected methylation level. Pre and post PCR methylation values are presented for each assay. 
Meth=methylation. 
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Figure 24: Composite figure of 10 assay validation plots. Pre-PCR methylation values are presented in 
blue and post-PCR methylation values in red. The R squared value is also displayed in the corresponding 
colour. An R squared value close to 1 indicates a very close correlation between observed and expected 
methylation levels. 
 
3.3.3 Pyrosequencing analysis 
Methylation was then quantified in duplicate, in all available blood DNA samples 
across all ten validated assays. Samples were considered to have been assayed 
successfully, using Pyrosequencing, if the resulting values for duplicates were within 
5%. A mean methylation level of these duplicates was calculated for each sample and 
this mean methylation value was used for all further analyses.  
 
The first stage in the analysis was the comparison of data generated by Pyrosequencing, 
with the DMP methylation values generated by the HM450 BeadChip, to assess 
concordance. Then, Pyrosequencing data were analysed to look for association between 
outcome (adjusted for covariates) and DNA methylation in the “discovery” cohort. If an 
association was observed in the discovery cohort (samples run on the HM450), data 
were analysed to look for associations between DNA methylation and outcome in the 
larger “Pyrosequencing” cohort.  
 
Of the ten technically validated assays, one, EIF4E3, a locus significantly associated 
with Braak staging, did not work on the Pyrosequencer when using the COGFAST 
blood samples. COGFAST blood DNA was successfully amplified and PCR products 
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were visible on an agarose gel, however the DNA samples repeatedly failed on the 
Pyrosequencer. Due to the successful amplification of DNA this was likely due to a 
Pyrosequencing technical error. Results from the remaining nine assays were taken 
forward for analysis in Stata.  
 
The data from each assay were analysed to test for associations between the outcome 
variable and methylation at the index CpG site (included on the HM450 BeadChip) in 
the “discovery” cohort and in a larger “Pyrosequencing” cohort. If multiple CpG sites 
were included on the Pyrosequencing assay, each neighbouring CpG site was analysed 
to test for associations with each outcome variable. Finally the mean methylation value 
across the region (mean of index and neighbouring CpG sites) was included in similar 
analyses. The results from these analyses will be displayed in the following sections. 
For seven of the nine assays no significant associations were identified for any CpG site 
included in the Pyrosequencing assays, indicating that these are likely to be false 
positive array hits. Six of these assays (CISD1, LIMK2, HSPB3, cg21463981, 
C17orf101 and cg18837178) had been found, on the HM450, to be associated with 
Braak staging and one (cg02490189) with total CAMCOG score.  These seven loci 
were thus deemed to be likely false positive array hits. However, two of the validated 
assays (APOB and NGF) showed significant associations between methylation at one or 
more of the CpG sites tested and the selected outcomes and these are described in more 
detail below.   
 
3.3.3.1 APOB and NGF 
 
3.3.3.1.1 Validation in discovery cohort 
All 29 blood DNA samples analysed on the HM450 were run on the Pyrosequencer and 
results for all duplicate analyses were within 5% of each other for the APOB assay and 
were taken forwards for analysis. Of the 29 samples using the NGF assay, there were 28 
concordant pairs of data, from which an average methylation value for each sample was 
taken.   
 
Spearman’s rank correlation was performed in Stata to test the correlation between the 
two platforms. In neither assay were the methylation values on each platform correlated. 
Spearman’s correlation gave a coefficient of 0.033 (p=0.865) for APOB and 0.028 
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(p=0.892) for NGF. This lack of correlation could be due to the majority of samples 
having a methylation value around 100% (Figure 25 and Figure 26).  
 
Figure 25: Correlation between methylation measured on the HM450 and Pyrosequencer at the APOB 
locus. 
 
Figure 26: Correlation between methylation measured on the HM450 and Pyrosequencer at the NGF 
locus. 
 
APOB and NGF were both highlighted in the HM450 analysis as being associated with 
Braak staging. When split up into the six Braak stages, the sample size issue becomes 
more apparent. Table 20 shows the number of samples within each Braak stage category 
in the discovery sample set. Only one Braak stage VI individual was available in the 
sample set in the analysis, meaning that any significance differentiating Braak stage VI 
from others is based on one individual. The HM450 analysis was repeated with this 
Braak stage VI individual removed and the QQ (Figure 27) and Manhattan (Figure 28) 
plots revealed that the majority of top hits associated with Braak staging were driven by 
this one outlier. Only three CpG sites remained significant with this one individual 
removed.  
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Braak 
stage 
N in  
HM450 
N in APOB 
discovery 
cohort 
N in APOB 
replication 
cohort 
N in NGF 
discovery 
cohort 
N in NGF 
replication 
cohort 
I 4 4 5 4 4 
II 7 7 14 7 11 
III 9 9 11 9 11 
IV 5 5 5 4 4 
V 3 3 4 3 4 
VI 1 1 1 1 1 
Total 29 29 40 28 35 
Table 20: Number of samples in each cohort by Braak staging. 
 
Figure 27: QQ plot for association between methylation and Braak staging with the Braak stage VI 
individual removed. The QQ plot shows the expected against the observed p values. Data points plotted in 
red reach the Bonferroni corrected significance threshold. 
 
 
Figure 28: Manhattan plot for association between methylation and Braak staging with the Braak stage VI 
individual removed. Each circle represents an individual CpG site. The continuous line marks the 
p<1.1x10-7 significance threshold. CpG sites with p values below the threshold are labelled with their 
Illumina ID. 
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Analysis of the complete dataset from the HM450 array identified one CpG site within 
APOB and one CpG sites within NGF which were differentially methylated in blood 
samples of stroke patients with varying levels of Braak staging. In both assays, lower 
methylation values were observed in Braak stage VI when compared to the other Braak 
stages (I-V).  
 
Figure 29 shows the mean methylation levels for each Braak stage measured at the 
APOB locus and Figure 30 shows the mean methylation levels for each Braak stage 
measured at the NGF locus, on both the HM450 and Pyrosequencer. Both graphs show 
the mean methylation levels for each Braak stage are similar across the two different 
platforms in Braak stages I-V. The standard deviation bars indicate that the 
Pyrosequencing data is slightly more variable than the HM450 in both assays, however 
on both platforms, the same pattern can be seen in relation to Braak staging, with the 
Braak stage VI individual having a much lower methylation level at both loci.  
 
 
Figure 29: Mean APOB locus methylation levels observed for each Braak stage measured on the HM450 
and Pyrosequencer. 
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Figure 30: Mean NGF locus methylation levels observed for each Braak stage measured on the HM450 
and Pyrosequencer. 
 
Figure 31 and Figure 32 show the spread of methylation measured at the index CpG site 
using both platforms, for APOB and NGF, respectively. Both graphs show the Braak 
stage VI individual as an outlier on both platforms; however the difference between this 
individual and the mean methylation level across all samples is much lower when 
measured using Pyrosequencing than the HM450.  
 
 
Figure 31: Box plot to show methylation levels measured using the HM450 and Pyrosequencing at the 
index CpG site in APOB. 
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Figure 32: Box plot to show methylation levels measured using the HM450 and Pyrosequencing at the 
index CpG site in NGF. 
 
The analysis model used to assess the relationship between Braak staging and the 
HM450 data was applied to the Pyrosequencing data. This was to test whether the 
association between methylation and Braak staging was still present in the 
Pyrosequencing data. In Stata, ANOVA was performed (as in the analysis of HM450 
data) to test for association between methylation at the index site and Braak staging, 
using sex and baseline age as covariates. 29 blood DNA samples were included in the 
APOB analysis and 28 were included in the analysis of the NGF locus. The results of 
the HM450 were validated using Pyrosequencing at each loci; APOB p=0.0003; NGF 
p= 0.008. However, the methylation data were found to have a non-normal distribution 
using the Shapiro-Wilk normality test. A Kruskal Wallis test was therefore applied to 
assess whether DNA methylation differed between Braak stages in both the APOB and 
NGF assay. In both assays, the results of the Kruskal Wallis suggests there was no 
difference in DNA methylation between the Braak stages (APOB p= 0.338; NGF p= 
0.392). The Kruskal Wallis test is equivalent to ANOVA but does not assume a normal 
distribution of the data, which ANOVA does. It compares distributions rather than 
means of the two groups. The Kruskal Wallis result is therefore likely to be a true 
reflection of the statistical comparison as the assumptions of ANOVA are violated by 
the non-normal distribution of the methylation data in this comparison.  
 
When the individual with Braak VI stage pathology was removed from the analysis, 
there was no significant association with methylation at either locus (APOB and NGF) 
and Braak staging using ANOVA (APOB p=0.119; NGF p=0.334), or Kruskal Wallis 
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(APOB p=0.543; NGF p=0.414). This indicates that the results are heavily influenced by 
this outlier.  
 
3.3.3.1.2 Validation in Pyrosequencing cohort 
The Pyrosequencing assay was run across a larger sample set (APOB: n=40; NGF: 
n=35) to test whether the association with Braak staging at the index CpG site was still 
observed in a larger cohort. ANOVA revealed that the association between Braak 
staging and methylation at the APOB locus was more significant using the larger cohort 
(p=0.0001) than the discovery cohort, whereas Kruskal Wallis highlighted no 
significant differences in DNA methylation (p=0.264). Likewise, the association 
between Braak staging and methylation at the NGF locus was also more significant 
when a larger samples size was used in ANOVA analysis (p=0.007) but not with 
Kruskal Wallis (p=0.505).  
 
3.3.3.1.3 Neighbouring CpG sites 
It is also possible to look at the methylation levels of neighbouring CpG sites i.e. CpG 
sites close to the index CpG site, to assess whether these CpG sites are also associated 
with Braak staging. The APOB assay included the index CpG site along with one 
neighbouring site. The NGF assay included the index CpG site plus three neighbouring 
sites. The Pyrosequencing data for the neighbouring CpG sites were also analysed using 
ANOVA and Kruskal Wallis in both the HM450 cohort and the larger Pyrosequencing 
cohort. Results of ANOVA and Kruskal Wallis analyses are presented in Table 21. 
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CpG site P value 
APOB NGF 
Index CpG    
Discovery 0.0003 (0.338) 0.008 (0.392) 
Pyrosequencing 0.0001 (0.264) 0.007 (0.505) 
Neighbouring site 1   
Discovery 0.677 (0.774) 0.488 (0.362) 
Pyrosequencing 0.617 (0.804) 0.633 (0.521) 
Neighbouring site 2   
Discovery NA 0.115 (0.422) 
Pyrosequencing NA 0.075 (0.306) 
Neighbouring site 3   
Discovery NA 0.343 (0.338) 
Pyrosequencing NA 0.821 (0.605) 
Region   
Discovery 0.017 (0.533) 0.339 (0.484) 
Pyrosequencing 0.007 (0.376) 0.500 (0.694) 
Table 21: ANOVA (and Kruskal Wallis) results for APOB and NGF Pyrosequencing. The methylation of 
the region is defined as the mean methylation across all CpGs covered in the Pyrosequencing assay. P 
values are displayed for both the discovery cohort and Pyrosequencing cohort for each CpG site/region. 
 
Although both index CpG sites within APOB and NGF were found to be significantly 
associated with Braak staging in both cohorts, no neighbouring CpG within the APOB 
and NGF locus, measured by Pyrosequencing, was associated with Braak staging using 
either the discovery or Pyrosequencing cohort. When the mean of all CpG sites in the 
amplicon were analysed using ANOVA, the methylation of the APOB locus remained 
significantly associated with Braak staging whereas the NGF locus did not. No 
difference in DNA methylation was detected between Braak stages when the non-
parametric Kruskal Wallis test was performed but this is likely due to the small sample 
size limiting the power to find differences. 
 
These data show that although the data generated on the HM450 and Pyrosequencer 
were not identical, nor found to be correlated by Spearman’s rank (possibly due to the 
non-linear relationship with almost all methylation values being close to 100%), the 
same patterns were seen in relation to Braak staging. The HM450 findings that the 
Braak VI individual had a significantly lower methylation level compared with the other 
Braak stages at the index CpG sites within APOB and NGF was validated using 
Pyrosequencing.  
 
The major caveat of this study is the small sample size especially when looking at an 
outcome measure such as Braak staging, which splits samples into several small groups 
which could indicate why analysis with Kruskal Wallis did not show significant 
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differences in DNA methylation levels between the Braak stages. Only one COGFAST 
participant was diagnosed with Braak stage VI pathology meaning that the differential 
methylation seen in this Chapter, at both the APOB and NGF loci, is in one individual 
only.  
 
To test whether the observed differential methylation seen in the COGFAST individual 
was also detected in other demented Braak stage VI individuals, five blood DNA 
samples were sought from other Braak stage VI individuals from the NBTR and 
analysed using both the APOB and NGF Pyrosequencing assays. All five blood samples 
were from demented patients with Braak stage VI pathology and none of them were 
known to have had a stroke prior to death. 
 
Figure 33 shows the methylation level of the index CpG within APOB, measured by 
Pyrosequencing, in these five individuals compared with the COGFAST participants. 
Figure 34 shows the methylation level of the index CpG within NGF, measured by 
Pyrosequencing, in these five individuals compared with the COGFAST participants.  
 
 
Figure 33: Methylation at APOB locus measured in COGFAST and demented Braak stage VI individuals. 
Braak Stages are displayed on the X axis with demented Braak stage VI denoted as VI-DS.  
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Figure 34: Methylation at NGF locus measured in COGFAST and demented Braak stage VI individuals. 
Braak Stages are displayed on the X axis with demented Braak stage VI denoted as VI-DS. 
 
In both assays, the COGFAST Braak stage VI individual was unique in its methylation 
patterns, indicating that the results from this Chapter are not representative of all those 
with Braak stage VI pathology. However, this finding does not necessarily mean that 
this is a false positive. There are several reasons why this individual may have 
differential methylation at these loci. Possible explanations are explored in the 
discussion section below.   
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3.4 Discussion 
The work carried out in this Chapter aimed to identify potential biomarkers of post-
stroke dementia using blood samples taken three months post-stroke, when the stroke 
survivors were cognitively normal. The HM450 array identified 76 potential CpG sites 
associated with post-stroke dementia, the vast majority of which were found to be 
associated with Braak staging. Following filtering of top hits, ten assays were run across 
a larger COGFAST cohort to test whether the association observed between Braak 
staging and methylation persisted, when measured using Pyrosequencing. Two of these 
assays (APOB and NGF) successfully validated the HM450 findings using ANOVA, 
suggesting that the observations were confirmed using an alternative technology and 
that they are potential biomarkers for post-stroke dementia. These novel results were 
promising since both of these genes have previously been implicated in cardiovascular 
(Gigante et al., 2012) and dementia related diseases (Zhang et al., 2013).  
 
Apolipoprotein B (APOB) is present in two forms in humans; APOB-100 and APOB-48 
(Benn, 2009), and is the protein component of lipoproteins (Benn et al., 2007), which 
have a role in transporting cholesterol and triglycerides in the blood. The role of APOB 
is vital, since an accumulation of excess cholesterol can lead to atherosclerotic plaques 
(Dallmeier and Koenig, 2014). An increased level of plasma APOB, believed to reflect 
increased levels of low-density lipoprotein (LDL), has been associated with 
atherogenesis (Gigante et al., 2012) and is a major risk factor for atherosclerosis and 
IHD (Sule et al., 2009; Vaverkova et al., 2009). It has been widely studied in many 
cohorts of complex disease (Sato et al., 1991; Ford et al., 2013). Increased APOB levels 
have also been reported to be associated with increased arterial stiffness and arterial 
pulse wave velocity in adults under the age of 45 years (Koivistoinen et al., 2011). 
Screening for atherosclerosis usually involves measuring levels of LDL cholesterol in 
the blood; however increasingly it is being suggested that APOB measures could be a 
better predictor of atherosclerosis risk (Benn, 2009; Sniderman et al., 2012).  
 
Whilst APOB and LDL levels are widely believed to increase the risk of cardiovascular 
diseases and IHD, it is only in recent years that increased APOB levels have also been 
associated with an increased risk for ischaemic stroke (Walldius et al., 2006; Benn, 
2009). These findings have been supported by studies identifying a reduction in risk of 
ischaemic stroke by treatment with statins, which can lower APOB levels by 25-45% 
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(Heart Protection Study Collaborative Group, 2002; Amarenco et al., 2006). High 
APOB levels have been associated with the thickening of intima-media, which could 
indicate the mechanistic link between atherosclerosis and stroke (Walldius et al., 2006).         
 
APOB has also been linked to dementia. Aggregation of β-amyloid (Aβ) deposits is 
regarded as the hallmark of Alzheimer’s disease and, in several tissues including the 
blood, APOB has been found to co-localise with Aβ at an intra-cellular level (Kuo et 
al., 1998; Galloway et al., 2009; Lam et al., 2011). A study comparing levels of a range 
of lipid-related measures between AD patients and healthy controls reported elevated 
levels of APOB in the blood of AD patients (p=0.004) (Caramelli et al., 1999). These 
studies highlight a possible mechanistic link between APOB and AD; however these 
mechanisms are currently unknown. The findings presented in this thesis indicate a 
possible mechanistic link for the aberrant methylation of APOB in post-stroke 
individuals with Braak stage VI pathology. At the time of writing, no papers had been 
published that reported the methylation patterns of APOB in any cardiovascular-related 
cohorts indicating that this may be a novel finding. Replication in a larger cohort is 
required to investigate whether this association is seen when more individuals with 
Braak stage VI pathology are included.  
 
Nerve growth factor (NGF) is a member of the neurotropic family and has an essential 
role in the development and maintenance of neurons, both during development and 
throughout adulthood. NGF is produced in several regions of the brain including the 
cortex and hippocampus. Since NGF has been found to have a role in the maintenance 
and survival of cortical neurons, it has been suggested that NGF may have a potentially 
protective role in conditions such as ischaemia and Alzheimer’s disease (Aloe et al., 
2012). It is also thought that NGF could be delivered to the brain to increase 
neurogenesis thereby enhancing brain recovery (Lee et al., 1998; Greenberg and Jin, 
2006).   
 
Many studies have compared the levels of NGF expression and protein abundance 
between AD brains and healthy controls. Several papers report increased levels of NGF 
expression in the CSF (Hock et al., 2000; Mashayekhi and Salehin, 2006) and brain 
regions of AD patients (Fahnestock et al., 2001). Other papers have reported conflicting 
findings with increased degradation of NGF in AD brains compared with controls 
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(Bruno et al., 2009) and reduced NGF expression levels in AD affected brains (Higgins 
and Mufson, 1989). These apparently conflicting findings could be due to the 
heterogeneity of the brain regions studied or differences in the severity of disease. 
Hellweg et al. (1998) reported differences in NGF proteins levels between preclinical 
cases, AD cases and healthy controls. Preclinical cases had reduced levels of NGF 
compared with healthy controls, whereas cases with later stage AD had much higher 
levels of NGF protein (Hellweg et al., 1998). The reasons for, and mechanisms which 
result in altered NGF levels, are currently not well understood. Although there is 
conflicting evidence, there is a general consensus that NGF is likely to be involved in 
the pathogenesis of AD. NGF is explored in more detail in Chapter 4.  
 
The major caveat of this study is the small sample size resulting in the most noteworthy 
associations being driven by the methylation profile of one individual. In both loci, the 
lone COGFAST individual with Braak stage VI pathology had a reduced methylation 
value when compared to other COGFAST participants with a lower Braak staging. The 
methylation profile seen in the COGFAST Braak stage VI individual was not seen in 
non-stroke, demented individuals with Braak stage VI pathology. This individual is 
clearly different in terms of their methylation profile but it would appear (due to the 
lack of replication in other high Braak stage individuals) that this is not attributable to 
Braak stage pathology per se. One plausible explanation is that this individual has some 
particular unmeasured feature that confounds the observed association. It would be 
extremely interesting to extend this study, using more blood DNA samples taken from 
stroke survivors who later developed Braak stage VI pathology. The possibility that this 
individual could have a lower methylation value across the genome was investigated. 
The mean beta level across all probes on the HM450 was 49.5% for each blood DNA 
sample indicating that this Braak stage VI individual did not experience a genome-wide 
methylation difference. COGFAST is a complex cohort with a potentially 
heterogeneous mix of underlying risk factors and this heterogeneity may contribute to 
the difficulty in elucidating clear DMPs. Due to the small sample size of COGFAST it 
was necessary for the Pyrosequencing cohort to include those samples used in the 
discovery phase (HM450) of the study. For this reason, the validation phase 
(Pyrosequencing) of this study cannot be considered as a true replication. It was decided 
that all 46 samples would be included in the Pyrosequencing study rather than just the 
16 samples which had not been included on the HM450 array, as a sample of sixteen 
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would not allow for significant differences in DNA methylation to be detected. To be 
able to replicate the findings, this study would require analysis in a larger independent 
cohort.  
 
The analysis model used is robust at the population level, however in order to explain 
differences at an individual level, the clinical characteristics of the COGFAST subject 
with Braak stage VI pathology has been investigated, to identify the possible reasons for 
the NGF and APOB methylation deviations from the norm. It would not be practical, 
due to time limitations, to look at this level of detail in every participant due to too 
many possible contributing factors. This level of detail is only useful when investigating 
difficult to explain results. If the influences on methylation are subtle then the 
population based approach used in this thesis can be too noisy to identify these 
differences, highlighting a need for a more in depth assessment of possible contributing 
clinical factors. Table 22 describes the clinical features for this individual.  
 
As shown in Table 22 this individual was initially diagnosed as having vascular 
dementia but this diagnosis was questionable. The individual had a high burden of brain 
vascular lesions as well as Braak stage VI neurofibrillary pathology indicating that a 
diagnosis of mixed dementia was more appropriate. Due to the fluctuations in cognition 
identified following the index stroke, there is a possibility that this individual may have 
had DLB pathology, since fluctuations are a common symptom of DLB (Taylor et al 
2013); however, a DaTscan was never performed to investigate this, so the absolute 
diagnosis of dementia type is somewhat incomplete1. This subject differs from other 
participants in a number of ways. This subject was recruited into COGFAST via a 
different route. Stroke physicians were the usual means of referral, however this 
individual was referred in by an Old Age Psychiatrist, meaning that the index stroke 
was not well characterised. The three strokes experienced prior to the index stroke are 
also ill-defined with little information available on the location and severity of strokes. 
COGFAST recruited participants who were referred following their first known stroke. 
This distinguishes the COGFAST Braak stage VI individual from the others since this 
case had experienced multiple strokes and was likely to have a higher burden of 
vascular pathology. The effect these previous strokes may have on DNA methylation 
and how this links in with disease is explored in Chapter 4.  
1 The same clinician (Louise Allan, personal communication), now more experienced, revisited this case 
and gave her expert opinion on the diagnosis of this case.  
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Clinical Feature Description 
Diagnosis Vascular dementia  
Previous stroke history Three recurrent strokes in 1995 
Evidence of a left occipital lobe infarct  
Previous stroke symptoms Left sided weakness  
Dizziness 
Confusion 
Slurred speech 
Delirium 
Recruitment route into study Old Age Psychiatrist 
Index stroke  Right posterior parietal infarct 
Cognitive symptoms post-index stroke Stepwise cognitive decline 
Accelerated memory loss 
Disorientation 
Fluctuations in cognition 
Aggressive behaviour 
Assistance required with all personal activities 
of daily living 
Past medical history Hypertension 
Atrial fibrillation 
Hypercholesterolaemia 
Chronic Obstructive Pulmonary Disease 
Colonic polypectomy 
Falls 
Drug history Warfarin 
Pravastatin 
Bedroflumethiazide 
Temazepam 
Amlodipine 
Salbutamol 
Beclomethasone inhalers 
Cod liver oil 
Table 22: Clinical features of COGFAST Braak stage VI individual. 
 
The initial study design of COGFAST had one major limitation. The study design did 
not allow for recurrent strokes, occurring after the index stroke, to be recorded. 
Consequently, it is possible that a number of participants had multiple strokes following 
recruitment into the study, but this information was not recorded. These recurrent 
strokes could have had an impact on both DNA methylation and cognition. For 
example, it is possible that those participants who developed dementia following the 
index stroke had experienced additional strokes, thereby making them more susceptible 
to cognitive decline (Tatemichi et al., 1993; Leys et al., 2005). This information would 
be vital for assessing the effect of multiple strokes on cognition.  
 
Although DNA methylation analyses were performed on a total of 46 blood DNA 
samples, differential DNA methylation was only observed in one individual. However, 
the findings may still be of interest. Validation in a larger cohort is required before these 
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loci can be considered as possible biomarkers. However, the methylation loci identified 
appeared to only discriminate the most severe end of the spectrum of Braak stage 
phenotype, casting doubt on whether they would be a useful sensitive biomarker of 
prediction.   
 
A number of further steps could be undertaken to give a more thorough analysis of the 
possible biomarkers for PSD. The HM450 data highlighted a number of CpG sites 
(n=24) that were differentially methylated between outcome groups which were not 
amenable to Pyrosequencing. There were several reasons why primers could not be 
designed for these CpG sites such as the region surrounding the index CpG being a 
densely populated CpG island. These CpG sites were not followed up and analysed 
using Pyrosequencing, however these CpG sites could still be potential biomarkers for 
PSD. These assays could be revisited and analysed using an alternative candidate gene 
platform such as the Sequenom® Epityper™ (Ehrich et al., 2005) or bisulphite 
sequencing (Herman et al., 1996). Similarly a number of CpG sites were removed 
because they were in fact a SNP or there was a SNP present in the probe sequence 
(n=18). Some of these SNPs had a very low frequency in a European population and 
were perhaps excluded when they may not have affected findings. These SNPs could 
therefore also have been potential biomarkers that were excluded from validation 
analyses. A number of CpG sites also dropped out of the validation phase due to failure 
of PCR optimisation (n=8). However, these CpG sites could also be potential 
biomarkers for PSD and the DNA methylation status of these CpG sites could be 
investigated using an alternative approach. To select CpG sites to validate by 
Pyrosequencing, two approaches were followed. The first selected hits solely based on p 
value. The second looked at publicly available expression data. The selection process 
implemented only considered those sites which showed an inverse relationship between 
methylation and expression, to help narrow down those sites most likely to be 
functionally related to PSD. However, this selection criterion may have excluded some 
potential biomarkers. An inverse relationship between methylation and expression is 
only expected within promoter regions. It is less clear that this relationship is true in 
other regions of the gene (Jjingo et al., 2012; Jones, 2012). For this reason it may be 
possible that any of the genes previously identified as being differentially expressed in 
AD may be potential biomarkers for PSD, regardless of the direction of effect. In 
addition, the selection of top hits were based on expression data from only one study. 
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Taking an average from multiple expression studies would have been a better, more 
accurate approach. Furthermore, due to the absence of available PSD expression data, 
the expression dataset used to select the top hits was composed of AD cases so not 
entirely comparable to PSD cases.    
 
In addition, this work only looked at individual CpG sites and their associations with 
outcome. It would be interesting to analyse the data in an alternative way and look at 
DMRs in addition to DMPs. Gene set enrichment could be used to identify correlated 
networks of loci that differ between groups. Furthermore, given that the epigenome-
wide association study (EWAS) approach used in this Chapter highlighted two loci 
previously implicated in stroke and dementia, a candidate or pathway based approach 
could be adapted to only analyse “known” loci involved in disease. This would 
therefore reduce the multiple testing burden caused by EWAS but would eliminate the 
possibility of uncovering novel biomarkers.  
 
Due to the heterogeneous nature of blood, it is possible that any differences  in DNA 
methylation observed between outcome groups is due to the cellular composition of the 
blood. Methylation beta values were adjusted for cellular composition to determine 
whether the differential methylation observed in relation to Braak staging were actually 
due to differences in cellular composition. Adjusting for cellular composition revealed 
very little difference in significance indicating that differences in cellular composition 
have very little effect on the methylation differences observed between outcome groups 
in this Chapter.   
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Chapter 4. Epigenetic mechanisms in post-stroke dementia 
 
4.1 Introduction 
In addition to identifying biomarkers for clinical use in the prediction and prognosis of 
post-stroke dementia (PSD), this project aims to identify possible mechanisms involved 
in the pathogenesis of PSD.  
 
As described in Chapter 3, epigenetic mechanisms including altered DNA methylation 
status, have been implicated in an increased risk of both stroke (Endres et al., 2000; 
Castillo-Diaz et al., 2010) and dementia (Wang et al., 2008; Bollati et al., 2011; 
Bakulski et al., 2012a; Chouliaras et al., 2013). In many instances, although a reliable 
association is observed between DNA methylation and a disease, a causal role of 
perturbed DNA methylation has not been demonstrated. To identify differential DNA 
methylation which may have a mechanistic role in disease, the analysis of the diseased 
tissue (in this case the brain) is required.  
 
As previously stated, the mechanisms which result in PSD are currently largely 
unknown (Section 1.2.3.5), but epigenetics could be one such mechanism. There have 
been several studies highlighting the potential role of DNA methylation in the 
pathophysiology of a number of diseases including cancer (Stefansson and Esteller, 
2013) and Alzheimer’s disease (Mastroeni et al., 2009; Chouliaras et al., 2010; 
Mastroeni et al., 2011), but to date there have been no studies investigating the role of 
DNA methylation in the pathophysiology of PSD. Epigenetic marks are increasingly 
being regarded as potential mechanistic links between exposures and disease risk, 
especially in the field of cancer.  
 
This approach is yet to be applied to PSD. It is postulated that DNA methylation 
signatures in the brain could indicate possible genes and pathways involved in the 
pathogenesis of disease. DNA methylation analysis alone is not sufficient to be able to 
infer causality, other measures such as gene expression and protein levels are required 
to strengthen the relationship. The COGFAST cohort was used to test whether DNA 
methylation alterations found in the brains of stroke patients can identify possible 
mechanisms involved in the pathogenesis of PSD.  
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4.2 Experimental design 
General methods are described in Chapter 2. Many of the methods used in this Chapter 
overlap with these that have already been described in Section 3.2. Additional details 
specifically relevant to this investigation are described in detail below.  
 
4.2.1 Study cohort 
Brain samples collected from participants of the COGFAST cohort (Section 2.1.1) were 
utilised in this study. The regions of the brain selected for use in this study were the 
dorsolateral prefrontal cortex (DLPFC) and the hippocampus. A diagnosis of dementia 
was given based on neuropathological examination in combination with results of a 
series of cognitive tests. Data relating to clinical history, including details of stroke 
severity as well as stroke risk factors, were available to analyse. Age at death, post-
mortem (PM) delay, Braak staging and years between stroke and death were collected at 
death. All other variables were collected at baseline (recruitment into study) and are 
described in the Glossary (Table 2). Paired (from the same individual) DLPFC and 
hippocampal samples were divided into a ‘discovery’ sample (n=30) and 
‘Pyrosequencing’ sample (n=46), the latter consisting of the discovery sample plus an 
additional sixteen samples drawn from the same cohort.  
 
4.2.2 Tissue DNA extraction, quantification and precipitation 
Sections of DLPFC and hippocampus were held in long-term storage at -80°C following 
sampling and were selected and removed from storage for the purposes of this study. 
DNA was extracted from 30µg DLPFC and 10µg hippocampus using the Tissue DNA 
Spin protocol as outlined in the EZNA Tissue DNA Kit (OMEGA bio-tek, USA) 
(Section 2.2.1). DNA samples were quantified using a ND1000 Spectrophotometer 
(Labtech International Ltd, UK) (Section 2.2.3). Samples with a concentration lower 
than 50ng/µl were ethanol precipitated and re-suspended in 30µl DEPC-treated water 
(Section 2.2.4).  
 
4.2.3 Illumina HumanMethylation450 BeadChip analysis 
Epigenome wide discovery analysis was performed using the Illumina HM450 
BeadChip. Thirty individuals with >1µg paired DLPFC and hippocampal derived DNA 
were selected for discovery phase DNA methylation analysis. Section 3.2.3 describes 
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how the DNA samples were processed and how the HM450 data were filtered and 
normalised.  
 
4.2.4 Analysis of HM450 data 
A total of 431,832 probes and 24 samples were included in the final DLPFC dataset. A 
total of 434,422 probes and 28 samples were included in the final hippocampal dataset. 
As in Chapter 3, exploratory analyses were performed across the methylation data by 
considering distribution density plots, mean-sd plots and hierarchical clustering with 
heat plots. The CpGassoc package (Barfield et al., 2012), which performs multiple 
linear regression analyses with a continuous predictor variable and ANOVA for 
categorical predictor variables was implemented in R (version 2.15.0). CpGassoc was 
performed to test for associations between methylation and; diagnosis (D/CN), the last 
MMSE and CAMCOG scores before death and Braak staging as predictor variables. For 
all analyses, age at death, sex and chip (i.e. the microarray chip upon which the samples 
were scanned) were included in the analysis model as covariates. Data generated 
provided a beta value as outlined in Section 3.2.4. To test for sensitivity to cellular 
composition, HM450 data were adjusted for cellular composition using the method 
described by Guintivano et al. (2013). Statistical analyses were then repeated to assess 
whether cell composition accounted for any significance observed between methylation 
and the outcome variable. 
 
4.2.5 Selection of top HM450 hits 
The selection of top HM450 hits is described in detail in Section 3.2.5. Brain data were 
treated in the same way as blood data, the only exception being the expression dataset 
used in the second approach. In this Chapter, GSE36980, a study which compared 
expression levels in both the frontal cortex and hippocampus between AD patients and 
healthy controls was used (Hokama et al., 2013). GSE36980 was chosen due to both 
brain regions of interest being included. However, GSE36980 uses AD cases whereas 
this study is interested in PSD cases so results are not entirely comparable. In brief, two 
approaches were taken. In the first approach, p values above the cut off imposed for 
multiple test correction (DLPFC: 0.05/431,832; hippocampus: 0.05/434,422) were not 
considered. The second approach included all CpG sites with a p value <1x10-5 (to 
include more hits) and compared methylation data with publicly available expression 
data. Loci were selected for further analysis if they displayed the expected DNA 
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methylation-expression relationship (i.e. hypermethylated and under expressed, 
hypomethylated and over expressed). This inverse relationship between methylation and 
expression is only expected in promoter regions, it is less clear that it is always the case 
in other regions such as gene bodies, indicating that this may be a potential limitation of 
the study. The next criterion in both approaches was that the effect size (difference 
between the outcome groups) was more than 5% due to the suggested technical 
limitation of the Pyrosequencer (Mikeska et al., 2011). Finally, a BLAT search was 
performed to test for the presence of a SNP within the CpG site. If the CpG site was 
indeed a SNP, or if a SNP was identified within the probe sequence, this site was 
removed from consideration. This step removed any CpG sites likely to be directly 
under genetic influence. 
 
4.2.6 Pyrosequencing 
Details of primer design (Section 2.6.2), primer optimisation (2.6.3) and assay 
validation (Section 2.6.5) can be found elsewhere (Section 3.2.6).  
 
Pyrosequencing assays (n=2 in DLPFC; n= 5 in hippocampus) were performed on the 
discovery sample (n=24 in DLPFC; n=28 in hippocampus) along with brain derived 
DNA samples from an additional sixteen individuals drawn from the same cohort. 
500ng of DNA was first bisulphite modified, amplified using the optimised 
Pyrosequencing PCR conditions in Table 23 and finally sequenced on a PyroMark MD 
Pyrosequencer (Qiagen, UK) following the standard protocol (Section 2.6.6). Details of 
all relevant Pyrosequencing primers are provided in Table 24.   
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Tissue Gene/DMP HM450 
probe ID 
Tm(°C) MgCl2 
+/- 
Size of 
product(bp) 
No. 
CpGs 
Successfully 
validated 
using 
Epitect 
controls 
D,H CTRC cg03096785 50.9 - 144 1  
D,H cg20583640 cg20583640 54.5 - 168 6  
D,H cg18837178 cg18837178 54.5 + 143 2 Yes 
D,H NGF cg00794813 53.6 - 305 4 Yes 
H EIF4E3 cg01228342 50.9 - 118 1 Yes 
H LMNA cg15447017 53.6 - 298 3  
H CTRL cg02126424 50.9 - 155 3  
H cg01063243 cg01063243 56.9 + 394 9 Yes 
H cg12010173 cg12010173 51.5 - 341 4 Yes 
H KIAA1026 cg02232840 50.4 - 265 2  
Table 23: Optimal PCR conditions for each assay. Tissue - D=DLPFC, H=Hippocampus. Tm=annealing 
temperature. 
 
Tissue Gene Forward primer 
(5’>3’) 
Reverse primer 
(5’>3’) 
Sequencing primer 
(5’>3’) 
D,H NGF GGAATTATATTTAGAG
AGTAA 
5Biosg/TACTCCTATAAA
TCCTATTAA 
ATTTTAGGTTGTTTAA
AAAG 
D,H cg18837178 5Biosg/TATGGTGATTTG
TGATTAG 
CCATCTTCTCAAATTAC
T 
AAATAAACCTACTTTC
TTCC 
H cg12010173 5Biosg/GGGATTTTAGTT
TATTGTA 
ACCCAAATCTACCTATT
C 
ACCTATATACCCCTCC
C 
H EIF4E3 TGTTTATAGGGTGTGAT
ATT 
5Biosg/ACACTAAAAACT
ACCATCTAAT 
TGTTTTTTATGTGGGA
AT 
H cg01063243 5Biosg/TAGTAGGGAGA
TTATAAAGATAG 
ACACTTTCCTTACTCTT
CTT 
CCCACAACTTCCCAT 
Table 24: Forward, reverse and sequencing primer for each successfully validated DMP Pyrosequencing 
assay. Tissue – D=DLPFC, H=Hippocampus. 5Biosg=biotin label 
 
4.2.7 Statistical analyses 
All statistical analyses were carried out in Stata as described in Section 3.2.7. When 
ANOVA was performed, sex and age at death were included as covariates.  
 
4.2.8 Protein extraction and quantification 
Sections of DLPFC and hippocampus were held in long-term storage at -80°C following 
sampling and were selected and removed from storage for the purposes of this study. 
Protein was extracted from 100µg DLPFC and 4x100µM sections of hippocampus in 
400µl extraction buffer (50mM Tris-HCl, 5mM EGTA, 10mM EDTA, pH 7.4), as 
outlined in Section 2.7.4.  
 
Total protein levels were quantified using the Thermo Scientific™ Pierce™ BCA™ 
Protein Assay (Thermo Scientific, USA) (Section 2.7.5). Protein samples were then 
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standardised to 25µg and made up to 15µl using the extraction buffer described in 
Section 2.7.4. 
 
4.2.9 Western blot optimisation 
Four different blotting conditions (Table 8) for anti-NGF were tested to find the 
optimum conditions. The conditions tested were; blocking in 5% milk followed by 
dilution of anti-NGF in either 5% milk or 1% milk, and blocking in 5% BSA followed 
by dilution of anti-NGF in either 5% BSA or 1% BSA. The optimum conditions were 
selected as the lane which produced the strongest band and least background. The 
optimum conditions were then used in all future Western blots (Section 2.7.6.1).  
 
4.2.10 Western blot 
The detailed protocol for the Western blot can be found in Section 2.7.6.2, but is 
described in brief below.  
 
15µl of each sample was loaded into a well on a 12% acrylamide gel (Aversham, GE 
Healthcare Life Sciences, UK) along with 15µl DLPFC standard, 15µl hippocampus 
standard and 10µl SpectraBr ladder (Fermentas, International) and run at 160V for 1 
hour. Following activation of the membrane in 100% methanol, the protein samples 
were transferred onto the membrane in a transfer tank kept cool using ice at 100V for 1 
hour. The membrane was blocked using a 5% milk solution for 1 hour. The membrane 
was then incubated in 1:200 anti-NGF in 5% milk for 1 hour and washed 3 times for 5 
minutes each in TBST to remove any unbound antibody. The membrane was then 
incubated in 1:1000 anti-rabbit in 1% milk for one hour and washed three times for 5 
minutes in TBST. Equal parts of A and B taken from the Amersham ECL Prime 
Western Blotting Detection Reagent (GE Healthcare Life Sciences, UK) were mixed 
and washed over the membrane. The membrane was then covered in a thin film and 
imaged using a Syngene G:Box camera (Syngene, UK) and Genesys software (Syngene, 
UK).  
 
To check that the total volume of protein loaded into each gel was the same in each lane 
a loading control was used. First, the membrane was stripped of all bound antibody by 
washing in Restore Western Blot Stripping Buffer (ThermoScientific, USA) for 15 
minutes. The membrane was then blocked with 5% milk and left at 4°C overnight. The 
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membrane was then incubated in α-tubulin antibody for 1 hour. 3 x 5 minute washes in 
TBST then followed. The membrane was then incubated in the secondary antibody for 1 
hour and washed 3 times for 5 minutes each in TBST. Again equal parts of A and B 
from the Amersham ECL Prime Western Blotting Detection Reagent (GE Healthcare 
Life Sciences, UK) were mixed and washed over the membrane. A plastic film was used 
to cover the membrane and imaged using a Syngene G:Box camera (Syngene, UK) and 
Genesys software (Syngene, UK). ImageJ software (National Institutes of Health, USA) 
was used to generate values for band density in each gel lane as described in Section 
2.8.4 and a relative value for NGF was calculated.  
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4.3 Results 
 
4.3.1 Discovery analysis 
Of the 60 brain (30 DLPFC, 30 Hippocampus) samples that underwent HM450 
analysis, 52 samples passed the quality control assessment of the inbuilt microarray 
controls assessed in GenomeStudio. The remaining eight samples failed due to 
incomplete bisulphite modification and were dropped from further analysis. 
 
In both tissues, low failure rates were observed on both a sample and probe by probe 
basis, assessed using detection p values generated by the array scanner. As described in 
Section 2.5.2, samples were only removed if ≥20% of probes had a detection p value 
>0.01. Probes were removed if ≥10% of samples had a detection p value >0.01. No 
samples were removed from analysis using these criteria in both brain regions. 25,006 
probes were removed from the DLPFC analysis and 22,416 probes were dropped from 
the hippocampal analysis. Summaries of the detection p values observed for samples 
and probes are shown in Figure 35 and Figure 36. 
 
Following data filtering and normalisation, as described in Section 2.5.2, 431,832 CpG 
sites were taken forward for analysis measured in DLPFC samples from 24 individuals; 
13 D vs 11 CN. 434,422 CpG sites were taken forward for analysis measured in 
hippocampus samples from 28 individuals; 16 D vs 12 CN.  
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Figure 35A: Average detection p values in each DLPFC sample. For each sample the average detection p 
value is very low and samples are of approximately equal quality. 
Figure 35B: Average detection p values in each hippocampus sample. For each sample the average 
detection p value is very low and samples are of approximately equal quality. 
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Figure 36A: Histogram to show the number of probes against the corresponding number of samples with 
p values greater than 0.01 across DLPFC samples. The red line indicates 10%. 411,541 probes had no 
missing data and for space reasons, this data is not shown on the histogram.  
Figure 36B: Histogram to show the number of probes against the corresponding number of samples with 
p values greater than 0.01 across hippocampus samples. The red line indicates 10%. 442,633 probes had 
no missing data and for space reasons, this data is not shown on the histogram. 
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4.3.1.1 Distribution of genome-wide methylation values 
Figure 37 (A-F) shows the distribution of methylation values using both raw (A-C) and 
normalised (D-F) DLPFC data. Figure 38 (A-F) shows the distribution of methylation 
values using both raw (A-C) and normalised (D-F) hippocampus samples. In both 
tissues, the raw data are much more variable, indicating that much of the variation was 
technical.  
 
4.3.1.2 Cluster analysis 
Hierarchical cluster analysis using the complete-linkage method was performed on the 
normalised data to look for natural groupings (either phenotypic or technical) amongst 
the samples based on the methylation data. No clear clusters were observed for 
diagnosis of dementia, indicating that DNA methylation signatures are not sufficiently 
distinct in either brain region drawn from this cohort (Figure 39 and Figure 42). 
 
However, as shown in Figure 40 and Figure 43, even after normalisation and removal of 
probes mapping to the sex chromosomes, there remained some subtle groupings 
amongst samples based on sex. Due to these results, like the analysis in blood, sex was 
included as a covariate in subsequent analyses of single-point CpG sites. In contrast, 
there were no apparent clusters based on experimental chip (Figure 41 and Figure 44) 
suggesting that these batch effects were removed. Nonetheless, to fully account for any 
remaining, albeit subtle, batch effects, chip was also included as a covariate in the 
single-point analysis model.  
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Figure 37: A composite figure showing the distributions of methylation using raw and normalised DLPFC data. A. Density plot showing methylation distribution in 24 DLPFC 
samples using raw data. B. Box plot showing mean methylation raw beta values across all DLPFC samples. C. Mean vs SD plot showing heteroskedasticity using raw data. D. 
Density plot showing methylation distribution in 24 DLPFC samples using normalised data. E. Box plot showing mean methylation normalised beta values across all DLPFC 
samples. F. Mean vs SD plot showing heteroskedasticity using normalised data.
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Figure 38: A composite figure showing the distribution of methylation using raw and normalised hippocampus data. A. Density plot showing methylation distribution in 28 
hippocampus samples using raw data. B. Box plot showing mean methylation raw beta values across all hippocampus samples. C. Mean vs SD plot showing heteroskedasticity using 
raw data. D. Density plot showing methylation distribution in 28 hippocampus samples using normalised data. E. Box plot showing mean methylation normalised beta values across 
all hippocampus samples. F. Mean vs SD plot showing heteroskedasticity using normalised data. 
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Figure 39: Cluster dendrogram for all 24 DLPFC samples coloured by diagnosis. 
 
 
Figure 40: Cluster dendrogram for all 24 DLPFC samples coloured by sex. 
 
 
Figure 41: Cluster dendrogram for all 24 DLPFC samples coloured by chip. 
 
153 
 
 
 
 
Figure 42: Cluster dendrogram for all 28 hippocampus samples coloured by diagnosis. 
 
 
Figure 43: Cluster dendrogram for all 28 hippocampus samples coloured by sex. 
 
 
Figure 44: Cluster dendrogram for all 28 hippocampus samples coloured by chip.
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4.3.1.3 Single-point analysis 
ANOVA was performed on all beta values across all CpG sites passing QC (431,822 
sites in DLPFC; 434,422 sites in hippocampus) against the following outcome 
measures: diagnosis (D/CN), last MMSE result before death, Braak staging and a 
number of CAMCOG scores (abstract thinking, attention, calculation, executive 
function, language comprehension, language expression, memory learning, memory 
recent, memory remote, memory total, orientation, perception, praxis, total CAMCOG 
score). Age at death, sex and chip were included in the analysis model as covariates. 
Results from this step were exported as a table in Microsoft Excel and ordered by 
ascending p value. 
 
As for the analysis of blood samples in Chapter 3, two approaches were employed when 
selecting top hits. These are described below. 
 
4.3.1.4 Selection of top hits – approach 1 
 
4.3.1.4.1 Dorsolateral prefrontal cortex 
The first approach selects hits which reach genome wide significance. When testing for 
association between methylation and diagnosis, last MMSE and all CAMCOG variables 
(abstract thinking, attention, calculation, executive function, language comprehension, 
language expression, memory learning, memory recent, memory remote, memory total, 
orientation, perception, praxis and total CAMCOG score), no CpG sites were 
highlighted as significant at the conservative genome wide corrected threshold of 
p<1.16x10-7. However, when Braak staging was included in the model as the outcome 
variable, methylation was significantly different at ten CpG sites (DMPs) (Figure 45 
and Figure 46). These ten DMPs were then considered as targets for validation by 
Pyrosequencing.  
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Figure 45: QQ plot for association between methylation and Braak staging in the DLPFC. The QQ plot 
shows the expected against the observed p values. Data points plotted in red reach the Bonferroni 
corrected significance threshold. 
 
 
 
Figure 46: Manhattan plot for association between methylation and Braak staging in the DLPFC. Each 
circle represents an individual CpG site. The continuous line marks the p<1.1x10-7 significance threshold. 
CpG sites with p values below the threshold are labelled with their Illumina ID. 
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Of the top ten hits, only four primer pairs were successfully designed (Table 25). Two 
CpG sites dropped out of the selection due to having a small (<5%) effect size. 5% was 
chosen as the minimum effect size due to the technical sensitivity of the Pyrosequencer. 
Although a number of SNPs were removed during the HM450 filtering step (Section 
2.5.2), an additional SNP search was incorporated into the work flow. A BLAT search 
(NCBI) of the probe sequence highlighted that three of the remaining eight CpG sites 
were in fact SNPs and these were removed from the selection. A search on the NHGRI 
GWAS Catalog (www.genome.gov/gwastudies) revealed that none of these three SNPs 
had previously been associated with PSD or any related disease. The remaining five loci 
were taken forward for primer design. As described in Section 2.6.2, only those sites 
where primers were able to be designed with a score of 70 and no warnings on the PSQ 
design software were selected for the validation stage. Figure 47 shows the selection of 
top hits. 
 
Variable CpG site P value Gene F 
statistic 
Effect 
size 
SNP Primers 
Braak 
Staging 
cg00794813 1.68E-15 NGF 5804.12 0.652 No Yes 
Braak 
Staging 
cg03096785 5.91E-10 CTRC 337.76 0.606 No Yes 
Braak 
Staging 
cg11796313 8.40E-10  312.23 0.588 No Yes 
Braak 
Staging 
cg20583640 8.90E-09  183.83 0.479 No Yes 
Braak 
Staging 
cg10616306 2.73E-08 TMEM161B 142.76 -0.062 No No 
Braak 
Staging 
cg23404610 5.63E-08  121.26 0.549 Yes  
Braak 
Staging 
cg27157669 5.19E-09 KLDHC5 207.54 0.525 Yes  
Braak 
Staging 
cg13723217 2.38E-09  247.25 -0.321 Yes  
Braak 
Staging 
cg10701801 8.30E-09  510.15 0.016   
Braak 
Staging 
cg10280035 9.02E-11  514.10 0.011   
Table 25: Details about top 10 CpG sites based on genome wide significance. 
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Figure 47: Flow diagram summarising the selection of top hits which reach genome wide significance in 
the DLPFC. 
 
The HM450 data were then adjusted for cellular composition using the method 
described by Guintivano et al. (2013) and the CpGassoc analyses were repeated. The 
before and after cell adjustment analyses were compared to look for differences. At the 
majority of CpG sites, cell adjustment only slightly altered the results (p value and F 
statistic). The effect, however, was significantly altered in three of the ten selected CpG 
sites with all three CpG sites losing their significance. The test statistics for before and 
after cellular adjustment are displayed in Table 26. 
 
Variable CpG site Pre-adjustment Post-adjustment 
F statistic P value F statistic P value 
Braak Staging cg00794813 5804.12 1.68E-15 6657.13 3.01E-14 
Braak Staging cg10280035 514.10 9.02E-11 582.87 5.05E-10 
Braak Staging cg03096785 337.76 5.91E-10 357.65 3.53E-09 
Braak Staging cg11796313 312.23 8.40E-10 280.23 9.31E-09 
Braak Staging cg13723217 247.25 2.38E-09 229.49 2.06E-08 
Braak Staging cg27157669 207.54 5.19E-09 184.21 4.91E-08 
Braak Staging cg20583640 183.83 8.90E-09 164.70 7.64E-08 
Braak Staging cg23404610 121.26 5.63E-08 126.44 2.17E-07 
Braak Staging cg10616306 142.76 2.73E-08 125.01 2.27E-07 
Braak Staging cg10701801 510.15 8.30E-09 339.54 2.86E-07 
Table 26: CpG sites showing an effect when adjusted for cellular composition. 
 
In the DLPFC, three of the ten CpG sites identified as being associated with Braak 
staging were no longer significant following adjustment for cellular composition. This 
suggests that cellular composition may be driving the significance identified at these 
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CpG sites. However, there is only a slight attenuation of significance at all ten CpG sites 
indicating that cellular composition is not wholly responsible for the significant 
association between methylation and Braak staging. At the remaining seven CpG sites, 
methylation is still significantly associated with Braak staging. As seen in Table 25, 
four of these CpG sites were taken forward for validation analyses on the 
Pyrosequencer. Significance at all four of these CpG sites remained following cellular 
adjustment, indicating that the methylation differences identified at these sites are only 
slightly affected by cellular composition. For this reason, they can still be considered as 
potential methylation markers which could be involved in the mechanistic pathway.  
 
4.3.1.4.2 Hippocampus 
When testing for association between methylation and diagnosis, and methylation and 
last MMSE, no CpG sites were highlighted as significant at the conservative genome 
wide corrected threshold of p<1.16x10-7. Likewise, a number of CAMCOG scores 
(abstract thinking, attention, calculation, executive function, language comprehension, 
language expression, memory learning, memory total, orientation, perception, praxis 
and total CAMCOG score) were not associated with methylation at any of the 431,832 
CpG sites included in the analysis. However, when Braak staging was included in the 
model as the outcome variable, methylation was significantly different at 30 CpG sites 
(DMPs) (Figure 48 and Figure 49). Three CpG sites were found to be associated with 
the CAMCOG variable “memory remote” (Figure 50 and Figure 51) and another with 
“memory recent” (Figure 52 and Figure 53). These 34 DMPs were then considered as 
targets for validation by Pyrosequencing.  
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Figure 48: QQ plot for association between methylation and Braak staging in the hippocampus. The QQ 
plot shows the expected against the observed p values. Data points plotted in red reach the Bonferroni 
corrected significance threshold. 
 
 
 
Figure 49: Manhattan plot for association between methylation and Braak staging in the hippocampus. 
Each circle represents an individual CpG site. The continuous line marks the p<1.1x10-7 significance 
threshold. CpG sites with p values below the threshold are labelled with their Illumina ID. 
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Figure 50: QQ plot for association between methylation and memory remote in the hippocampus. The QQ 
plot shows the expected against the observed p values. Data points plotted in red reach the Bonferroni 
corrected significance threshold. 
 
 
Figure 51: Manhattan plot for association between methylation and memory remote in the hippocampus. 
Each circle represents an individual CpG site. The continuous line marks the p<1.1x10-7 significance 
threshold. CpG sites with p values below the threshold are labelled with their Illumina ID. 
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Figure 52: QQ plot for association between methylation and memory recent in the hippocampus. The QQ 
plot shows the expected against the observed p values. Data points plotted in red reach the Bonferroni 
corrected significance threshold. 
 
 
Figure 53: Manhattan plot for association between methylation and memory recent in the hippocampus. 
Each circle represents an individual CpG site. The continuous line marks the p<1.1x10-7 significance 
threshold. CpG sites with p values below the threshold are labelled with their Illumina ID. 
 
Of the 34 top hits, only nine primer pairs were successfully designed (Table 27). All 
CpG sites had an effect size >5%. Although a number of SNPs were removed during the 
HM450 filtering step (Section 2.5.2), an additional SNP search was incorporated into 
the work flow. A BLAT search (NCBI) of the probe sequence highlighted that 13 of the 
34 CpG sites were in fact SNPs and these were removed from the selection. A search on 
the NHGRI GWAS Catalog (www.genome.gov/gwastudies) revealed that none of these 
13 SNPs had previously been associated with PSD or any related disease. The 
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remaining 21 loci were taken forward for primer design. As described in Section 2.6.2, 
only those sites where primers were able to be designed with a score of 70 and no 
warnings on the PSQ design software were selected for the validation stage. Figure 54 
shows the selection of top hits. 
 
Variable CpG site P value Gene Test 
statistic 
Effect 
size 
SNP Primers 
Braak Staging cg16966201 4.44E-12  219.57 -0.685 No No 
Braak Staging cg03771731 7.75E-13 SLC6A5 288.12 0.650 No No 
Braak Staging cg02126424 1.40E-09 CTRL 88.76 0.597 No Yes 
Braak Staging cg11796313 2.76E-13  338.25 0.541 No Yes 
Braak Staging cg03096785 2.19E-11 CTRC 171.10 0.484 No Yes 
Braak Staging cg18837178 3.06E-08  54.03 0.478 No Yes 
Braak Staging cg00794813 9.33E-14 NGF 400.29 0.464 No Yes 
Braak Staging cg20583640 1.09E-07  43.91 0.432 No Yes 
Braak Staging cg16765928 1.17E-09 NRXN3 91.33 0.419 No No 
Braak Staging cg12010173 6.23E-08  48.11 0.293 No Yes 
Braak Staging cg09257092 9.27E-09 ITPR2 65.57 -0.264 No No 
Braak Staging cg08148379 9.22E-09  65.63 0.235 No No 
Braak Staging cg06304097 3.71E-13 TCERG1L 323.11 -0.177 No No 
Braak Staging cg14520944 1.28E-08  62.20 0.170 No No 
Memory 
remote 
cg08350126 2.06E-08 HPX 9.81 -0.139 No No 
Braak Staging cg01228342 1.44E-08 EIF4E3 61.07 -0.136 No Yes 
Memory 
remote 
cg02232840 1.09E-07 KIAA1026 8.73 -0.124 No Yes 
Braak Staging cg06897790 1.06E-10 TMEM161B 133.54 -0.121 No No 
Braak Staging cg10616306 1.27E-13 TMEM161B 381.49 -0.094 No No 
Memory recent cg22666015 8.60E-08 INPP5D -8.88 0.091 No No 
Memory 
remote 
cg12352601 5.29E-08 KDM2B 9.19 -0.077 No No 
Braak Staging cg16529007 7.94E-08  46.23 0.768 Yes  
Braak Staging cg23357764 6.65E-08  56.07 0.676 Yes  
Braak Staging cg20095669 9.30E-08 PPFIBP1 52.86 0.675 Yes  
Braak Staging cg03721887 5.97E-10 CTDP1 164.41 0.648 Yes  
Braak Staging cg04698472 1.09E-07 SIGLEC12 43.85 0.608 Yes  
Braak Staging cg15411736 2.43E-09 CLECL1 170.46 0.602 Yes  
Braak Staging cg23404610 6.40E-11  144.56 0.567 Yes  
Braak Staging cg05273049 4.29E-11 ARHGAP22 153.95 -0.540 Yes  
Braak Staging cg27157669 2.21E-11 KLHDC5 170.87 0.489 Yes  
Braak Staging cg00991192 5.81E-08  48.66 0.472 Yes  
Braak Staging cg13723217 4.03E-15  650.96 -0.285 Yes  
Braak Staging cg18854398 3.47E-09 C1orf66 76.77 -0.138 Yes  
Braak Staging cg10701801 1.36E-10 OSBPL9 216.00 0.053 Yes  
Table 27: Details about top 34 CpG sites based on genome wide significance in the hippocampus. 
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Figure 54: Flow diagram summarising the selection of top hits which reach genome wide significance in 
the hippocampus. 
 
The HM450 data were then adjusted for cellular composition using the method 
described by Guintivano et al. (2013) and the CpGassoc analyses were repeated. The 
before and after cell adjustment analyses were compared to look for differences. At the 
majority of CpG sites, cell adjustment only slightly altered the results (p value and F/t 
statistic). The effect, however, was significantly altered in six of the 34 selected CpG 
sites with all six CpG sites losing their significance. The before and after cellular 
adjustment test statistics are displayed in Table 28. 
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Variable CpG site Pre-adjustment Post-adjustment 
F/t statistic P value F/t statistic P value 
Braak Staging cg13723217 650.96 4.03E-15 699.66 2.33E-14 
Braak Staging cg00794813 400.29 9.33E-14 415.91 5.19E-13 
Braak Staging cg10616306 381.49 1.27E-13 364.04 1.15E-12 
Braak Staging cg11796313 338.25 2.76E-13 304.44 3.32E-12 
Braak Staging cg06304097 323.11 3.71E-13 289.30 4.50E-12 
Braak Staging cg03771731 288.12 7.75E-13 267.98 7.09E-12 
Braak Staging cg16966201 219.57 4.44E-12 231.38 1.69E-11 
Braak Staging cg27157669 170.87 2.21E-11 154.36 1.85E-10 
Braak Staging cg03096785 171.10 2.19E-11 153.65 1.90E-10 
Braak Staging cg23404610 144.56 6.40E-11 146.41 2.53E-10 
Braak Staging cg05273049 153.95 4.29E-11 141.52 3.09E-10 
Braak Staging cg06897790 133.54 1.06E-10 133.16 4.41E-10 
Braak Staging cg10701801 216.00 1.36E-10 197.67 1.17E-09 
Braak Staging cg03721887 164.41 5.97E-10 153.35 4.08E-09 
Braak Staging cg18854398 76.77 3.47E-09 89.16 4.60E-09 
Braak Staging cg08148379 65.63 9.22E-09 88.36 4.85E-09 
Braak Staging cg16765928 91.33 1.17E-09 83.39 6.78E-09 
Braak Staging cg02126424 88.76 1.40E-09 80.05 8.59E-09 
Braak Staging cg15411736 170.46 2.43E-09 148.27 2.31E-08 
Memory 
Remote 
cg02232840 8.73 1.09-07 9.95 2.93E-08 
Braak Staging cg23357764 56.07 6.65E-08 75.08 4.01E-08 
Braak Staging cg09257092 65.57 9.27E-09 59.20 4.87E-08 
Memory 
Remote 
cg12352601 9.19 5.29E-08 9.58 4.96E-08 
Memory 
Remote 
cg08350126 9.81 2.06E-08 9.53 5.37E-08 
Braak Staging cg14520944 62.20 1.28E-08 56.11 6.62E-08 
Braak Staging cg18837178 54.03 3.06E-08 55.52 7.03E-08 
Braak Staging cg01228342 61.07 1.44E-08 54.92 7.48E-08 
Braak Staging cg20583640 43.91 1.09E-07 54.51 7.81E-08 
Braak Staging cg04698472 43.85 1.09E-07 48.73 1.47E-07 
Braak Staging cg20095669 52.86 9.30E-08 57.26 1.67E-07 
Memory 
Recent 
cg22666015 -8.88 8.60E-08 -8.66 1.95E-07 
Braak Staging cg00991192 48.66 5.81E-08 44.12 2.58E-07 
Braak Staging cg12010173 48.11 6.23E-08 43.35 2.85E-07 
Braak Staging cg16529007 46.23 7.94E-08 42.33 3.26E-07 
Table 28: CpG sites showing an effect when adjusted for cellular composition. 
 
In the hippocampus, six of the 34 CpG sites identified as being associated with an 
outcome variable (Braak staging: n=5; Memory recent: n=1) were no longer significant 
following adjustment for cellular composition. This suggests that cellular composition 
may be driving the significance identified at these CpG sites. However, there is only a 
slight attenuation of significance at all 34 CpG sites indicating that cellular composition 
is not wholly responsible for the significant association between methylation and 
outcome variable. At the remaining 28 CpG sites, methylation is still significantly 
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associated with outcome following adjustment for cellular composition. As seen in 
Table 27, nine of these CpG sites were taken forward for validation analyses on the 
Pyrosequencer. Significance at eight of the nine CpG sites remained following cellular 
adjustment, indicating that the methylation differences identified at these sites are only 
slightly affected by cellular composition. For this reason, they can still be considered as 
potential methylation markers which could be involved in the mechanistic pathway. 
Following cellular adjustment, the significant association was lost between methylation 
at cg12010173 and Braak staging, however, since the association was only slightly 
attenuated and only narrowly missed the threshold for genome-wide significance 
(p=2.85E-07), methylation at cg12010173 was still considered as a potential 
methylation marker. 
 
4.3.1.5 Summary of approach 1 
Single-point analysis highlighted ten hits reaching genome-wide significance in the 
DLPFC samples and 34 in the hippocampus. Eight hits were significant in both tissues 
giving a total of 36 different significant hits across the brain regions. Correlation 
analyses were performed on the top-ranked list of probes identified in both brain regions 
to assess the correlation between effect sizes in each tissue. The effect sizes were 
strongly correlated between tissues in both the ten significant DLPFC hits (Rho=0.794, 
p=0.006) and 34 significant hippocampal hits (Rho=0.862, p=5.69E-11).  
 
The pie charts in Figure 55 (A-D) shows the distribution of the most significant 36 hits 
across the different probe chemistries and genomic region (chromosome, position 
relative to nearby CpG island and regions within gene). 
 
A chi squared goodness of fit test was performed to test whether the distributions of hits 
observed were as expected. A significantly lower number of significant CpG sites were 
measured using probe type I chemistry than expected (14% vs 27%, p=0.003) (Figure 
55A). 14% of the top CpG sites were located within CpG islands (Figure 55B). 
Differences in the position of the CpG site in relation to CpG island were also not as 
expected with fewer significant CpG sites being observed in the CpG islands 
(p=2.79x10-8). 31% of all significant CpG sites were located within gene promoters 
(Figure 55C); this indicates that some of these CpG sites may have functional relevance. 
No differences in functional genomic location (eg. Promoter, gene body) were identified 
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between the number of CpG sites observed and expected in each region (p=0.109). The 
number of CpG sites identified on each chromosome is not as one would expect by 
chance. In particular, chromosomes 1, 10 and 12 had many more significant CpG sites 
than was expected (p=1.50x10-7) (Figure 55D). 
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Figure 55: Description of statistically significant CpG sites identified in one or more brain region. A. Distribution of CpG sites measured using different probe types. B. position 
relative to nearby CpG island. C. Functional genomic location. D. Proportion of statistically significant CpGs located on each chromosome. 
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4.3.1.6 Selection of top hits – approach 2 
 
4.3.1.6.1 Dorsolateral prefrontal cortex 
The second approach utilised for selecting top hits from the HM450 analysis using 
ANOVA involved lowering the significance threshold to p<1x10-5 and comparing with 
publicly available expression data. The expression data set used is described in Section 
4.2.5.  
 
Table 29 shows the number of hits that were considered for Pyrosequencing follow-up 
using the second selection approach. Lowering the threshold from p<10-7 to p<10-5 
greatly increased the number of top hits in the selection pool, the number of significant 
hits increased from 10 to 128. Of these 128 hits, 114 had expression data available. Four 
of these were differentially expressed in AD. These four hits were then considered in 
terms of the direction of effect, i.e. whether the CpG sites were hyper or hypo 
methylated in PSD and whether they were up or down regulated in AD. Two CpG sites 
were found to have the expected methylation-expression relationship (hypermethylated 
and downregulated in AD, hypomethylated and upregulated in AD).  
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Variable Hits 
significant 
to <1x10-5 
(n) 
Hits 
represented 
on the 
expression 
array (n) 
Hits 
differentially 
expressed (n) 
Hits with the expected 
methylation-expression 
relationship (n) 
Diagnosis 1 1   
Braak staging 65 55 2 1 
MMSE 4 3   
Orientation 2 2   
Language 
comprehension 
1 1   
Language 
expression 
4 4 1 1 
Memory remote 14 13   
Memory recent 5 3   
Memory 
learning 
10 10   
Memory total 4 4   
Attention 6 6 1  
Praxis 3 3   
Abstract 
thinking 
2 2   
Perception 2 2   
Executive 
function 
2 2   
Total 
CAMCOG score 
3 3   
Total number of 
hits 
128 114 4 2 
Table 29: Number of CpG sites taken forward at each stage in the selection of DLPFC top hits. 
 
Figure 56 shows the relationship between methylation and expression in each of the 
significant CpG sites that had both methylation and expression data available. Sites 
(n=2) within the shaded regions showed the expected methylation-expression 
relationship. Two loci were identified as being hypermethylated in PSD and down 
regulated in AD. These two sites were taken forwards for further investigation (Table 
30).  
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Figure 56: Quadrant plot of DMPs and associated expression levels in the DLPFC. DNA methylation (x 
axis) and gene expression (y axis) are graphically presented as log10 p values. Significance is defined as 
p< 1x10-5 for methylation and p<1.13 for expression (as indicated by the vertical and horizontal dashed 
lines). The direction of effect is indicated by the red text. The shaded areas represent sites with the 
expected inverse relationship between methylation and expression. Sites within these shaded areas were 
taken forward for further analysis. 
 
Variable CpG site 
Gene 
Gene Meth  
p value 
Meth 
effect 
size 
Exp  
p value 
SNP Primers 
Braak 
staging 
cg10616306 TMEM161B 6.18E-09 -0.062 0.021 No No 
Language 
expression 
cg06758670 GRIN2A 5.98E-06 0.012 0.028   
Table 30: Description of the 2 CpG sites showing differential expression in AD DLPFC samples. 
Meth=methylation, Exp = expression. 
 
Only one of the two CpG sites had an effect size >5%. However, primers could not be 
designed for this CpG site so neither locus was taken forward for Pyrosequencing 
analysis.  
 
4.3.1.6.2 Hippocampus 
Table 31 shows the number of hits that were considered for Pyrosequencing validation 
using the second selection approach. Lowering the threshold from p<10-7 to p<10-5 
greatly increased the number of top hits in the selection pool. The number of significant 
hits increased from 36 to 170. Of these 170 hits, 148 had expression data available. 
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Forty of these were differentially expressed in AD. The 40 remaining hits were then 
considered in terms of the direction of effect, i.e. whether the CpG sites were hyper or 
hypo methylated in PSD and whether they were up or down regulated in AD. 21 CpG 
sites were found to have the expected methylation-expression relationship 
(hypermethylated and downregulated in AD, hypomethylated and upregulated in AD).  
 
 
Variable Hits 
significant 
to <1x10-5 
(n) 
Hits 
represented 
on the 
expression 
array (n) 
Hits 
differentially 
expressed (n) 
Hits with the expected 
methylation-expression 
relationship (n) 
Diagnosis 4 4 1 1 
Braak staging 100 91 26 11 
MMSE 4 2   
Orientation 2 2   
Language 
comprehension 
6 5 3 3 
Language 
expression 
5 4 1  
Memory remote 12 10 3 1 
Memory recent 2 1   
Memory 
learning 
9 8   
Memory total 11 9 3 2 
Attention 4 4 1 1 
Praxis 1 1 1 1 
Abstract 
thinking 
1 1   
Calculation 1 1 1 1 
Executive 
function 
1 0   
Total 
CAMCOG score 
7 5   
Total number of 
hits 
170 148 40 21 
Table 31: Number of CpG sites taken forward at each stage in the selection of hippocampus top hits. 
 
Figure 57 shows the relationship between methylation and expression in each of the 
significant CpG sites with both methylation and expression data. Sites (n=21) within the 
shaded regions showed the expected methylation-expression relationship. Twelve loci 
were identified as being hypomethylated in PSD and upregulated in AD. Nine loci were 
identified as having the reverse relationship, with hypermethylation of a site within the 
gene in PSD and down regulation of the gene in AD. These 21 sites were taken 
forwards for further investigation (Table 32).  
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Figure 57: Quadrant plot of DMPs and associated expression levels in the hippocampus. DNA 
methylation (x axis) and gene expression (y axis) are graphically presented as log10 p values. 
Significance is defined as p< 1x10-5 for methylation and p<1.13 for expression (as indicated by the 
vertical and horizontal dashed lines). The direction of effect is indicated by the red text. The shaded areas 
represent sites with the expected inverse relationship between methylation and expression. Sites within 
these shaded areas were taken forward for further analysis. 
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Variable CpG site Gene Meth  
p value 
Meth 
effect 
size 
Exp 
p value 
SNP Primers 
Braak staging cg00794813 NGF 3.51E-15 0.464 0.041 No Yes 
Braak staging cg20583640 FAM53A 9.06E-09 0.432 0.005 No Yes 
Braak staging cg15447017 LMNA 9.84E-06 0.334 0.032 No  Yes 
Memory 
remote 
cg06872721 HOMER3 3.71E-06 -0.290 0.029 No No 
Braak staging cg01063243 MYCBP2 2.73E-07 -0.284 0.024 No Yes 
Braak staging cg06872721 HOMER3 3.71E-06 0.164 0.029 No No 
Memory total cg13223682 OLA1 2.70E-06 0.142 0.003 No Yes 
Memory total cg18109033 NIPAL2 2.75E-06 0.090 0.025 No No 
Calculation cg10071848 ABCD4 2.48E-06 -0.080 0.042 No No 
Braak staging cg13223682 OLA1 2.70E-06 -0.068 0.003 No Yes 
Diagnosis cg15549700 AJAP1 6.44E-06 0.062 0.021 No No 
Braak staging cg10633931 HMGA1 4.27E-07 -0.061 0.012 No No 
Braak staging cg23404610 BTAF1 3.70E-12 0.567 0.032 Yes  
Braak staging cg02061626 APPL2 2.44E-06 0.239 0.008 Yes  
Language 
comprehension 
cg20125971 PDLC2 9.92E-06 -0.174 0.002 Yes  
Language 
comprehension 
cg22303739 COX4I2 3.51E-06 -0.038 0.005   
Braak staging cg18109033 NIPAL2 2.75E-06 -0.037 0.025   
Language 
comprehension 
cg01206910 NARF 8.36E-06 0.020 0.001   
Praxis cg02560638 DYNLRB2 4.34E-06 -0.014 0.025   
Attention cg12782834 PIGX 8.65E-06 0.011 0.004   
Braak staging cg20125971 PDCL2 9.92E-06 -0.004 0.002   
Table 32: Description of the 21 CpG sites showing expression differences in AD hippocampus samples. 
 
Six of the CpG sites had an effect size <5% and were thus dropped from further 
analysis. Three of the remaining fifteen CpG sites were in fact SNPs on the HM450 
array. Primers could be designed for six of the remaining twelve loci. Two of these 
(NGF and cg20583640) reached genome wide significance and so were already selected 
using approach 1 (Section 4.3.1.4.2). The other four loci were followed up for 
Pyrosequencing analysis. 
 
Twelve primer pairs were designed for analysis in at least one brain region. Table 33 
shows a summary of loci followed up for validation in the brain.  
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Brain region Variable CpG site Gene 
D,H Braak staging cg00794813 NGF 
D,H Braak staging cg03096785 CTRC 
D,H Braak staging cg11796313  
D,H Braak staging cg20583640  
H Braak staging cg02126424 CTRL 
H Braak staging cg18837178  
H Braak staging cg12010173  
H Braak staging cg01228342 EIF4E3 
H Memory remote cg02232840 KIAA1026 
H Braak staging cg15447017 LMNA 
H Braak staging cg01063243 MYCBP2 
H Braak staging and Memory total cg13223682 OLA1 
Table 33: Summary of assays designed for Pyrosequencing analysis in the brain. D=DLPFC, 
H=Hippocampus. 
 
4.3.2 Primer optimisation and validation 
Using both approaches to select top hits, primer pairs for twelve loci were successfully 
designed as in Table 33. All twelve primer pairs targeted at least the index CpG (CpG 
included on the HM450). Where possible, amplicons were designed to capture 
neighbouring CpG sites.  
 
Primer pairs for two loci could not be optimised and were removed from further 
analysis. The primer pairs for the remaining ten successfully optimised assays were 
used to amplify, by PCR, a range of methylation concentrations spanning 0% to 100% 
to ensure the assay was able to measure the full range of possible methylation values. 
An assay was considered to be validated if three conditions were reached: 1) the 
observed methylation value for 100% was above 80%; 2) the observed methylation 
value for 0% was below 10% and 3) there was a linear relationship with an R2 value 
above 0.99. Five assays were unable to measure the full range of methylation values and 
were subsequently dropped from further analysis. Five assays were successfully 
validated. Concordance of observed and reference methylation values are shown in 
Table 34, using the mean methylation value across all CpG sites in each amplicon. The 
validation results for both the pre-PCR and post-PCR mixes were plotted as a scatter 
graph with a trend line and R2 values presented (Figure 58).  
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Expected 
Methylation 
(%) 
Observed Methylation (%) 
NGF cg18837178 cg12010173 EIF4E3 cg01063243 
Pre Post Pre Post Pre Post Pre Post Pre Post 
100 93.8 93.8 85.7 85.7 94.02 95.43 99.3 99.3 95.15 95.13 
95 91.1 91.9 81.6 81.3 87.72 89.4 93.5 94.9 89.77 89.64 
90 85.1 87.0 75.3 78.0 86.68 88.51 92.3 89.5 89.3 89.68 
75 75.9 83.0 61.5 65.4 73.15 73.83 78.0 73.5 84.71 84.37 
50 62.0 57.5 36.8 43.7 49.91 54.01 55.3 47.7 64.08 63.39 
25 27.7 29.9 26.0 23.6 31.03 32.64 28.1 25.2 32.97 34.54 
10 15.7 14.3 12.7 11.2 13.46 12.07 13.9 12.8 19.58 18.07 
5 7.5 8.0 7.6 7.9 7.99 6.91 5.7 7.8 12.91 13.03 
0 5.3 5.3 3.4 3.4 0.00 3.69 3.7 3.7 8.56 12.07 
Table 34: Observed mean methylation across all CpGs significant in brain compared with reference 
expected methylation level. Pre and post PCR methylation values are presented for each assay. 
 
 
Figure 58: Composite figure of 5 assay validation plots. Pre-PCR methylation values are presented in blue 
and post-PCR methylation values in red. The R squared value is also displayed in the corresponding 
colour. An R squared value close to 1 indicates a very close correlation between observed and expected 
methylation levels.  
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4.3.3 Pyrosequencing analysis 
All available DLPFC and hippocampus samples were then run across the validated 
assays in duplicate. Samples passed Pyrosequencing QC if duplicates were within 5% of 
one another. A mean methylation level for these duplicates was calculated for each 
sample and this mean methylation value was used in all further analyses.  
 
Data generated by Pyrosequencing were first compared to the DMP methylation values 
generated by the HM450 BeadChip, to assess concordance and then analysed in relation 
to the outcomes and covariates observed to be associated with methylation in the 
discovery sample.  
 
NGF was the only assay differentially methylated in DLPFC. All five validated assays 
were run across hippocampus samples and taken forward for analysis in Stata.  
 
Each assay was analysed to test for an association between the outcome variable and the 
index CpG site (included on HM450) in the discovery sample set and a larger 
replication cohort. If multiple CpG sites were included on the Pyrosequencing assay, 
each neighbouring CpG site was analysed to test for association with outcome and 
finally the mean methylation value across the region (mean of index and neighbouring 
CpG sites).  
 
In the DLPFC, the only validated assay associated with Braak staging, NGF, failed to 
work on the Pyrosequencer when using the COGFAST samples. It is likely this was due 
to a technical problem, possibly due to the DNA source, although faint PCR products 
were visualised. So at this stage, no assays were run on the Pyrosequencer to validate 
the HM450 findings in DLPFC tissue.  
 
In the hippocampus, three of the assays which the HM450 identified as being associated 
with Braak staging (cg1201017, cg01063243 and EIF4E3) did not validate the findings 
of the HM450 and were deemed unlikely methylation markers for PSD. Two of the 
validated assays (NGF and cg18837178) did show significance at some of the tested 
CpG sites, the results of which are presented below.  
 
 
177 
 
 
 
4.3.3.1 NGF and cg18837178 
 
4.3.3.1.1 Validation in discovery cohort 
All 28 hippocampus samples analysed on the HM450 were run on the Pyrosequencer. 
Duplicates for 23 of the 28 samples were within 5% of one another for the NGF assay 
and were taken forwards for analysis. A number of samples for cg18837178 either 
failed on the Pyrosequencer or had duplicates with a difference greater than 5% and 
were dropped from analysis, leaving data from 17 of the HM450 discovery cohort 
available for cg18837178 analysis.  
 
Spearman’s rank correlation was performed in Stata to test the correlation between the 
two platforms. In both assays, the methylation values on each platform showed a weak 
correlation. Spearman’s correlation gave a coefficient of -0.250 (p=0.333) for 
cg18837178 and -0.198 (p=0.365) for NGF although this could be due to the majority of 
samples having a methylation score very close to 100% (Figure 59 and Figure 60).  
 
 
Figure 59: Correlation between methylation measured on the HM450 and Pyrosequencer at the 
cg18837178 locus. 
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Figure 60: Correlation between methylation measured on the HM450 and Pyrosequencer at the NGF 
locus. 
 
cg18837178 and NGF were both highlighted in the HM450 analysis as being associated 
with Braak staging. When split up into the six Braak stages the sample size issue 
becomes more apparent. Table 35 shows the number of samples within each Braak stage 
category in the discovery sample set. Only one Braak stage VI individual is included in 
the analysis meaning that any significance differentiating Braak stage VI from others is 
based on one individual. As with the blood samples, the HM450 data analysis was 
repeated with the Braak stage VI individual removed using the hippocampal and 
DLPFC data. Fewer hits were found to be significantly associated with Braak staging, 
as can be seen in the hippocampus plots (Figure 61 and Figure 62) and the DLPFC plots 
(Figure 63 and Figure 64). This indicates that the majority of CpG sites found to be 
associated with Braak staging were driven by this one individual.  
 
Braak stage N in HM450 N in NGF 
discovery 
cohort 
N in NGF 
replication 
cohort 
N in 
cg18837178 
discovery 
cohort 
N in 
cg18837178 
replication 
cohort 
I 4 4 6 3 4 
II 7 6 10 5 9 
III 10 8 13 5 10 
IV 3 2 4 1 3 
V 3 2 2 2 2 
VI 1 1 1 1 1 
Total 28 23 36 17 29 
Table 35: Number of hippocampal samples in each cohort by Braak staging. 
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Figure 61: QQ plot for association between hippocampal methylation and Braak staging with the Braak 
stage VI individual removed. The QQ plot shows the expected against the observed p values. Data points 
plotted in red reach the Bonferroni corrected significance threshold. 
 
 
Figure 62: Manhattan plot for association between hippocampal methylation and Braak staging with the 
Braak stage VI individual removed. Each circle represents an individual CpG site. The continuous line 
marks the p<1.1x10-7 significance threshold. CpG sites with p values below the threshold are labelled 
with their Illumina ID. 
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Figure 63: QQ plot for association between DLPFC methylation and Braak staging with the Braak stage 
VI individual removed. The QQ plot shows the expected against the observed p values. Data points 
plotted in red reach the Bonferroni corrected significance threshold. 
 
 
Figure 64: Manhattan plot f or association between DLPFC methylation and Braak staging with the Braak 
stage VI individual removed. Each circle represents an individual CpG site. The continuous line marks 
the p<1.1x10-7 significance threshold. CpG sites with p values below the threshold are labelled with their 
Illumina ID. 
 
The HM450 array identified one CpG site within both cg18837178 and NGF to be 
differentially methylated in hippocampus samples of stroke patients with varying levels 
of Braak staging. Altered methylation values were found in Braak stage VI when 
compared to the other Braak stages (I-V).  
 
Figure 65 shows the mean methylation levels for each Braak stage measured at the 
cg18837178 locus and Figure 66 shows the mean methylation levels for each Braak 
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stage measured at the NGF locus on both the HM450 and Pyrosequencer. Both graphs 
show the mean methylation levels for each Braak stage are similar across the two 
different platforms in Braak stages I-V. The standard deviation bars indicate that the 
Pyrosequencing data is slightly more variable than the HM450 in both assays, however 
on both platforms the same pattern can be seen in relation to Braak staging, with the 
Braak stage VI individual having a much lower methylation level at both loci.  
 
 
Figure 65: Mean cg18837178 locus methylation levels observed for each Braak stage measured on the 
HM450 and Pyrosequencer. 
 
 
Figure 66: Mean NGF locus methylation levels observed for each Braak stage measured on the HM450 
and Pyrosequencer. 
 
Figure 67 and Figure 68 show the spread of methylation measured at the index CpG site 
using both platforms for cg18837178 and NGF, respectively. Both graphs show the 
Braak stage VI individual as an outlier on both platforms; however the difference 
between this individual and the mean methylation level across all samples is much 
lower in Pyrosequencing than HM450.  
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Figure 67: Box plot to show methylation levels measured using the HM450 and Pyrosequencing at the 
CpG site cg18837178. 
 
 
Figure 68: Box plot to show methylation levels measured using the HM450 and Pyrosequencing at the 
index CpG site in NGF. 
 
The analysis model used to assess the relationship between Braak staging and the 
HM450 data was applied to the Pyrosequencing data. This was to test whether the 
association between methylation and Braak staging was still present in the 
Pyrosequencing data. In Stata, ANOVA was performed (as in the analysis of HM450 
data) to test for association between methylation at the index site and Braak staging, 
using sex and age at death as covariates. 17 hippocampal DNA samples were included 
in the cg18837178 analysis. 23 were included in the analysis of the NGF locus. Both 
loci were validated using Pyrosequencing when analysed using ANOVA; cg18837178 
p=0.003; NGF p= 0.0004. Due to the non-normally distributed nature of the DNA 
methylation data (tested using a Shapiro-Wilk normality test), a Kruskal Wallis test was 
also applied but no significant differences were observed; (cg18837178 p= 0.295; NGF 
p= 0.216).  
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When the individual with Braak stage VI pathology was removed from the analysis, 
there was no significant association between methylation at either locus (cg18837178 
and NGF) and Braak staging using ANOVA (cg18837178 p=0.999; NGF p=0.752) or 
Kruskal Wallis (cg18837178 p=0.832; NGF p=0.337). This indicates that the results are 
heavily influenced by this outlier.  
 
4.3.3.1.2 Validation in Pyrosequencing cohort 
The Pyrosequencing assays were run across a larger sample set (cg18837178 - n=29; 
NGF – n=36) to test whether the association with Braak staging at the index CpG site 
was still observed in a larger cohort. ANOVA revealed that the association between 
Braak staging and methylation at the cg18837178 locus was indeed even more 
significant using the larger cohort (p=5.322E-07), but this significance was not 
replicated when analysed using Kruskal Wallis (p=0.522). Likewise, the association 
between Braak staging and methylation at the NGF locus was also more significant 
when a larger sample size was used with ANOVA (p=0.0001) but not with Kruskal 
Wallis analysis (p= 0.1877).  
 
4.3.3.1.3 Neighbouring CpG sites 
It is also of interest to look at neighbouring CpG sites to assess whether these CpG sites 
are also associated with Braak staging. The cg18837178 assay was designed to include 
the index CpG site along with one neighbouring site. The NGF assay was designed to 
include the index CpG site plus three neighbouring sites. The Pyrosequencing data for 
the neighbouring CpG site was also analysed using ANOVA and Kruskal Wallis in both 
the HM450 cohort and the larger Pyrosequencing cohort. Results of ANOVA and 
Kruskal Wallis analyses are presented in Table 36. 
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CpG site P value 
cg18837178 NGF 
Index CpG    
Discovery 0.003 (0.295) 0.0004 (0.216) 
Pyrosequencing 5.32E-07 (0.522) 0.0001 (0.189) 
Neighbouring site 1   
Discovery 0.220 (0.730) 0.071 (0.514) 
Pyrosequencing 0.516 (0.455) 0.833 (0.218) 
Neighbouring site 2   
Discovery NA 0.550 (0.902) 
Pyrosequencing NA 0.534 (0.497) 
Neighbouring site 3   
Discovery NA 0.326 (0.846) 
Pyrosequencing NA 0.904 (0.791) 
Region   
Discovery 0.003 (0.293) 0.294 (0.623) 
Pyrosequencing 0.0001 (0.687) 0.268 (0.223) 
Table 36: ANOVA (and Kruskal Wallis) results for cg18837178 and NGF Pyrosequencing. The 
methylation of the region is defined as the mean methylation across all CpG sites covered in the 
Pyrosequencing assay. P values are displayed for both the discovery and Pyrosequencing cohort for each 
CpG site/region. 
 
 
Although both index CpG sites within cg18837178 and NGF were found to be 
significantly associated with Braak staging in both cohorts when analysed using 
ANOVA, no neighbouring CpG within either assay measured by Pyrosequencing was 
associated with Braak staging using either the discovery or replication cohort. When the 
mean of all CpG sites in the amplicon were analysed, the cg18837178 locus still 
remained significantly associated with Braak staging whereas the NGF locus did not. 
All data analysis performed using Kruskal Wallis showed no statistically significant 
differences in DNA methylation between Braak staging.  
 
These data show that although the data generated on the HM450 and Pyrosequencer 
were not identical and only weakly correlated by Spearman’s rank, the same patterns 
were seen in relation to Braak staging. The HM450 findings that the Braak stage VI 
individual had a significantly different methylation level to other Braak stages at the 
index CpG site within cg18837178 and NGF were validated using Pyrosequencing.  
 
4.3.3.1.4 Further Braak staging analysis 
Like the analysis in the blood samples in Chapter 3, additional samples were analysed 
by Pyrosequencing. Three Braak stage V and seven Braak stage VI (demented, no 
stroke) hippocampal samples were analysed in both assays.  
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Figure 69 shows the methylation of the index CpG within cg18837178 measured by 
Pyrosequencing in these additional Braak stage V and VI individuals compared to the 
COGFAST participants. Figure 70 shows the methylation of the index CpG within NGF 
measured by Pyrosequencing in Braak stage V and VI individuals compared to the 
COGFAST participants.  
 
In both assays, the COGFAST Braak stage VI individual was unique in its methylation 
patterns, indicating that the results in this Chapter are not representative of all Braak 
stage VI pathology. However, this finding does not necessarily mean that this is a false 
positive, as described in Chapter 3.  
 
 
Figure 69: Methylation at cg18837178 locus measured in hippocampal DNA in COGFAST and demented 
Braak stage V and Braak stage VI individuals. Braak stages are displayed on the X axis with demented 
Braak stage V and Braak stage VI denoted as V DS and VI DS, respectively. 
  
 
Figure 70: Methylation at NGF locus measured in hippocampal DNA in COGFAST and demented Braak 
stage V and Braak stage VI individuals. Braak stages are displayed on the X axis with demented Braak 
stage V and Braak stage VI denoted as V DS and VI DS, respectively. 
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4.3.3.2 cg18837178 in the dorsolateral prefrontal cortex 
Although cg18837178 was not found to be differentially methylated in the DLPFC, 
based on the two selection processes used in this Chapter, it was decided to run the 
cg18837178 assay across DLPFC samples since HM450 results were validated in the 
hippocampus.  
 
4.3.3.2.1 Validation in discovery cohort 
22 of the 24 DLPFC DNA samples analysed on the HM450 were successfully run on 
the Pyrosequencer, with repeats within 5% of one another.  
 
Spearman’s rank correlation was performed in Stata to test the correlation between the 
two platforms. The coefficient showed a very weak correlation (Rho=-0.098) between 
the two platforms, possibly due to the non-linear relationship, with almost all 
methylation values being close to 100%, although this was not significant (p=0.965) 
(Figure 71).  
 
 
Figure 71: Correlation between methylation measured on the HM450 and Pyrosequencer at the 
cg18837178 locus. 
 
Although not reaching genome-wide significance, the HM450 did detect differences 
between Braak stages at the cg18837178 locus in DLPFC samples. Figure 72 shows the 
mean methylation levels for each Braak stage measured at the cg18837178 locus on 
both the HM450 and Pyrosequencer. The mean methylation levels for each Braak stage 
are similar across the two different platforms in Braak stages I-V. The standard 
deviation bars indicate that the Pyrosequencing data are slightly more variable than the 
HM450 in both assays, however on both platforms the same pattern can be seen in 
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relation to Braak staging, with the Braak stage VI individual having a much lower 
methylation level at both loci.  
 
 
Figure 72: Mean cg18837178 methylation levels observed for each Braak stage measured in the DLPFC 
on the HM450 and Pyrosequencer. 
 
Figure 73 shows the spread of methylation measured at cg18837178 using both 
platforms. This shows the Braak stage VI individual as an outlier on both platforms; 
however the difference between this individual and the mean methylation level across 
all samples is lower in Pyrosequencing than HM450.  
 
 
Figure 73: Box plot to show methylation levels measured using the HM450 and Pyrosequencing at the 
CpG site cg18837178. 
 
The analysis model used to assess the relationship between Braak staging and the 
HM450 data was applied to the Pyrosequencing data. This was to test whether the 
association between methylation and Braak staging was still present in the 
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Pyrosequencing data. In Stata, ANOVA was performed (as in the analysis of HM450 
data) to test for association between methylation at the index site and Braak staging, 
using sex and age at death as covariates. 22 DLPFC DNA samples were included in the 
analysis and the HM450 findings were validated using ANOVA on the Pyrosequencing 
data at this CpG site (p= 0.0004). As with all other CpG sites, analysis using Kruskal 
Wallis did not find significant differences (p=0.498). 
 
When the individual with Braak stage VI pathology was removed from the analysis 
there was no significant association with methylation and Braak staging using ANOVA 
(p=0.853) or Kruskal Wallis (p=0.150). This indicates that the results are heavily 
influenced by this outlier.  
 
4.3.3.2.2 Validation in Pyrosequencing cohort 
The Pyrosequencing assay was run across a larger sample size (n=36) to test whether 
the association with Braak staging at the index CpG site was still observed in a larger 
cohort. ANOVA revealed that the association between Braak staging and methylation at 
the cg18837178 locus was not significant using the larger cohort (p=0.210), nor was it 
significant when analysed using the non-parametric Kruskal Wallis (p=0.482).  
 
4.3.3.2.3 Neighbouring CpG sites 
The cg18837178 assay was designed to include the index CpG site along with one 
neighbouring site. The Pyrosequencing data for the neighbouring CpG site were also 
analysed using ANOVA and Kruskal Wallis in both the HM450 cohort and the larger 
Pyrosequencing cohort but no significance was observed using either test. Methylation 
across the region (mean methylation of both CpG sites targeted in the Pyrosequencing 
assay) was found to be associated with Braak staging when analysed using ANOVA, 
but there was no evidence of a statistically significant methylation difference using 
Kruskal Wallis (Table 37). 
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CpG site P value 
 cg18837178 
Index CpG   
Discovery 0.0004 (0.498) 
Pyrosequencing 0.210 (0.482) 
Neighbouring site 1  
Discovery 0.144 (0.959) 
Pyrosequencing 0.109 (0.814) 
Region  
Discovery 0.004 (0.699) 
Pyrosequencing 0.297 (0.645) 
Table 37: ANOVA (and Kruskal Wallis) results for cg18837178 Pyrosequencing. The methylation of the 
region is defined as the mean methylation across all CpG sites covered in the Pyrosequencing assay. P 
values are displayed for both the discovery and Pyrosequencing cohort for each CpG site/region. 
 
These findings show that in the HM450 discovery cohort there were significant 
differences in methylation levels between Braak stages, however when analysed in a 
larger cohort, these differences were no longer significant, indicating that cg18837178 
is unlikely to be a methylation marker of PSD in the DLPFC.    
 
4.3.4 Protein analysis 
In the hippocampus, two Pyrosequencing assays successfully validated the HM450 
findings. These were NGF and cg18837178. NGF is a well described gene whereas 
cg18837178 is a non-coding RNA. For this reason, NGF was selected to be taken 
forward for protein analysis by Western blotting, to test whether the changes in 
methylation seen in the blood and hippocampus were seen at the protein level in the 
brain. Although the Pyrosequencing assay failed to work using the DLPFC samples, 
protein levels were measured in both the hippocampus and DLPFC.  
 
4.3.4.1 NGF optimisation 
Four different conditions were tested to find the optimum blotting conditions for anti-
NGF. Figure 74 shows the different conditions tested.  
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Figure 74: Optimisation of anti-NGF. 1- 5% milk block, 5% milk blot. 2- 5% milk block, 1% milk blot. 3- 
5% BSA block, 5% BSA blot. 4- 5% BSA block, 1% BSA blot. 
 
Lane 1 was selected as the optimum blotting conditions for anti-NGF as it gave the 
brightest band with little background. The optimum conditions for anti-NGF were 
identified as blocking with 5% milk followed by preparation of anti-NGF antibody in a 
5% milk diluent.  
 
4.3.4.2 Western blots 
Ten COGFAST participants were selected for Western blot analysis. Two participants 
for each Braak stage, with the exception of Braak stage VI, were included in the 
Western blot analysis. Unfortunately, insufficient tissue was available for the Braak 
stage VI sample used in the methylation analysis and could not be included in this 
experiment. For this reason, it was impossible to investigate whether the methylation 
differences seen in the COGFAST Braak stage VI individual were translated at the 
protein level. However, it was still of interest to investigate whether NGF protein levels 
differed across the various remaining Braak stages, and since it has been implicated in 
Alzheimer’s disease, it was also of interest to look at NGF levels in AD compared to 
controls and COGFAST participants. In addition to the ten COGFAST participants 
already mentioned, six Alzheimer’s disease samples (DS) were included, two had Braak 
stage V pathology and four had Braak stage VI pathology. In order to test whether there 
were differences between dementia, stroke and controls, six healthy controls (CA) with 
no known stroke or dementia history were also included, four of these had Braak stage 
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II pathology and two had Braak stage III pathology. Numbers of samples per Braak 
stage in each of the cohort groups used in the Western blot are summarised in Table 38. 
All Western blots can be found in Appendix B. 
 
Cohort Braak stage (n) 
I II III IV V VI 
COGFAST 2 2 2 2 2  
DS     2 4 
CA  4 2    
Table 38: Number of samples with each Braak stage pathology in each of the cohort groups. DS refers to 
Alzheimer’s cases with no stroke. CA refers to healthy controls. 
 
First, DLPFC and hippocampal levels of NGF were compared across all samples. Due 
to much lower alpha-tubulin levels observed in either the DLPFC or hippocampal 
samples across five individuals, NGF values for both tissues measured in these 
participants were removed from this analysis. There was a very weak correlation 
between NGF levels in the DLPFC and hippocampus although this difference was not 
significant (Spearman’s Rho = -0.027, p=0.594) (Figure 75A). 
 
For all further analysis, the DLPFC and hippocampus were considered separately. One 
DLPFC sample was removed from the analysis due to low alpha-tubulin levels and five 
hippocampal samples were removed for the same reason.  
 
Next, NGF levels were analysed in regard to cohort group. No differences in relative 
NGF protein were observed between COGFAST, DS and CA cohort groups in the 
DLPFC (p=0.083) (Figure 75B) or hippocampus (p=0.194) (Figure 75C).  
 
Braak stages were then grouped across cohorts and NGF levels were compared between 
Braak stages. No differences were observed between Braak stage in either the DLPFC 
(p=0.218) (Figure 75D) and hippocampus (p=0.281) (Figure 75E).  
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Figure 75: Western blot analysis. A. Comparison between relative NGF levels in the DLPFC and 
hippocampus. B. Relative NGF levels in the DLPFC across cohort groups. C. Relative NGF levels in the 
hippocampus across cohort groups. D. Relative NGF levels in the DLPFC across Braak stages. E. 
Relative NGF levels in the hippocampus across Braak stages. Each dot represents a data point, the centre 
line represents the mean value and the two outer lines represent 1 standard deviation (SD) from the mean. 
Any points outside of these lines are more than 1SD away from the mean. DS= demented, no stroke. CA= 
healthy controls. 
 
Finally, correlation analysis was performed to look for correlation between methylation 
and protein levels. Since the DLPFC assay did not work on the Pyrosequencer, 
correlation analysis was only performed on the hippocampal samples. Five of the 
hippocampal COGFAST samples included in the protein analysis were successfully run 
using the NGF assay. Spearman’s rank correlation was performed and a strong inverse 
association was observed (Spearman’s Rho = -0.900, p=0.037) (Figure 76), indicating 
that increased methylation is associated with reduced protein levels.  
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Figure 76: Correlation between hippocampal NGF methylation and NGF protein levels. 
 
4.3.5 APOB in the brain 
Since APOB was identified as a possible blood based biomarker, the DLPFC and 
hippocampal samples were run across the APOB assay to see whether the differential 
methylation in Braak stage VI was also observed in brain tissue. Neither the DLPFC or 
hippocampal tissues showed the same methylation differences as blood (Figure 77 and 
Figure 78), nor was methylation at the APOB locus associated with Braak staging when 
analysed using ANOVA (DLPFC p=0.330; hippocampus p= 0.268) and Kruskal Wallis 
(DLPFC p=0.629; hippocampus p= 0.582). 
 
 
Figure 77: Comparison of mean methylation levels by Braak staging in the blood and DLPFC using 
Pyrosequencing. 
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Figure 78: Comparison of mean methylation levels by Braak staging in the blood and hippocampus using 
Pyrosequencing. 
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4.4 Discussion 
The work carried out in this Chapter aimed to identify DMPs which may be useful in 
determining the mechanisms involved in PSD using hippocampal and DLPFC brain 
samples. The HM450 array identified ten CpG sites in the DLPFC and 34 CpG sites in 
the hippocampus that reached genome-wide significance. An additional 23 sites were 
identified to be differentially expressed in either the DLPFC or hippocampus in AD. 
Following the filtering of top hits, two assays were run across DLPFC samples and five 
assays were run across the hippocampal samples using a larger COGFAST cohort to test 
whether the association seen between Braak staging and methylation still persisted 
when measured using Pyrosequencing. When Pyrosequencing data were analysed using 
ANOVA, two of these assays (cg18837178 and NGF) successfully validated the 
HM450 findings in at least one tissue, suggesting that they may be potential methylation 
markers mechanistically involved in the pathogenesis of PSD. No significance was 
observed when data were analysed using Kruskal Wallis, however this is likely to be 
due to the low sample size limiting the power to detect differences.  
 
As described in Chapter 3, the sample size used in this study is small making analysis of 
methylation by Braak staging difficult. The results of both this and the previous Chapter 
are based on the methylation differences observed in one individual. However, the 
finding that this methylation difference is observed across all three tissues (blood, 
DLPFC and hippocampus) studied in COGFAST adds confidence to this finding and 
suggests that the methylation difference unique to this individual is not just an artefact. 
Again, like in Chapter 3, the methylation differences seen in the COGFAST Braak stage 
VI individual were not seen in other Braak stage VI individuals with dementia who had 
not experienced a stroke. This indicates that the methylation signatures are likely due to 
a combination of stroke and Braak stage VI pathology or some confounding factor. As 
described in Chapter 3, the Braak stage VI COGFAST case had experienced three 
recurrent strokes prior to recruitment It is thought that these events may have altered the 
methylation patterns which were detected here. The clinical characteristics of this case 
were described in detail in Chapter 3.  
 
Due to cg18837178 being located within a long non-coding RNA (CT49), protein 
analysis was confined only to NGF. NGF was a very relevant protein to investigate due 
to previous research indicating that differences in protein levels exist between AD and 
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controls, in addition to the possible role of NGF in disease pathogenesis, explored 
below. NGF was also particularly interesting since the publicly available expression 
data set used here revealed differential expression of NGF in the hippocampus of AD 
cases. This suggests that differences may also be seen at the protein level. Although the 
expression data set used in this study was an AD cohort and therefore not entirely 
comparable to PSD it is expected that similar pathways are involved in the progression 
of disease.    
 
β-Amyloid precursor protein (APP) plays a key role in the development of AD as 
cleavage of APP forms β-Amyloid (Aβ), the component of extracellular senile plaques 
in the brain which are an important hallmark of AD. APP has also been associated with 
reduced transportation of NGF in the brain of Alzheimer’s cases. It has been found that 
the overexpression of NGF is associated with reduced transport of this protein. The 
molecular mechanisms and pathways linking APP with NGF signalling are yet to be 
identified. This reduction in transport of NGF has been found to increase the 
vulnerability of cholinergic neurons in AD and lead to Aβ deposition and associated 
memory deficits (Zhang et al., 2013). These findings indicate that NGF may have a 
mechanistic role in the progression of AD and possibly other dementias; however, more 
research is required to elucidate the mechanistic pathways involved. Interestingly, NGF 
levels have been studied in other neurodegenerative disorders such as Parkinson’s 
disease and NGF is not thought to be involved in disease pathogenesis as no differences 
in NGF levels have previously been observed between PD cases and controls (Scott et 
al., 1995).  
 
Unfortunately, due to the omission of the COGFAST participant with Braak stage VI 
pathology from the protein work described here, it is not within the scope of this thesis 
to investigate whether the methylation changes observed at the NGF locus in the 
DLPFC and hippocampus are translated to the protein level. However, although the 
COGFAST Braak stage VI individual was not included in the protein analysis, it can be 
predicted, based on the correlation analysis, that the COGFAST Braak stage VI 
individual would have higher levels of NGF than other COGFAST participants. This 
theory is supported by previous researchers who have identified higher Braak stages and 
AD pathology to be associated with increased NGF protein levels in the brain (Scott et 
al., 1995; Fahnestock et al., 1996; Mufson et al., 2012b). Although the majority of 
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publications support the finding of increased NGF levels in AD cases, some findings 
within dementia cohorts are inconsistent. AD patients have been shown to exhibit 
dysfunctional transportation of NGF between brain regions (Zhang et al., 2013). Due to 
this, depending on which brain region a particular study has sampled, the level of NGF 
measured may not be comparable to studies that have used an alternative brain region. 
Some papers have reported reduced levels of NGF in the brains of AD cases when 
compared to controls (Mufson et al., 1999). In a study investigating serum NGF levels, 
healthy controls were found to have significantly higher NGF levels than AD cases 
(Konukoglu et al., 2012). The protein study carried out in this Chapter did not however 
detect any differences in NGF protein level between AD cases and cognitively normal 
controls in either the DLPFC or hippocampus.  
 
One of the strengths of this study is that the protein levels were analysed to try and 
identify an association between DNA methylation and protein levels. However, this 
approach could not tell us whether methylation had a direct impact on the protein level. 
An alternative approach to study this would be to use a cell culture approach. Cells 
could be cultured in the presence of 5-aza in order to cause genome-wide demethylation 
(Enright et al., 2003). The expression of the target gene could be assessed at a transcript 
level using quantitative PCR (Yang et al., 2002) and at a protein level using Western 
blotting (Palii et al., 2008). This would determine whether the expression of the gene in 
question is affected by DNA methylation. The link between transcription and translation 
for the target gene could be assessed through the use of small interfering RNAs 
(siRNA) which would transiently knock down the level of gene transcript. Conversely, 
expression vectors could be used to drive the expression of the gene of interest 
(Alekseev et al., 2009). The subsequent effects on protein level could then be assessed 
by Western blotting.  
  
The finding that NGF methylation levels are reduced in a PSD case who had 
experienced recurrent strokes is very interesting. Although brain protein levels were not 
measured in this individual it can be tentatively postulated that increased NGF protein 
levels would be observed. A stroke is known to promote angiogenesis, the formation of 
new blood vessels in the brain to restore blow flow to affected areas. Angiogenesis 
requires growth factors and a number of growth factors have been found to be increased 
following a stroke (Krupinski et al., 1994; Font et al., 2010). In the case of recurrent 
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strokes it can be expected that due to increased ischaemia and therefore increased 
angiogenesis, levels of NGF protein and other growth factors are found at increased 
levels. This theory correlates well with the findings of this thesis, which identified 
reduced DNA methylation levels of NGF in the individual who had experienced 
recurrent strokes. As decreased DNA methylation is often associated with increased 
gene expression and protein levels it can be hypothesised that the COGFAST Braak 
stage VI case would have increased NGF protein levels. Given the biological 
plausibility of this scenario, it would be very interesting to perform this experiment if 
suitable tissue was available to see if this hypothesis is valid.  
 
CT49 is a potential candidate for future functional investigation. The expression of 
CT49 has been directly linked to DNA methylation, as demonstrated by Adair and 
Hogan (2008) who treated ovarian cancer cell lines with 5-aza and observed an 
increased level of CT49 transcript (Adair and Hogan, 2009). It would be interesting to 
investigate the role of CT49 in PSD by first quantifying its expression using quantitative 
PCR in a validation cohort. If an association between DNA methylation and expression 
was established in these cases, a functional study could be performed. The biological 
function of CT49 is currently unknown, however it is thought that many long non-
coding RNAs have a functional role (Dinger et al., 2009; Mercer et al., 2009), for 
example, in the regulation of gene-specific transcriptional regulation (Goodrich and 
Kugel, 2006). After driving the expression of CT49 using an expression construct, an 
expression array could be utilised to determine which genes, if any, are regulated by 
CT49. These targets could then be followed up to determine their role in PSD.   
 
In summary, the work described in this Chapter sought to establish whether 
identification of differential DNA methylation in post-mortem brain tissue from PSD 
cases could shed light on potential mechanisms in this disease. The study findings were 
constrained by sample size and the availability of samples with the most severe form of 
brain pathology (Braak stage VI).  
 
Strengths of the approach included use of the target (brain) tissue rather than reliance on 
surrogate (blood) tissue. The inclusion of Western blot analysis to quantify differences 
in protein levels also added strength to the study design, providing an opportunity to 
interrogate functional links between differential DNA methylation and disease.  
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Due to the assay design limitations, only a few loci were followed right through to the 
validation phase by Pyrosequencing. Other techniques such as Sequenom EpiTYPER 
(Ehrich et al., 2005) or bisulphite sequencing (Herman et al., 1996) could be employed 
to quantify DNA methylation levels at these loci. There are a number of limitations 
associated with the selection of top hits which have been outlined in Chapter 3. Briefly 
these limitations include the selection of only those hits which showed an inverse 
relationship between DNA methylation and expression, which is unlikely to be true. In 
addition, the selection of top hits was based on expression data from only one study. 
Taking an average from multiple expression studies would have been a better, more 
accurate approach. The study used was chosen due to the brain regions included, 
however these were AD cases so not entirely comparable to PSD cases.    
 
The HM450 analysis was adjusted for age, sex and chip. PM delay was not found to 
affect DNA methylation and so was not included as a confounder. It is possible, 
however, that differential DNA methylation identified here is due to other confounders, 
not adjusted for in the analysis, rather than statistically significant loci having a 
mechanistic role in the pathogenesis of disease. Further validation is required in a larger 
cohort to strengthen the associations identified here.  
 
Due to the heterogeneous nature of brain tissue, it is possible that any differences in 
DNA methylation observed between outcome groups is due to the cellular composition 
of the brain. Methylation beta values were adjusted for cellular composition, to 
determine whether the differential methylation observed in relation to Braak staging 
was actually due to differences in cellular composition. Adjusting for cellular 
composition revealed small differences in the significance level, indicating that 
differences in cellular composition have very little effect on the methylation differences 
observed between outcome groups in this Chapter.   
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Chapter 5. Blood-based methylation signatures as a predictor of 
Parkinson’s disease 
 
5.1 Introduction 
Parkinson’s disease (PD) is the second most common neurodegenerative disorder 
affecting approximately 1% of the over-65 population (Saracchi et al., 2014). It is 
characterised by the presence of certain motor deficits and is primarily a motor disorder, 
however many patients are affected by cognitive impairments. Parkinson’s disease 
dementia (PDD) affects up to 80% of PD patients. Many more PD patients are 
diagnosed with mild cognitive impairment (PD-MCI) and are still able to live 
independently (Yarnall et al., 2013). It is unknown why some PD patients develop MCI 
and even PDD whilst others remain cognitively normal. It is therefore difficult to 
develop treatments when the mechanisms which result in MCI are not well understood. 
Often, the cognitive symptoms precede the motor symptoms (Saracchi et al., 2014) so 
the ability to predict those who are likely to develop PD-MCI would be beneficial, so 
that preventative treatments could be implemented for those individuals who were at 
highest risk of progressing to PDD or developing other PD traits.  
 
As previously mentioned in Section 3.1, associations between DNA methylation and 
many disorders including cancer (Teschendorff et al., 2009), cardiovascular (Baccarelli 
et al., 2010) and metabolic diseases (Grundberg et al., 2013) have been identified, 
indicating that DNA methylation may have a role in disease aetiology. Epigenetic 
mechanisms, including DNA methylation have previously been implicated in PD 
(Jowaed et al., 2010; Lu et al., 2013). Due to the tissue specific nature of DNA 
methylation patterns, to assess the mechanistic link between DNA methylation and 
disease, the diseased tissue (in this case the brain) would ideally be required. However, 
DNA methylation can also be employed as a biomarker to predict disease or aid 
prognosis. In this instance, the identification of a biomarker does not require a causal 
relationship to be identified, nor does it require the target disease tissue to be studied. 
Peripheral blood DNA provides a more readily accessible source of DNA for this 
application.  
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Epigenetic biomarkers, including global and gene-specific DNA methylation markers, 
are beginning to emerge as biomarkers of disease risk and prognosis, particularly within 
the field of cancer (Schwalbe et al., 2013). This approach has yet to be applied to PD-
MCI. It is postulated that DNA methylation signatures detectable in peripheral blood, 
drawn following diagnosis of PD, will be predictive of subsequent cognitive decline and 
possibly overt dementia. In order to pursue this hypothesis, a prospective study is 
required composed of individuals who have been diagnosed with idiopathic PD, had 
biological samples collected and stored at this time and that have been followed up over 
several years with cognitive assessments undertaken at multiple intervals. To test this 
hypothesis the prospectively collected ICICLE study is used (Section 2.1.2). 
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5.2 Experimental design 
General methods are described in Chapter 2, with additional details relevant to this 
investigation described in detail here.  
 
5.2.1 Study cohort 
Blood DNA samples taken from participants of the ICICLE study (Section 2.1.2), who 
were newly diagnosed Parkinson’s disease patients in the Newcastle and Gateshead 
area, were utilised for this study. The ICICLE study recruited 158 PD patients along 
with 99 controls. Once a diagnosis of idiopathic PD had been confirmed by a specialist 
neurologist, participants underwent a medical assessment and information on their 
education level, medical history and lifestyle were recorded. A number of tests and 
scales were used in the assessment of disease severity including MMSE, MoCA, Hoehn 
and Yahr and the MDS-UPDRS. All cases and controls were invited to a follow-up at 
18 months, where the medical assessments were repeated to check for any disease 
progression. A peripheral blood sample was collected from 150 PD cases and 90 
controls at baseline. Samples were divided into a ‘discovery’ cohort (n=48 PD cases) 
and a ‘replication’ cohort (n=192; 102 PD cases and 90 controls), the latter consisting of 
all ICICLE samples not included in the discovery phase. 
 
5.2.2 Blood DNA quantification  
Blood DNA samples were held in long-term storage at -80°C following extraction and 
were selected and removed from storage for the purpose of this study. DNA samples 
were quantified using a ND1000 Spectrophotometer (Labtech International Ltd, UK) 
(Section 2.2.3).  
 
5.2.3 Illumina HumanMethylation450 BeadChip analysis 
Epigenome wide discovery analysis was performed using the Illumina 
HumanMethylation450 (HM450) BeadChip. 48 individuals with >1µg blood derived 
DNA were selected for discovery phase DNA methylation analysis. 24 samples were 
from PD-MCI participants and 24 from Parkinson’s disease participants without MCI. 
All samples selected for inclusion in the discovery phase were age and sex matched. 
The PD-MCI samples selected were those with the most substantially impaired 
cognition (at 2SD below normative levels). Sections 2.4 and 2.5 describe how samples 
were processed and data were filtered and normalised.  
203 
 
 
 
5.2.4 Analysis of HM450 data 
A total of 455,981 probes and 46 PD samples were included in the final dataset. 
Exploratory analyses were performed across the methylation data by considering 
distribution density plots, mean-sd plots and hierarchical clustering with heat plots. The 
CpGassoc package (Barfield et al., 2012), which performs multiple linear regression 
analysis with a continuous predictor variable and ANOVA for categorical predictor 
variables, was implemented in R (version 2.15.0). CpGassoc was performed to test for 
associations between methylation and; cognition variables (MCI, animals, cognitive 
complaint, language, language total, MMSE, MoCA, naming, NMSQ concentration, 
NMSQ memory, one touch stockings, paired associates learning, pentagon copying, 
power of attention, pattern recognition memory, spatial recognition memory and total 
FAS) and motor variables (digit vigilance accuracy, Hoehn and Yahr, MDS-UPDRS 
Part II and III, PIGD phenotype and tremor dominant phenotype) as outcome variables. 
For all analyses, age, sex and chip (i.e. the microarray chip upon which the samples 
were scanned) were included in the analysis model as covariates. Data generated 
provided a beta value difference between the comparison groups (for categorical 
variables) and a beta value per unit change in the predictor variable (for ordinal and 
continuous variables). The beta values had an associated p-value denoting the strength 
of statistical significance with standard errors (SE) denoting the confidence around the 
statistical estimate of association. HM450 data were adjusted for cellular composition 
using the method described by Houseman et al. (2012) in a sensitivity analysis, i.e. the 
CpGassoc analyses were repeated to assess whether cell composition accounted for any 
significance observed between methylation and the outcome variable. 
 
5.2.5 Selection of top HM450 hits 
To select which CpG sites were the most promising candidates to validate and most 
likely to be functionally relevant, all CpG sites with a p value <1x10-5 were compared 
against publicly available expression data. The GEO website (NCBI) 
(http://www.ncbi.nlm.nih.gov/geo/) was searched for an appropriate expression dataset 
with which to compare the methylation data generated in this project. The closest 
expression dataset found was GSE18838, a study which compared expression levels in 
blood between PD patients and healthy controls (Shehadeh et al., 2010). Each of the 
methylation hits were categorised into either hypomethylated or hypermethylated in PD 
and hits were searched within the expression dataset. Any locus differentially expressed 
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in PD was categorised into either over or under expressed in PD. Those hits which 
showed the expected methylation-expression relationship (i.e. hypermethylated and 
under expressed, hypomethylated and over expressed) were taken forward to the next 
step. The next criterion was that the effect size (difference between the outcome groups) 
was more than 5%. This criterion is based upon the technical limitations of validating 
any observed differences using Pyrosequencer (Mikeska et al., 2011). Hence, 
differences of less than this may simply be due to random technical variation between 
groups. Finally, a BLAT search was performed to test for the presence of a SNP within 
the CpG site. If the CpG site was indeed a SNP, or if there was a SNP in the probe 
sequence, this site was removed from further consideration. This step removed any CpG 
sites likely to be directly under genetic influence.  
 
The HM450 data were processed and analysed as described to generate a priority list of 
target differentially methylated positions (DMPs). The Illumina gene ID was used to 
assign a gene name to the probe; where this was not possible, the HM450 probe ID was 
retained. These DMPs were then taken forward for validation and replication using 
Pyrosequencing. 
 
5.2.6 Pyrosequencing 
Primers for amplicons covering DMPs were designed using the PSQ Assay Design 
software (Section 2.6.2) and synthesised by Integrated DNA Technologies (IDT, USA). 
Where possible, primers were designed not only to cover the target DMP, but also cover 
any neighbouring CpG sites that could be captured within a technically feasible 
amplicon size (50-250bp).  Primers were first optimised (Section 2.6.3) and then 
validated on the Pyrosequencer using Epitect PCR controls (Qiagen, UK) (Section 
2.6.5), prior to assays being run using ICICLE samples. PCR controls containing a 
100% methylated DNA sample and a 0% methylated DNA sample were used to make 
reference methylation levels ranging from 0% to 100%. These mixes were created both 
pre-PCR and post-PCR. Thirteen of the twenty DMP primer sets were optimised 
successfully. All ICICLE samples were run in duplicate and repeated if duplicate 
discordance was >5%.  
 
Pyrosequencing assays (n=3) were performed on the discovery sample (n=46) along 
with blood derived DNA samples from an additional 102 PD cases and 90 controls 
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drawn from the same cohort. 500ng of DNA was bisulphite modified, amplified using 
the optimised Pyrosequencing PCR conditions in Table 39 and finally sequenced on a 
PyroMark MD Pyrosequencer (Qiagen, UK), following the standard protocol (Section 
2.6.6). Details of all Pyrosequencing primers are provided in Table 40. The primer 
optimisation, assay validation and Pyrosequencing undertaken in this Chapter were 
performed by Polly Usher, a technician within the Epigenetics Research Group at 
Newcastle University.  
 
Gene/DMP HM450 
probe ID 
Tm (°C) MgCl2 
+/- 
Size of 
product 
(bp) 
No. 
CpGs 
Successfully 
validated 
using 
Epitect 
controls 
CHCHD5 cg21934564 49.8 + 118 1 Yes 
TRIM15 cg09769113 52.4 - 338 2 Yes 
CUTA cg09977865 52.4 + 247 1  
CDK14 cg23251279 54.4 + 214 2  
BDH1 cg10728473 49.8 + 134 1  
ARHGEF7 cg14666946 50.0 + 100 3  
ALDHA3A1 cg18957070 49.8 + 139 2  
GSX1 cg25778304 51.1 - 243 4  
PROCA1 cg02206852 49.8 - 310 1 Yes 
GPR17 cg20074593 51.1 + 204 1  
FTCD cg10394047 52.4 + 99 5  
SAT2B cg26236655 52.4 + 167 1  
NFU1 cg10354495 52.4 + 145 1  
Table 39: Optimal PCR conditions for each assay. Tm=annealing temperature. 
 
Gene Forward primer 
(5’>3’) 
Reverse primer  
(5’>3’) 
Sequencing primer 
(5’>3’) 
CHCHD5 AATAGGGATGAAGTAAT
T 
5Biosg/CCCTTTAAAACTAATCT
AT 
GGGTAGGAAGAAGAGGT
AG 
TRIM15 GTTGGGAGAAATTTATT
G 
5Biosg/CCAAAAACTACCACAC
AT 
GAAATTTATTGAGAGGA
GTA 
PROCA1 GGAGGGAGAGAATAGT
AGTA 
5Biosg/AACAACTAACCAAAAT
ATC 
AGTAGAGGGTTAGTTATA
GG 
Table 40: Forward, reverse and sequencing primers for each successfully validated DMP Pyrosequencing 
assay. 5Biosg=biotin label. 
 
5.2.7 Statistical analyses 
Summary statistics of sub-samples used from the ICICLE cohort were calculated using 
chi squared tests, t-tests or Wilcoxon rank sum tests depending on whether data 
followed a normal distribution. Within each cohort, differences between MCI and NCI 
participants were investigated. Following correction for multiple testing, a p value 
<4.27x10-4 was considered significant. Tests were also performed to look for 
differences between the discovery cohort and the entire ICICLE cohort, as well as the 
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replication cohort and the entire ICICLE cohort. This was to investigate whether the 
sample subsets were representative of the entire ICICLE cohort. To reduce the risk of 
false positives, the p value was adjusted for the number of independent tests performed 
and a p value <3.21x10-4 was considered significant.  
 
The association between methylation and the outcome variable of interest was first 
assessed in the initial HM450 discovery sample set (n=46) using ANOVA analyses, 
adjusted for baseline age and sex (Pyrosequenced validation samples). Subsequently, 
association analyses were repeated including data from the additional samples 
(Pyrosequenced replication samples). Given the non-normally distributed nature of 
methylation data, sensitivity analyses were also performed by comparing mean 
methylation levels between sample groups using non-parametric Wilcoxon rank-sum or 
Kruskal-Wallis tests. In addition to assessing individual DMPs, for loci in which 
multiple CpG sites were Pyrosequenced, regional methylation levels were assessed by 
taking the average methylation value across all CpG sites. These validation analyses 
were performed in Stata. 
 
To check whether there was any correlation between each CpG site measured by the 
HM450 array and Pyrosequencing, Spearman’s rank was performed in Stata.  
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5.3 Results 
Summary statistics for clinical variables of ICICLE participants and sub-groups utilised 
in this study are summarised in Table 41, Table 42 and Table 43.  
 
The MCI group were significantly older (75.63 vs 65.87 years, p=5.43E-06), had a 
lower score on the NART (110.08 vs 117.72, p=3.35E-06) and had a lower number of 
years in education (11.57 vs 13.40 years, p=0.001) than the no cognitive impairment 
(NCI) group. The fact that the MCI group had a lower number of years in education and 
a lower NART score is not surprising as you would expect those who were less 
academically capable during childhood to also be less academically capable during 
adulthood and older age. In addition, those with MCI were more likely to have 
hypertension (44.90% vs 24.72%, p=0.015) and had higher depression scores (3.67 vs 
2.57, p=0.026) but had a lower weekly alcohol intake (5.04 vs 9.78 units/week, 
p=0.012) (Table 41). All cognitive outcomes were distributed in the expected fashion 
with the MCI group displaying more impaired cognition in all tests (Table 42). 
Interestingly, the MCI group also displayed worse motor function in all motor outcome 
variables tested (Table 43). 
 
Both the discovery and replication (Pyrosequencing) cohorts were highly representative 
of the entire ICICLE cohort, with no significant differences being observed between 
sample groups for any variable.  
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 Entire ICICLE Discovery Cohort Replication Cohort 
Variables MCI NCI P value MCI NCI P value MCI NCI P value 
Age (Yrs) 
mean(SD) 
73.64 (7.93) 65.87 (9.83) 5.43E-06§ 70.39 (7.55) 67.45 (5.53) 0.078‡ 75.88 (7.51) 65.18 (11.17) 1.63E-05§ 
Sex (% males) 32.65 33.71 0.9† 40.00 37.03 0.836† 32.26 27.59 0.653† 
Education (Yrs) 
mean(SD) 
11.57 (3.37) 13.40 (3.65) 0.001‡ 12.65 (3.60) 14.93 (4.50) 0.036‡ 10.83 (3.05) 12.73 (3.01) 0.001‡ 
NART mean(SD) 110.08 (10.37) 117.72 (9.73) 3.35E-06‡ 111.68 
(10.12) 
118.63 
(11.76) 
0.001‡ 109.03 
(10.57) 
117.32 (8.78) 0.0003‡ 
Height (m) 
mean(SD) 
1.69 (0.10) 1.71 (0.09) 0.605§ 1.69 (0.10) 1.68 (0.08) 0.786§ 1.70 (0.09) 1.72 (0.09) 0.373§ 
Weight (kg) 
mean(SD) 
76.74 (16.21) 79.40 (14.62) 0.327§ 77.89 (16.76) 79.32 (12.39) 0.742§ 75.94 (16.07) 79.44 (15.56) 0.326§ 
BMI mean(SD) 26.66 (4.75) 27.26 (4.45) 0.466§ 27.10 (4.47) 28.00 (3.75) 0.464§ 26.36 (4.99) 26.95 (4.71) 0.588§ 
IHD n(%) 9 (18.37) 7 (7.87) 0.065† 1 (5.00) 3 (11.11) 0.426† 8 (27.59) 4 (6.45) 0.016† 
DM n(%) 6 (12.24) 5 (5.62) 0.197† 2 (10.00) 4 (14.81) 0.488† 4 (13.79) 1 (1.61) 0.034† 
HT n(%) 22 (44.90) 22 (24.72) 0.015† 8 (40.00) 7 (25.93) 0.306† 14 (48.28) 15 (24.19) 0.022† 
Hyperchol n(%) 8 (16.33) 10 (11.24) 0.395† 2 (10.00) 5 (18.52) 0.352† 6 (20.69) 5 (8.06) 0.098† 
Levodopa daily 
dose (mg) n(SD) 
400.2 (222.1) 393.1 (202.2) 0.850§ 359.65 
(223.46) 
362.93 
(187.76) 
0.958§ 428.1 (220.7) 406.2 (208.3) 0.648§ 
GDS  mean (SD) 3.67 (3.17) 2.57 (2.73) 0.026‡ 3.1 (3.01) 2.04 (2.03) 0.207‡ 4.07 (3.27) 2.79 (2.97) 0.048‡ 
RCF (µg/L) 
mean(SD) 
278.63 (89.48) 225.92 
(107.89) 
0.228‡ 295.36 
(202.72) 
269.25 
(151.59) 
0.549‡ 288.1 (162.4) 265.1 (138.9) 0.197‡ 
B12 (ng/L) 
mean(SD) 
365.70 
(126.72) 
394.73 
(139.91) 
0.400‡ 379.12 
(138.44) 
425.17 
(174.76) 
0.326‡ 373.16 
(132.04) 
415.75 
(164.53) 
0.180‡ 
Homocysteine 
(µmol/L) mean(SD) 
13.10 (4.99) 12.33 (3.63) 0.458‡ 13.80 (4.36) 11.43 (3.14) 0.015‡ 13.50 (4.60) 11.71 (3.30) 0.014‡ 
Alcohol (units/wk) 
mean(SD) 
5.04 (7.92) 9.78 (12.02) 0.012‡ 5.70 (8.86) 12.69 (14.25) 0.063‡ 4.59 (7.33) 8.56 (10.86) 0.062‡ 
Smoking n(%)   0.104†   0.874†   0.110† 
Current 1 (2.04) 8 (9.09)  1 (4.76) 1 (4.35)  1 (3.33) 5 (8.20)  
Ex 22 (44.9) 27 (30.68)  9 (42.86) 8 (34.78)  13(43.33) 18 (29.51)  
Never 26 (53.06) 53 (60.23)  11 (52.38) 14 (60.87)  16 (53.33) 38 (62.30)  
Table 41: Summary statistics for exposure variables. Data are presented for the entire ICICLE cohort, the initial discovery sample set and the replication cohort. † = chi squared, ‡ = Wilcoxon rank sum, 
§= t test. Hyperchol=hypercholesterolaemia. 
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 Entire ICICLE Discovery Cohort Replication Cohort 
Variables MCI NCI P value MCI NCI P value MCI NCI P value 
MoCA 23.00 (4.01) 27.25 (2.76) 5.39E-11‡ 23.00 (4.24) 27.11 (3.34) 0.0003‡ 23.00 (3.92) 27.31 (2.50) 4.91E-08‡ 
MMSE 26.98 (2.10) 29.02 (1.21) 7.48E-10‡ 26.95 (2.28) 29.04 (0.94) 0.0005§ 27.00 (2.00) 29.02 (1.31) 5.45E-07‡ 
FAS 27.88 (8.80) 40.10 (13.25) 1.85E-09§ 28.50 (9.28) 45.41 (15.88) 3.99E-05§ 27.45 (8.60) 37.75 (11.27) 3.59E-05§ 
Animals 16.88 (6.23) 23.75 (6.65) 2.42E-08§ 18.05 (6.04) 25.81 (6.34) 0.0001§ 16.07 (6.33) 22.84 (6.63) 1.46E-05§ 
NMSQ memory 
n(%) 
31 (63.27) 45 (50.56) 0.151† 13 (65.00) 11 (40.74) 0.100† 18 (62.07) 34 (54.84) 0.516† 
NMSQ 
concentration 
n(%) 
15 (30.61) 26 (29.21) 0.863† 6 (30.00) 5 (18.52) 0.358† 9 (31.03) 21 (33.87) 0.789† 
Total number of 
NMS  
9.35 (4.20) 8.55 (4.25) 0.292‡ 9.55 (4.96) 7.89 (4.20) 0.221§ 9.21 (3.68) 8.84 (4.27) 0.690‡ 
Power of 
Attention 
1610.4 
(256.0) 
1317.7 
(124.7) 
4.45E-10‡ 1621.0 
(274.9) 
1295.3 (96.6) 2.13E-06§ 1603.5 (247.5) 1327.9 
(134.9) 
2.27E-06‡ 
Digit vigilance 
accuracy 
79.86 (17.88) 95.97 (6.04) 2.15E-12‡ 77.08 (20.89) 96.21 (6.49) 6.95E-06‡ 81.69 (15.73) 95.85 (5.88) 1.12E-07‡ 
PRM 17.52 (2.96) 21.03 (2.09) 1.52E-10‡ 17.95 (3.03) 21.40 (2.12) 0.0001§ 17.21 (2.92) 20.89 (2.07) 4.92E-07‡ 
PAL 3.12 (1.16) 1.92 (0.62) 1.53E-10‡ 3.05 (1.17) 1.94 (0.68) 0.001‡ 3.17 (1.16) 1.91 (0.59) 8.87E-08‡ 
SRM 12.52 (2.81) 15.65 (2.09) 2.65E-09§ 12.25 (2.95) 15.84 (2.17) 2.71E-05§ 12.71 (2.75) 15.57 (2.07) 4.75E-07§ 
OTS 10.42 (5.37) 16.05 (3.08) 1.40E-11‡ 9.75 (5.91) 16.32 (2.17) 0.0001§ 10.89 (5.01) 15.93 (3.39) 4.57E-07‡ 
Pentagon copying 1.37 (0.78) 1.93 (0.25) 4.87E-08‡ 1.35 (0.81) 1.96 (0.19) 0.001‡ 1.38 (0.78) 1.92 (0.27) 2.52E-05‡ 
Naming 2.88 (0.33) 2.92 (0.27) 0.401‡ 2.95 (0.22) 2.93 (0.27) 0.741‡ 2.83 (0.38) 2.92 (0.27) 0.195‡ 
Language 1.33 (0.77) 1.74 (0.53) 0.001‡ 1.50 (0.76) 1.70 (0.61) 0.317‡ 1.21 (0.77) 1.76 (0.50) 0.0002‡ 
Language total 4.20 (0.84) 4.66 (0.66) 0.0003‡ 4.45 (0.76) 4.63 (0.74) 0.307‡ 4.03 (0.87) 4.68 (0.62) 0.0001‡ 
Cognitive 
complaint n(%) 
34 (69.39) 52 (58.43) 0.204† 14 (70.00) 13 (48.15) 0.134† 20 (68.97) 39 (62.90) 0.573† 
Table 42: Summary statistics for variables relating to cognitive-based outcomes. Data are presented for the entire ICICLE cohort, the initial discovery sample set and the replication 
cohort. † = chi squared, ‡ = Wilcoxon rank sum, §= t test. Unless stated, mean (SD) are presented. 
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 Entire ICICLE Discovery Cohort Replication Cohort 
Variables MCI NCI P value MCI NCI P value MCI NCI P value 
Hoehn and 
Yahr n(%) 
  0.002†   0.214†   0.021† 
1 0 8 (8.99)  0 3 (11.11)  0 5 (8.06)  
2 34 (69.39) 69 (77.53)  14 (70.00) 20 (74.07)  20 (68.97) 49 (79.03)  
3 11 (22.45) 12 (13.48)  5 (25.00) 4 (14.81)  6 (20.69) 8 (12.90)  
4 4 (8.16) 0  1 (5.00) 0  3 (10.34) 0  
MDS-
UPDRS II 
mean(SD) 
15.02 (5.88) 11.18 (5.96) 0.0004§ 13.7 (5.18) 8.44 (5.54) 0.002‡ 15.93 (6.24) 12.37 (5.79) 0.009§ 
MDS-
UPDRS III 
mean(SD) 
41.67 
(12.37) 
30.54 (9.88) 4.82E-08§ 41.00 
(11.10) 
28.63 
(10.84) 
0.0004§ 42.14 
(13.35) 
31.37 (9.40) 0.0003§ 
Tremor 
phenotype 
mean(SD) 
0.90 (0.48) 0.69 (0.37) 0.008§ 0.91 (0.54) 0.68 (0.39) 0.089§ 0.90 (0.44) 0.69 (0.36) 0.021§ 
PIGD 
phenotype 
mean(SD) 
1.04 (0.63) 0.63 (0.44) 0.0001‡ 0.96 (0.58) 0.58 (0.45) 0.007‡ 1.09 (0.66) 0.65 (0.43) 0.002‡ 
Table 43: Summary statistics for variables relating to motor-based outcomes. Data are presented for the entire ICICLE cohort, the initial discovery sample set and the replication 
cohort. † = chi squared, ‡ = Wilcoxon rank sum, §= t test.
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5.3.1 Discovery analysis 
Of the 48 blood DNA samples that underwent HM450 analysis, 46 samples passed the 
QC assessment of the inbuilt microarray controls assessed in GenomeStudio. Two 
samples failed due to incomplete bisulphite modification and were dropped from further 
analysis. 
 
Low failure rates were observed on both a sample and a probe by probe basis, assessed 
using detection p values generated from the array scanner. As described in the Methods 
(Section 2.5.2), samples were only removed if ≥20% of probes had a detection p value 
>0.01. Probes were removed if ≥10% of samples had a detection p value >0.01. No 
samples were removed from analysis using these criteria. 857 probes were removed. 
Summaries of the detection p values observed for samples and probes are shown in 
Figure 79A and B. 
 
Following data filtering and normalisation, as described in Section 2.5.2, 455,981 CpG 
sites were taken forward for analysis measured in baseline blood samples from 46 PD 
individuals; 23 PD-MCI and 23 PD-NCI.   
 
 
The small sample size of this study limited the power to detect methylation differences. 
This study had 29.8% power to detect a mean difference of 5% methylation between 
groups, with a standard deviation of 3 and alpha=1.1x10-7. 
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Figure 79A: Average detection p values in each blood sample. For each sample the average detection p 
value is very low and samples are of approximately equal quality. 
Figure 79B: Histogram to show the number of probes against the corresponding number of samples with 
p values greater than 0.01 across blood. The red line indicates 10%. 467052 probes had no missing data 
and for space reasons, this data is not shown on the histogram.  
 
 
5.3.1.1 Distribution of genome-wide methylation values 
Figure 80 (A-F) shows the distribution of methylation values using both raw (A-C) and 
normalised (D-F) data. Figure 80A is a density plot showing the distribution of raw 
methylation beta values for each blood sample. This shows a commonly observed 
bimodal distribution; the majority of CpG sites are very lowly or very highly methylated 
with much fewer CpG sites exhibiting intermediate methylation levels. The distribution 
for each individual can be more easily seen in a box plot (Figure 80B). This shows that 
there is some variability in the methylation levels of each blood sample, particularly 
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with regard to the median methylation and IQR. Each sample has a minimum 
methylation level of 0% and a maximum of 100%, with a median around 60-70% 
methylated. Some of this variation could be due to batch effects and sample processing. 
The position of the sample on the chip is also thought to have an effect on the 
measurement of methylation values (Dedeurwaerder et al., 2013), but this variation 
should be removed after normalisation. Mean and SD methylation beta values across all 
probes, prior to normalisation and QC, are depicted in Figure 80C to show 
heteroskedasticity. Heteroskedasticity refers to the phenomenon whereby the variance in 
a measure, such as methylation beta values, is not constant across all levels of that 
measure. As can be seen, there is a wide range of variance across the probes. In 
particular, probes with a mid-range methylation value between 30-80% show greater 
variability compared to those at the extreme ends of the methylation spectrum. 
 
Figure 80 (D-F) shows the distribution of methylation after normalisation. All plots 
using normalised data show that there is much less variation between samples. All 
samples have a median methylation value of around 50%. This suggests that most of the 
technical variation was removed during normalisation.  
 
5.3.1.2 Cluster analysis 
Hierarchical cluster analysis, using the complete-linkage method, was performed on the 
normalised data to look for natural groupings (either phenotypic or technical) amongst 
the samples based on the methylation data. No clear clusters were observed for 
diagnosis of MCI indicating that DNA methylation signatures are not sufficiently 
different to distinguish between groups in the blood DNA drawn from this cohort 
(Figure 81). 
 
However, as shown in Figure 82, even after normalisation and the removal of probes 
mapping to the sex chromosomes, there remained some subtle groupings amongst 
samples based on sex. Due to these results, sex was included as a covariate in 
subsequent analyses of single-point CpG sites. In contrast, there were no apparent 
clusters based on experimental chip (Figure 83), suggesting that any chip-derived batch 
effects were removed. Nonetheless, to fully account for any remaining, albeit subtle, 
batch effects, chip was also included as a covariate in the single-point analysis model.  
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Figure 80: A composite figure showing the distributions of methylation using raw and normalised data. A. Density plot showing methylation distribution in 46 blood samples using 
raw data. B. Box plot showing mean methylation raw beta values across all blood samples. C. Mean vs SD plot showing heteroskedasticity using raw data. D. Density plot showing 
methylation distribution in 46 blood samples using normalised data. E. Box plot showing mean methylation normalised beta values across all blood samples. F. Mean vs SD plot 
showing heteroskedasticity using normalised data.  
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Figure 81: Cluster dendrogram for all 46 blood samples coloured by diagnosis. 
 
 
Figure 82: Cluster dendrogram for all 46 blood samples coloured by sex. 
 
 
Figure 83: Cluster dendrogram for all 46 blood samples coloured by chip. 
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5.3.1.3 Single-point analysis 
ANOVA was performed on all beta values across all CpG sites passing QC (455,981) 
against the following outcome measures: MCI, animals, cognitive complaint, digit 
vigilance accuracy, language, language total, MMSE, MoCA, naming, NMSQ 
concentration, NMSQ memory, one touch stockings, paired associates learning, 
pentagon copying, power of attention, pattern recognition memory, spatial recognition 
memory, total FAS, Hoehn and Yahr, MDS-UPDRS Part II and III, PIGD phenotype 
and tremor dominant phenotype. Age, sex and chip were included in the analysis model 
as covariates. Results from this step were exported as a table in Microsoft Excel and 
ordered by ascending p value.  
 
5.3.1.4 Selection of top hits 
To select the most functionally relevant potential biomarkers, top hits were selected 
based on p value (p<1x10-5) and compared to results of publicly available expression 
data. The expression data set used is described in Section 5.2.5. 
 
Table 44 shows the number of hits associated with cognition that were considered for 
Pyrosequencing validation. The number of hits reaching the significance threshold 
(p<1x10-5) across all outcomes was 548. Of these 548 hits, 466 had expression data 
available and 102 of these were differentially expressed in PD. The 102 hits were then 
considered in terms of the direction of effect, i.e. whether the CpG sites were hyper or 
hypo methylated and up or down regulated in PD. 46 CpG sites were found to have the 
expected methylation-expression relation (hypermethylated and downregulated in PD, 
hypomethylated and upregulated in PD).  
 
Table 45 shows the number of hits associated with motor outcome that were selected for 
Pyrosequencing consideration. The number of hits reaching the significance threshold 
(p<1x10-5) across all outcomes was 25. Of these 25 hits, 19 had expression data 
available and six of these were differentially expressed in PD. The six remaining hits 
were then considered in terms of the direction of effect, i.e. whether the CpG sites were 
hyper or hypo methylated and up or down regulated in PD. Three CpG sites were found 
to have the expected methylation-expression relationship (hypermethylated and 
downregulated in PD, hypomethylated and upregulated in PD).  
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 Variable Hits 
significant to 
<1x10-5 (n) 
Hits also on 
the 
expression 
array (n) 
Hits 
differentially 
expressed (n) 
Hits with the expected 
methylation-expression 
relationship (n) 
MCI 2 1 0 0 
Animals 5 4 0 0 
Cognitive 
complaint 
9 7 2 2 
Language 8 6 1 1 
MMSE 39 36 7 4 
MoCA 6 5 2 1 
Naming 287 251 52 18 
NMSQ 
concentration 
13 9 3 2 
NMSQ 
memory 
5 5 1 1 
OTS 28 24 9 6 
PAL 7 7 3 2 
Pentagon 
copying 
61 50 10 6 
Power of 
attention 
38 31 5 3 
PRM 8 4 2 0 
SRM 2 2 1 0 
Total FAS 3 2 0 0 
Digit vigilance 
accuracy 
27 22 4 0 
Total hits (n) 548 466 102 46 
Table 44: Number of CpG sites significantly associated with cognition taken forward at each stage in the 
selection of top hits. 
 
 
Variable Hits 
significant to 
<1x10-5 (n) 
Hits also on 
the 
expression 
array (n) 
Hits 
differentially 
expressed (n) 
Hits with the expected 
methylation-expression 
relationship (n) 
MDS-UPDRS 
II 
2 1 0 0 
MDS-UPDRS 
III 
6 4 2 1 
PIGD 
phenotype 
4 4 0 0 
Tremor 
dominant 
phenotype 
13 10 4 2 
Total number 
of hits 
25 19 6 3 
Table 45: Number of CpG sites significantly associated with motor outcome taken forward at each stage 
in the selection of top hits. 
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Cognitive Outcome 
Figure 84 shows the relationship between methylation and expression in each of the 
statistically significant CpG sites associated with cognition. Sites (n=46) within the 
shaded regions showed the expected methylation-expression relationship and at the 
significance threshold imposed. 26 loci were identified as being hypomethylated in PD 
and upregulated in PD. 20 loci were identified as having the reverse relationship with 
hypermethylation of a site within the gene in PD and down regulation of the gene in PD. 
These 46 sites were taken forward for further investigation (Table 46).  
 
Fifteen CpG sites had an effect size <5% so were removed from further analysis. Two 
of the remaining sites were in fact SNPs and were also removed from further analysis. 
This left 29 loci which were inputted into the Pyrosequencing assay design software. 
Primers were successfully designed for 18 of these loci (cg18957070 features twice on 
this table, significant with both OTS and pentagon copying). Adjusting for cellular 
composition (Houseman et al., 2012) had no effect on the vast majority of CpG sites 
included in the selection in Table 46. Methylation at two CpG sites associated with 
naming were shown to have a very small effect when adjusted for cellular composition, 
as shown in Table 47. In both instances, adjusting for cellular composition slightly 
increased the significance. These results suggest that the methylation differences 
observed between outcome groups are largely unrelated to cellular composition.  
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Figure 84: Quadrant plot of DMPs and associated expression levels for cognition outcomes. DNA 
methylation (x axis) and gene expression (y axis) are graphically presented as log10 p value. Significance 
is defined as p< 1x10-5 for methylation and p<1.13 for expression (as indicated by the vertical and 
horizontal dashed lines). The direction of effect is indicated by the red text. The shaded areas represent 
sites with the expected inverse relationship between methylation and expression. Sites within these 
shaded areas were taken forward for further analysis. 
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Variable CpG site Gene Meth  
p value 
Meth  
effect  
size 
Exp  
p value 
SNP Primers 
Naming cg07719523 PALM 2.61E-07 -0.202 0.044 No No 
OTS cg19350270 DPP4 2.90E-06 0.186 0.049 No No 
PoA cg26236655 SATB2 7.44E-06 0.172 0.047 No Yes 
Pentagon 
copying 
cg19026233 UNC80 5.73E-07 -0.149 0.041 No No 
MoCA cg19350270 DPP4 9.69E-06 0.136 0.049 No No 
Naming cg10728473 BDH1 9.78E-06 0.128 0.003 No Yes 
Naming cg23251279 CDK14 7.64E-07 -0.103 0.042 No Yes 
Pentagon 
copying 
cg10394047 FTCD 3.97E-06 -0.086 0.014 No Yes 
Naming cg23519637 C7orf50 4.08E-06 -0.077 0.003 No Yes 
Naming cg16252933 CCDC6 9.09E-06 0.074 0.001 No No 
Naming cg01974375 PI4KB 7.09E-07 0.062 0.004 No No 
Naming cg03162143 PCGF3 2.32E-06 -0.060 0.034 No Yes 
NMSQ 
conc 
cg05022061 CARD14 5.19E-06 0.060 0.046 No No 
Naming cg09769113 TRIM15 7.71E-08 -0.058 0.049 No Yes 
Naming cg26915799 IPO9 2.36E-07 0.057 0.011 No No 
NMSQ 
conc 
cg14666946 ARHGEF7 6.15E-06 -0.057 0.022 No Yes 
PoA cg06351643 FGF3 2.22E-06 0.056 0.045 No No 
MMSE cg10354495 NFU1 9.18E-06 -0.055 0.027 No Yes 
Naming cg09977865 CUTA 7.73E-08 0.055 0.044 No Yes 
PAL cg03768106 TIMM8B 5.41E-06 -0.054 0.021 No Yes 
Pentagon 
copying 
cg20074593 GPR17 1.20E-06 -0.054 0.047 No Yes 
Pentagon 
copying 
cg02206852 PROCA1 6.57E-08 -0.052 0.004 No Yes 
OTS cg18957070 ALDH3A1 2.09E-06 -0.051 0.019 No Yes 
Language cg03936721 RUNDC3A 7.91E-06 0.051 0.017 No Yes 
Naming cg21934564 CHCHD5 2.86E-08 0.051 0.006 No Yes 
MMSE cg07667522 INPPL1 2.15E-06 -0.050 0.019 No No 
MMSE cg16514838 C16orf45 2.12E-06 0.050 0.021 No Yes 
Pentagon 
copying 
cg18957070 ALDH3A1 2.31E-06 -0.050 0.019 No Yes 
PAL cg25778304 GSX1 3.96E-06 -0.050 0.008 No Yes 
Naming cg25246894 SDS 6.10E-06 -0.232 0.002 Yes  
Naming cg16357930 PLXNB1 1.93E-06 -0.073 0.036 Yes  
Naming cg04318855 DOCK10 1.12E-07 0.049 0.009   
OTS cg02208529 DBN1 7.50E-07 -0.048 0.025   
Cognitive 
complaint 
cg05410587 KIAA1530 5.28E-07 0.044 0.017   
OTS cg03902642 ROBLD3 1.34E-06 -0.041 0.041   
Naming cg26418433 VPS52 3.69E-07 0.041 0.010   
NMSQ 
memory 
cg05410587 KIAA1530 3.12E-07 0.038 0.017   
Naming cg15322876 KRT5 2.04E-06 -0.034 0.032   
Naming cg20249462 AP1B1 6.45E-06 0.029 0.020   
OTS cg16687450 CHEK1 8.58E-06 -0.023 0.041   
Naming cg19925791 RPS6KA1 1.07E-06 0.021 0.023   
MMSE cg23056047 PFN4 4.09E-06 0.017 0.008   
PoA cg05918679 RPL18 5.97E-07 -0.011 0.0004   
OTS cg22734480 ABHD8 9.80E-07 0.009 0.009   
221 
 
 
 
 
 
Variable CpG site Pre-adjustment Post-adjustment 
t statistic p value t statistic p value 
Naming cg09769113 6.76 7.71E-08 7.08 3.02E-08 
Naming cg04318855 -6.64 1.12E-07 -6.82 6.63E-08 
Table 47: CpG sites affected by cellular composition adjustment. 
 
Motor Outcome 
Figure 85 shows the relationship between methylation and expression in each of the 
statistically significant CpG sites with motor outcome. Sites (n=3) within the shaded 
regions showed the expected methylation-expression relationship and at the significance 
threshold imposed. Two loci were identified as being hypomethylated in PD and 
upregulated in PD. One locus was identified as having the reverse relationship with 
hypermethylation of a site within the gene in PD and down regulation of the gene in PD. 
These three sites were taken forward for further investigation (Table 48).  
 
All three CpG sites related to a motor variable had an effect size >5% and none of the 
CpG sites were found to be SNPs. Therefore all loci were taken forwards for 
Pyrosequencing assay design. Primers were successfully designed for two of these loci. 
When adjusted for cellular composition using the method outlined in Houseman et al. 
(2012), the significance level of each of these three CpG sites was not attenuated, 
suggesting that cellular composition was not responsible for these differences in 
methylation.  
 
 
Pentagon 
copying 
cg02517488 RP1L1 4.89E-06 -0.003 0.012   
Cognitive 
complaint 
cg09213106 DHX35 7.99E-06 -0.002 0.009   
Table 46: Description of 46 CpG sites associated with cognitive traits showing expression differences in 
PD, ranked in order of effect size. Meth =methylation, Exp=expression, OTS=one touch stockings, 
PoA=power of attention, PAL=paired associates learning. 
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Figure 85: Quadrant plot of DMPs and associated expression levels for motor outcomes. DNA 
methylation (x axis) and gene expression (y axis) are graphically presented as log10 p value. Significance 
is defined as p< 1x10-5 for methylation and p<1.13 for expression (as indicated by the vertical and 
horizontal dashed lines). The direction of effect is indicated by the red text. The shaded areas represent 
sites with the expected inverse relationship between methylation and expression. Sites within these 
shaded areas were taken forward for further analysis. 
 
 
 
 
 
 
 
Variable CpG site Gene Meth  
p value 
Meth 
effect size 
Exp  
p value 
SNP Primers 
Tremor 
dominant 
phenotype 
cg16099282 PGS1 1.59E-06 -0.070 0.014 No Yes 
Tremor 
dominant 
phenotype 
cg24560729 KIAA1530 4.32E-06 0.057 0.017 No No 
MDS-
UPDRS 
III 
cg18067096 MOGAT1 4.99E-06 0.050 0.010 No Yes 
Table 48: Description of 3 motor sites showing expression differences in PD. Meth=methylation, 
Exp=expression. 
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5.3.2 Primer optimisation and validation 
Using the selection criteria described above, primer pairs for twenty loci (eighteen 
associated with a cognitive variable and two associated with a motor variable) were 
successfully designed as in Table 46 and Table 48. All twenty primer pairs targeted at 
least the index CpG (CpG included on the HM450). Where possible, amplicons were 
designed to capture additional neighbouring CpG sites.  
 
Primer pairs for seven assays could not be optimised and were removed from further 
analysis. The primer pairs for the remaining thirteen successfully optimised assays were 
used to amplify, by PCR, a range of methylation concentrations spanning 0% to 100%, 
to ensure the assay was able to measure the full range of possible methylation values. 
An assay was considered to be validated if three conditions were reached: 1) the 
observed methylation value for 100% was above 80%; 2) the observed methylation 
value for 0% was below 10% and 3) there was a linear relationship with an R2 value 
above 0.99. Ten assays were unable to measure the full range of methylation values and 
were subsequently dropped from further analysis. Three assays were successfully 
validated. Concordance of observed and reference methylation values are shown in 
Table 49, using the mean methylation value across all CpG sites in each amplicon. The 
validation results for both the pre-PCR and post-PCR mixes were plotted on a scatter 
graph with a trend line and R2 values presented (Figure 86).  
 
Expected 
Methylation 
(%) 
Observed Methylation (%) 
PROCA1 CHCHD5 TRIM15 
Pre Post Pre Post Pre Post 
100 88.1 84.40 95.67 95.71 98.21 100.00 
95 87.07 84.21 77.53 80.67 91.58 92.96 
90 82.76 83.33 70.09 73.31 84.74 87.04 
75 65.77 64.41 59.93 59.37 69.25 72.10 
50 48.20 48.16 41.06 42.80 54.24 59.44 
25 19.66 19.22 23.44 26.02 20.91 19.86 
10 10.38 10.66 14.75 13.92 8.17 9.12 
5 4.51 4.85 9.68 9.12 7.91 5.57 
0 3.16 3.37 2.97 1.97 4.00 3.60 
Table 49: Observed mean methylation across all CpGs compared with reference expected methylation 
level. Pre and post PCR methylation values are presented for each assay. 
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Figure 86: Composite figure of 3 assay validation plots. Pre-PCR methylation values are presented in blue 
and post-PCR methylation values in red. The R squared value is also displayed in the corresponding 
colour. An R squared value close to 1 indicates a very close correlation between observed and expected 
methylation levels. 
 
5.3.3 Pyrosequencing analysis 
All available blood DNA samples taken from ICICLE participants with PD were then 
run across all three validated assays in duplicate, along with all available blood DNA 
samples from healthy controls recruited into ICICLE. Samples were considered to have 
been assayed successfully using Pyrosequencing if the resulting values for duplicates 
were within 5%. A mean methylation level of these duplicates was calculated for each 
sample and this mean methylation value was used in all further analyses.  
 
The data generated by Pyrosequencing were firstly compared to the DMP methylation 
values generated by the HM450 BeadChip to assess concordance. DNA methylation 
levels measured by Pyrosequencing were then analysed to investigate association 
between outcome (adjusted for covariates) and DNA methylation in the “discovery” 
cohort (samples run on the HM450). If associations were observed in the “discovery 
cohort, data were then analysed to look for associations in the larger “replication” 
cohort.  
 
Of the three technically validated assays, two did not work on the Pyrosequencer when 
using ICICLE blood DNA samples, these being; TRIM15 (associated with naming 
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score) and PROCA1 (associated with pentagon copying score). In both assays, the 
ICICLE blood DNA samples were successfully amplified with PCR products visible on 
an agarose gel, however DNA samples repeatedly failed on the Pyrosequencer. Since 
the PCR was successful, the error therefore occurred at the Pyrosequencing stage of the 
validation phase. Results of the remaining assay, CHCHD5, which was associated with 
naming score using the HM450 data, were taken forward for analysis in Stata.  
 
5.3.3.1 CHCHD5 
 
5.3.3.1.1 Validation in discovery cohort 
All 46 blood DNA samples analysed on the HM450 were run on the Pyrosequencer in 
duplicate. Within the Pyrosequencing data there were 32 concordant pairs of data, from 
which an average methylation value for each sample was taken.  
 
Spearman’s rank correlation was performed in Stata to test the correlation between the 
two platforms. A weak correlation of 0.256 was observed between the HM450 data and 
Pyrosequencing data, however this was not statistically significant (p=0.173) (Figure 
87).  
 
 
Figure 87: Correlation between methylation measured on the HM450 and Pyrosequencer at the CHCHD5 
locus. 
 
Analysis of the HM450 data identified one CpG site within CHCHD5 which was 
differentially methylated with naming score. At this CpG site, PD patients with a lower 
score on the naming test had an increased methylation level.  
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Figure 88 shows the mean methylation levels for naming score measured at the 
CHCHD5 locus. The naming variable was a test scored out of 3, in which all 
participants scored either 2 or 3 out of the maximum 3 points. In both the HM450 and 
Pyrosequencing data, those participants achieving the lower score of 2 displayed 
increased methylation levels at the CHCHD5 locus. The Pyrosequencer measured much 
higher levels of methylation than the HM450 and data were also much more variable as 
shown by the standard deviation bars, however the same pattern can be seen in relation 
to the naming score, with those scoring lower on the naming test exhibiting increased 
mean methylation levels.  
 
 
Figure 88: Mean methylation levels for naming score measured at the CHCHD5 locus on the HM450 and 
Pyrosequencer. 
 
The analysis model used to assess the relationship between naming and the HM450 data 
was applied to the Pyrosequencing data. This was to test whether the association 
between methylation and naming was still present using the Pyrosequencing data. In 
Stata, regression was performed (as in the analysis of HM450 data) to test for 
association between methylation at the index site and naming, using sex and age as 
covariates. The results of the HM450 were validated using Pyrosequencing (t=-4.53, 
p=1.16E-04). The methylation data were found to have a non-normal distribution using 
the Shapiro Wilk normality test. Therefore, Spearman’s rank correlation was used to 
assess whether the association observed between CHCHD5 DNA methylation and 
naming was also observed in the Pyrosequencing data. The results of the HM450 were 
validated using Pyrosequencing at this locus using a non-parametric test (Rho = -0.520, 
p=0.003).  
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5.3.3.1.2 Validation in replication cohort 
The Pyrosequencing assay was run across a larger independent sample subset (n=105) 
to test whether the association with naming score, at the index CpG site, was still 
observed. Of the samples run on the Pyrosequencer, 82 concordant pairs of data were 
identified. A mean methylation value for each sample was taken and used in the 
following analysis. Using both regression and Spearman’s rank (due to the non-normal 
distribution of the methylation data) to analyse the Pyrosequencing data, a significant 
association was observed between methylation at the CHCHD5 locus and naming score 
(regression: t=-3.07, p=0.003; Spearman’s: Rho=-0.325, p=0.006). This increase in 
sample size led to a slight weakening of the significance level between DNA 
methylation and naming score; however there was still a significant association between 
naming and DNA methylation, indicating that this is likely to be a real association.  
 
5.3.3.1.3 Comparison with healthy controls 
In order to determine whether the observed differences in DNA methylation were 
unique to Parkinson’s disease, DNA samples from 90 healthy controls were also 
included in the Pyrosequencing assay in duplicate. 79 pairs of concordant data were 
identified and a mean methylation value was calculated for each sample. In controls, 
there was no association between CHCHD5 methylation and naming (Rho=0.012, 
p=0.918). Significant differences were observed in the DNA methylation levels at the 
CHCHD5 locus between PD cases and controls (z=3.727, p=0.0002). The results of the 
methylation analysis for the CHCHD5 locus in both controls and PD cases are displayed 
in Figure 89. This difference between PD and controls suggest that the differential 
methylation observed in both the HM450 and Pyrosequencing data, when analysing the 
DNA methylation data in relation to naming, is unique to PD cases. This suggests that 
there may be other variables influencing DNA methylation levels in PD cases, as 
naming score is not associated with DNA methylation in controls.  
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Figure 89: CHCHD5 DNA methylation analysis with language score in both PD cases and controls. PD 
cases (Pyrosequencing cohort only) are shown in blue and controls are displayed in red. 
 
DNA methylation at the CHCHD5 locus was not found to be associated with any other 
cognitive or motor outcome variable.  
 
5.3.4 Further Pyrosequencing analysis 
Due to the high failure rate of the assays designed for the index CpG sites, an additional 
approach was adopted. Primers for seven Pyrosequencing assays failed to be optimised 
(Section 5.3.2). For five of these genes, predesigned Pyromark CpG Assays (Qiagen, 
UK) were available. None of these assays targeted the index CpG site, however it was 
still of interest to assess whether any other CpG sites within the gene exhibited the 
differential methylation seen between methylation and outcome in the HM450 data. 
Pyromark CpG Assays were obtained for the following genes: C7orf50, C16orf45, 
MOGAT1, PGS1 and RUNDC3A. Due to very limited sample quantity a reduced 
number of samples were run in each assay compared to CHCHD5.  
 
Like previously tested assays, a number failed when ICICLE DNA samples were run on 
the Pyrosequencer. Pyrosequencing data are not available for C16orf45 and C7orf50 
due to all samples repeatedly failing. The remaining three assays were successfully run 
across a number of DNA samples.  
 
5.3.5 RUNDC3A 
Methylation at a CpG site within RUNDC3A was found to be associated with language 
score. The language test is scored out of 2, with the majority of participants scoring the 
maximum of 2 points. The HM450 identified those scoring 0 points on the language test 
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had lower levels of methylation compared to those scoring >1 point (5.1% vs 10.2%, 
p=7.91E-06). The Pyrosequencing data cannot be used to validate these findings as the 
assay does not include the index CpG site; however the Pyrosequencing data were used 
to assess whether this differential methylation observed at a CpG site within RUNDC3A 
is also observed at other CpG sites within the gene. Four CpG sites were included in the 
Pyrosequencing array. 26 pairs of concordant data were available for RUNDC3A 
Pyrosequencing analysis. Spearman’s rank correlation was used to test for association 
between language score and DNA methylation at each individual CpG site as well as 
the mean methylation across the region (i.e. mean across 4 CpG sites). Results of these 
tests are displayed in Table 50. At neither CpG site, nor across the region, was DNA 
methylation found to be associated with language score.  
 
CpG site Rho  P value 
Site 1 0.247 0.224 
Site 2 0.194 0.344 
Site 3 0.172 0.401 
Site 4 0.052 0.800 
Region 0.170 0.408 
Table 50: Association between RUNDC3A methylation and language score. 
 
In addition to the PD samples, DNA from twelve healthy age and sex matched controls 
were also run across the RUNDC3A assay. Eight pairs of concordant data were 
identified and a mean methylation value calculated for each sample. DNA methylation 
at these specific loci within RUNDC3A did not differ between controls and PD cases. 
The results of the methylation analysis for the RUNDC3A region in both controls and 
PD cases are displayed in Figure 90. 
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Figure 90: Regional RUNDC3A DNA methylation analysis with language score in both PD cases and 
controls. PD cases are shown in blue and controls are displayed in red. 
 
 
5.3.6 MOGAT1 
Methylation at a CpG site within MOGAT1 was found to be associated with MDS-
UPDRS III. The HM450 identified those with a higher score on the MDS-UPDRS III 
scale and therefore more severe motor impairment had lower levels of methylation 
compared to those whose motor disease was not as severe (effect size= 0.050, p=4.99E-
06). The Pyrosequencing data cannot be used to validate these findings as the assay 
does not include the index CpG site; however the Pyrosequencing data were used to 
assess whether this differential methylation observed at a CpG site within MOGAT1 is 
also observed at other CpG sites within the gene. Five CpG sites were included in the 
Pyrosequencing array, however due to limited number of data points available for the 
final two CpG sites included in the assay, only the first three CpG sites were included in 
the analysis. For CpG sites 1 and 2, there were 62 pairs of concordant data available for 
MOGAT1 Pyrosequencing analysis, and in CpG site 3 there were 43 pairs of concordant 
data available for Pyrosequencing analysis. Spearman’s rank correlation was used to test 
for association between MDS-UPDRS III and DNA methylation at each individual CpG 
site, as well as the mean methylation across the region (i.e. mean across 3 CpG sites). 
Results of these tests are displayed in Table 51. At neither CpG site, nor across the 
region, was DNA methylation found to be associated with MDS-UPDRS III.  
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CpG site Rho  P value 
Site 1 0.167 0.253 
Site 2 0.119 0.412 
Site 3 0.190 0.267 
Region 0.250 0.142 
Table 51: Association between MOGAT1 methylation and MDS-UPDRS III. 
 
5.3.7 PGS1 
Methylation at a CpG site within PGS1 was found to be associated with tremor 
dominant phenotype. The HM450 identified those with a more severe tremor had 
increased levels of methylation compared to those whose motor disease was not as 
severe (effect size= -0.070, p=1.59E-06). The Pyrosequencing data however cannot be 
used to validate these findings as the assay does not include the index CpG site. As 
above, the Pyrosequencing data were used to assess whether this differential 
methylation observed at the CpG site (included on the HM450 BeadChip) within PGS1 
is also observed at other CpG sites within this gene. Four CpG sites were included in the 
Pyrosequencing array. 23 pairs of concordant data were available for PGS1 
Pyrosequencing analysis. Spearman’s rank correlation was used to test for association 
between tremor dominant phenotype score and DNA methylation at each individual 
CpG site as well as the mean methylation across the region (i.e. mean across 4 CpG 
sites). Results of these tests are displayed in Table 52. At neither CpG site, nor across 
the region, was DNA methylation found to be associated with tremor dominant 
phenotype.  
 
CpG site Rho P value 
Site 1 -0.182 0.407 
Site 2 -0.143 0.515 
Site 3 -0.149 0.497 
Site 4 0.097 0.659 
Region 0.002 0.995 
Table 52: Association between PGS1 methylation and tremor dominant phenotype. 
 
Due to MDS-UPDRS III and tremor dominant phenotype being motor related outcomes 
and therefore not present in healthy controls, there is no control data available for 
comparison for either MOGAT1 or PGS1.  
 
In summary, no HM450 findings were validated using the predesigned assays for three 
of the genes (RUNDC3A, MOGAT1, PGS1). This may be due to different CpG sites 
within the gene being investigated.  
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5.4 Discussion 
This work aimed to identify potential biomarkers of PD-MCI using blood samples taken 
following idiopathic PD diagnosis. In the ICICLE cohort, differences between MCI and 
NCI samples were as expected, with the MCI cases scoring worse on all cognitive 
outcomes when compared to NCI samples. MCI cases were also more likely to have had 
fewer years in education and suffer from hypertension and depression. In addition to 
being more cognitively impaired, the MCI group were also more likely to have a worse 
motor function than the NCI group.  
 
The HM450 array identified 46 CpG sites, in which the gene they were located in had 
previously been found to be differentially expressed in PD, to be associated with 
cognitive deficits in the ICICLE cohort. In addition, six CpG sites that had previously 
been found to be differentially expressed in PD were found to be associated with motor 
deficits in the ICICLE cohort. Following filtering of top hits, three assays were run 
across a larger independent ICICLE cohort to confirm whether the association observed 
was replicated when measured using Pyrosequencing. One of these assays (CHCHD5) 
successfully validated the HM450 findings, suggesting that the observations were 
confirmed using an alternative technology and that this may be a potential biomarker for 
PD-MCI.  
 
These novel results were promising; however the function of CHCHD5 is unclear. A 
study by Banci et al. (2012) showed that it is recognised as a substrate for the Mia40-
dependent mitochondrial membrane import machinery, suggesting that CHCHD5 is 
taken up into the mitochondrial membrane space, where it may perform its yet to be 
determined role (Banci et al., 2012). Another CHCHD family member, CHCHD10 has 
previously been implicated in pathologically proven frontotemporal dementia-
amyotrophic lateral sclerosis (FTD-ALS). A missense point mutation (c.176C>T; 
p.Ser59Leu) was discovered in this gene in a family with a history of FTD-ALS 
(Bannwarth et al., 2014). Similarly to CHCHD5, the authors showed that CHCHD10 is 
located within the mitochondrial membrane space indicating that they may have related 
roles. A later study on a larger cohort of FTD-ALS patients discovered a second 
mutation (c.100C>T; p.Pro34Ser) (Chaussenot et al., 2014). Although the overall 
prevalence of these mutations was low (n=115, 2.6%), these discoveries still indicate a 
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possible role for CHCHD family proteins in mitochondrial function related to cognitive 
and motor decline. 
 
These results suggest that the CpG site within CHCHD5 could be a potential biomarker 
of PD-MCI. However, only one CpG site within CHCHD5 was found to be associated 
with one cognitive outcome, the naming test. Due to only one CpG site being included 
in the Pyrosequencing assay, it is therefore unknown whether the differential 
methylation observed at this CpG site is also observed at neighbouring CpG sites, or if 
this is a feature of this CpG site alone. More extensive interrogation of the region is 
warranted and this could be achieved using a technology such as targeted bisulphite 
sequencing (Herman et al., 1996). In addition, the accuracy of the naming test also 
needs to be considered. The naming test was scored out of 3, and all participants (cases 
and controls) had a score of either 2 or 3. This suggests that there is not much variation 
between participants so the differential methylation observed at the CHCHD5 locus 
may not have the range, or power, to discriminate between relatively subtle differences 
in cognitive traits. The validity of this biomarker as a predictor of later cognition is 
therefore uncertain. DNA methylation levels were measured at the CHCHD5 locus in 
PD cases and healthy controls. Interestingly, the differential methylation observed at 
this locus was only observed in the PD cases, and the healthy controls did not exhibit 
any differences in methylation that were attributable to naming score. This suggests that 
there may be another factor, in addition to, or independently of naming score, 
contributing to DNA methylation in PD cases. This may be an unmeasured confounder 
unrelated to cognition.  
 
As discussed in other Chapters in this thesis, potential biomarkers may have been lost 
during the selection and filtering of HM450 top hits. Firstly, CpG sites were selected 
based on methylation p value and publicly available expression data. Only those hits 
showing an inverse methylation-expression relationship were selected for the follow up. 
This inverse relationship is only expected within promoter regions (Jjingo et al., 2012; 
Jones, 2012) so this criterion could have potentially removed possible biomarkers from 
the selection. The CpG sites identified to be SNPs were removed from the selection of 
top hits to be taken forward for Pyrosequencing validation. The SNPs identified as 
being associated with outcome were not investigated in this thesis, but it is possible that 
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they could also be useful biomarkers of disease. This would be a possible field for 
further research in this area.  
 
Secondly, potential biomarkers may have been removed from the selection when 
designing primers using the Pyrosequencing assay design software. Some CpG sites 
were not amenable for Pyrosequencing due to densely populated CpG island regions 
and potential mispriming sequences. For this reason, these CpG sites were dropped 
from the selection, however an additional technique could be used to interrogate DNA 
methylation at these sites, such as the Sequenom® Epityper™ (Ehrich et al., 2005) or 
bisulphite sequencing (Herman et al., 1996).  
 
Finally, a number of assays could not be optimised or failed validation (could not 
measure the full range of methylation values). For five of these assays, predesigned 
Pyromark assays were used, however these assays did not target the index CpG site and 
so were not able to be used to validate the HM450 findings, but were able to assess 
whether DNA methylation at other CpG sites within the same gene are differentially 
methylated with outcome. In none of the assays assessed was DNA methylation found 
to be associated with outcome. This approach was only adopted for those assays which 
could not be optimised, however this approach could also be adopted for those which 
failed validation or for assays which could not be designed using the Pyrosequencing 
Assay Design software.  
 
Small sample sizes pose problems in most statistical tests. A test of correlation assumes 
a linear relationship and roughly even distribution of values across a scale. With few 
samples, these assumptions can easily be violated and the correlation estimates can 
therefore be imprecise. A source of bias with potentially greater influence is outliers. A 
single outlier can completely change the slope of a regression line and therefore the 
correlation coefficient. Firm conslusions therefore cannot be drawn from correlation 
value alone. More clarity on the true correlation of the methylation generated would be 
gained with a larger sample size and close scrutiny of the impact of outliers.  
 
Due to the heterogeneous nature of blood, it is possible that any differences  in DNA 
methylation observed between outcome groups is due to the cellular composition of the 
blood. Methylation beta values were adjusted for cellular composition to determine 
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whether the differential methylation observed in relation to the outcome variables (both 
cognitive and motor) were actually due to differences in cellular composition. Adjusting 
for cellular composition revealed very little difference in significance, indicating that 
differences in cellular composition have no significant effect on the methylation 
differences observed between outcome groups in this Chapter.   
 
In summary, limited evidence was generated to support the potential use of DNA 
methylation signatures as predictive biomarkers of PD-MCI. Conclusions were limited 
largely by technical issues encountered (such as the inability to design assays to validate 
discovery observations) and more extensive analysis of DNA methylation using other 
approaches is warranted. Due to the resources available, many potential biomarkers 
remained under-investigated and should form the basis of further studies.  
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Chapter 6. DNA methylation signatures as exposure indicators in 
post-stroke dementia and Parkinson’s disease 
 
6.1 Introduction 
As previously discussed in Chapter 1, PSD and PD are likely to be caused by a 
combination of genetic, epigenetic and environmental factors. Several environmental 
factors have been identified in the literature. These disease-specific exposures will be 
explored in more detail in Sections 6.1.1 and 6.1.2.  However, evidence for the 
associations between exposure and outcome has sometimes been contradictory and 
inconclusive. One possible explanation for this is the inaccuracy inherent in the 
measurement of exposures, and biomarkers are increasingly being applied to index such 
exposures. For example, smoking can be difficult to accurately measure due to recall 
and reporting bias on self-reported questionnaires. Smoking is likely to be therefore 
under reported. Cotinine is a metabolite of nicotine, detectable in blood or urine, and is 
commonly used as a biomarker to estimate the smoking level. However, cotinine has a 
short half-life (16 hours) and is unable to inform about former smoking habits 
(Vartiainen et al., 2002).  
 
An emerging area in the field of epigenetics is to utilise DNA methylation as an 
indicator of exposure. DNA methylation has previously been identified as an indicator 
of smoking status and has been used to distinguish between smokers and never smokers 
(Elliott et al., 2014) and never and former smokers (Shenker et al., 2013).  
 
Given the potential of environmental factors to permanently alter DNA methylation, 
these markers could give an indication of exposures that occurred many years before 
(Section 1.3.4) and therefore be a longer term archive of exposure compared to 
biomarkers such as cotinine. Using DNA methylation as a biomarker for exposure could 
help to eliminate the problem of recall and reporting bias, especially for long term 
historical exposures.   
 
The use of biomarkers in this way does not necessarily require the biomarker to be on 
the causal pathway between exposure and outcome. For example CRP is a very useful 
clinical biomarker of atherosclerosis but it is not causally involved in the development 
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of atherosclerosis, it is simply a marker of the inflammatory processes that occur in 
atherosclerosis (Patel et al., 2001; Timpson et al., 2005; Trion et al., 2005). Evidence 
such as this underscores that biomarkers can have clinical utility without the necessity 
for causal involvement in a disease pathway. Conversely, if a causal relationship is 
observed, this may fuel intervention to prevent disease initiation or progression, so 
aiming to establish causal relationships is imperative. This applies equally to 
establishing the causal (or non-causal) role of DNA methylation linking exposures with 
diseases, so that the relevance of DNA methylation as a predictive biomarker or 
intervention target can be prioritised.  
 
The aim of the work presented in this Chapter is to assess whether DNA methylation 
profiles can act as indicators/biomarkers for environmental exposures of PSD and PD 
and to determine in such cases whether these biomarkers are directly mediating the 
effects of exposure on disease or simply acting as a non-causal proxy. Figure 91 shows 
the associations tested in this thesis to investigate whether DNA methylation can act as 
a mechanism linking exposure with disease.  
 
 
Figure 91: Associations tested in this thesis to assess the role of DNA methylation in the exposure-
outcome association (Adapted from Michels, 2012).  
 
6.1.1 Exposures affecting post-stroke dementia 
PSD most commonly affects the elderly, those with a lower level of education and those 
with other co-morbidities (Leys et al., 2005). Many of the risk factors for stroke are also 
thought to affect the risk of PSD. There are a number of medical conditions which have 
been associated not only with an increased risk of stroke, but also an increased risk of 
PSD. Cardiovascular risk factors are major contributors to the risk of PSD (Leys et al., 
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2005). Hypertension and atrial fibrillation are considered, after age, the second largest 
risk factors for PSD. Possible mechanisms linking these disorders to cognitive decline 
include a reduced perfusion of the brain caused by a reduced and impaired regularity of 
cerebral blood flow, which may lead to subsequent brain damage and cognitive decline 
(Ott et al., 1997). A variety of heart problems such as ischaemic heart disease, angina 
and cardiac failure may also affect the risk of stroke in the same way (Paciaroni and 
Bogousslavsky, 2013). Another related indicator of high risk is intermittent claudication 
caused by reduced blood flow to the legs causing muscle pain (Tilvis et al., 2004). 
 
The severity of the stroke indicated by the size and location of the infarct has also been 
linked to the risk of dementia. Multiple lesions, seen in patients with recurrent stroke 
are also strongly associated with a doubling in risk of PSD (Pendlebury and Rothwell, 
2009). Imaging techniques can provide a lot of information regarding the severity of 
stroke, providing evidence for location, number and size of lesions, degree of cerebral 
atrophy, all of which may indicate the risk of PSD (Gorelick, 1997). In addition, 
symptoms suffered at the time of stroke may also be able to indicate those at an 
increased risk of developing dementia.  
 
Factors relating to a poor lifestyle including low levels of physical activity and obesity, 
and smoking are also thought to impact upon PSD risk. Due to the increased risk of 
cardiovascular related disease, obesity and poor physical activity have been associated 
with increased risk of stroke and PSD (Leys et al., 2005). Smoking is a known risk 
factor for both stroke and dementia. It has been suggested that, compared to never 
smokers, heavy smoking can double the risk of both AD and VaD (Ott et al., 1998; 
Sahathevan et al., 2012). Alcohol has also been associated with an increased risk of 
cognitive decline among the elderly (Thomas and Rockwood, 2001) although this 
association has not been studied with respect to post-stroke dementia.  
 
6.1.2 Exposures affecting mild cognitive impairment in Parkinson’s disease 
Like PSD, there are a number of exposures which have been associated with an 
increased risk of PD-MCI. A number of demographic risk factors have been associated 
with PD-MCI including increasing age, male sex, working in the agricultural sector 
(Section 1.2.4.2) and low levels of education (Palavra et al., 2013).  
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Lifestyle factors have also been associated with PD-MCI risk, including smoking and 
alcohol consumption. Data on smoking as a risk factor for PD-MCI is inconsistent with 
some papers reporting a protective effect (Wang et al., 2010; Schapira and Jenner, 
2011) whilst others suggest it is a significant risk factor for cognitive impairment 
(Anstey et al., 2007). This disparity could be due to the difficulty in gaining accurate 
information on smoking behaviour due to the tendency of participants to under report 
smoking habits. As described in Section 6.1.1, alcohol consumption has been associated 
with an increased risk of dementia in the elderly population so may also be a relevant 
risk factor for PD-MCI.  
 
A decrease in body mass index (BMI) following Parkinson’s disease diagnosis has been 
associated with an increased risk of cognitive decline although it is not clear whether 
this is a causal relationship (Kim et al., 2012a) as it may be indicative of underlying 
disease processes that confound the associations. 
 
A number of biochemical measures can also indicate risk of MCI in the general 
population and possibly can be extrapolated to PD. Reduced red cell folate (RCF) and 
vitamin B12 levels have been shown to lead to increased levels of homocysteine. In 
turn, elevated homocysteine levels have been associated with both MCI and AD. In 
addition to RCF and B12 levels, homocysteine levels can also be affected by Levodopa 
usage, the golden standard treatment for PD (Rodriguez-Oroz et al., 2009). 
 
A number of medical conditions may also increase the risk of developing PD-MCI. 
Diabetes, hypertension and hypercholesterolaemia have all been associated with                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
increased risk of PD-MCI with a higher prevalence of these diseases observed in PD-
MCI cases compared to cognitively normal PD cases. However, findings in this field 
have not proven consistent (Kandiah et al., 2013). Finally, greater depression scores 
have also been reported to be higher in PD-MCI cases than PD cases with normal 
cognition (Yarnall et al., 2013). 
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6.2 Experimental design 
 
6.2.1 COGFAST exposures 
COGFAST is a well characterised study with a wealth of exposure data providing an 
excellent opportunity to study the effects of exposures on post-stroke dementia and 
DNA methylation. A number of exposures were recorded at the time of stroke which 
relate to the index stroke (i.e. not previous or subsequent strokes that may have 
occurred). In addition, a number of exposure variables were recorded at recruitment into 
COGFAST including baseline CAMCOG scores. Table 53 describes all exposures 
collected in COGFAST that were used in the analysis reported in this Chapter. 
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Exposure Type Exposure Description Time recorded 
Stroke-related OCSP class The type of stroke 
experienced according to the 
Oxfordshire Community 
Stroke Project 
Index stroke 
Stroke-related Side of body The side of the body, if any, 
affected by the stroke 
Index stroke 
Stroke-related Degree of weakness arm The degree of weakness 
experienced in arm following 
stroke 
Index Stroke 
Stroke-related Degree of weakness leg The degree of weakness 
experienced in leg following 
stroke 
Index Stroke 
Stroke-related Dysphasia Whether dysphasia was a 
symptom following the stroke 
Index Stroke 
Medical 
history 
Hypertension Present or absent, defined by 
blood pressure >140/90 
mmHg 
Recruitment 
Medical 
history 
Atrial fibrillation Present or absent, defined by 
WHO criteria 
Recruitment 
Medical 
history 
IHD Present or absent, defined by 
WHO criteria 
Recruitment 
Medical 
history 
Angina Present or absent, defined by 
WHO criteria 
Recruitment 
Medical 
history 
Cardiac failure Present or absent, defined by 
WHO criteria 
Recruitment 
Medical 
history 
Intermittent claudication Present or absent, defined by 
WHO criteria 
Recruitment 
Medical 
history 
No of CVD risk factors Number of Cardiovascular 
risk factors (Smoking, 
Diabetes, Hyperlipidaemia, 
Peripheral vascular disease, 
IHD, Atrial fibrillation, 
Hypertension) 
Recruitment 
Lifestyle Smoking Current, ex or never smoker Recruitment 
Lifestyle Alcohol Average units of alcohol per 
week 
Recruitment 
Baseline 
cognition 
MMSE Score at baseline (max=30) Recruitment 
Baseline 
cognition 
Orientation Score at baseline (max=10) Recruitment 
Baseline 
cognition 
Language 
comprehension 
Score at baseline (max=9) Recruitment 
Baseline 
cognition 
Language expression Score at baseline (max=21) Recruitment 
Baseline 
cognition 
Memory remote Score at baseline (max=6) Recruitment 
Baseline 
cognition 
Memory recent Score at baseline (max=4) Recruitment 
Baseline 
cognition 
Memory learning Score at baseline (max=17) Recruitment 
Baseline 
cognition 
Memory total Score at baseline (max=27) Recruitment 
Baseline Attention Score at baseline (max=7) Recruitment 
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cognition 
Baseline 
cognition 
Praxis Score at baseline (max=12) Recruitment 
Baseline 
cognition 
Calculation Score at baseline (max=2) Recruitment 
Baseline 
cognition 
Abstract thinking Score at baseline (max=8) Recruitment 
Baseline 
cognition 
Perception Score at baseline (max=11) Recruitment 
Baseline 
cognition 
Executive function Score at baseline (max=28) Recruitment 
Baseline 
cognition 
Total CAMCOG score Score at baseline (max=107) Recruitment 
Table 53: List of exposures measured in COGFAST. 
  
6.2.2 ICICLE exposures 
ICICLE is a very well characterised study with detailed exposure data upon which the 
utility of DNA methylation as a marker of exposure and the relationship between 
exposures and PD-MCI can be investigated. A number of exposures were recorded at 
recruitment into the ICICLE study. They are described in Table 54.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
 
Exposure Type Exposure Description Time recorded 
Demographic Education Years in education Recruitment 
Demographic NART National Adult Reading 
Test score 
Recruitment 
Lifestyle Alcohol Average units of alcohol per 
week 
Recruitment 
Lifestyle Smoking Current, ex or never smoker Recruitment 
Anthropometric Height Height (m) Recruitment 
Anthropometric Weight Weight (kg) Recruitment 
Anthropometric BMI Body Mass Index (kg/m2) Recruitment 
Biochemical RCF Red cell folate measurement 
(µg/L) 
Recruitment 
Biochemical B12 Vitamin B12 measurement 
(ng/L) 
Recruitment 
Biochemical Homocysteine Homocysteine measurement 
(µmol/L) 
Recruitment 
Medical history IHD Present or absent, defined 
by WHO criteria 
Recruitment 
Medical history Diabetes Present or absent, defined 
by WHO criteria 
Recruitment 
Medical history Hypertension Present or absent, defined 
by WHO criteria 
Recruitment 
Medical history Hypercholesterolaemia Present or absent, defined 
by WHO criteria 
Recruitment 
Medical history GDS Geriatric Depression Scale 
score 
Recruitment 
Medical history Levodopa dosage Levodopa daily dose (mg) Recruitment 
Table 54: List of exposures measured in ICICLE. 
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6.2.3 Relationship between exposures and outcomes 
In Stata, the association between exposure and outcome was assessed using either 
Spearman’s rank, Kruskal Wallis, Wilcoxon rank sum, t tests or chi squared.  
 
The outcome variables tested in COGFAST are described in detail in the Glossary 
(Table 2). In summary these were; diagnosis, Braak staging, MMSE, orientation, 
language comprehension, language expression, memory remote, memory recent, 
memory learning, memory total, attention, praxis, calculation, abstract thinking, 
perception, executive function and total CAMCOG score. For the analyses using 
COGFAST data, tests with p values <1.05x10-4 were accepted as indicating an 
association between exposure and outcome after applying Bonferroni correction based 
on the number of tests conducted and α=0.05.  
 
The outcomes tested in ICICLE are described in detail in the Glossary (Table 4). In 
summary the motor outcomes were; Hoehn and Yahr, MDS-UPDRS II, MDS-UPDRS 
III, tremor dominant phenotype and PIGD phenotype.  The cognitive outcomes tested in 
ICICLE were; MoCA, MMSE, total FAS, animals, pentagon copying, naming, 
language, language total, NMSQ memory, NMSQ concentration, total number of NMS, 
power of attention, digit vigilance accuracy, cognitive complaint, MCI, PRM, SRM, 
PAL and OTS. For the analyses using ICICLE data, tests with p values <1.30x10-4 were 
accepted as indicating an association between exposure and outcome after applying 
Bonferroni correction based on the number of tests conducted and α=0.05.  
 
6.2.4 Associations between exposures and DNA methylation 
The CpGassoc package (Barfield et al., 2012), which performs multiple linear 
regression analyses with continuous predictor variables and ANOVA for categorical 
predictor variables, was implemented in R (version 2.15.0). For all analyses, age, sex 
and chip (i.e. the microarray chip upon which the samples were scanned) were included 
in the analysis model as covariates. Significant results were considered as those 
reaching genome-wide significance (p<1.13x10-7). To assess the influence of cellular 
composition in the samples, HM450 data were subsequently adjusted for cellular 
composition using the method described by Houseman et al. (2012) and the CpGassoc 
analyses were repeated, as a sensitivity analyses, to assess whether adjustment for 
cellular composition impacted on the initial analysis.  
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6.2.5 Using methylation scores to predict smoking exposure status 
The method used here has been described by Elliott et al. (2014). Methylation values 
published by Zeilinger et al. (2013) were used as a reference data set. Zeilinger et al. 
(2013) identified 187 CpG sites to be associated with smoking. Four of these CpG sites 
in the ICICLE cohort were dropped in the initial QC (Section 5.3.1). Methylation at the 
remaining 183 CpG sites was used to calculate weighted methylation scores for each 
DNA sample. Median methylation values of never smokers identified in Zeilinger et al. 
(2013) were used as the reference values and the associated effect sizes were used as 
weights. The difference between the ICICLE beta value and reference beta value was 
calculated for each CpG site. The sum of all CpG site scores was calculated to give a 
final weighted score in each person. The threshold score able to distinguish current from 
never smokers was calculated using random forests (Breiman, 2001) in R (Version 
3.1.0) 
        
6.2.6 Identifying CpG sites associated with both an exposure and outcome 
To assess whether any CpG sites were associated with both an exposure and outcome 
the analyses using the CpGassoc package (Barfield et al., 2012) were repeated. First, the 
ANOVA analysis was performed to look for association between outcome variables and 
methylation of those CpG sites significantly associated (i.e. reaching genome-wide 
significance) with an exposure variable. Then, the reverse was tested to look for 
association between exposure and methylation at only those CpG sites reaching 
genome-wide significance with an outcome. Any CpG sites which were significant with 
both an exposure and outcome were then tested for interaction.  
 
6.2.7 Testing for interaction 
First, multiple regression was used to test whether the addition of DNA methylation into 
the regression model altered the relationship between exposure and outcome. If DNA 
methylation was found to alter the relationship between exposure and outcome then 
DNA methylation could be considered to be involved in the relationship between them. 
If DNA methylation was thought to link the exposure with outcome, an interaction term 
was included in the model, to test whether the effect of methylation on outcome is 
affected by the presence or absence of the exposure. All analyses were performed in 
Stata.                                                                                                                                                                                                                                                                                                                                                                                                                          
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6.3 Results 
 
6.3.1 Relationship between exposure and outcome 
Both cohorts (COGFAST and ICICLE) measured a range of exposures, detailed in 6.2.1 
and 6.2.2. For each cohort, the relationship between exposure and outcome in the entire 
cohort was assessed using either Spearman’s rank correlation, Kruskal Wallis, 
Wilcoxon rank sum, t tests or a chi squared test, as appropriate. 
 
6.3.1.1 Post-stroke dementia 
All measured exposures relating to the index stroke, lifestyle factors and medical history 
previously associated with PSD in the literature were compared to outcome variables, to 
test whether these exposure variables are associated with outcome in the COGFAST 
cohort. The associations were tested on all COGFAST participants that had a complete 
data set (including final diagnosis and Braak staging information). Participants who 
were still living and did not have information on final diagnosis and Braak staging were 
excluded from this analysis. All associations between exposure and outcome in PSD 
where the Bonferroni corrected p<0.05 are displayed in Table 55. Complete results 
tables can be found in Appendix C.  
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Exposure Type Exposure Outcome Test statistic P value 
Baseline Cognition Orientation MMSE 0.732 6.40E-06¶ 
Baseline Cognition Orientation Language expression 0.661 0.0001¶ 
Baseline Cognition Orientation Memory learning 0.675 0.0001¶ 
Baseline Cognition Orientation Memory total 0.726 8.36E-06¶ 
Baseline Cognition Orientation Attention 0.705 1.99E-05¶ 
Baseline Cognition Orientation Total CAMCOG 0.672 0.0001¶ 
Baseline Cognition Language 
comprehension 
Language expression 0.657 0.0001¶ 
Baseline Cognition Language 
expression 
Language expression 0.689 3.64E-05¶ 
Baseline Cognition Memory remote Memory remote 0.650 0.0001¶ 
Baseline Cognition Memory remote Memory total 0.681 4.72E-05¶ 
Baseline Cognition Perception Perception 0.671 0.0001¶ 
Baseline Cognition MMSE MMSE 0.776 7.77E-07¶ 
Baseline Cognition MMSE Orientation 0.674 0.0001¶ 
Baseline Cognition MMSE Language 
comprehension 
0.666 0.0001¶ 
Baseline Cognition MMSE Language expression 0.698 2.54E-05¶ 
Baseline Cognition MMSE Memory learning 0.771 1.01E-06¶ 
Baseline Cognition MMSE Memory total 0.735 5.62E-06¶ 
Baseline Cognition MMSE Attention 0.695 2.88E-05¶ 
Baseline Cognition MMSE Praxis 0.827 3.14E-08¶ 
Baseline Cognition MMSE Total CAMCOG 0.807 1.28E-07¶ 
Baseline Cognition Total CAMCOG  Diagnosis 5.066 0.0001§ 
Baseline Cognition Total CAMCOG  MMSE 0.766 1.31E-06¶ 
Baseline Cognition Total CAMCOG  Orientation 0.703 2.10E-05¶ 
Baseline Cognition Total CAMCOG Language expression 0.765 1.35E-06¶ 
Baseline Cognition Total CAMCOG  Memory learning 0.702 2.23E-05¶ 
Baseline Cognition Total CAMCOG  Memory total 0.726 8.14E-06¶ 
Baseline Cognition Total CAMCOG  Attention 0.675 0.0001¶ 
Baseline Cognition Total CAMCOG  Praxis 0.686 3.98E-05¶ 
Baseline Cognition Total CAMCOG  Executive function 0.659 0.0001¶ 
Baseline Cognition Total CAMCOG  Total CAMCOG 0.795 2.63E-07¶ 
Table 55: Significant associations between exposures and outcomes in the COGFAST cohort. § = t test, ¶ 
= Spearman’s rank. Number of tests performed = 476. Statistical threshold = p<1.05x10-4. 
 
Several baseline CAMCOG scores were found to be associated with the last CAMCOG 
score recorded prior to death. A positive correlation was observed between all 
significant associations between CAMCOG variables. Baseline orientation, language 
comprehension, language expression, memory remote, perception, MMSE and total 
CAMCOG scores were associated with several CAMCOG scores recorded at the final 
follow up prior to death. In all cases, a worse baseline score was associated with a worse 
score prior to death. A lower baseline total CAMCOG score was also found to be 
associated with a later diagnosis of dementia. Previous work using the COGFAST 
cohort had identified significant associations between baseline executive function score 
(CAMCOG test) and onset of dementia as well as memory total (combined score across 
all CAMCOG memory tests; recent, remote and learning) and onset of dementia (Allan 
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et al., 2011). None of these baseline CAMCOG scores were found to be associated with 
later cognitive outcome in the COGFAST samples used in this study. In addition, 
previously published work using the entire COGFAST cohort identified the number of 
CVD risk factors to be associated with onset of dementia (Allan et al., 2011), however, 
this observation was not identified in the cohort sub-sample used in this thesis. Another 
study using the COGFAST cohort identified hypertension to be associated with 
cognition at baseline (three months post-stroke) (Rowan et al., 2005), but hypertension 
was not found to be associated with cognitive outcome prior to death in this study. 
Although the majority of associations did not attain statistical significance many of the 
effect estimates were in the right direction. All exposure-outcome relationships were 
considered for analysis irrespective of whether the more widely reported association 
was observed in the sub-sample of COGFAST data utilised here, due to the power 
limitations of replicating such associations in this particular study.  
 
6.3.1.2 Mild cognitive impairment in Parkinson’s disease 
All measured exposures relating to the lifestyle, anthropometric and medical history 
previously associated with PD-MCI in the literature were compared to both motor and 
cognitive outcome variables, to test whether these exposure variables are associated 
with outcome in the ICICLE cohort. In addition to assessing cognitive decline, 
associations with motor outcomes, a strong hallmark of PD, were also explored here. 
All associations between exposures and motor outcomes which reach the stringent 
significance threshold (as described in Section 6.2.3) are displayed in Table 56. All 
associations between exposures and cognitive outcomes with p<1.30E-04 are displayed 
in Table 57. A comprehensive results table can be found in Appendix C.  
 
 
Exposure Type Exposure Outcome Test 
statistic 
P value 
Medical history GDS MDS-UPDRS II 0.632 2.13E-14¶ 
Medical history GDS MDS-UPDRS III 0.459 1.97E-07¶ 
Medical history GDS PIGD phenotype 0.553 1.06E-10¶ 
Table 56: Significant associations between exposures and motor outcomes in the ICICLE cohort. ¶ = 
Spearman’s rank. Number of tests performed = 384. Statistical threshold = p<1.30x10-4. 
 
Of all exposures tested, depression, as measured by the GDS was the only exposure 
found to be associated with motor outcome when the stringent significance threshold of 
1.13x10-4 was applied. A higher score on the GDS (where > 5 is categorised as 
depressed) was associated with a higher score on all three associated motor tests, 
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indicative of a worse motor function, however these results are not able to indicate 
whether depression is causally linked with motor outcome. Other associations were 
observed however they did not reach significance once Bonferroni correction was 
applied. Again, all exposure-motor outcome relationships were considered for analysis 
irrespective of whether the more widely reported association was observed in the 
ICICLE data, due to the power limitations of replicating such associations in this 
particular study. 
 
Exposure Type Exposure Outcome Test 
statistic 
P value 
Demographic Education MoCA 0.336 0.0001¶ 
Demographic Education MMSE 0.338 0.0001¶ 
Demographic Education Total FAS 0.426 4.25E-07¶ 
Demographic Education Animals 0.392 3.92E-06¶ 
Demographic Education Digit vigilance 
accuracy 
0.386 5.59E-06¶ 
Demographic Education  PRM  0.419 7.23E-07¶ 
Demographic NART MoCA 0.369 1.60E-05¶ 
Demographic NART MMSE 0.379 8.88E-06¶ 
Demographic NART Total FAS 0.459 3.87E-07¶ 
Demographic NART PRM  0.401 2.21E-06¶ 
Demographic NART PAL -0.361 2.49E-05¶ 
Demographic NART Language total 0.327 0.0001¶ 
Demographic NART MCI 4.283 1.84E-05‡ 
Medical history Levodopa daily dose Total number NMS 0.482 1.41E-08¶ 
Table 57: Significant associations between exposures and cognitive outcomes in the ICICLE cohort. ‡ = 
Wilcoxon rank sum, ¶ = Spearman’s rank. Number of tests performed = 384. Statistical threshold = 
p<1.30x10-4. 
 
Education and NART were found to be associated with a number of cognitive outcomes 
when the Bonferroni correction was applied. As expected, a higher number of years in 
education is associated with a better score on all cognitive tests (Table 57). Similarly, a 
higher NART score is associated with better cognition in all tests, as shown in Table 57. 
Due to the moderate correlation between education and NART (Rho=0.577, p=3.33E-
15), many of these associations do, as expected, overlap. These results are similar to a 
previous study using the ICICLE cohort which also identified education to be associated 
with poorer cognitive outcome (Yarnall et al., 2014). A higher Levodopa daily dose is 
associated with an increased number of non-motor symptoms (NMS). Again, these tests 
do not give any indication of the causal relationship between the two variables 
(exposure and outcome), however all exposure variables used in this analysis have been 
previously associated with an increased risk of PD and are considered possible risk 
factors for this disease in the literature. Previous studies using the ICICLE cohort found 
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participants with a higher score on the GDS and therefore had a more severe depression 
were more likely to have PD-MCI (Yarnall et al., 2014). Although some exposures 
(such as other medical conditions and smoking) were not found to be associated with 
cognitive outcome in the ICICLE cohort, there is enough evidence in the literature to 
suggest that all exposures tested could have an impact on disease risk. The effect 
estimates were in the expected direction in the majority of cases, although the p value 
may not have attained statistical significance. For these reasons, all exposures were 
included in subsequent analysis.  
 
6.3.2 Relationship between exposure and DNA methylation 
 
6.3.2.1 Post-stroke dementia 
ANOVA was performed on all beta values measured against the exposure variables in 
Table 53. Baseline age, sex and chip were included in the analysis model as covariates 
when analysing blood DNA samples. Age at death, sex and chip were included as 
covariates in the analysis model using DLPFC and hippocampal DNA samples.  
 
6.3.2.1.1 Baseline blood samples 
To test for association between methylation and exposures, ANOVA was performed on 
all beta values calculated across 455,173 CpG sites measured in 29 baseline blood 
samples, against the exposures in Table 53. Manhattan plots are shown for exposure 
variables for which significant associations were observed with CpG sites in blood 
DNA. Summary and test statistics for each CpG site significantly associated (reaching 
genome-wide significance) with the exposure are displayed in the following tables. A 
number of variables (Side of body - Figure 92, Table 58; Degree of weakness arm, and 
Degree of weakness leg - Figure 93, Table 59), which can be used to indicate the 
severity of the stroke, were associated with methylation at several CpG sites. Due to the 
high degree of correlation identified between degree of weakness in the arm and leg 
(coefficient = 0.718, p<0.001), results for the degree of weakness in the arm are 
omitted.  
 
Interestingly, DNA methylation at the same four CpG sites was associated with both 
degree of weakness in the arm and leg. This may be due to the fact that these variables 
are closely correlated. The CpG site associated with the side of the body affected by the 
stroke is unique to that variable and does not appear to be significantly associated with 
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degree of weakness in either the arm or leg. None of these CpG sites associated with an 
exposure were found to reach genome-wide significance with any outcome in Chapter 
3. In addition, none of these CpG sites have previously been associated with stroke or 
stroke-related variable, although literature in this domain is still very limited.  
 
When the analyses were repeated after adjustment for cellular composition, using the 
method described by Houseman et al. (2012), no large deviations in associations were 
observed for any CpG site. This indicates that cellular composition is not causing the 
differences in methylation associated with the exposure measures displayed here.  
 
 
Figure 92: Manhattan plot for association between blood DNA methylation and the side of the body 
affected by stroke. Each circle represents an individual CpG site. The continuous line marks the 
p<1.1x10-7 significance threshold. CpG sites with p values below the threshold are labelled with their 
Illumina ID.  
 
CpG site Gene ID Relation to CpG 
island 
Effect size F statistic P value 
cg21101720 ANKRD13B CpG Island 0.14 257.70 9.05E-12 
Table 58: Summary and test statistics for the CpG site in blood associated with the side of the body 
affected by stroke. 
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Figure 93: Manhattan plot for association between blood DNA methylation and degree of weakness in the 
leg. Each circle represents an individual CpG site. The continuous line marks the p<1.1x10-7 significance 
threshold. CpG sites with p values below the threshold are labelled with their Illumina ID.  
 
CpG site Gene ID Relation to CpG 
island 
Effect size F statistic P value 
cg16900604   0.26 260.48 1.30E-10 
cg01500733 C7orf28A North shore 0.13 128.19 3.71E-10 
cg19611612   0.35 94.53 3.14E-09 
cg19151808 HERC3A  0.57 60.19 6.82E-08 
Table 59: Summary and test statistics for the 4 CpG sites in blood associated with degree of weakness in 
leg. 
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6.3.2.1.2 Dorsolateral prefrontal cortex samples 
To test for association between methylation and exposures, ANOVA was performed on 
all beta values calculated across 431,822 CpG sites measured in 24 DLPFC samples, 
against the exposures in Table 53. Manhattan plots are shown for exposure variables for 
which significant associations were observed with CpG sites in the DLPFC. Summary 
and test statistics for each CpG site significantly associated (reaching genome-wide 
significance) with the exposure are displayed in the following tables. A number of 
variables (Side of body - Figure 94, Table 60; degree of weakness in arm (not 
presented) and degree of weakness in leg - Figure 95, Table 61), which indicate the 
severity of stroke, were significantly associated with methylation at a number of CpG 
sites. In addition, intermittent claudication was also associated with methylation at five 
CpG sites (Figure 96, Table 62). Due to the strong correlation between degree of 
weakness in the arm and leg, only data for the leg are presented.  
 
None of the CpG sites highlighted here have previously been associated with stroke or 
stroke-related variables. CpG sites associated with intermittent claudication and the side 
of the body affected by stroke are not significantly associated with any other exposure. 
None of these CpG sites were found to be associated with an outcome variable in 
Chapter 4. In addition, none of the CpG sites associated with an exposure in the DLPFC 
were also identified in the blood.  
 
When the analyses were repeated after adjustment for cellular composition, using the 
method described by Guintivano et al. (2013), no large deviations in associations were 
observed for any CpG site. This indicates that cellular composition is not causing the 
differences in methylation associated with the exposure measures displayed here.  
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Figure 94: Manhattan plot for association between DLPFC DNA methylation and the side of the body 
affected by stroke. Each circle represents an individual CpG site. The continuous line marks the 
p<1.1x10-7 significance threshold. CpG sites with p values below the threshold are labelled with their 
Illumina ID. 
 
CpG site Gene ID Relation to CpG 
island 
Effect size F statistic P value 
cg00272484 TSNARE1 South shore -0.54 5251.05 7.79E-16 
cg07917614 CASZ1  -0.78 1231.02 1.08E-12 
cg25722644 XKR5 South shore -0.58 1146.85 1.54E-12 
cg16446617   -0.75 805.42 8.94E-12 
cg08136432 GALNS CpG island -0.65 782.10 6.70E-10 
cg17823943 OBSCN North shelf -0.67 319.79 8.65E-10 
cg23945952 CRTC1 South shore -0.13 283.54 1.56E-09 
cg03548463 CDK11B South shore -0.57 267.82 2.07E-09 
cg00420922 TBC1D8 CpG island 0.21 258.75 2.45E-09 
cg02489478  North shore -0.51 256.78 2.54E-09 
cg17200161 KCNK5 CpG island 0.09 203.96 7.84E-09 
cg02278728  North shelf -0.34 196.90 9.32E-09 
cg00416475 GMIP CpG island -0.21 180.89 1.41E-08 
cg01081586  CpG island 0.12 173.71 1.71E-08 
cg24101492  CpG island 0.08 173.65 1.72E-08 
cg11770920 DIRC3  -0.33 167.68 2.04E-08 
cg19982221   -0.35 167.60 2.04E-08 
cg05983640 HPS3 CpG island 0.11 141.89 4.57E-08 
cg01121712 TPPP3 CpG island 0.18 134.60 5.89E-08 
cg04508405 ARPC1B North shore -0.13 122.93 9.12E-08 
cg06730756 DENND3  -0.75 120.59 1.00E-07 
Table 60: Summary and test statistics for the 21 CpG sites in DLPFC associated with the side of body 
affected by stroke. 
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Figure 95: Manhattan plot for association between DLPFC DNA methylation and the degree of weakness 
in the leg. Each circle represents an individual CpG site. The continuous line marks the p<1.1x10-7 
significance threshold. CpG sites with p values below the threshold are labelled with their Illumina ID. 
 
CpG site Gene ID Relation to CpG 
island 
Effect size F statistic P value 
cg27540232   0.49 2177.16 6.32E-14 
cg10980293 ASB10  0.63 1638.83 2.60E-13 
cg03251852 PRX  0.87 1595.43 2.98E-13 
cg25451082 ARSJ South shore -0.38 900.84 5.12E-12 
cg15990955 NEDD4L  0.69 891.34 5.40E-12 
cg07416885  CpG island 0.54 798.79 9.31E-12 
cg08311403 ROBO3 CpG island -0.12 768.09 1.13E-11 
cg08682341 INPP5A South shore -0.51 605.35 3.69E-11 
cg05674406 INTS1 North shore 0.68 529.30 7.18E-11 
cg15421087 CTNNB1 CpG island -0.44 445.81 1.68E-10 
cg12771281 TRMT5 CpG island -0.17 592.41 2.80E-10 
cg12525096  South shore 0.19 352.17 5.38E-10 
cg22295064 CTTN CpG island -0.08 326.82 7.77E-10 
cg10290814 TNK1 CpG island -0.19 306.20 1.07E-09 
cg07179329 CDH13  0.81 435.93 1.10E-09 
cg10482224 PTPN14 CpG island 0.27 296.73 1.25E-09 
cg22637594  South shelf -0.36 290.58 1.39E-09 
cg22007227 ZBTB8B CpG island -0.09 272.90 1.89E-09 
cg11944324 TOLLIP North shore 0.28 266.29 2.13E-09 
cg02049017 RPS6KA2 South shelf 0.17 263.24 2.25E-09 
cg23558601 TNK1 CpG island -0.20 262.06 2.30E-09 
cg21874832 FAM178B CpG island 0.27 252.77 2.75E-09 
cg07820548  South shore 0.23 243.78 3.28E-09 
cg17590805 FLI1 CpG island 0.54 242.90 3.34E-09 
cg18835493 KLHL29 South shore 0.18 235.47 3.89E-09 
cg22207479 SLC14A2  0.51 231.50 4.22E-09 
cg16268160 ROBO3 CpG island -0.13 221.48 5.24E-09 
cg19461260 TRIM14 CpG island 0.34 211.23 6.61E-09 
cg09110402 PREX1 CpG island -0.10 205.14 7.63E-09 
cg00788222  North shelf 0.34 204.82 7.68E-09 
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cg25358565 FAM172A CpG island -0.07 201.15 8.39E-09 
cg21634064 SMTN CpG island -0.11 199.70 8.69E-09 
cg24341759 SSBP3  0.42 198.95 8.86E-09 
cg12765935 METAP2  0.65 195.79 9.58E-09 
cg13393408 GPR107  0.22 182.41 1.35E-08 
cg12098873 TRIP10 North shore 0.50 178.19 1.51E-08 
cg11010528 HCG4P6 CpG island -0.28 176.86 1.57E-08 
cg19854900 SDK1  0.20 171.27 1.84E-08 
cg24933115  CpG island 0.07 322.09 2.26E-08 
cg21295678   0.12 143.34 4.35E-08 
cg06779945 TNFAIP3  -0.01 142.58 4.46E-08 
cg09474331 TTYH1 North shore -0.09 141.76 4.59E-08 
cg13442116 KCNT1 North shelf 0.39 140.04 4.87E-08 
cg16711291  South shelf 0.55 129.13 7.20E-08 
cg18001180 KCNK17 CpG island -0.24 126.34 8.00E-08 
cg05175540 SERPINB9 North shore 0.25 125.71 8.19E-08 
cg11244695 SLC9A1  0.10 125.27 8.33E-08 
Table 61: Summary and test statistics for the 47 CpG sites in DLPFC associated with degree of weakness 
in leg. 
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Figure 96: Manhattan plot for association between DLPFC DNA methylation and intermittent 
claudication. Each circle represents an individual CpG site. The continuous line marks the p<1.1x10-7 
significance threshold. CpG sites with p values below the threshold are labelled with their Illumina ID. 
 
CpG site Gene ID Relation to CpG 
island 
Effect size F statistic P value 
cg17951978 HSD3B2  -0.05 3589.19 3.47E-15 
cg19976628  North shelf -0.05 2618.46 1.95E-14 
cg23290664 TSHZ1 CpG island 0.71 807.92 1.20E-11 
cg13632328  North shore -0.02 685.41 1.52E-10 
cg20805368   -0.05 486.43 1.87E-10 
Table 62: Summary and test statistics for the 5 CpG sites in DLPFC associated with intermittent 
claudication. 
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6.3.2.1.3 Hippocampus samples 
To test for association between methylation and exposures, ANOVA was performed on 
all beta values calculated across 434,422 CpG sites measured in 28 hippocampal 
samples, against the exposures in Table 53. Manhattan plots are shown for exposure 
variables for which significant associations were observed with CpG sites in the 
hippocampus. Summary and test statistics for each CpG site significantly associated 
(reaching genome-wide significance) with the exposure are displayed in the following 
tables. A number of variables (Side of body - Figure 97, Table 63; degree of weakness 
in arm (not presented) and degree of weakness in leg - Figure 98, Table 64) associated 
with the severity of stroke were associated with methylation at a number of CpG sites. 
Again, due to the high correlation between degree of weakness in the arm and leg, only 
data relating to the leg are presented. 
 
Like in the blood and DLPFC, the CpG sites associated with the side of the body 
affected by the stroke were not associated with any other exposure in the hippocampus. 
None of the CpG sites associated with a stroke-related variable here have previously 
been reported to be associated with stroke or any stroke-related variable. Additionally, 
none of these CpG sites were also significantly associated with any outcome variable in 
Chapter 4. No CpG site significantly associated with an exposure in the hippocampus 
were also associated with an exposure in the blood, however there were a few 
overlapping CpG sites between the DLPFC and the hippocampus. Two CpG sites 
(cg12765935 and cg05674406) were associated with both the degree of weakness in the 
arm and leg in the DLPFC and the degree of weakness in the arm and leg in the 
hippocampus. One CpG (cg22207479) associated with both degree of weakness in arm 
and leg in the DLPFC was also associated with the degree of weakness in the arm in the 
hippocampus.  
 
Adjustment for cellular composition using the method described by Guintivano et al. 
(2013) identified no large deviations in associations observed for any CpG site. This 
indicates that cellular composition is not causing the differences in methylation 
associated with the exposure measures displayed here.  
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Figure 97: Manhattan plot for association between hippocampal DNA methylation and the side of body 
affected by stroke. Each circle represents an individual CpG site. The continuous line marks the 
p<1.1x10-7 significance threshold. CpG sites with p values below the threshold are labelled with their 
Illumina ID. 
 
CpG site Gene ID Relation to CpG 
island 
Effect size F statistic P value 
cg00788222  North shelf -0.15 96.21 6.60E-09 
cg17808183   -0.22 72.04 4.27E-08 
Table 63: Summary and test statistics for the 2 CpG sites in the hippocampus associated with the side of 
body affected by stroke. 
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Figure 98: Manhattan plot for association between hippocampal DNA methylation and the degree of 
weakness in leg. Each circle represents an individual CpG site. The continuous line marks the p<1.1x10-7 
significance threshold. CpG sites with p values below the threshold are labelled with their Illumina ID. 
 
 
CpG site Gene ID Relation to 
CpG island 
Effect size F statistic P value 
cg27540232   0.60 2324.30 2.20E-18 
cg05291178 C3orf24 North shore 0.65 2207.15 3.16E-18 
cg02574952 DPF2 South shelf 0.93 1050.60 5.56E-16 
cg11270017 ADARB2 North shelf 0.75 931.43 1.28E-15 
cg10980293 ASB10  0.58 760.80 5.24E-15 
cg21604803 CPT1C CpG island -0.33 623.05 2.09E-14 
cg05674406 INTS1 North shore 0.68 550.95 4.89E-14 
cg24233211   0.18 449.80 1.98E-13 
cg21658515  South shelf 0.61 442.46 2.22E-13 
cg07224531 B3GNT9 CpG island 0.28 359.41 9.29E-13 
cg12765935 METAP2  0.47 307.98 2.68E-12 
cg08158105 BRI3BP North shore 0.45 539.40 1.05E-11 
cg17707690 ORC5L  -0.12 221.38 2.54E-11 
cg06542302  South shore 0.37 216.08 3.00E-11 
cg26959392 SPATA19  0.38 192.45 6.56E-11 
cg21909391 LPP  0.38 187.99 7.69E-11 
cg23954153 ARTN CpG island -0.19 186.35 8.15E-11 
cg21159390  CpG island 0.20 180.78 1.00E-10 
cg18640509 SORD CpG island -0.23 178.42 1.09E-10 
cg23386236 CAPN3  0.55 140.54 5.41E-10 
cg06350542 MCF2L North shelf 0.23 505.30 5.70E-10 
cg04688828 LYNX1 CpG island -0.15 129.58 9.29E-10 
cg15365320 DKFZp686O24166 CpG island -0.20 128.87 9.63E-10 
cg07160793   0.50 125.64 1.14E-09 
cg25086501  North shore 0.25 125.41 1.15E-09 
cg25627675 RPL27A North shelf 0.69 124.09 1.24E-09 
cg13470341 DMRT3 CpG island -0.09 115.79 1.96E-09 
cg03953196 COX4NB  0.12 113.19 2.27E-09 
cg09762043 TUBGCP5 CpG island -0.26 111.07 2.57E-09 
cg18544365 DNM2  0.54 110.48 2.67E-09 
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cg23365345 ZNF792 CpG island -0.05 107.61 3.17E-09 
cg25717470   0.21 104.58 3.82E-09 
cg19008693 VDR  0.17 100.31 5.02E-09 
cg11919138 ATP5E CpG island -0.11 98.48 5.67E-09 
cg12449685 ROBO4  -0.39 134.03 6.19E-09 
cg08304190 MIR663 CpG island -0.39 89.62 1.05E-08 
cg10409248  CpG island -0.17 88.99 1.10E-08 
cg07549406 CGREF1 CpG island -0.09 81.61 1.92E-08 
cg03162251 MLLT1 CpG island 0.74 106.15 2.34E-08 
cg25237970 DIS3L2  0.17 78.95 2.38E-08 
cg26856330 NR2C2AP CpG island -0.06 78.85 2.40E-08 
cg21765235 ODZ4  -0.31 74.98 3.31E-08 
cg11094040 DOCK1 CpG island 0.12 74.77 3.37E-08 
cg15035278 PRDM16 North shelf -0.10 74.31 3.50E-08 
cg27032232 DPP6 CpG island -0.23 72.51 4.10E-08 
cg19611612   0.54 72.14 4.24E-08 
cg17521156  CpG island 0.40 71.65 4.42E-08 
cg00834858  North shelf 0.03 71.09 4.65E-08 
cg01182690 PPHLN1 North shore -0.22 70.99 4.69E-08 
cg24373760 LGR5 CpG island -0.05 69.96 5.15E-08 
cg20210376 LTBP3 CpG island 0.21 68.84 5.71E-08 
cg04033850  South shelf 0.13 67.95 6.20E-08 
cg20069738 ZBTB45 CpG island -0.05 66.25 7.28E-08 
cg07312880   -0.46 64.37 8.73E-08 
cg03556243 ZBTB20  -0.19 64.34 8.75E-08 
cg10744079  CpG island -0.91 63.98 9.07E-08 
cg06678279 ERC2 CpG island -0.04 63.67 9.35E-08 
cg09354050 UBASH3A  0.09 62.84 1.02E-07 
Table 64: Summary and test statistics for the 58 CpG sites in the hippocampus associated with degree of 
weakness in leg. 
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6.3.2.2 Parkinson’s disease 
ANOVA was performed on all beta values across 455,981 CpG sites against the 
exposure measures described in Table 54. Age, sex and chip were included in the 
analysis model as covariates.  
 
Manhattan plots are shown for exposure variables, for which significant associations 
were observed with CpG sites in blood. Summary and test statistics for each CpG site 
significantly associated (reaching genome-wide significance) with the exposure are 
displayed in the following tables. One CpG site was associated with homocysteine 
levels (Figure 99, Table 66), 8 CpG sites were associated with IHD (Figure 100, Table 
67), 24 CpG sites were associated with smoking status (Figure 101, Table 68) and 7 
CpG sites were associated with weight (Figure 102, Table 69). 
 
No CpG sites were identified as being significantly associated with more than one 
exposure. Interestingly five of the 24 CpG sites significantly associated with smoking 
were within the GATA3 gene, however none of the CpG sites associated with smoking 
here have previously been reported to be differentially methylated between smokers and 
non-smokers. It may be that the sample size used here (with only two current smokers) 
was too small to detect the usual hits associated with smoking such as AHRR (Shenker 
et al., 2013; Zeilinger et al., 2013). A power calculation was performed to calculate the 
number of smokers required to detect methylation differences at the AHRR locus. To 
detect a methylation difference of 5% with alpha=1.1x10-7, 26 smokers would be 
required. 
 
One of the CpG sites associated with smoking is located within the DLG2 gene which 
has previously been associated with Parkinson’s disease. No other CpG site associated 
with an exposure in the ICICLE cohort has previously been associated with the 
exposure in the literature. In addition, no CpG sites identified here also reached genome 
wide significance when an association between methylation and an outcome variable 
was tested in Chapter 5.  
 
When the CpGassoc analyses were repeated on data adjusted for cellular composition 
(Houseman et al., 2012), very few differences were observed. No CpG site associated 
with weight, IHD or homocysteine were affected by cellular composition adjustment. 
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Two CpG sites associated with smoking status showed very slight alterations (Table 
65). Adjusting for cellular composition very slightly increased the significance level and 
F statistic at both CpG sites. These results suggest that cellular composition is not a 
major influence on methylation at any CpG site associated with any of the exposures 
highlighted in the ICICLE cohort.  
 
Variable CpG site Pre-adjustment Post-adjustment 
F statistic P value F statistic P value 
Smoking 
status 
cg09769113 30.01 3.75E-08 30.15 3.57E-08 
Smoking 
status 
cg04318855 29.18 5.05E-08 31.47 2.25E-08 
Table 65: CpG sites affected by cellular composition. 
 
 
 
Figure 99: Manhattan plot for association between blood DNA methylation and homocysteine. Each 
circle represents an individual CpG site. The continuous line marks the p<1.1x10-7 significance threshold. 
CpG sites with p values below the threshold are labelled with their Illumina ID. 
 
CpG site Gene ID Relation to CpG 
island 
Effect size T statistic P value 
cg12053442   0.44 -6.89 6.20E-08 
Table 66: Summary and test statistics for the CpG site associated with homocysteine. 
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Figure 100: Manhattan plot for association between blood DNA methylation and IHD. Each circle 
represents an individual CpG site. The continuous line marks the p<1.1x10-7 significance threshold. CpG 
sites with p values below the threshold are labelled with their Illumina ID. 
 
CpG site Gene ID Relation to CpG 
island 
Effect size F statistic P value 
cg24651215  North shelf 0.15 58.57 5.59E-09 
cg16451306 MAP1B  0.19 53.51 1.50E-08 
cg03750034   0.19 52.05 2.39E-08 
cg23157360   0.22 47.62 5.13E-08 
cg04138976 ATPAF1 South shore 0.15 46.35 6.77E-08 
cg27105183  South shore -0.12 44.55 1.01E-07 
cg17367472 KRTAP11-1  0.17 44.12 1.11E-07 
cg22827011 SERPINA6  0.23 44.07 1.12E-07 
Table 67: Summary and test statistics for the 8 CpG sites associated with IHD. 
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Figure 101: Manhattan plot for association between blood DNA methylation and smoking status. Each 
circle represents an individual CpG site. The continuous line marks the p<1.1x10-7 significance threshold. 
CpG sites with p values below the threshold are labelled with their Illumina ID. 
 
CpG site Gene ID Relation to CpG 
island 
Effect size F statistic P value 
cg07217075 BFSP1 CpG island 0.05 178.25 2.05E-18 
cg13814485 GATA3 CpG island 0.07 99.14 1.11E-14 
cg23098371  CpG island -0.28 75.46 4.88E-13 
cg06022942 GATA3 CpG island 0.08 60.76 8.65E-12 
cg04210284 SLC6A3 CpG island 0.21 54.19 3.75E-11 
cg05170353  North shelf -0.10 53.60 4.31E-11 
cg26207909 CKB North shore -0.04 51.79 6.62E-11 
cg18713528 SRRM3 CpG island 0.11 48.93 1.34E-10 
cg06897927 HMX3 CpG island 0.12 47.98 1.71E-10 
cg13939859 BARHL2 CpG island 0.13 39.52 1.74E-09 
cg16703220   -0.30 37.51 3.18E-09 
cg16485682 GATA6 CpG island 0.13 37.18 3.52E-09 
cg05493509 STK32C CpG island -0.26 34.85 7.31E-09 
cg18105709 C10orf71 CpG island -0.03 34.25 8.88E-09 
cg16550651 KAT2A North shore -0.17 33.64 1.09E-08 
cg02346970 PDZD2 CpG island 0.04 32.82 1.42E-08 
cg11018337 GATA3 CpG island 0.09 31.96 1.90E-08 
cg08347183 GATA3 CpG island 0.06 30.87 2.77E-08 
cg03554406 SS18L1 CpG island -0.05 30.43 3.23E-08 
cg07578663 GATA3 CpG island 0.03 30.25 3.45E-08 
cg07759394 GLB1L2 CpG island 0.18 30.00 3.75E-08 
cg18045575 CGREF1 CpG island 0.08 29.18 5.05E-08 
cg21578457 DLG2  -0.16 27.32 1.00E-07 
cg24359323 FGF3 CpG island 0.10 27.03 1.12E-07 
Table 68: Summary and test statistics of the 24 CpG sites associated with smoking status. 
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Figure 102: Manhattan plot for association between blood DNA methylation and weight. Each circle 
represents an individual CpG site. The continuous line marks the p<1.1x10-7 significance threshold. CpG 
sites with p values below the threshold are labelled with their Illumina ID. 
 
CpG site Gene ID Relation to 
CpG island 
Effect size T statistic P value 
cg25871543 XAB2 CpG island 0.28 -7.81 3.55E-09 
cg17629685 NDUFAF2 CpG island -0.08 7.28 1.65E-08 
cg23498273 SGCE North shore -0.10 7.24 1.90E-08 
cg06046317  North shore 0.42 -7.20 2.14E-08 
cg12319004 LEFTY1 South shelf 0.55 -7.13 2.58E-08 
cg22984380 RPTOR South shelf 0.38 -7.11 2.77E-08 
cg01649867   0.13 -6.73 8.46E-08 
Table 69: Summary and test statistics for the 7 CpG sites associated with weight. 
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6.3.3 Is DNA methylation a good predictor of exposure status? 
If DNA methylation is to be used as a robust predictor of exposure status, it must be 
measured in a readily accessible tissue such as the blood. Analysis in this Section was 
therefore limited to blood DNA methylation in both ICICLE and COGFAST.  
 
In the ICICLE cohort, DNA methylation was found to be significantly associated with 
IHD, weight, homocysteine and smoking (Section 6.3.2.2). As previously mentioned, 
DNA methylation has previously been used to predict smoking status. The same 
approach as used by Elliott et al. (2014) was utilised here to demonstrate whether a 
methylation score could be used to distinguish between smokers and never smokers in 
ICICLE.  
 
Methylation scores were calculated for each ICICLE participant with HM450 
methylation data (n=46). Using random forests, the average threshold score segregating 
current smokers from never smokers in 500 trees was 13.66. This score distinguished 
current smokers from never smokers (Figure 103). The majority of former smokers had 
a methylation score below 13.66 and were indistinguishable from never smokers. This 
supports previously reported data that suggests that following smoking cessation, 
methylation levels return, over time, to similar levels found in never smokers (Zeilinger 
et al., 2013; Elliott et al., 2014).  
 
Two ICICLE participants had unknown smoking status, however their prior smoking 
exposure could be predicted using the methylation scores generated. Both subjects had a 
score below 0 (-0.23 and -1.92) indicating that these were likely to be either never or 
former smokers. The smoking score of 13.66 is of similar magnitude to the score of 
17.55 identified by Elliott et al. (2014), indicating that using the methylation data 
published by Zeilinger et al. (2013) as a reference, a methylation score can be used to 
successfully distinguish between current and non-smokers in this data set.  
 
No difference was observed between smoking score and self-reported smoking with 
respect to the association with outcomes in this study population. 
 
Homocysteine, IHD and weight were also found to be associated with DNA methylation 
and although DNA methylation could potentially refine the exposure status of each of 
these variables, none were taken forward.  
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Figure 103: Smoking scores by reported smoking status (current, ex, never). Boxplots show the median 
and interquartile ranges. The line at 13.66 is the smoking score threshold separating smokers from non-
smokers. Individuals above the line were considered to be smokers.  
 
The analysis looking for associations between COGFAST blood DNA methylation and 
exposures (Section 6.3.2.1.1) yielded several useful candidates; Side of body affected 
by stroke, degree of weakness in arm and degree of weakness in leg. In this study, these 
variables were directly recorded from clinical notes and therefore would not have 
benefitted from the addition of DNA methylation data. 
 
6.3.4 Is methylation associated with both an exposure and outcome? 
It was of interest, in this Chapter, to investigate whether the CpG sites associated with 
an exposure were also associated with an outcome variable (as well as the reverse; 
whether CpG sites associated with an outcome were also associated with an exposure 
variable) and whether there was any interaction between methylation and the exposure 
to affect outcome. 
 
6.3.4.1 Parkinson’s disease 
In Section 6.3.2.2, methylation at a number of CpG sites was found to be associated 
with a range of exposures (Homocysteine, 1 CpG site; IHD, 8 CpG sites; Smoking, 24 
CpG sites; Weight, 7 CpG sites). For each exposure, the CpG sites reaching genome-
wide significance were analysed using ANOVA to look for association between 
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methylation and motor outcome (Hoehn and Yahr, MDS-UPDRS II, MDS-UPDRS III, 
tremor dominant phenotype and PIGD phenotype), and methylation and cognitive 
outcome (MoCA, MMSE, total FAS, animals, NMSQ memory, NMSQ concentration, 
power of attention, digit vigilance accuracy, PRM, PAL, SRM, OTS, pentagon copying, 
naming, language, language total, cognitive complaint, MCI and total number of NMS). 
No association was observed between an outcome variable and any CpG site associated 
with homocysteine, IHD and weight. Of the 24 CpG sites associated with smoking, nine 
of these were also associated with language (part of the MoCA test where participants 
have to verbally repeat sentences). Table 70 summarises these results.  
 
CpG site Gene ID Relation 
to CpG 
island 
Smoking Language 
Effect 
size 
F stat P value Effect 
size 
T stat P value 
cg18045575 CGREF1 Island 0.08 29.18 5.05E-08 0.03 -4.11 2.29E-04 
cg11018337 GATA3 Island 0.09 31.96 1.90E-08 0.04 -4.05 2.69E-04 
cg13814485 GATA3 Island 0.07 99.14 1.11E-14 0.02 -3.74 6.62E-04 
cg06022942 GATA3 Island 0.08 60.76 8.65E-12 0.02 -3.62 9.11E-04 
cg23098371  Island -0.28 75.46 4.88E-13 -0.07 3.56 0.001 
cg02346970 PDZD2 Island 0.04 32.82 1.42E-08 0.01 -3.53 0.001 
cg26207909 CKB North 
shore 
-0.04 51.79 6.62E-11 -0.01 3.40 0.002 
cg13939859 BARHL2 Island 0.13 39.52 1.74E-09 0.04 -3.33 0.002 
cg24359323 FGF3 Island 0.10 27.03 1.12E-07 0.03 -3.23 0.003 
Table 70: 9 CpG sites associated with both smoking and language. 
 
Regression was used to highlight an association between smoking and language (F = 
3.48, p = 0.041). At each CpG site, methylation was found to be associated with 
smoking (Table 71).  
 
CpG site F statistic P value 
cg18045575 11.02 0.002 
cg11018337 -12.91 0.003 
cg13814485 9.54 0.004 
cg06022942 7.12 0.011 
cg23098371 5.30 0.027 
cg02346970 10.48 0.002 
cg26207909 4.25 0.046 
cg13939859 5.38 0.025 
cg24359323 5.47 0.024 
Table 71: Methylation is associated with smoking at 9 CpG sites. 
 
An interaction term was used in the regression model to test for an interaction between 
methylation and smoking. There was no evidence that the presence or absence of 
smoking changes the effect of methylation on language at any CpG site. Figure 104 
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shows the results for cg18045575. Results for all other CpG sites were very similar and 
are therefore not presented.  
 
 
Figure 104: Graph of predicted values and linear fit lines from regression model for cg18045575. Blues 
points indicate current smokers, green indicates ex-smokers and red indicates never smokers. 
 
CpG sites which were found to be associated with an outcome (Chapter 5) were 
analysed using ANOVA to look for association between methylation and an exposure 
variable. MDS-UPDRS III (a variable assessing the motor symptoms of PD) was found 
to be associated with methylation at one CpG site (T statistic = -7.06, p = 3.20E-08). 
Analysis using ANOVA revealed that this CpG site was also significantly associated 
with weekly alcohol consumption (T statistic = 2.49, p = 0.018), however no association 
was observed between MDS-UPDRS III and alcohol, so this CpG site was not 
investigated further.  
 
In conclusion, there was no evidence that the presence or absence of any exposure 
changes the effect of methylation on any outcome variable in the ICICLE cohort. 
 
6.3.4.2 Post-stroke dementia 
The same methodology was applied to the post-stroke dementia data. Table 72 
summarises the observed associations in each tissue. Two CpG sites were associated 
with both an exposure and outcome in the blood, whilst one CpG site was found to be 
associated with both an exposure and outcome variable using the DNA extracted from 
the hippocampus. No associations were observed between DLPFC DNA methylation in 
both an exposure and outcome. 
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Tissue CpG site Exposure Exposure - 
Methylation 
Statistic 
Outcome Methylation 
- Outcome 
Statistic 
Exposure - 
Outcome 
Statistic 
B cg07438999 Side of 
body 
F=44.92, 
p=3.94E-08 
Braak 
staging 
F=17.00, 
p=1.40E-04 
F=0.84, 
p=0.44 
B cg02490189 No of 
CVD risk 
factors 
t=2.13, 
p=0.049 
Total 
CAMCOG 
score 
t=8.78, 
p=6.33E-08 
F=-2.51, 
p=0.126  
H cg22666015 Degree of 
weakness 
in arm 
F=4.45, 
p=0.032 
Recent 
memory 
t=-8.88, 
p=8.60E-08 
F=6.19, 
p=0.007 
Table 72: Statistics for associations between exposures and outcomes identified in COGFAST samples. 
Tissue – B=Blood, H=Hippocampus. For each association statistic, the test statistic and p value are 
presented. 
 
In both CpG sites identified in the blood as being associated with both an exposure and 
outcome, there was no observed association between exposure and outcome and 
therefore no possible interaction between DNA methylation and exposure. As an 
association was observed between the degree of weakness in the arm (exposure) and 
recent memory (outcome) in the hippocampus, multiple regression was performed to 
assess the association between exposure and outcome, with methylation and an 
interaction term included in the model. However, there was still a significant association 
between exposure and outcome (F = 10.09, p=0.0002) indicating that the effect of 
methylation is not altered by the presence or absence of degree of weakness in the arm. 
However, due to the small sample size, the robustness of this observation was 
questionable.   
 
In conclusion, there was no evidence that the presence or absence of any exposure 
changes the effect of methylation on any outcome variable in the COGFAST cohort. 
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6.4 Discussion 
The main aim of this Chapter was to identify whether DNA methylation was involved 
in any pathways linking an exposure or risk factor of PSD or PD with disease (outcome 
variable). Due to the small sample size of both cohorts, few exposures were found to be 
associated with outcome. However, due to a wealth of literature suggesting that many of 
the exposures measured in these cohorts are in fact associated with either PSD or PD, 
they were all considered as possible pathways acting through methylation.  
 
DNA methylation was found to be associated with several exposure variables including 
variables relating to the severity of stroke (side of body affected by stroke, degree of 
weakness in arm and leg and intermittent claudication) in all tissues analysed (blood, 
DLPFC and hippocampus) in the COGFAST cohort and a range of variables (weight, 
IHD, homocysteine and smoking) in the ICICLE cohort. Associations between DNA 
methylation at two CpG sites and exposure variables were of particular interest. One of 
the CpG sites found to be associated with smoking in the ICICLE cohort was located 
within the DLG2 gene. DLG2 encodes a protein that has been shown to be involved 
with the formation of membrane-associated protein scaffolds at postsynaptic synapses 
(Kim et al 1996). It is thought that a SNP within the DLG2 gene may increase the risk 
of PD (Fung et al 2006). In addition, one of the CpG sites associated with weight in the 
ICICLE cohort was within the RPTOR gene, a component of the signalling pathway 
regulating cell growth in response to nutrient, hormone and insulin levels (Kim et al., 
2002). RPTOR has also previously been associated with obesity (Berndt et al., 2013).  
 
DNA methylation had previously been associated with a range of outcome variables 
affecting cognition (and motor control) in PD. This suggested that methylation may be 
involved in a causal pathway linking exposure with disease phenotype. However, in 
both the PSD and PD cohorts utilised in this study, DNA methylation was not found to 
interact with any exposure to affect outcome. It may be that DNA methylation is not 
involved in the pathway linking exposure and outcome, or at least in mediating the 
effect of the limited number of exposures considered in this study.  
 
Another aim of this Chapter was to determine whether DNA methylation could be used 
as an exposure indicator. Current evidence suggests that DNA methylation could 
provide a more refined measure of smoking exposure (Shenker et al., 2013; Elliott et 
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al., 2014) and this technique could be applied in a similar way to measure the exposure 
status of other variables. This approach is particularly relevant to exposures which are 
difficult to accurately measure or exposures which are susceptible to recall or reporting 
bias. The aim of this Chapter was to use DNA methylation data to predict exposure 
status of such variables. 
 
In the ICICLE cohort, DNA methylation was found to be associated with smoking. As 
this had already been studied and had successfully shown DNA methylation differences 
between smokers and non-smokers, the approach used by Elliott et al. (2014) was 
applied to the ICICLE cohort to test whether this method could distinguish smokers 
from non-smokers in the ICICLE cohort. The data presented in this Chapter shows that 
DNA methylation can be used to predict smoking status, with current smokers 
exhibiting a different methylation profile to never and ex-smokers, supporting previous 
research that suggests over time, the methylation profiles of ex-smokers reverts back to 
that of never smokers (Zeilinger et al., 2013; Elliott et al., 2014). This approach was 
also used to predict the smoking status of two participants whose smoking status was 
unknown. This approach does have some limitations however. The methylation score 
was only able to detect between current and never smokers and did not account for the 
number of cigarettes smoked. The addition of more detailed information such as pack 
years (the number of packs of cigarettes smoked per day multiplied by the number of 
years the person has smoked) would enable a more accurate methylation score to be 
calculated. Furthermore, ex smokers were regarded as ex smokers regardless of the time 
since smoking cessation. The addition of this information would also provide a more 
accurate calculation of DNA methylation score. Another factor that has not been 
accounted for in this model is passive smoking. A non smoker who has been subject to 
heavy passive smoking may exhibit a methylation profile different to a non smoker who 
has not been subject to any passive smoking, which could confound results (Elliott et 
al., 2014). Before being used as a marker of smoking status, further validation is 
required to assess the effect of passive smoking on DNA methylation, in addition to 
more detailed information regarding smoking habits and time since since cessation.   
 
In addition, associations between DNA methylation and IHD, and DNA methylation 
and weight were also observed in the ICICLE cohort. However, neither IHD nor weight 
could be estimated with more precision using DNA methylation data, as phenotypic 
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data was complete, but methylation data could in theory, be used to predict missing 
data, should this be required. DNA methylation was also observed to be associated with 
homocysteine levels. Homocysteine was a possible candidate, as the accurate 
measurement of homocysteine relies on the quick sample processing of plasma samples 
(collected in EDTA tubes) to be immediately (within a matter of hours) centrifuged 
(Salazar et al., 1999) upon collection to prevent the deterioration of the analyte. It is 
possible that DNA methylation data may therefore provide a better estimate for 
homocysteine status. However, due to the unavailability of a reference data set and a 
small sample size, which would have made results produced from separating the 
ICICLE cohort into a training and test set unreliable, homocysteine was not considered 
a suitable candidate for implementation of this approach on this occasion. 
 
Using COGFAST data, DNA methylation was found to be associated with variables 
relating to stroke severity. In COGFAST, all of these variables were well recorded and 
DNA methylation data were not required to refine exposure status. However, it is 
important to note that DNA methylation data could be useful in the measurement of 
these stroke-related variables in certain situations, for example, in cohorts where these 
detailed clinical data were not available. If the biomarker is sufficiently robust, the 
methylation information can be used to predict these clinical characteristics. 
Methylation data can therefore be used to both refine exposure measures, but also in 
some instances, to provide a proxy or surrogate measure where the information is not 
available/has not been collected. 
 
The ability to predict smoking status using DNA methylation data is a very valuable 
resource with great clinical utility due to the smoking-associated reporting bias. The 
success of this approach using DNA methylation to predict smoking status suggests that 
this could also be useful for estimating other exposure levels which are prone to the 
same reporting bias or are difficult to accurately measure. Using a larger sample set, so 
that samples can be split into a training and a testing set, would enable a wider range of 
exposures to be assessed in this way.  
 
Analyses reported here are likely to be severely limited in their power to discern 
associations due to the small sample size. A much larger study sample is required to 
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resolve these outstanding questions and the work presented here should be considered 
exploratory.  
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Chapter 7. Methylation age as a risk factor for post-stroke dementia 
and Parkinson’s disease 
 
7.1 Introduction 
Epigenetic factors are thought to be heavily involved in the ageing process with 
growing evidence of differential methylation seen in elderly subjects (Fraga et al., 2005; 
Talens et al., 2012), changes in chromatin organization with age (Oberdoerffer and 
Sinclair, 2007) and evidence suggesting that DNA damage can accelerate the ageing 
process (Campisi and Vijg, 2009). However, it is unclear whether the effect of this 
accumulation of DNA damage on ageing is tissue-specific (Campisi and Vijg, 2009). 
Due to associations between epigenetics and ageing it has been suggested that DNA 
methylation could be used to predict the age of certain tissues and cell types. Due to the 
tissue-specific nature of DNA methylation and the finding that ageing may affect DNA 
methylation profiles in a tissue-specific manner, it is thought that the DNA methylation 
age of different tissues may vary (Horvath, 2013).  
 
A method to predict age using DNA methylation has been developed (Horvath, 2013). 
This method, termed the “Epigenetic clock” predicts the DNA methylation age of 
tissues and cell types by using a weighted average methylation value of 353 CpG sites. 
Using a calibration function, the weighted average can then be transformed to DNA 
methylation age. The method is able to predict methylation age to a high accuracy, the 
median error rate is just 3.6 years (Horvath, 2013). This method can be used to predict 
DNA methylation age in heterogeneous tissue as well as single cell types. It is also 
thought that the DNA methylation age is not affected by differences in cellular 
composition making it a suitable resource for predicting DNA methylation of 
heterogeneous tissue, such as whole blood and brain tissue. It is unclear whether the 
DNA methylation of easily accessible tissue such as blood and saliva could be used as a 
surrogate for more inaccessible tissues such as brain tissue (Horvath, 2013). The 
epigenetic clock method has been used to predict the DNA methylation age of cancer 
samples. Each affected tissue showed significantly increased age acceleration with an 
average of 36.2 years, meaning that the DNA methylation age was predicted to be 36.2 
years older than the chronological age (Horvath, 2013). Other age predictors have been 
described in the literature (Hannum et al., 2013; Weidner et al., 2014) however, none 
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that are so far able to achieve such a high level of accuracy across all tissue types as the 
epigenetic clock method (Weidner et al., 2014).  
 
Due to the findings using cancer samples, it would be interesting to see if age 
acceleration was found in other age-related disorders such as post-stroke dementia 
(PSD) and Parkinson’s disease (PD). This Chapter aims to predict the DNA methylation 
age of COGFAST and ICICLE participants using the epigenetic clock method (Horvath, 
2013). It is hypothesised that participants with an older DNA methylation age than their 
chronological age will be more likely to develop cognitive deficits.  
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7.2 Experimental design 
Using the HM450 data described in Section 3.2.3 and Section 5.2.3, the DNA 
methylation age of blood samples in COGFAST and ICICLE was calculated using the 
epigenetic clock method described by Horvath (2013). The epigenetic clock analysis 
was also performed on the HM450 data described in Section 4.2.3, to calculate the DNA 
methylation age of brain samples in COGFAST. In all epigenetic clock analyses, there 
were three output measures, as described in Table 73. 
 
Output Variable Description 
DNA Methylation Age Methylation age of the tissue 
Age Acceleration Difference 
(AAD) 
Difference between DNA methylation age and 
chronological age (DNAm age – chronological age) 
Age Acceleration Residual 
(AAR) 
Residual from regressing DNA methylation age on 
chronological age, i.e. DNA methylation age corrected for 
chronological age 
Table 73: Description of the output variables resulting from epigenetic clock analysis. 
 
HM450 data were then analysed using regression or ANOVA to investigate associations 
between the age acceleration residual (AAR) and outcome variables relating to disease. 
For COGFAST, the following outcome variables were considered; diagnosis (D/CN), 
Braak staging, MMSE, orientation, language comprehension, language expression, 
memory remote, memory recent, memory learning, memory total, attention, praxis, 
calculation, abstract thinking, perception, executive function and total CAMCOG score 
(Glossary, Table 2) . Following Bonferroni correction, associations between AAR and 
COGFAST outcomes were accepted as significant when p<0.0029. For ICICLE, the 
following motor outcome variables were used; Hoehn and Yahr, MDS-UPDRS II, 
MDS-UPDRS III, tremor dominant phenotype and PIGD phenotype (Glossary, Table 
4). The cognitive outcomes testing in ICICLE were; MoCA, MMSE, total FAS, 
animals, pentagon copying, naming, language, language total, NMSQ memory, NMSQ 
concentration, total number of NMS, power of attention, digit vigilance accuracy, 
cognitive complaint, MCI, PRM, SRM, PAL and OTS (Glossary, Table 4). Following 
Bonferroni correction, associations between AAR and ICICLE outcomes were regarded 
as indicative of association when p<0.0021. 
 
Analyses were also repeated to look for associations between AAR and exposure 
variables to ascertain determinants of age acceleration. The exposure variables 
measured in COGFAST and tested in the analysis were; OCSP class, Side of the body 
affected by stroke, degree of weakness in arm/leg, dysphasia, hypertension, atrial 
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fibrillation, IHD/angina, cardiac failure, intermittent claudication, no of CVD risk 
factors, smoking, alcohol, baseline MMSE, baseline orientation, baseline language 
comprehension, baseline language expression, baseline memory remote, baseline 
memory recent, baseline memory learning, baseline memory total, baseline attention, 
baseline praxis, baseline calculation, baseline abstract thinking, baseline perception, 
baseline executive thinking and baseline total CAMCOG score (Glossary, Table 1). 
Associations between COGFAST exposures and AAR were regarded as significant if 
p<0.002, following Bonferroni correction. The exposure variables tested in ICICLE 
were; education, NART, alcohol, smoking, height, weight, BMI, RCF, B12, 
homocysteine, IHD, diabetes, hypertension, hypercholesterolaemia, GDS and Levodopa 
daily dose (Glossary, Table 3). Associations between ICICLE exposures and AAR were 
regarded as significant if p<0.003, following Bonferroni correction.  
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7.3 Results 
 
7.3.1 DNA methylation age of COGFAST participants 
The epigenetic clock method (Horvath, 2013) was used to calculate the DNA 
methylation age of individuals who had provided the blood, DLPFC and hippocampus 
samples. Results of the epigenetic clock method are displayed for blood (Table 74), 
DLPFC (Table 75) and hippocampus (Table 76).  
 
Sample ID Chronological 
age (Years) 
DNA methylation 
age (Years) 
Age acceleration 
difference (Years) 
Age acceleration 
residual 
20030067 80 79.00 -1.00 1.87 
20060127 83 70.21 -12.79 -8.62 
20040031 75 71.24 -3.76 -3.08 
20040044 78 73.72 -4.28 -2.29 
20080030 80 69.42 -10.58 -7.72 
20080048 78 87.06 9.06 11.05 
20060102 86 68.49 -17.51 -12.03 
20070044 80 71.69 -8.31 -5.45 
20090066 85 69.58 -15.42 -10.37 
20080043 77 64.46 -12.54 -10.99 
20030057 85 84.06 -0.94 4.11 
20060068 77 70.50 -6.50 -4.95 
20070008 86 83.14 -2.86 2.63 
20120048 78 91.93 13.93 15.92 
20080090 82 79.83 -2.17 1.57 
20060001 80 78.73 -1.27 1.59 
20110315 75 75.25 0.25 0.93 
20110694 83 85.50 2.50 6.67 
20080044 78 78.40 0.40 2.39 
20060092 90 85.02 -4.98 2.25 
20100307 86 82.99 -3.01 2.47 
20100709 83 83.81 0.81 4.99 
20040036 76 75.51 -0.49 0.63 
20090073 81 82.75 1.75 5.05 
20040032 86 90.56 4.56 10.04 
20070004 85 79.61 -5.39 -0.34 
20120082 85 73.48 -11.52 -6.47 
20070087 85 76.06 -8.94 -3.89 
20070057 92 85.93 -6.07 2.03 
Table 74: COGFAST blood DNA epigenetic clock data. For each sample, the chronological age of the 
blood at collection, DNA methylation predicted age, age acceleration difference (DNA methylation age 
minus chronological age) and the age acceleration residual is presented. 
 
Table 74 shows that the majority of samples (21/29) have a lower DNA methylation age 
than chronological age. Only eight samples have a chronological age that is younger 
than the DNA methylation age. The largest age acceleration difference (AAD) is -17.51 
years indicating that the DNA methylation age is 17.51 years younger than the 
chronological age. The AAR is however a more accurate way of looking at differences 
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in age, since this measure is the DNA methylation age accounted for chronological age. 
AARs in the blood of COGFAST participants range from -12.03 to 15.92. A paired t 
test revealed significant differences between predicted and actual age of the blood 
samples (F=2.850, p=0.008).  
 
Sample ID Chronological 
age (Years) 
DNA methylation 
age (Years) 
Age acceleration 
difference (Years) 
Age acceleration 
residual 
20030067 80 59.46 -20.54 -2.47 
20040031 76 54.84 -21.16 -6.69 
20040044 78 46.68 -31.32 -15.06 
20080030 84 66.48 -17.52 4.13 
20080048 82 73.67 -8.33 11.53 
20060102 89 68.44 -20.56 5.58 
20070044 84 62.05 -21.95 -0.30 
20090066 91 57.93 -33.07 -5.14 
20080043 82 65.99 -16.01 3.85 
20070008 93 73.45 -19.55 10.18 
20120048 88 71.90 -16.10 9.14 
20080090 88 62.55 -25.45 -0.21 
20110315 86 74.14 -11.86 11.59 
20110694 92 62.59 -29.41 -0.57 
20060092 94 71.36 -22.64 7.99 
20100307 94 66.40 -27.60 3.03 
20100709 93 62.42 -30.58 -0.85 
20040036 79 66.70 -12.30 4.87 
20090073 88 61.87 -26.13 -0.88 
20040032 88 64.08 -23.92 1.33 
20070004 92 45.60 -46.40 -17.56 
20120082 95 58.08 -36.92 -5.40 
20070087 90 48.94 -41.06 -14.03 
20070057 98 59.71 -38.29 -4.07 
Table 75: COGFAST DLPFC DNA epigenetic clock data. For each sample, the chronological age of the 
blood at collection, DNA methylation predicted age, age acceleration difference (DNA methylation age 
minus chronological age) and the age acceleration residual is presented. 
 
Table 75 shows that every DLPFC sample has a younger DNA methylation age than 
chronological age when looking at AAD. Differences range from -8.33 to -46.40 years. 
However, the AAR, which is the methylation age adjusted for chronological age, 
reveals that actually only 13/24 have a younger predicted age than actual age. The 
remaining eleven samples have an older predicted age than their actual age. A paired t 
test highlighted significant differences between predicted and actual age (F=12.71, 
p=6.96E-12). 
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Sample ID Chronological 
age (Years) 
DNA 
methylation age 
(Years) 
Age acceleration 
difference (Years) 
Age 
acceleration 
residual 
20030067 80 58.26 -21.74 -5.15 
20060127 86 62.25 -23.75 -6.51 
20040031 76 68.27 -7.73 8.42 
20040044 78 53.69 -24.31 -7.95 
20080030 84 58.68 -25.32 -8.30 
20060102 89 69.94 -19.06 -1.50 
20070044 84 64.42 -19.58 -2.56 
20090066 91 59.26 -31.74 -13.95 
20080043 82 61.73 -20.27 -3.47 
20030057 88 70.39 -17.61 -0.15 
20070008 93 75.15 -17.85 0.15 
20120048 88 91.11 3.11 20.57 
20080090 88 63.64 -24.36 -6.91 
20060001 84 61.53 -22.47 -5.45 
20110315 86 71.30 -14.70 2.53 
20110694 92 83.75 -8.25 9.64 
20030080 93 82.64 -10.36 7.65 
20080044 84 71.22 -12.78 4.24 
20060092 94 84.27 -9.73 8.38 
20100307 94 72.77 -21.23 -3.12 
20100709 93 70.47 -22.53 -4.53 
20040036 79 69.02 -9.98 6.50 
20090073 88 73.62 -14.38 3.07 
20040032 88 81.87 -6.13 11.33 
20070004 92 64.87 -27.13 -9.24 
20120082 95 71.11 -23.89 -5.67 
20070087 90 75.40 -14.60 3.08 
20070057 98 78.36 -19.64 -1.09 
Table 76: COGFAST hippocampal DNA epigenetic clock data. For each sample, the chronological age of 
the blood at collection, DNA methylation predicted age, age acceleration difference (DNA methylation 
age minus chronological age) and the age acceleration residual is presented. 
 
The AAD in Table 76 shows that only one of the 28 hippocampal samples has a DNA 
methylation age older than the chronological age. The AAR however, shows that when 
predicted age is adjusted for chronological age there is more variation between samples. 
AARs range from -9.24 to 20.56 indicating that some hippocampal samples do have a 
much older predicted age than their actual age. A paired t test showed that there were 
significant differences between predicted and actual age (F=12.05, p=2.26E-12).  
 
7.3.2 DNA methylation age of ICICLE participants 
The epigenetic clock method (Horvath, 2013) was used to predict the age of the blood 
samples. Results of the epigenetic clock method are displayed in Table 77. 
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Sample ID Chronological 
age (Years) 
DNA 
methylation age 
(Years) 
Age acceleration 
difference (Years) 
Age 
acceleration 
residual 
IN061 72.9 68.37 -4.53 0.56 
IN102 73.6 71.44 -2.16 3.08 
IN040 77.6 75.46 -2.14 3.98 
IN075 70.7 73.39 2.69 7.29 
IN107 76.3 73.07 -3.23 2.60 
IN042 78 74.13 -3.87 2.33 
IN127 74.5 67.53 -6.97 -1.53 
IN135 64.3 64.52 0.22 3.41 
IN039 67.9 63.74 -4.16 -0.17 
IN045 65.6 60.98 -4.62 -1.14 
IN121 63.6 59.19 -4.41 -1.37 
IN104 74.5 62.47 -12.03 -6.59 
IN091 77.8 55.39 -22.41 -16.24 
IN090 62.9 56.14 -6.76 -3.87 
IN081 61.2 52.60 -8.60 -6.09 
IN067 79.2 72.36 -6.84 -0.36 
IN055 61.8 56.39 -5.41 -2.76 
IN009 67.3 67.95 0.65 4.50 
IN108 68.5 63.92 -4.58 -0.46 
IN025 61.9 64.91 3.01 5.68 
IN074 64.2 61.23 -2.97 0.21 
IN003 76.3 77.42 1.12 6.95 
IN013 78.5 68.68 -9.82 -2.11 
IN089 65.4 64.17 -1.23 1.89 
IN080 62.1 55.23 -6.87 -4.91 
IN083 69.8 66.37 -3.43 1.23 
IN049 66.3 59.05 -7.25 -3.82 
IN072 49.6 59.63 10.03 7.62 
IN028 63.7 53.36 -10.34 -7.82 
IN112 67.1 66.46 -0.64 3.08 
IN058 69 61.89 -7.11 -2.73 
IN115 73.9 67.13 -6.77 -0.67 
IN001 69.2 68.87 -0.33 4.12 
IN140 75.8 77.82 2.02 8.79 
IN056 61.9 52.50 -9.40 -7.51 
IN051 67.4 63.98 -3.42 0.40 
IN094 75.5 72.50 -3.00 3.65 
IN086 70.2 61.71 -8.49 -3.69 
IN067 79.2 59.21 -19.99 -12.03 
IN035 61.9 60.33 -1.57 0.32 
IN046 67.6 63.26 -4.34 -0.44 
IN019 75.8 77.24 1.44 8.21 
IN012 77.3 74.63 -2.67 4.61 
IN124 66.2 64.61 -1.59 1.81 
Table 77: ICICLE blood DNA epigenetic clock data. For each sample, the chronological age of the blood 
at collection, DNA methylation predicted age, age acceleration difference (DNA methylation age minus 
chronological age) and the age acceleration residual is presented. 
 
The results for the ICICLE blood DNA (Table 77) are similar to those of the COGFAST 
blood DNA samples (Table 74) in that some samples have an older predicted age and 
some have a younger predicted age when compared to their actual chronological age. 
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The AARs (Table 77) show that just over half of all ICICLE blood DNA samples 
(23/44) have an older predicted age than actual age. A paired t test was used to show 
that predicted age does significantly differ from actual age (F=5.207, p=5.12E-06). 
 
7.3.3 Does the methylation age of the brain differ from the blood? 
The COGFAST cohort provides a unique opportunity to assess whether the brain tissue, 
following stroke, ages differently to the blood and whether a peripheral blood sample 
can be used as a surrogate to predict DNA methylation age of the brain.  
 
Figure 105 shows the DNA methylation age against the actual age of each of the 81 
samples (blood, DLPFC and hippocampal samples). This graph depicts the AAD and 
AAR for each sample.  
 
 
 
Figure 105: Scatter plot of DNA methylation age against chronological age for each of the three tissues 
analysed in COGFAST. Data points above the line of equality (orange) have a positive AAD indicating 
that their DNA methylation age is older than their actual age. The distance from the regression fitted line 
(grey) to each data point indicates the AAR. A positive AAR residual indicates a DNA methylation age 
above their actual age. 
 
Figure 105 shows that more blood samples have a positive AAR (and therefore older 
DNA methylation age than actual age) than DLPFC and hippocampus samples. A 
multilevel linear regression model was used to compare AAR across tissue types while 
accounting for non-independence of multiple measurements within individuals. There 
was no evidence for a difference in AAR between peripheral blood and either DLPFC 
(95% confidence interval for difference -2.79, 3.29; p=0.873) or hippocampus (95% 
confidence interval for difference -2.81, 3.20; p=0.898). No difference was observed 
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between the three tissue types indicating that; 1) the brain does not age differently to 
blood in the tissues and samples included in this analysis and 2) in this case, the blood 
can be used as a surrogate to predict DNA methylation age of brain tissue. This would 
be useful in future studies where blood samples were taken from living individuals.  
 
In addition, correlation analyses were performed to assess whether inter-individual 
variation in DNA methylation age was correlated across tissues. A moderate correlation 
was observed between the two brain regions tested (Rho=0.392, p=0.064). Methylation 
age was observed to be more strongly correlated between the hippocampus and blood 
(Rho=0.744, p=4.69E-05) than the DLPFC and blood (Rho=0.195, p=0.373). This 
indicates that the blood may be a better surrogate for the hippocampus than the DLPFC.   
 
7.3.4 Does an older methylation age increase the risk of developing cognitive 
decline? 
 
Post-stroke dementia 
Regression and ANOVA analyses were used to look for associations between blood-
derived AAR and the outcome variables (Section 7.2) measured in COGFAST. Since 
this Chapter is concerned with the effect of DNA methylation age, the AAR was used 
over AAD in the analysis. AAR was found to differ between sexes (t=2.39, p=0.024) 
with females showing a negative mean AAR (-2.85), indicating a lower than expected 
DNA methylation age whereas males had a positive mean AAR (+2.66), indicating a 
DNA methylation age older than their actual age. For this reason, sex was included in 
the model as a covariate.  
 
Figure 106 shows the correlation between predicted age and chronological age of the 
blood, coded for diagnosis (Dementia (D)/Cognitively Normal (CN)). A weak 
correlation (Rho=0.35, p=0.063) was observed between DNA methylation age and 
chronological age. When the correlation analysis was split by diagnosis, there was a 
strong correlation between predicted and chronological age in participants with 
dementia (Rho=0.727, p=0.001) and a weak negative correlation between predicted and 
chronological age in CN participants (Rho=-0.073, p=0.814). Figure 106 shows more 
CN samples have an older DNA methylation age than actual age (above the line of 
equality), however no significant difference in AAR was observed between stroke 
survivors with dementia and stroke survivors who remained cognitively normal prior to 
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death (F=2.45, p=0.130) (Figure 107). No associations were observed between AAR 
and any outcome variable measured, suggesting that in the blood of stroke survivors, the 
methylation age does not increase the risk of developing PSD.  
 
 
Figure 106: DNA methylation age against chronological age of the blood. Samples with dementia are 
coded D (black), cognitively normal samples are coded CN (red). Any samples above the line of equality 
have a DNA methylation age older than their actual age.  
 
 
Figure 107: Age acceleration residual of the blood by diagnosis of post-stroke dementia. 
 
To assess whether any exposures could explain the variances in AAR, ANOVA and 
regression analyses were performed to look for association between AAR and the 
exposure variables measured in COGFAST (Section 7.2). No associations reaching the 
Bonferroni corrected significance threshold were observed between AAR and any 
exposure. However, AAR was found to be associated with smoking status at the 
uncorrected significance threshold of p<0.05 (F=3.92, p=0.036). Figure 108 shows that 
ex-smokers have a positive AAR indicating a DNA methylation age above what would 
be predicted from their actual age, whereas current and never smokers have a negative 
AAR (DNA methylation age younger than actual age). This is not what would be 
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expected based on methylation data that suggests the methylation profiles of ex-smokers 
reverts back to that of never smokers over time (Zeilinger et al., 2013; Elliott et al., 
2014). Analysis by Elliott et al. (2014) and Zeilinger et al. (2013) used a subset of CpG 
sites sensitive to smoking, however the epigenetic clock method uses CpG sites which 
are very likely to behave differently. This would need to be tested in a much larger 
cohort before any conclusions can be drawn from this, as this finding may only be 
significant due to the small sample size used. A possible explanation for this seemingly 
strange finding could relate to reasons why participants stopped smoking. For example, 
the presence of any co-morbidities which affect the health of the participant may 
encourage this individual to quit smoking but may also result in changes to DNA 
methylation and the subsequent detection of accelerated ageing. No other significant 
associations were observed between AAR and exposure variables.  
 
 
Figure 108: Age acceleration residual of the blood by smoking status. Data bars with error bars are 
presented for current, ex and never smokers. A bar above the line at y=0 indicates a positive AAR. A bar 
below the line at y=0 indicates a negative AAR. 
 
The regression and ANOVA analyses were repeated in the DLPFC and hippocampus to 
look for associations between AAR of the brain and outcome variables (Section 7.2) 
and AAR and exposure variables (Section 7.2). Although sex wasn’t found to be 
associated with the AAR in the DLPFC (t=0.134, p=0.895) or hippocampus (t=1.287, 
p=0.198), sex was still included in the model as it was associated with AAR in blood.  
 
Figure 109 shows the correlation between DNA methylation age and actual age coded 
for diagnosis in the DLPFC (A) and hippocampus (B). No correlation was observed 
between DNA methylation and chronological age in the DLPFC (Rho = 0.076, p=0.72). 
When correlation analysis split by diagnosis was performed, a weak positive correlation 
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was observed in the CN participants (Rho=0.248, p=0.463) and a weak negative 
correlation between the predicted age and chronological age in the participants with 
dementia (Rho=-0.099, p=0.747). A moderate correlation was observed between DNA 
methylation age and chronological age in the hippocampus (Rho= 0.550 p=0.002). 
When correlation was split by diagnosis, a moderate correlation was observed between 
predicted and chronological age in both participants with dementia (Rho = 0.657, 
p=0.006) and CN participants (Rho=0.541, p=0.069). No difference in AAR was 
observed between demented and cognitively normal participants in either tissue 
(DLPFC: F=0.56, p=0.464; hippocampus: F=0.70, p=0.409) (Figure 110).  
 
AAR was not found to be associated with any outcome variable or any exposure 
variable in either the DLPFC or hippocampus. PM delay was not found to be associated 
with AAR in either tissue (DLPFC: t=0.36, p=0.720; hippocampus: t=-0.20, p=0.846). 
 
 
 
Figure 109: DNA methylation age against chronological age of the brain. A. DNA methylation age 
against chronological age in the DLPFC. B. DNA methylation age against chronological age in the 
hippocampus. Samples with dementia are coded D (black), cognitively normal samples are coded CN 
(red). Any samples above the line of equality have a DNA methylation age older than their actual age. 
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Figure 110: Age acceleration residual of the brain by diagnosis of post-stroke dementia. A. Age 
acceleration of the DLPFC. B. Age acceleration of the hippocampus.  
 
Parkinson’s disease 
The same approach was applied to test for associations between AAR and the outcome 
variables measured in ICICLE (Section 7.2). No sex differences in AAR were observed 
(t=0.47 p=0.642), however sex was still included in the model as a covariate.   
 
Figure 111 shows the correlation between DNA methylation age and actual age of the 
blood, coded for MCI diagnosis (MCI/NCI). A strong correlation was observed between 
DNA methylation age and chronological age (Rho = 0.660 p=1.10E-06). When 
correlation analysis was repeated, split by MCI diagnosis, there was a moderate 
correlation between predicted and actual age in the MCI participants (Rho=0.452, 
p=0.045) and there was a strong correlation between predicted and chronological age in 
the NCI participants (Rho=0.886, p= 2.02E-07). No difference in AAR was observed 
between PD-MCI and PD-NCI participants (F=0.55, p=0.462) (Figure 112).  
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Figure 111: DNA methylation age against chronological age of the blood. Samples with MCI are coded 
MCI (red), cognitively normal samples are coded NCI (black). Any samples above the line of equality 
have a DNA methylation age older than their actual age. 
 
 
Figure 112: Age acceleration residual of the blood by diagnosis of PD-MCI. 
 
AAR was not found to be associated with any cognitive outcome measured in ICICLE 
(Section 7.2), suggesting that the DNA methylation age of the blood does not affect the 
risk of developing cognitive deficits. AAR was found to be weakly correlated with 
MDS-UPDRS II (Rho= 0.310 p=0.041), a variable recording the self-evaluation of the 
activities of daily life, indicating that DNA methylation age of the blood may have some 
effect on basic motor ability (Figure 113). However, this did not reach the significance 
threshold after multiple test correction had been applied. No other association was 
observed between AAR and a motor outcome variable.  
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Figure 113: Correlation between AAR and MDS-UPDRS II coded for diagnosis of MCI. 
 
Similarly to the COGFAST analysis, to test whether any exposure could explain the 
variation in AAR, ANOVA and regression analyses were performed to investigate 
associations between AAR and exposures variables measured in ICICLE (Section 7.2).  
No associations were observed that reached the Bonferroni corrected significance 
threshold (0.003), however one association did reach p<0.05. A difference in AAR was 
observed between participants with diabetes and participants without (F=3.44, p=0.042) 
(Figure 114). Participants with diabetes had a positive AAR and therefore had an older 
DNA methylation age compared with their actual age. No other significant association 
was observed between AAR and an exposure variable.  
 
 
Figure 114: Age acceleration residual of the blood by diabetes. 
 
AAR was associated with both an exposure (diabetes) and an outcome (MDS-UPDRS 
II) at the p<0.05 significance threshold in ICICLE. It is possible that diabetes may cause 
differences in AAR which then affects motor outcome, however regression analysis 
revealed that diabetes is not associated with MDS-UPDRS II (t=-1.03, p=0.310) making 
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potential mediation by AAR unlikely. The relationship between AAR and MDS-
UPDRS II is therefore unaffected by the presence or absence of diabetes.  
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7.4 Discussion 
This Chapter aimed to identify the DNA methylation age of all samples used in the 
HM450 analyses of COGFAST and ICICLE and whether those participants with an 
older predicted age using methylation data than their actual age were more likely to 
develop cognitive decline.  
 
The results in this Chapter outline that there were differences between DNA 
methylation age and chronological age in the blood of ICICLE samples and in each 
tissue (blood, DLPFC and hippocampus) from COGFAST participants.  
 
In the PSD (COGFAST) samples, there were no strong associations observed between 
the age acceleration residual (AAR) and disease outcome in the blood or either brain 
region. Using the COGFAST samples there was an association, although it did not reach 
the stringent significance threshold following Bonferroni correction, between smoking 
status and AAR when regression was performed to look for association between 
exposures and AAR in the blood. Ex-smokers were seen to have an older DNA 
methylation age than chronological age whilst the current and never smokers had a 
younger DNA methylation age than actual age. These results are not seemingly 
biologically plausible due to the previously reported findings that the DNA methylation 
profiles of ex-smokers reverts back to that of a never smoker over time (Zeilinger et al., 
2013; Elliott et al., 2014). For this reason, it would be expected that ex-smokers and 
never smokers had a more similar AAR than current and never smokers. It is counter-
intuitive for ex-smokers to have a higher age than current and never smokers but the 
confidence intervals are very wide and therefore the age estimates are imprecise. 
However, to establish that these results are not just due to the small sample used in this 
analysis, this study would need to be replicated using a much larger cohort. A possible 
explanation for this finding is that the accelerated ageing observed in the ex-smokers is 
due to the presence of co-morbidities that caused them to stop smoking and also altered 
DNA methylation levels.  
 
In ICICLE, no associations were observed between any outcome or exposure and AAR 
following Bonferroni correction. However, a weak correlation was observed between 
AAR and the outcome variable MDS-UPDRS II, a self-reported evaluation of the 
activities of daily life (Rho=0.310, p=0.041). In addition, PD samples with diabetes 
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exhibited an older DNA methylation age compared with those participants without 
diabetes (F=3.44, p=0.042). However, no association was observed between diabetes 
and MDS-UPDRS II, indicating that they are unlikely to form part of a causal pathway.  
 
The major limitation of this Chapter, as has already been alluded to, is the small sample 
size used, which has limited the statistical power to detect differences in AAR between 
samples. In addition a relatively small range of ages was used in these studies therefore 
limiting the ability to detect larger differences in accelerated ageing.  
 
Since the method to predict the DNA methylation age of samples is a new technique, 
this is the first study (at the time of writing) that has attempted to look at the 
relationship between AAR and cognitive decline in a PSD and PD cohort. This 
technique has the ability to identify the risks of an older DNA methylation age, 
however, the sample sizes used in this current study were modest, with limited power to 
detect potential associations. It would be of interest to increase the sample size of the 
cohort used, to assess whether any associations, particularly those which reached the 
threshold of p<0.05, would be strengthened in a larger cohort. However, the lack of 
association between AAR and phenotype is not surprising. This has been the case in 
other studies which have used the epigenetic clock method or similar techniques to look 
at age-related DNA methylation and subsequent effects on phenotype (Bell et al., 2012; 
Boks et al., 2014). In a cohort of soldiers, trauma was associated with an accelerated 
ageing process. However, this accelerated ageing was not found to have an effect on 
phenotype, but rather a younger epigenetic age was associated with the development of 
post-traumatic stress disorder (Boks et al., 2014). This supports the findings of this 
Chapter and indicates that although there are differences in age acceleration, these may 
not necessarily have a subsequent effect on phenotype. Another study highlighted many 
age-related DNA methylation differences in twins however very few of these loci were 
found to be associated with an age-related phenotype, further supporting these findings 
(Bell et al., 2012).   
 
The COGFAST cohort provided a great opportunity to assess whether there were any 
differences in the DNA methylation age of tissues. No differences were observed 
between the blood and either brain region. This supports the findings of Horvath (2013) 
who reported that there were very few differences in DNA methylation age between 
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brain regions. It is interesting to note that in this case, blood does not show a different 
age acceleration to brain tissues, suggesting that blood could be used as a surrogate for 
assessing the predicted age of the brain in future studies. The use of an easily accessible 
tissue such as the blood would enable this method to be used in cohorts where brain 
tissue was not available. This would first require validation in a larger cohort with 
greater power to detect differences.  
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Chapter 8. Discussion 
 
8.1 Summary of aims and objectives 
This thesis addressed a total of 6 aims. Key observations and discussion relating to each 
of these aims are summarised below. 
 
8.1.1 To identify blood-based biomarkers of post-stroke dementia 
Due to the ageing population and a worsening of lifestyle factors such as a poor diet and 
sedentary lifestyle, the prevalence of stroke is increasing. A major consequence of 
stroke is that of post-stroke dementia (PSD). The mechanisms resulting in PSD are 
currently unknown and it is therefore unclear why some stroke survivors develop PSD 
whilst others remain with their cognition intact. Therefore, prognostic indicators that 
can help clinicians distinguish those stroke survivors most likely to develop PSD are 
required so that early preventative treatments can be implemented. DNA methylation 
has been identified as a valuable prognostic indicator in several cancers including 
medulloblastoma (Schwalbe et al., 2013), myelodysplastic syndromes (Shen et al., 
2010) and ovarian cancer (Wei et al., 2006). 
 
The aim of Chapter 3 was to identify blood-based biomarkers which could be used to 
predict stroke survivors at risk of developing post-stroke dementia. To address this aim 
the COGFAST cohort was utilised. This cohort consists of stroke survivors over the age 
of 75 years who regained full cognition three months post-stroke. A blood sample taken 
at recruitment onto the study (three months post-stroke) was used in the epigenetic 
analysis. The methylation profile of the baseline blood samples was analysed using the 
HM450 BeadChip, to look for differentially methylated positions associated with 
cognitive outcome at the time of death. A selection of the HM450 top hits were 
analysed across a wider sample of the same cohort using Pyrosequencing.  
 
These analyses identified two potential biomarkers; APOB and NGF, both of which 
have previously been implicated in cardiovascular (Gigante et al., 2012) and dementia 
related diseases (Zhang et al., 2013). Methylation at one CpG site within each of these 
genes was found to be significantly reduced in the individual with Braak stage VI 
pathology. Adjustment for cellular composition revealed that this difference in 
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methylation was not due to differences in cellular composition between samples. This 
difference in DNA methylation was not seen in AD patients with Braak stage VI 
pathology who had not suffered a stroke, indicating this difference may be caused by a 
combination of stroke and Braak stage VI pathology. Since only one COGFAST 
participant was diagnosed with Braak stage VI pathology, this differential methylation 
could however just be a sample issue. Based on this study, it is unclear whether this is a 
‘real’ (i.e. biologically meaningful) association and that all stroke patients with a Braak 
staging of VI would have a reduced methylation level at these CpG sites, or whether 
this methylation level is different in this individual to others. On further examination of 
the clinical background of this individual, it was found that this participant had had 
three recurrent strokes prior to the index stroke which saw the individual recruited onto 
the COGFAST study. This makes the individual unique and could explain why the 
methylation profile of this individual at these particular sites is different. It may be that 
this methylation difference is caused by recurrent strokes. This is explored further in 
Section 8.1.2. Alternatively, the observations, although validated using two 
complementary methods, could be a chance event peculiar to the individual concerned 
and be unrelated to dementia or stroke.  
 
Due to the small sample size of COGFAST, with limited numbers of participants with 
the more severe Braak staging pathology, this study requires repeating in a larger 
cohort, to assess whether the differential methylation seen here is in fact associated with 
the combination of stroke and Braak stage VI pathology, or whether it is associated with 
recurrent strokes or some other unidentified variable. If analysis in a larger cohort 
identified a significant association between DNA methylation at these CpG sites within 
APOB and NGF and Braak staging, they could be used as biomarkers to predict later 
cognitive deficits. However, given the threshold effect observed, i.e. the association was 
not linear between methylation and Braak staging but only occurred at the most severe 
end of the Braak stage spectrum, these markers would only be able to predict those at 
risk of developing the most severe dementia. These biomarkers would not be suitable 
for predicting the development of dementia in the majority of stroke survivors.  
 
In conclusion, two potential biomarkers were identified. Due to the small sample size, it 
is unclear whether the association between DNA methylation and Braak staging is a true 
association, or whether some other variable, such as recurrent strokes, is confounding 
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the identified relationship. Replication in a larger cohort is required to determine the 
cause of the differential methylation.   
 
8.1.2 To identify differentially methylated positions in the brain which are 
associated with impaired cognitive function in stroke patients 
As previously mentioned, the mechanisms resulting in PSD are currently unknown. 
Whilst a biomarker used in the prediction of disease does not need to be causally 
implicated and can therefore be measured in any suitable and readily accessible tissue, 
e.g. blood/saliva, the search for a mechanistic link must be undertaken in the affected 
tissue, in this case the brain. The aim of Chapter 4 was to identify differentially 
methylated positions associated with cognitive decline in the brain, to try to elucidate 
the mechanisms involved in the pathogenesis of PSD.  
 
To address this aim, brain samples (DLPFC and hippocampus) from the COGFAST 
cohort were utilised. The methylation profile of the brain samples were analysed using 
the HM450 BeadChip to look for differentially methylated positions associated with 
cognitive outcome and pathological markers at the time of death. A selection of the 
HM450 top hits were analysed across a wider cohort using Pyrosequencing.  
 
These analyses identified two methylation markers of interest; cg18837178 and NGF. 
NGF was also identified as a potential blood-based biomarker, and as discussed 
previously, has been associated with AD in the literature. cg18837178 is a CpG site 
within a non-coding RNA (CT49). Both cg18837178 and the CpG site within NGF had 
a reduced methylation level in the only Braak stage VI individual studied, compared 
with individuals with Braak stage V or below. Again, these differences were not due to 
cellular composition and were not identified in non-stroke Braak stage VI AD cases. 
These differences were again found to be unique to the COGFAST individual with 
Braak stage VI pathology and a history of recurrent strokes. These data were therefore 
inconclusive with respect to the role of NGF and CT49 in mechanistic pathways leading 
to PSD. NGF is known to play a role in the development and maintenance of neurons, 
both during early development and throughout adulthood (Aloe et al., 2012). This 
function relates to dementia and related cognitive decline, suggesting that NGF could be 
mechanistically involved in the pathogenesis of dementias. The biological function of 
CT49 is unknown.  
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To assess the possibility that DNA methylation may be involved in the mechanisms 
resulting in PSD, it was necessary to undertake some functional analyses. The quality of 
RNA was too poor to undertake gene expression analysis. For this reason, protein was 
extracted from brain tissue and Western blotting was performed to look for differences 
in NGF protein levels between samples from individuals of different Braak stages. As 
CT49 is a non-coding RNA, protein analysis was unable to be performed. 
Unfortunately, no brain tissue was available for the COGFAST participant with Braak 
stage VI pathology, so it remains unclear whether this differential methylation at NGF 
is translated at the protein level. There was no difference in NGF protein levels between 
non-stroke Braak stages, nor AD cases and controls. This does not support previous 
findings which have identified significant differences in NGF levels in the brains of AD 
patients compared to controls (Scott et al., 1995; Fahnestock et al., 1996; Mufson et al., 
2012b). Protein analysis in this case was unable (due to the omission of the individual 
with Braak stage VI pathology) to provide evidence for a mechanistic link between 
NGF methylation and the development of PSD.  
 
The methylation differences identified within NGF and at cg18837178 were unique to 
the Braak stage VI individual with a history of recurrent strokes. The finding that NGF 
methylation levels are reduced in a PSD case with a history of recurrent strokes is of 
particular interest. Although brain protein levels were not measured in this individual, it 
can be tentatively postulated that increased NGF protein levels would be observed due 
to the anticipated relationship of an inverse relationship between methylation and 
expression. As a stroke is known to promote angiogenesis, and angiogenesis requires 
growth factors (Krupinski et al., 1994; Font et al., 2010), it could be postulated that 
following a recurrent stroke, there is an increase in angiogenesis and therefore an 
increase in growth factor levels, although this has yet to be proven. This suggests that 
following a recurrent stroke there may be an increased level of NGF in the brain. Due to 
the biological plausibility of this scenario, if suitable tissue was sought, it would be very 
interesting to assess whether the NGF protein levels in a recurrent stroke patient were 
increased compared to stroke survivors who had experienced only one stroke.  
 
In conclusion, differential methylation at two CpG sites (NGF and cg18837178) was 
identified in post-stroke cases. At both CpG sites, Braak stage VI pathology was 
associated with a decreased methylation level. These sites could indicate involvement in 
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the mechanistic pathway resulting in the development of PSD. However, as with the 
analysis of the blood samples, the involvement of these CpG sites is limited to only the 
most severe cases. Alternatively, methylation at these CpG sites may be associated with 
the recurrent strokes experienced prior to recruitment into the COGFAST study. To 
elucidate whether recurrent strokes or the combination of stroke plus Braak stage VI 
pathology are contributing to this differential methylation, replication in a larger cohort 
with an increased number of samples with the most severe form of brain pathology is 
required. The detection of aberrant methylation in this individual was observed and 
validated in DNA extracted from peripheral blood (described in Chapter 3) and in DNA 
from brain tissue, which provides strong evidence that these observations were real and 
not artefactual. The consistent differences across different tissues seen at the NGF locus 
could plausibly be explained by underlying genetic variation. Some corrections were 
made for known common variants that underlie HM450 probes but this may not have 
accounted for all possible genetic variation which is located further away from the CpG 
site but still exerts an effect on methylation levels. No genotype information was 
available for the individual concerned to persue this potential explanation. Despite 
removing SNPs (as suggested by Illumina) from the data analysis and using a genome 
browser to check for the presence of a SNP in the list of top hits, further investigation 
into recent literature revealed that this CpG site was in fact a SNP (Naeem et al., 2014) 
which had not previously been detected during the data analysis phase of this project. 
This difference in DNA methylation observed at this CpG site is likely, therefore, to be 
due to genetic variation. This really underscores how fast the field of epigenetics is 
moving with this information being published in only the most recent literature and 
highlights the importance of regular literature searches.  
 
A recent study by Lunnon et al. (2014) identified a number of differentially methylated 
loci associated with Braak staging. However, none of the loci identified in my study 
were also identified by Lunnon et al. (2014). This may be due to COGFAST being a 
much smaller cohort and therefore lacking the power to detect these more subtle 
methylation differences. Alternatively, the differences in the loci identified in each of 
these studies could be due to the different phenotypes used. The study by Lunnon et al. 
(2014) used AD samples, whereas COGFAST is comprised of stroke patients. This 
theory is strengthened by the fact that the AD (non-stroke) cases used as controls in my 
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study did not show the same DNA methylation differences as the stroke patients, 
suggesting that a stroke may alter DNA methylation patterns at certain loci.   
 
8.1.3 To identify blood-based biomarkers of mild cognitive impairment in 
Parkinson’s disease 
Parkinson’s disease is predominantly known as a motor disorder (Saracchi et al., 2014), 
however it is thought that up to 80% of PD patients could also experience cognitive 
deficits in the form of mild cognitive impairment (PD-MCI) or the more severe 
Parkinson’s disease dementia (PDD) (Yarnall et al., 2013). As is the case with PSD, the 
mechanisms which result in PD-MCI and PDD are unknown. It is therefore difficult to 
develop treatments when the mechanisms which result in MCI are not well understood. 
Cognitive deficits usually precede any motor impairment (Saracchi et al., 2014) and so 
the ability to predict those likely to develop cognitive deficits would be highly 
beneficial in the administration of early preventative treatments. The aim of Chapter 5 
was to identify a blood-based biomarker which may be used in the prediction of newly 
diagnosed PD patients at increased risk of developing PD-MCI.  
 
To address this aim, the ICICLE cohort was utilised. This cohort consists of individuals 
with newly diagnosed idiopathic PD. A blood sample taken at recruitment was used in 
the epigenetic analysis undertaken in Chapter 5 of this thesis. The methylation profile of 
the baseline blood samples was analysed using the HM450 BeadChip, to look for 
differentially methylated positions associated with cognitive (and motor) outcome at the 
18 month follow up. A selection of the HM450 top hits were analysed across a wider 
cohort using Pyrosequencing.  
 
These analyses identified one potential biomarker, CHCHD5, a gene whose function is 
unclear, but is thought to perform a role in the mitochondrial membrane space. 
Methylation at one CpG site within the CHCHD5 gene was found to be significantly 
reduced in the PD cases with a higher score on the naming test, a test that specifically 
evaluates the participant’s ability to name pictured animals. Adjustment for cellular 
composition revealed that this difference in methylation was not due to differences in 
cellular composition between samples. These results suggest that the CpG site within 
CHCHD5 could be a potential biomarker of PD-MCI. DNA methylation levels were 
also measured at this locus in healthy controls. No association between naming score 
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and DNA methylation were observed in healthy controls, suggesting that this 
differential methylation is unique to PD cases. This suggests that differences in 
methylation associated with naming in the PD cases may be associated with another 
factor, in addition to, or independently of, naming score. This may be an unmeasured 
confounder unrelated to cognition. The accuracy of the naming test also needs to be 
considered. The naming test was scored out of 3, and all participants, both cases and 
controls, had a score of either 2 or 3. This suggests that there is not much variation 
between participants, so the differential methylation observed at the CHCHD5 locus 
may not be effective in discerning subtle shifts in cognition. The validity of this 
biomarker as a predictor of later cognition is therefore uncertain and sensitivity and 
specificity analyses are warranted using more granular measures of cognition.  
 
In addition to looking for biomarkers of PD-MCI, the methylation data were also used 
to look for biomarkers of motor impairment. No significant associations between DNA 
methylation and motor outcome were able to be validated.  
 
In conclusion, only one potential biomarker for PD-MCI was identified. Methylation at 
CHCHD5 was found to be lower in participants with a higher (better) score on the 
naming test. This association was only true in PD cases. There was no association 
between methylation of CHCHD5 and naming score in healthy controls. This 
association observed between CHCHD5 methylation and naming could be true, but it is 
also possible that there could be some other confounder, possibly relating to cognition 
which has an effect on the methylation level in PD cases. It would be interesting to 
perform functional analyses in a PD cohort to assess whether CHCHD5 could be acting 
on a mechanistic pathway leading to PD-MCI. For this, the brains of PD cases would 
need to be used.  
 
8.1.4 To assess whether DNA methylation can mediate the relationship between 
exposure and outcome 
Both PSD and PD are thought to be caused by a combination of genetic, epigenetic and 
environmental factors. A number of environmental factors have been identified in the 
literature as outlined in Chapter 6. One of the aims of this Chapter was to assess 
whether any exposures or risk factors were associated with outcome in the cohorts 
(COGFAST and ICICLE) used throughout this thesis. It was also of interest to assess 
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whether any of these associations were mediated by DNA methylation. Very few 
associations were identified between an exposure/risk factor and outcome variable in 
both cohorts, however many of the effect estimates were in the right direction, even 
though p values did not attain statistical significance. This may be due to the small 
sample sizes of both cohorts and therefore a lack of power. In the ICICLE cohort, 
methylation at nine CpG sites was associated with both smoking status (exposure) and 
language score (outcome), however there was no evidence that the presence or absence 
of smoking changes the effect of methylation on language at any CpG site, that is, there 
is no support for a mediating role of DNA methylation in this instance. In COGFAST, 
no CpG site was identified that was associated with both an exposure and outcome 
variable. In both the PSD and PD cohorts utilised in this thesis, methylation was not 
found to interact with any exposure to affect outcome. It may be that DNA methylation 
is not involved in the pathway linking any of the measured exposures with outcome. 
However, it may be a power issue and elucidating this relationship would benefit from 
repeating this analysis in a larger cohort. 
 
8.1.5 To assess whether DNA methylation can be used as an indicator of exposure 
status 
There is evidence to suggest that blood DNA methylation levels could be a useful 
indicator of exposure status (Shenker et al., 2013; Elliott et al., 2014). This is 
particularly useful for exposures which are frequently under-reported, difficult to 
accurately measure or simply unavailable. If DNA methylation was found to accurately 
predict exposure level, rather than relying on self-reported data that could be 
confounded by recall or reporting bias, DNA methylation could be used to predict the 
exposure level. DNA methylation has previously been identified as an indicator of 
smoking status and can be used to distinguish between smokers and  never smokers 
(Elliott et al 2014) and never and former smokers (Shenker et al., 2013). One of the 
aims of Chapter 6 was to assess whether DNA methylation could be used to predict 
exposure level in one of the cohorts used in this thesis.  
 
Using the method outlined by Elliott et al. (2014), a methylation score was predicted for 
each ICICLE sample and a threshold score was used to distinguish between current and 
never smokers. The data presented in this Chapter show that DNA methylation can be 
used to successfully predict smoking status, with current smokers exhibiting a different 
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methylation profile to never and ex-smokers. This finding supports previous research 
which suggests that over time, the methylation profiles of ex-smokers reverts back to 
that of never smokers (Zeilinger et al., 2013; Elliott et al., 2014). 
 
In conclusion, DNA methylation was used to distinguish between current smokers and 
ex/never smokers in the ICICLE cohort. The ability to predict smoking status using 
DNA methylation data is a very valuable resource with high clinical utility due to 
smoking-associated reporting bias. The success of this approach in predicting smoking 
exposure suggests that it would also be useful in the prediction of other exposure levels 
that are prone to the same reporting bias’ and inaccurate methods of measurement. 
Using a larger sample set to enable samples to be split into a training and testing set 
would allow more exposures, such as homocysteine, to be assessed in this way.   
 
8.1.6 To assess whether age predicted from DNA methylation can identify 
individuals at risk of cognitive decline 
Epigenetic factors are thought to affect the ageing process with growing evidence of 
differential methylation observed in elderly subjects (Fraga et al., 2005; Talens et al., 
2012) and the suggestion that DNA damage can accelerate the ageing process (Campisi 
and Vijg, 2009). Due to these temporal associations and the tissue-specific nature of 
DNA methylation, it has been suggested that DNA methylation could be used to predict 
the age of specific tissues and cell types (Horvath, 2013). The aim of Chapter 7 was to 
predict the age of tissues using DNA methylation data and assess whether this predicted 
age could determine individuals at greatest risk of cognitive decline. It was also of 
interest to assess whether any exposure variables were associated with predicted age of 
tissues and discordance between predicted and actual age. 
 
To address these aims, blood and brain samples (DLPFC and hippocampus) from the 
COGFAST cohort and blood samples from the ICICLE cohort were utilised. The 
methylation profile of each sample was analysed using the HM450 BeadChip and the 
epigenetic clock method (Horvath, 2013) was used to predict the age of each sample. 
Differences were observed between the chronological age and predicted age of the 
sample and an age acceleration residual (AAR) (DNA methylation age adjusted for 
chronological age) was calculated for each sample. Regression analyses were then 
performed to look for association between AAR and outcome variables, and AAR and 
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exposure variables. In neither cohort, nor tissue, was there any association reaching the 
Bonferroni corrected significance threshold identified. A number of other associations 
significant at the uncorrected significance threshold of p<0.05 were identified however. 
In the ICICLE cohort, a weak association was observed between AAR and MDS-
UPDRS III (Rho=-0.131, p=0.041), suggesting that a lower methylation age was 
associated with a more severe motor phenotype and between AAR and diabetes 
(F=3.44, p=0.042), suggesting that a higher methylation age was associated with an 
increased risk of diabetes. In the COGFAST cohort, the blood AAR was not associated 
with any outcome variable but was found to be associated with smoking status (F=3.92, 
p=0.036), indicating that individuals who smoke have a higher methylation age. No 
associations were observed between AAR and any exposure or outcome variable in the 
brain samples.  
 
The COGFAST cohort provided an excellent opportunity to assess whether the blood 
could act as a surrogate to predict DNA methylation age of the brain. No differences 
were observed between the three tissue types (blood, DLPFC, hippocampus) indicating 
that; 1) the brain does not age differently to blood in the tissues and samples included in 
this analysis and 2) in this case, the blood can be used as a surrogate to predict DNA 
methylation age of brain tissue. This could be useful in future studies where blood 
samples were taken from living individuals. The observation that the blood and brain 
have similar methylation profiles is in agreement with previous reports (Davies et al., 
2012; Oh et al., 2014), however here a methylation score is used representing 353 CpG 
sites.  
 
In conclusion, the predicted age of samples did significantly differ from the 
chronological age of samples in both cohorts. However, no associations were observed 
between AAR and any exposure or outcome, indicating that in these cohorts, the AAR 
is not hugely influenced by exposures, nor is the AAR itself influencing disease 
outcome. The lack of association between AAR and exposure/outcome variables may 
indicate that the predicted age of samples based on DNA methylation levels (which 
could be interpreted as a form of biological ageing) is not involved in these disease 
pathways. Repetition of this study in a larger cohort could help to clarify this.  
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The main strength of this aim was that the COGFAST cohort enabled the relationship 
between AAR across the different tissues to be assessed. The results showed that the 
DNA methylation profile of the blood did not differ from either brain region. This 
suggests that the blood could therefore be used as a surrogate for brain tissue in studies 
analysing DNA methylation age. This would enable current cohorts, with living 
participants, to predict the DNA methylation age of the brain, without the need to wait 
until brain samples became available and would enable more cohorts to be involved in 
the analysis of DNA methylation age.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
306 
 
 
 
8.2 Strengths of the study 
Biomarkers are being increasingly used to aid both the prediction and prognosis of a 
number of diseases including cardiovascular disease (Kim et al., 2010) and cancer 
(Schwalbe et al., 2013), but to date there are no published studies that have assessed 
blood-based biomarkers to aid the prediction of stroke survivors at risk of developing 
PSD. In addition, there have been no published studies with the aim of identifying 
biomarkers of PD-MCI. The two main aims of this thesis; the identification of 
biomarkers for PSD and PD-MCI are therefore addressing novel areas of epigenetic 
research. This thesis highlighted two potential biomarkers which may be useful in the 
prediction of PSD and one potential biomarker for the prediction of PD-MCI. These 
novel findings could, if robustly replicated, greatly benefit public health care services in 
the administration of preventative treatments and care.  
 
A key strength of this study was the inclusion of brain tissue to assess possible 
mechanisms involved in the development of PSD. Post-mortem studies are still 
relatively uncommon, due to the difficulty in obtaining such samples, as are paired 
blood and post-mortem brain tissue from the same individuals. The latter allowed 
valuable comparisons to be made between different tissue types. Although there have 
been questions highlighted over the quality of post-mortem tissue and the different 
storage conditions that may be experienced (Ferrer et al., 2008; Pidsley and Mill, 2011), 
this study identified no associations between DNA methylation at any CpG site 
included on the HM450 BeadChip and PM delay.  
 
In addition to the novelty of this study, it was also strengthened by the addition of 
controls in both cohorts. The addition of blood and brain samples taken from non-stroke 
cases with dementia highlighted that DNA methylation differences were unique to 
COGFAST samples. There were no differences in DNA methylation across Braak 
stages in non-stroke cases with dementia in either brain tissue or blood detectable using 
the methods I applied. Similarly, the addition of healthy controls in the ICICLE cohort 
allowed for the discovery that DNA methylation was associated with naming score in 
PD cases alone.  
 
This study also attempted to investigate, not only DNA methylation differences between 
samples, but also extended this to functional analyses. Although the quality of RNA was 
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not suitable for gene expression analyses due to the long-term storage of the post-
mortem tissue and resultant degradation of RNA, protein extracted from both brain 
regions was used for Western blotting. This was an important feature of the study 
required to assess possible mechanisms involved in the pathogenesis of PSD. Although 
no differences in NGF protein levels were observed across brain samples with a range 
of Braak staging, this may be due to the small sample number used and the lack of 
availability of protein from the COGFAST Braak stage VI sample.  
 
A further strength of this study was the consideration of cellular composition which is 
recognised as a possible confounder in epigenetic studies. Due to the heterogeneous 
nature of both blood and brain tissue, it is possible that any differences  in DNA 
methylation observed between outcome groups is due to the cellular composition of the 
blood and brain. Adjusting the methylation beta values for cellular composition enabled 
any effect of cellular composition on DNA methylation to be identified. In the blood 
samples, very little effect of cellular composition was identified. In the brain samples, 
cellular composition was seen to have a greater effect on DNA methylation than in the 
blood, however these effects were, for the most part, very small. Other confounders 
known to affect DNA methylation profiles (sex and age) were also accounted for in the 
analysis.  
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8.3 Limitations of the study 
The key limitation of this study was the small sample sizes used, particularly that of the 
COGFAST cohort. Sample size is an issue affecting many EWAS due to the expense of 
performing such a study (Rakyan et al., 2011; Michels et al., 2013). In a recent review 
by Michels et al. (2013) which summarised 257 EWAS, 90 of these were identified to 
utilise 30 or less samples (i.e. were of the same or smaller size than the COGFAST 
samples used in the HM450 BeadChip), and 143 of these included 48 or less samples 
(i.e. were of the same or smaller size than the ICICLE samples used in the HM450 
BeadChip) (Michels et al., 2013).   
 
As discussed in Chapters 3 and 4, the finding that Braak staging was associated with 
DNA methylation at certain loci was driven by DNA methylation levels in one 
individual. With the small sample size of COGFAST, it is impossible to tell whether 
this is a true biological association and a common finding in all stroke survivors with 
Braak stage VI pathology, or whether this single individual with Braak stage VI 
pathology phenotypically differs from the other COGFAST participants in some other 
way. One possible difference is the discovery that this individual had actually 
experienced recurrent strokes prior to recruitment. This could have affected the 
methylation level, as hypothesised in Chapter 4, or this could just be something inherent 
to that individual and DNA methylation differences may not be related to stroke plus 
Braak stage VI pathology or recurrent strokes. To elucidate which possible theory is 
correct, this study requires replication in a much larger cohort.    
 
Due to there being only one COGFAST participant with Braak stage VI pathology, 
there was limited availability of this brain tissue. There was no tissue available from this 
individual for the protein analysis. The omission of this sample from the Western 
blotting prevented the relationship between NGF methylation and NGF protein levels to 
be deduced in this individual. It was therefore impossible to conclude whether NGF 
could have a mechanistic (or causal) role in the pathogenesis of PSD based upon the 
evidence at my disposal.  
 
Another limitation of the study was that information relating to subsequent strokes 
experienced after recruitment into COGFAST was not available. The study design of 
COGFAST did not allow for recurrent strokes occurring after the index stroke to be 
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recorded. Consequently, it is possible that a number of participants had multiple strokes 
once they were recruited onto the study. These unknown strokes may have influenced 
both DNA methylation levels and cognition recorded after baseline measures were 
taken. For example, it is possible that those participants who developed dementia 
following the index stroke had experienced additional strokes thereby making them 
more susceptible to cognitive decline. This information would be vital for assessing the 
effect of multiple strokes on cognition.  
 
In Chapter 6, the small sample size of ICICLE also limited which exposure variables 
could be used to test the utility of DNA methylation as an exposure indicator. 
Homocysteine and smoking were identified as suitable candidate variables. Due to there 
not being an independent homocysteine reference data set and the size of the ICICLE 
cohort being too small to split the sample set into two, it was deemed neither ideal nor 
reliable to use DNA methylation data to predict homocysteine levels. If the sample size 
of ICICLE had been larger, it would have been possible to split the cohort into two and 
use one half as a training set and the other as a testing set. In this circumstance it would 
have been possible to use DNA methylation to try to better predict homocysteine levels. 
As an alternative, DNA methylation was used to predict smoking status which, although 
had already been done and therefore this Chapter did not add anything novel to current 
findings, it does support previous research and suggests that DNA methylation data can 
be used to predict smoking status in a PD cohort, and its predictive utility is 
unconfounded by disease status.  
 
Another limitation of the study concerned the reliability of some of the outcome 
variables measured in ICICLE. In Chapter 5, DNA methylation at a CpG site within the 
CHCHD5 gene was found to be associated with naming score in PD participants. The 
naming test was scored out of three. All participants scored either 2 or 3 points 
suggesting that either the test is not sensitive enough to detect large differences in 
naming ability, or that the participants’ ability did not differ greatly. This means that if 
the association between CHCHD5 methylation and naming was successfully replicated 
in an independent cohort, the biomarker would only be clinically useful at predicting 
specific differences in cognition. Due to no other associations being identified between 
CHCHD5 methylation and cognition, it is unlikely that the biomarker would be able to 
predict other cognitive deficits affecting PD patients.  
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Top HM450 hits were selected if they had an effect size greater than 5%, were not SNPs 
and if suitable primers for Pyrosequencing could be designed using the PSQ assay 
design software. There is some evidence that the Pyrosequencer cannot reliably measure 
differences of less than 5% (Mikeska et al., 2011), hence an effect size cut off of 5% 
was implemented. This may have removed potential biomarkers of cognitive decline. 
Other hits which were not amenable to Pyrosequencing, such as those where suitable 
primers could not be designed, were also removed. These could however be potential 
biomarkers, but they were not considered in this analysis. These CpG sites were 
removed from the selection because they were not suitable for Pyrosequencing analysis. 
Another selection criterion was whether HM450 hits had previously been associated 
with differential expression in AD/PD. CpG sites were only taken forward if there was 
an inverse relationship between methylation and gene expression. This inverse 
relationship is expected in promoter regions, but it is less clear if this relationship is 
found in other regions of the gene. For this reason, potential biomarkers may have been 
removed from consideration because they did not show the typical inverse relationship. 
To widen the search for a potential biomarker, it may have been more suitable to 
increase the selection, to include all CpG sites which were within a gene previously 
shown to be differentially expressed in AD/PD. Furthermore, assays targeting potential 
biomarkers may have also been omitted from further consideration based on their failure 
to optimise or failure to validate on the Pyrosequencer. These failures do not make them 
unsuitable biomarkers. These assays may be better suited to analysis using an 
alternative platform, as suggested above. In Chapter 5 of this thesis, another approach 
was adopted to target assays which had failed to be optimised. Predesigned Pyromark 
assays (Qiagen, UK) were used for five of these assays, however these assays did not 
target the index CpG site and unsurprisingly, DNA methylation measured using these 
assays did not show any associations with outcome variables of interest.  
 
Finally, cellular composition analysis was undertaken to assess whether observed 
differences in DNA methylation, were in fact, due to cellular composition. This analysis 
does strengthen the study, however the technique used does come with some 
limitations. Blood samples were adjusted for cellular composition using the algorithm 
described by Houseman et al. (2012) and the brain samples were adjusted for cellular 
composition using the CETS package (Guintivano et al., 2013). Both of these methods 
use algorithms to estimate the proportions of cellular components in the samples. The 
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cellular components of blood estimated using this technique are B cells, granulocytes, 
monocytes, NK cells, and T cells subsets and the proportions of neurons and glia are 
estimated in the brain samples. This is an estimation of cell counts and is therefore not 
entirely accurate and is susceptible to some error. The only way to accurately calculate 
the cellular proportions of each sample is to measure the proportion of each cellular 
component in each sample itself. In the blood, FACS could be performed to count the 
number of each cellular component and in the brain, laser capture microdissection 
(LCM) could be performed to separate neurons from glia. DNA methylation analysis 
would then be performed on each cell type to assess whether the DNA methylation 
profiles of samples differ due to cellular composition. Both techniques would be more 
time-consuming and would require considerably larger amounts of initial sample than 
using the estimation technique. However, the estimation techniques, although imperfect, 
are deemed suitable for use in many circumstances due to their high accuracy and time 
and sample limitations of other, more accurate methods.     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
312 
 
 
 
8.4 Future work 
There are a number of steps which could be taken to further the research performed in 
this thesis. Possible next steps are explored below.  
 
As previously alluded to, this study requires replication in a larger cohort. The size of 
COGFAST, in particular, was too small to be able to determine whether the association 
between DNA methylation and Braak staging was true, or whether the differences in 
DNA methylation were associated with some other factor, such as recurrent stroke. 
Adding more samples, particularly those with the most severe Braak staging pathology, 
into the analysis would help to determine the reason for this association. COGFAST is 
still an ongoing living cohort with brain samples still to be collected. This, together with 
associated brain pathology data may increase the number of both blood and brain 
samples with an associated Braak stage VI pathology. Once all COGFAST brain 
samples are collected it would be of interest to repeat the analysis performed here to 
assess whether the increase in sample number provides a more robust detection of DNA 
methylation differences. Future work could also focus on exploring other reasons for 
this large difference in DNA methylation such as recurrent strokes. Including more 
recurrent stroke samples into the study would help to elucidate the cause of this large 
methylation difference. Another possible explanation, and possibly the most likely 
explanation for the large differences in DNA methylation observed in this project, is 
that of genetics. The study by Naeem et al. (2014) considers the NGF locus to be a 
SNP. Genotyping data were not available for this individual so the only means of 
obtaining conclusive evidence for this would be by way of sequencing.   
 
A power calculation was performed to estimate the number of samples required to 
detect significant DNA methylation differences between groups. Based on the 
difference in blood NGF DNA methylation (the loci with the smallest difference in 
DNA methylation between groups) observed (14%) between Braak stage VI and the 
other Braak stages (I-V) with a power of 99.9% and alpha=0.05, I would require only 
one additional Braak stage VI sample to significantly detect these methylation 
differences, assuming that the difference in methylation observed in this individual is 
due to Braak stage pathology. This may be feasible within the COGFAST cohort.  
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In addition, there is scope for the ICICLE cohort to include brain samples for each 
participant. DNA methylation analysis of the blood, as was used in this thesis, enables 
us to look for biomarkers which may predict those participants most at risk of 
developing PD-MCI, but cannot be informative about mechanisms resulting in disease. 
The addition of brain samples into this cohort would enable the involvement of DNA 
methylation in the mechanisms resulting in PD-MCI to be assessed.  
 
To be accepted as a clinically useful biomarker, any potential biomarkers would need to 
be analysed, and findings robustly replicated in a large independent cohort. 
 
This study could also be expanded by using less rigorous selection criteria for top 
HM450 hits. Potential biomarkers may have been lost in the locus prioritisation process 
used in this thesis. SNPs were removed from the top HM450 hits due to Pyrosequencing 
not being the most ideal method of looking at SNPs. However, these SNPs may be 
useful biomarkers of either PSD or PD. It would be interesting to extend the work 
performed in this thesis and take forward the SNPs highlighted as being associated with 
disease for further analysis. All SNPs associated with outcome in this thesis were 
searched in the NHGRI GWAS Catalog (www.genome.gov/gwastudies), but none of 
these SNPs had previously been associated with PSD, PD or any related disease. This 
thesis may have identified novel SNPS so it would be of interest to follow up each of 
the SNPs identified here to assess whether any are potential risk factors for disease.  
 
In addition to SNPs being removed, hits which had previously been found to be 
differentially expressed in disease were removed from the selection if they did not 
display an inverse relationship between DNA methylation and gene expression. As 
previously discussed, this relationship is only expected at promoter regions, so this 
selection criterion could have removed some potential biomarkers. If enough time and 
funds were available it would be interesting to assess each of these hits, regardless of 
the directionality to widen the pool of potential biomarkers.  
 
Furthermore, HM450 hits were removed from the selection if suitable primers with a 
score >70 on the PSQ assay design software could not be designated. As this does not 
necessarily make them unsuitable biomarkers, these hits could be analysed using an 
alternative platform such as Sequenom EpiTYPER (Ehrich et al., 2005) or bisulphite 
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sequencing (Herman et al., 1996). In addition, these techniques could also be applied to 
those assays which failed optimisation and validation.  
 
In Chapter 4, Western blotting was used to assess the functional relevance of the 
differential methylation observed at the NGF locus. Due to the extracted RNA being too 
degraded for gene expression analysis, protein analysis was performed. The Western 
blotting technique used is able to assess levels of protein and this can then be linked 
with DNA methylation levels, however, this technique does not inform about causality 
and the direction of effect. Other approaches, such as a cell culture approach, could be 
taken to assess the directionality. Cells could be cultured in the presence of 5-
azacytidine in order to cause genome-wide demethylation (Enright et al., 2003). The 
expression of the target gene could be assessed at a transcript level using quantitative 
PCR (Yang et al., 2002) and at a protein level using Western blotting (Palii et al., 
2008). This would determine whether the expression of the gene in question is affected 
by DNA methylation. The link between transcription and translation for the target gene 
could be assessed through the use of small interfering RNAs (siRNA) which would 
transiently knock down the level of gene transcript. Conversely, expression vectors 
could be used to drive the expression of the gene of interest (Alekseev et al., 2009). The 
subsequent effects on protein level could then be assessed by Western blotting. In 
addition, since CT49 is a non-coding RNA, and only protein samples were available for 
the COGFAST cohort, functional analyses were not undertaken, however, it would be 
interesting to assess CT49 further to determine whether CT49 could provide a 
mechanistic link between DNA methylation and PSD. This could be assessed firstly by 
quantifying expression levels using quantitative PCR. If an association between DNA 
methylation and expression was established in these cases, a functional study could be 
performed. The biological function of CT49 is currently unknown, however it is thought 
that many long non-coding RNAs have a functional role (Mercer et al., 2009; Dinger et 
al., 2009), for example, in the regulation of gene-specific transcriptional regulation 
(Goodrich and Kugel, 2006). After driving the expression of CT49 using an expression 
construct, an expression array could be utilised to determine which genes, if any, are 
regulated by CT49. These targets could then be followed up to determine their role in 
PSD.   
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A common problem with EWAS is that the majority are cross-sectional studies 
(Michels et al., 2013), with reverse causation being a possible problem. Therefore, a 
cross-sectional study, which is focussed on one time point cannot be used to infer 
causality (Relton and Davey Smith, 2010; Mill and Heijmans, 2013). To assess 
causality, multiple time points using the same tissue are required, or at least can be 
helpful in establishing temporal relationships (Ng et al., 2012). In diseases affecting the 
brain this is impossible, since the brain is only accessible post-mortem. This study tried 
to overcome this by assessing the DNA methylation profiles of the blood prior to 
disease onset; however these methylation differences may reflect tissue-specificity 
rather than temporal differences and in this case cannot be used to strengthen causality. 
A method recently developed to overcome the problem with inferring causality in a 
cross-sectional study is that of two-step Mendelian randomisation (Relton and Davey 
Smith, 2012). Firstly, a SNP is used as a genetic proxy for the environmentally 
modifiable exposure which is investigated in regards to DNA methylation. This is used 
to determine whether the exposure causes DNA methylation. Secondly, an additional 
SNP is used as a proxy for DNA methylation levels to assess the relationship (and 
causality) between the methylation site of interest and disease phenotype or outcome 
(Relton and Davey Smith, 2012). In this study, the main aim was to identify potential 
biomarkers of PSD and PD. In this circumstance, disease causality was not of high 
priority as a biomarker does not need to be involved in disease aetiology in order to be a 
robust and sensitive biomarker for disease.  
 
This thesis aimed to identify DMPs associated with disease. This approach identified 
single CpG sites which are associated with disease and was unable to inform about 
DNA methylation at neighbouring CpG sites. An alternative approach would be to look 
at differentially methylation regions (DMRs). DMRs are genomic regions in which 
correlated groups of CpG sites show differential methylation. The identification of 
DMRs, as opposed to DMPs, is considered to reduce the risk of false positives and 
technical artefacts. A DMR is thought to be more likely to have a biological role than a 
DMP, as neighbouring CpG sites also demonstrate differential methylation. HM450 
data can be analysed in such a way that DMRs are identified rather than DMPs using 
methods such as bump hunting (Jaffe et al., 2012).  
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Another way of reducing the risk of false positives is to target the search to only those 
within genes previously found to be associated with disease. Both hits identified as 
being associated with Braak staging in Chapter 3 had previously been associated with 
PSD related disorders. Had this strategy been applied, these hits would have still been 
identified; however this approach would obviously have limited the ability to identify 
novel biomarkers and novel genes associated with disease mechanisms. A candidate 
gene approach could be used in order to reduce the burden of multiple testing and to 
keep the number of hits to validate low.  
 
8.5 Conclusion 
In conclusion, this study identified possible biomarkers of both PSD and PD, however 
both studies were limited by sample size. Care must therefore be taken in the 
interpretation of the findings and further replication is of crucial importance.  
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Appendix A: Pyrosequencing dispensation sequences 
 
Cohort Assay Dispensation Order 
COGFAST CISD1 CATCGATATATCAGATCATCGATAC 
COGFAST cg21463981 TGTCGTAG  
COGFAST LIMK2 CTACAGACAC 
COGFAST HSPB3 TATCGATAGATGATGAGTGATCGTTATTAGAGTTGATC
GAT 
COGFAST EIF4E3 ATCGTTATAG 
COGFAST cg02490189 TATCGTTAGTCGTATGTCGTGATCGTAGTAGTCGTT 
COGFAST APOB GTCGATAGTCGAT 
COGFAST C17orf101 GATGTCGTATGTCGTAGTTATGTCGAGGTATCAGTCGT
GTTGATCGTG 
COGFAST cg18837178 TCGACATACGACTC 
COGFAST cg01063243 ATATCAGATACCAGATCAGATATATCAGATATATCAG
ATATATCAGATCAGACATATCAGACATCGACTC 
COGFAST NGF ATCTGTCGTATTCGTGATTCGTG 
COGFAST cg12010173 CGACATCTCTCAACATATTACACACACATATAATCATC
AGATCGATATACTACGACAC 
ICICLE PROCA1 ATCGATGT 
ICICLE CHCHD5 AGTCTGTCAGTCGTG 
ICICLE TRIM15 ATCTGTCGAGA 
ICICLE C7orf50* GTCGATATGGTCTAGTGGTCGTAGAGTGAGTATCG 
ICICLE C16orf45* TGTTCGAGTCGCTCAGATCGTGAGTGTTGTGAGTCG 
ICICLE PGS1* GTCGTGATCGTAGTCTATGAGATTGTCGTCG 
ICICLE RUNDC3A* GTCGTTCGTCATCGATGTGTAGAGTCG 
ICICLE MOGAT1* GTCGTATCAGTATGATGATCGTCGTCGTGTAGATCG 
* indicates a pre-designed assay (Qiagen, UK). 
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Appendix B: Western blots 
 
Gels 1 and 2=DLPFC samples. Gels 3 and 4=Hippocampal samples. F=pooled DLPFC 
standard. H=pooled hippocampal standard. NGF=27kDA, α-tubulin=55kDA. 
 
Sample Number Diagnosis Sex Age at death Braak staging 
1 SC F 83 1 
2 SD F 80 1 
3 SC M 83 2 
4 SD M 83 2 
5 SC M 84 3 
6 SD M 84 3 
7 SC F 83 4 
8 SD F 84 4 
9 SC M 88 5 
10 SD M 84 5 
11 DS M 92 6 
12 DS M 90 6 
13 DS F 86 6 
14 DS F 89 6 
15 DS M 80 5 
16 DS F 83 5 
17 CA M 87 2 
18 CA F 89 2 
19 CA M 83 2 
20 CA F 87 3 
21 CA F 88 3 
22 CA M 91 2 
SC=COGFAST cognitively normal, SD=COGFAST demented, DS=Alzheimer’s non-
stroke, CA=healthy control. F=female, M=male. 
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Appendix C: Associations between exposures and outcome 
 
PSD 
Associations for stroke-related and lifestyle variables with outcome. P values in red 
show a significant association. * = Kruskal Wallis, † = chi squared, ‡ = Wilcoxon rank 
sum, §= t test, ¶ = Spearman’s rank 
 Stroke-related variables Lifestyle factors 
Outcome 
Variable 
OCSP 
class 
Side of 
body 
Degree of 
weakness 
arm 
Degree of 
weakness 
leg 
Dysphasia Smoking Alcohol 
 
Diagnosis 
1.903 
0.610† 
0.283 
0.868† 
0.081 
0.947† 
0.346 
0.841† 
0.251 
0.616† 
2.343 
0.307† 
-1.034 
0.301‡ 
 
Braak staging 
9.579 
0.699† 
11.99 
0.348† 
8.631 
0.343† 
5.406 
0.727† 
2.531 
0.693† 
8.490 
0.207† 
7.397 
0.116* 
 
MMSE 
3.176 
0.365* 
0.133 
0.936* 
0.473 
0.789* 
2.955 
0.228* 
0.121 
0.728‡ 
0.730 
0.694* 
0.093 
0.262¶ 
 
Orientation 
3.178 
0.365* 
3.139 
0.208* 
0.095 
0.954* 
1.465 
0.481* 
0.270 
0.6033‡ 
0.847 
0.655* 
0.083 
0.326¶ 
Language 
comprehension 
2.288 
0.515* 
1.437 
0.488* 
0.645 
0.724* 
4.604 
0.100* 
2.302 
0.129‡ 
0.824 
0.662* 
0.088 
0.301¶ 
Language 
expression 
0.898 
0.826* 
0.517 
0.772* 
0.765 
0.682* 
0.413 
0.814* 
0.250 
0.803‡ 
0.361 
0.835* 
-0.035 
0.682¶ 
Memory remote 0.820 
0.845* 
4.397 
0.111* 
1.004 
0.605* 
1.036 
0.596* 
1.298 
0.194‡ 
4.716 
0.095* 
0.083 
0.326¶ 
 
Memory recent 
3.887 
0.274* 
0.593 
0.743* 
1.575 
0.455* 
1.428 
0.490* 
0.264 
0.794‡ 
1.975 
0.373* 
0.064 
0.451¶ 
Memory 
learning 
2.703 
0.440* 
3.261 
0.196* 
0.769 
0.681* 
2.798 
0.247* 
-1.208 
0.227‡ 
1.346 
0.510* 
0.015 
0.863¶ 
 
Memory total 
1.267 
0.737* 
0.578 
0.749* 
2.932 
0.231* 
2.954 
0.228* 
-0.579 
0.563‡ 
1.199 
0.549* 
0.072 
0.396¶ 
 
Attention 
6.874 
0.076* 
0.757 
0.685* 
1.244 
0.537* 
2.879 
0.237* 
-0.241 
0.809‡ 
3.794 
0.150* 
0.090 
0.288¶ 
 
Praxis 
5.915 
0.116* 
0.555 
0.758* 
3.843 
0.146* 
4.467 
0.107* 
-0.645 
0.519‡ 
0.324 
0.850* 
-0.029 
0.735¶ 
 
Calculation 
5.360 
0.147* 
0.267 
0.875* 
0.788 
0.674* 
1.311 
0.519* 
0.938 
0.348‡ 
5.255 
0.072* 
-0.001 
0.992¶ 
Abstract 
thinking 
2.684 
0.443* 
0.338 
0.845* 
1.033 
0.597* 
3.123 
0.210* 
1.187 
0.235‡ 
0.445 
0.801* 
0.076 
0.368¶ 
 
Perception 
3.972 
0.265* 
1.597 
0.450* 
0.278 
0.870* 
1.258 
0.533* 
-1.798 
0.072‡ 
3.945 
0.139* 
0.140 
0.097¶ 
Executive  
function 
4.506 
0.212* 
0.633 
0.729* 
1.268 
0.530* 
2.954 
0.228* 
-0.579 
0.563§ 
1.199 
0.549* 
0.072 
0.396¶ 
 
Total CAMCOG 
4.104 
0.250* 
0.555 
0.758* 
0.304 
0.859* 
3.395 
0.183* 
-0.400 
0.689‡ 
1.491 
0.474* 
0.112 
0.184¶ 
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Associations for medical history related variables with outcome. P values in red show a 
significant association. * = Kruskal Wallis, † = chi squared, ‡ = Wilcoxon rank sum, §= t 
test, ¶ = Spearman’s rank 
Outcome 
Variable 
HT AF IHD/Angina Cardiac 
failure 
IC No of 
CVD 
risk 
factors 
 
Diagnosis 
0.366 
0.545† 
1.919 
0.239† 
0.838 
0.360† 
0.340 
0.560† 
1.065 
0.390† 
-0.736 
0.462‡ 
 
Braak staging 
1.251 
0.890† 
4.555 
0.330† 
2.569 
0.743† 
3.524 
0.469† 
8.077 
0.169† 
2.733 
0.603* 
 
MMSE 
1.438 
0.150‡ 
-1.133 
0.257‡ 
-0.002 
0.998‡ 
-1.145 
0.248‡ 
-1.263 
0.207‡ 
-0.030 
0.716¶ 
 
Orientation 
0.894 
0.371‡ 
-0.848 
0.396‡ 
0.301 
0.764‡ 
-0.965 
0.335‡ 
-1.891 
0.059‡ 
-0.014 
0.868¶ 
Language  
comprehension 
0.174 
0.862‡ 
0.919 
0.358‡ 
-1.256 
0.209‡ 
-1.596 
0.111‡ 
-0.621 
0.535‡ 
0.040 
0.637¶ 
Language 
expression 
0.751 
0.452‡ 
-0.365 
0.715‡ 
0.761 
0.447‡ 
0.859 
0.391‡ 
-1.427 
0.154‡ 
0.003 
0.971¶ 
Memory remote 1.711 
0.087‡ 
-0.538 
0.590‡ 
0.007 
0.995‡ 
0.189 
0.850‡ 
-2.763 
0.006‡ 
0.011 
0.893¶ 
 
Memory recent 
0.998 
0.318‡ 
-0.690 
0.491‡ 
-1.145 
0.252‡ 
-1.322 
0.186‡ 
-1.461 
0.144‡ 
0.070 
0.406¶ 
Memory 
learning 
0.283 
0.777‡ 
-1.738 
0.082‡ 
1.874 
0.061‡ 
0.205 
0.838‡ 
-0.207 
0.836‡ 
-0.016 
0.854¶ 
 
Memory total 
1.109 
0.267‡ 
-1.661 
0.097‡ 
1.364 
0.172‡ 
0.037 
0.970‡ 
-1.288 
0.198‡ 
0.001 
0.995¶ 
 
Attention 
1.037 
0.300‡ 
-0.455 
0.649‡ 
0.553 
0.580‡ 
-0.249 
0.804‡ 
-1.382 
0.167‡ 
0.004 
0.966¶ 
 
Praxis 
1.919 
0.055‡ 
-1.131 
0.258‡ 
0.425 
0.671‡ 
0.451 
0.652‡ 
0.754 
0.451‡ 
-0.143 
0.090¶ 
 
Calculation 
0.166 
0.868‡ 
0.081 
0.935‡ 
0.305 
0.760‡ 
1.038 
0.299‡ 
-0.188 
0.851‡ 
0.003 
0.972¶ 
Abstract 
thinking 
0.503 
0.615‡ 
-0.674 
0.500‡ 
1.021 
0.307‡ 
0.156 
0.876‡ 
-1.957 
0.051‡ 
0.014 
0.090¶ 
 
Perception 
0.560 
0.575‡ 
-0.377 
0.706‡ 
-0.572 
0.567‡ 
0.194 
0.847‡ 
-1.050 
0.294‡ 
0.014 
0.866¶ 
Executive 
function 
0.703 
0.483§ 
-0.096 
0.924‡ 
0.941 
0.348§ 
-0.288 
0.773‡ 
-2.515 
0.013§ 
0.046 
0.589¶ 
 
Total CAMCOG 
1.768 
0.077‡ 
-1.065 
0.287‡ 
0.590 
0.555‡ 
0.194 
0.847‡ 
-1.050 
0.294‡ 
0.099 
0.241¶ 
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Associations for baseline cognition variables with outcome part 1. P values in red 
indicate an association where p<0.05. * = Kruskal Wallis, † = chi squared, ‡ = Wilcoxon 
rank sum, §= t test, ¶ = Spearman’s rank. B=baseline. Lang comp = language 
comprehension 
 
Outcome 
Variable 
B MMSE B lang comp B 
language 
expression 
B 
memory 
remote 
B 
memory 
recent 
B 
memory 
learning 
B 
memory 
total 
 
Diagnosis 
4.528 
0.0003§ 
3.661 
0.002§ 
3.555 
0.001§ 
2.282 
0.023‡ 
2.418 
0.016‡ 
2.539 
0.011‡ 
0.352 
0.002§ 
 
Braak 
staging 
5.643 
0.343* 
7.743 
0.171* 
8.319 
0.140* 
5.358 
0.374* 
11.90 
0.036* 
11.60 
0.041* 
8.626 
0.125* 
 
MMSE 
0.776 
7.77E-07¶ 
0.614 
0.0004¶ 
0.605 
0.001¶ 
0.471 
0.010¶ 
0.473 
0.010¶ 
0.518 
0.004¶ 
0.606 
0.001¶ 
 
Orientation 
0.674 
0.0001¶ 
0.593 
0.001¶ 
0.520 
0.004¶ 
0.360 
0.055¶ 
0.556 
0.002¶ 
0.451 
0.014¶ 
0.534 
0.003¶ 
Lang comp 0.666 
0.0001¶ 
0.397 
0.033¶ 
0.434 
0.019¶ 
0.241 
0.208¶ 
0.410 
0.027¶ 
0.406 
0.029¶ 
0.449 
0.015¶ 
Language 
expression 
0.698 
2.54E-05¶ 
0.657 
0.0001¶ 
0.689 
3.64E-05¶ 
0.273 
0.152¶ 
0.536 
0.003¶ 
0.505 
0.005¶ 
0.576 
0.001¶ 
Memory 
remote 
0.508 
0.005¶ 
0.576 
0.001¶ 
0.241 
0.208¶ 
0.650 
0.0001¶ 
0.402 
0.031¶ 
0.367 
0.050¶ 
0.461 
0.012¶ 
Memory 
recent 
0.479 
0.009¶ 
0.457 
0.013¶ 
0.120 
0.537¶ 
0.385 
0.039¶ 
0.449 
0.015¶ 
0.387 
0.038¶ 
0.437 
0.018¶ 
Memory 
learning 
0.771 
1.01E-06¶ 
0.577 
0.001¶ 
0.418 
0.024¶ 
0.509 
0.005¶ 
0.592 
0.001¶ 
0.563 
0.002¶ 
0.642 
0.0002¶ 
 
Memory 
total 
0.735 
5.62E-06¶ 
0.574 
0.001¶ 
0.524 
0.004¶ 
0.681 
4.72E-
05¶ 
0.601 
0.001¶ 
0.503 
0.006¶ 
0.626 
0.0003¶ 
 
Attention 
0.695 
2.88E-05¶ 
0.592 
0.001¶ 
0.651 
0.0001¶ 
0.340 
0.071¶ 
0.280 
0.141¶ 
0.440 
0.017¶ 
0.510 
0.005¶ 
 
Praxis 
0.827 
3.14E-08¶ 
0.402 
0.031¶ 
0.578 
0.001¶ 
0.323 
0.087¶ 
0.339 
0.072¶ 
0.290 
0.127¶ 
0.376 
0.045¶ 
 
Calculation 
0.370 
0.048¶ 
0.539 
0.003¶ 
0.304 
0.110¶ 
0.347 
0.065¶ 
0.496 
0.006¶ 
0.202 
0.293¶ 
0.304 
0.109¶ 
Abstract 
thinking 
0.328 
0.083¶ 
0.166 
0.388¶ 
0.211 
0.273¶ 
0.217 
0.258¶ 
0.366 
0.051¶ 
0.257 
0.178¶ 
0.331 
0.080¶ 
 
Perception 
0.640 
0.0002¶ 
0.476 
0.009¶ 
0.376 
0.044¶ 
0.324 
0.087¶ 
0.623 
0.0003¶ 
0.398 
0.032¶ 
0.484 
0.008¶ 
Executive  
function 
0.586 
0.001¶ 
0.407 
0.028¶ 
0.529 
0.003¶ 
0.268 
0.159¶ 
0.442 
0.016¶ 
0.331 
0.079¶ 
0.430 
0.020¶ 
Total 
CAMCOG 
0.807 
1.28E-07¶ 
0.601 
0.001¶ 
0.580 
0.001¶ 
0.446 
0.015¶ 
0.565 
0.001¶ 
0.532 
0.003¶ 
0.624 
0.0003¶ 
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Associations for baseline cognition variables with outcome part 2. P values in red 
indicate an association where p<0.05. * = Kruskal Wallis, † = chi squared, ‡ = Wilcoxon 
rank sum, §= t test, ¶ = Spearman’s rank. B=baseline. Lang=language. 
Comp=comprehension. Orient=Orientation. Calc=calculation. Perc=perception 
 
Outcome 
Variable 
B 
Orient 
B 
Attention 
B 
Praxis 
B 
Calc 
B 
Abstract 
Thinking 
B Perc B 
Executive 
Function 
B Total 
CAMCOG 
score 
 
Diagnosis 
3.024 
0.003‡ 
3.320 
0.001‡ 
2.490 
0.013‡ 
1.904 
0.057‡ 
0.817 
0.421§ 
3.145 
0.0004§ 
1.280 
0.211§ 
5.066 
0.0001§ 
 
Braak 
staging 
7.213 
0.205* 
6.428 
0.267* 
7.827 
0.166* 
2.858 
0.722* 
1.493 
0.914* 
2.444 
0.785* 
3.383 
0.641* 
5.252 
0.386* 
 
MMSE 
0.732 
6.40E-
06¶ 
0.456 
0.013¶ 
0.475 
0.009¶ 
0.475 
0.009¶ 
0.211 
0.271¶ 
0.502 
0.006¶ 
0.425 
0.022¶ 
0.766 
1.31E-06¶ 
 
Orient 
0.597 
0.001¶ 
0.469 
0.010¶ 
0.351 
0.062¶ 
0.469 
0.010¶ 
0.234 
0.223¶ 
0.571 
0.001¶ 
0.408 
0.028¶ 
0.703 
2.10E-05¶ 
Lang 
comp 
0.560 
0.002¶ 
0.478 
0.009¶ 
0.638 
0.0002¶ 
0.565 
0.001¶ 
0.172 
0.371¶ 
0.366 
0.051¶ 
0.355 
0.059¶ 
0.606 
0.001¶ 
Lang 
expression 
0.661 
0.0001¶ 
0.360 
0.055¶ 
0.406 
0.029¶ 
0.539 
0.003¶ 
0.274 
0.150¶ 
0.554 
0.002¶ 
0.446 
0.015¶ 
0.765 
1.35E-06¶ 
Memory 
remote 
0.482 
0.008¶ 
0.206 
0.285¶ 
0.177 
0.358¶ 
0.175 
0.003¶ 
0.073 
0.708¶ 
0.136 
0.483¶ 
0.075 
0.698¶ 
0.386 
0.039¶ 
Memory 
recent 
0.489 
0.007¶ 
0.412 
0.026¶ 
0.039 
0.840¶ 
0.210 
0.275¶ 
-0.066 
0.734¶ 
0.213 
0.267¶ 
0.077 
0.691¶ 
0.387 
0.038¶ 
Memory 
learning 
0.675 
0.0001¶ 
0.577 
0.001¶ 
0.293 
0.123¶ 
0.433 
0.019¶ 
0.156 
0.420¶ 
0.501 
0.005¶ 
0.239 
0.211¶ 
0.702 
2.23E-05¶ 
Memory 
total 
0.726 
8.36E-
06¶ 
0.457 
0.013¶ 
0.394 
0.034¶ 
0.409 
0.028¶ 
0.196 
0.309¶ 
0.500 
0.006¶ 
0.298 
0.116¶ 
0.726 
8.14E-06¶ 
 
Attention 
0.705 
1.99E-
05¶ 
0.455 
0.013¶ 
0.448 
0.015¶ 
0.500 
0.006¶ 
0.057 
0.770¶ 
0.348 
0.064¶ 
0.282 
0.140¶ 
0.675 
0.0001¶ 
 
Praxis 
0.570 
0.001¶ 
0.585 
0.001¶ 
0.643 
0.0002¶ 
0.541 
0.002¶ 
0.125 
0.519¶ 
0.511 
0.005¶ 
0.300 
0.114¶ 
0.686 
3.98E-05¶ 
 
Calc 
0.352 
0.061¶ 
0.317 
0.094¶ 
0.203 
0.292¶ 
0.488 
0.007¶ 
0.195 
0.310¶ 
0.249 
0.194¶ 
0.363 
0.053¶ 
0.410 
0.027¶ 
Abstract 
thinking 
0.169 
0.381¶ 
0.047 
0.811¶ 
0.234 
0.222¶ 
0.179 
0.354¶ 
0.338 
0.073¶ 
0.336 
0.074¶ 
0.350 
0.062¶ 
0.395 
0.034¶ 
 
Perc 
0.563 
0.002¶ 
0.488 
0.007¶ 
0.397 
0.033¶ 
0.518 
0.004¶ 
0.313 
0.098¶ 
0.671 
0.0001¶ 
0.397 
0.033¶ 
0.638 
0.0002¶ 
Executive  
function 
0.462 
0.012¶ 
0.387 
0.038¶ 
0.483 
0.008¶ 
0.443 
0.016¶ 
0.327 
0.084¶ 
0.511 
0.005¶ 
0.453 
0.014¶ 
0.659 
0.0001¶ 
Total 
CAMCOG 
0.672 
0.0001¶ 
0.514 
0.004¶ 
0.456 
0.013¶ 
0.484 
0.008¶ 
0.235 
0.220¶ 
0.588 
0.001¶ 
0.404 
0.030¶ 
0.080 
2.63E-07¶ 
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PD 
Associations for lifestyle and anthropometric variables with motor outcomes. Test 
statistics and p values in red indicate an association where p<0.05. * = Kruskal Wallis, † 
= chi squared, ‡ = Wilcoxon rank sum, §= t test, ¶ = Spearman’s rank 
Outcome variable Education NART Alcohol Smoking Height Weight BMI 
 
Hoehn and Yahr 
7.348 
0.062* 
1.890 
0.596* 
3.017 
0.389* 
2.921 
0.842† 
4.273 
0.206* 
5.083 
0.166* 
2.734 
0.434* 
 
MDS-UPDRS II 
-0.146 
0.0968¶ 
-0.102 
0.250¶ 
-0.176 
0.058¶ 
1.092 
0.579* 
0.088 
0.321¶ 
0.133 
0.130¶ 
0.068 
0.440¶ 
 
MDS-UPDRS III 
-0.255 
0.003¶ 
-0.149 
0.092¶ 
-0.087 
0.352¶ 
2.451 
0.264* 
0.052 
0.556¶ 
0.038 
0.665¶ 
-0.002 
0.985¶ 
 
Tremor dominant 
phenotype 
-0.194 
0.027¶ 
-0.072 
0.419¶ 
-0.114 
0.223¶ 
0.064 
0.969* 
0.037 
0.677¶ 
0.031 
0.725¶ 
0.046 
0.603¶ 
 
PIGD phenotype 
-0.271 
0.002¶ 
-0.118 
0.183¶ 
-0.126 
0.174¶ 
2.779 
0.249* 
-0.034 
0.702¶ 
0.001 
0.993¶ 
0.014 
0.877¶ 
 
 
 
Associations for medical history variables with motor outcomes. Test statistics and p 
values in red indicate an association where p<0.05. * = Kruskal Wallis, † = chi squared, 
‡ = Wilcoxon rank sum, §= t test, ¶ = Spearman’s rank Homocys=homocysteine.  
Outcome 
variable 
RCF B12 Homocys IHD DM HT HC GDS LD 
Hoehn and 
Yahr 
15.00 
0.002* 
4.060 
0.255* 
9.928 
0.019* 
11.41 
0.033† 
5.852 
0.085† 
1.593 
0.697† 
2.388 
0.449† 
17.61 
0.001* 
2.919 
0.404* 
MDS-
UPDRS II  
0.037 
0.693¶ 
-0.004 
0.970¶ 
0.174 
0.061¶ 
-1.421 
0.158§ 
-0.388 
0.708§ 
-0.647 
0.519§ 
0.335 
0.738 
0.632 
2.13E-14¶ 
0.182 
0.050¶ 
MDS-
UPDRS III 
-0.071 
0.450¶ 
-0.215 
0.020¶ 
0.182 
0.049¶ 
-1.778 
0.078§ 
-1.512 
0.131§ 
-2.778 
0.006‡ 
-2.034 
0.044§ 
0.459 
1.97E-07¶ 
0.056 
0.548¶ 
Tremor 
dominant 
phenotype 
-0.006 
0.948¶ 
0.041 
0.663¶ 
0.033 
0.728¶ 
-1.143 
0.255§ 
-0.639 
0.524§ 
-1.456 
0.150§ 
-1.612 
0.109§ 
0.086 
0.357¶ 
-0.147 
0.114¶ 
PIGD 
phenotype 
0.016 
0.867¶ 
-0.086 
0.359¶ 
0.236 
0.011¶ 
-3.011 
0.003‡ 
-1.304 
0.192‡ 
-1.926 
0.054‡ 
-0.176 
0.860‡ 
0.553 
1.06E-10¶ 
0.096 
0.301¶ 
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Associations for lifestyle and anthropometric variables with cognitive outcomes. Test 
statistics and p values in red indicate an association where p<0.05. * = Kruskal Wallis, † 
= chi squared, ‡ = Wilcoxon rank sum, §= t test, ¶ = Spearman’s rank. 
Conc=concentration. Dig vig accuracy = digit vigilance accuracy. 
Outcome 
variable 
Education NART Alcohol Smoking Height Weight BMI 
MoCA total 0.336 0.0001¶ 
0.369 
1.60E-05¶ 
0.177 
0.050¶ 
5.708 
0.058* 
0.023 
0.795¶ 
0.028 
0.751¶ 
0.045 
0.615¶ 
MMSE total 0.338 0.0001¶ 
0.379 
8.88E-06¶ 
0.174 
0.055¶ 
2.951 
0.229* 
0.038 
0.667¶ 
-0.066 
0.457¶ 
-0.056 
0.527¶ 
Total FAS 0.426 4.25E-07¶ 
0.459 
3.87E-08¶ 
0.059 
0.519¶ 
0.020 
0.990* 
-0.048 
0.586¶ 
-0.068 
0.442¶ 
-0.039 
0.664¶ 
Animals 0.392 3.92E-06¶ 
0.274 
0.002¶ 
0.035 
0.698¶ 
6.181 
0.046* 
0.009 
0.916¶ 
0.084 
0.342¶ 
0.126 
0.154¶ 
NMSQ 
memory 
1.309 
0.191‡ 
0.536 
0.592‡ 
0.899 
0.369‡ 
4.392 
0.111† 
-0.396 
0.692‡ 
0.352 
0.725§ 
0.603 
0.548§ 
NMSQ conc -0.603 
0.547‡ 
1.056 
0.291‡ 
-0.641 
0.522‡ 
1.097 
0.503† 
-1.732 
0.083‡ 
-1.305 
0.194§ 
-0.198 
0.844§ 
Power of 
attention 
-0.201 
0.022¶ 
-0.320 
0.0002¶ 
-0.120 
0.199¶ 
2.799 
0.247* 
-0.026 
0.773¶ 
0.018 
0.837¶ 
0.024 
0.790¶ 
Dig vig 
accuracy 
0.386 
5.59E-06¶ 
0.320 
0.0002¶ 
0.044 
0.641¶ 
2.316 
0.314* 
-0.120 
0.173¶ 
-0.1124 
0.203¶ 
-0.032 
0.716¶ 
PRM  0.419 
7.23E-07¶ 
0.401 
2.21E-06¶ 
0.271 
0.003¶ 
6.841 
0.033* 
0.085 
0.339¶ 
0.042 
0.631¶ 
0.003 
0.970¶ 
PAL  
 
-0.316 
0.0002¶ 
-0.361 
2.49E-05¶ 
-0.153 
0.099¶ 
9.383 
0.009* 
-0.028 
0.752¶ 
-0.088 
0.317¶ 
-0.089 
0.314¶ 
SRM  0.232 
0.008¶ 
0.284 
0.001¶ 
0.158 
0.089¶ 
3.277 
0.194* 
0.050 
0.570¶ 
-0.043 
0.631¶ 
-0.024 
0.896¶ 
OTS  0.284 
0.001¶ 
0.236 
0.007¶ 
0.238 
0.010¶ 
2.777 
0.250* 
0.093 
0.295¶ 
0.124 
0.159¶ 
0.094 
0.288¶ 
Pentagon 
copying 
0.216 
0.014¶ 
0.276 
0.002¶ 
0.152 
0.102¶ 
0.706 
0.703* 
0.120 
0.175¶ 
0.017 
0.857¶ 
-0.012 
0.893¶ 
 
Naming 
0.293 
0.001¶ 
0.225 
0.010¶ 
0.182 
0.050¶ 
0.392 
0.822* 
0.103 
0.242¶ 
0.096 
0.279¶ 
0.038 
0.671¶ 
 
Language 
0.135 
0.127¶ 
0.278 
0.001¶ 
0.233 
0.011¶ 
6.170 
0.046* 
-0.005 
0.955¶ 
-0.026 
0.769¶ 
-0.018 
0.837¶ 
Language 
total 
0.215 
0.014¶ 
0.327 
0.0001¶ 
0.260 
0.005¶ 
4.791 
0.091* 
0.053 
0.547¶ 
0.030 
0.733¶ 
0.013 
0.881¶ 
Cognitive 
complaint 
1.615 
0.106‡ 
1.335 
0.182‡ 
0.098 
0.922‡ 
1.645 
0.47† 
-1.027 
0.305‡ 
-0.540 
0.590§ 
0.188 
0.851§ 
 
MCI 
3.358 
0.001‡ 
4.283 
1.84E-05‡ 
2.169 
0.030 
3.469 
0.209† 
0.332 
0.741§ 
0.828 
0.409§ 
0.793 
0.429§ 
TOTAL 
number NMS 
-0.145 
0.109¶ 
-0.076 
0.401¶ 
-0.070 
0.440¶ 
0.716 
0.699* 
0.186 
0.039¶ 
0.046 
0.610¶ 
-0.061 
0.498¶ 
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Associations for medical history variables with cognitive outcomes. Test statistics and p 
values in red indicate an association where p<0.05. * = Kruskal Wallis, † = chi squared, 
‡ = Wilcoxon rank sum, §= t test, ¶ = Spearman’s rank. Conc=concentration. 
Homocys=homocysteine. LD=Levodopa dose. Dig vig accuracy = digit vigilance 
accuracy. 
Outcome 
variable 
RCF B12 Homocys IHD DM HT HC GDS LD 
 
MoCA 
total 
-0.086 
0.346¶ 
0.104 
0.254¶ 
-0.134 
0.139¶ 
2.351 
0.019‡ 
2.086 
0.037‡ 
2.206 
0.027‡ 
1.330 
0.183‡ 
-0.253 
0.005¶ 
0.040 
0.661¶ 
 
MMSE 
total 
-0.065 
0.475¶ 
-0.003 
0.971¶ 
-0.093 
0.304¶ 
1.376 
0.169‡ 
1.194 
0.233‡ 
3.782 
0.0002‡ 
1.098 
0.272‡ 
-0.265 
0.003¶ 
0.010 
0.911¶ 
 
Total FAS 
-0.057 
0.530¶ 
0.199 
0.027¶ 
-0.161 
0.075¶ 
2.483 
0.013‡ 
1.803 
0.071‡ 
2.298 
0.022‡ 
0.085 
0.932‡ 
-0.265 
0.003¶ 
0.009 
0.923¶ 
 
Animals 
0.050 
0.586¶ 
0.035 
0.698¶ 
-0.153 
0.092¶ 
2.041 
0.049§ 
1.303 
0.195§ 
2.007 
0.047§ 
1.103 
0.272§ 
-0.301 
0.001¶ 
0.030 
0.740¶ 
NMSQ 
memory 
2.254 
0.024‡ 
0.129 
0.897‡ 
-1.707 
0.088‡ 
0.874 
0.350† 
1.962 
0.297† 
0.241 
0.624† 
0.006 
0.941† 
-3.184 
0.002‡ 
-1.158 
0.002‡ 
NMSQ 
conc 
0.283 
0.777‡ 
-0.774 
0.439‡ 
-0.134 
0.894‡ 
0.054 
0.816† 
0.230 
0.632† 
0.678 
0.410† 
0.158 
0.778† 
-3.301 
0.001‡ 
-3.301 
0.001§ 
Power of 
attention 
0.197 
0.034¶ 
-0.155 
0.096¶ 
-0.025 
0.788¶ 
-1.308 
0.191‡ 
-1.064 
0.287‡ 
-1.097 
0.273‡ 
-1.687 
0.092‡ 
-0.076 
0.419¶ 
0.228 
0.014¶ 
Dig vig 
accuracy 
-0.121 
0.194¶ 
0.241 
0.009¶ 
-0.116 
0.215¶ 
0.033 
0.973‡ 
0.796 
0.426‡ 
0.967 
0.334‡ 
1.241 
0.215‡ 
-0.031 
0.740¶ 
-0.267 
0.004¶ 
PRM -0.024 
0.796¶ 
0.147 
0.114¶ 
-0.209 
0.024¶ 
1.247 
0.212‡ 
3.048 
0.002‡ 
3.680 
0.0002‡ 
0.460 
0.645‡ 
0.067 
0.475¶ 
-0.143 
0.125¶ 
PAL 0.128 
0.170¶ 
-0.055 
0.555¶ 
0.101 
0.278¶ 
-1.303 
0.193‡ 
-1.543 
0.123‡ 
-2.893 
0.004‡ 
-1.419 
0.156‡ 
-0.013 
0.890¶ 
0.196 
0.034¶ 
SRM -0.134 
0.151¶ 
0.289 
0.002¶ 
-0.170 
0.068¶ 
0.125 
0.901‡ 
1.704 
0.091‡ 
0.527 
0.598§ 
-0.456 
0.648‡ 
-0.156 
0.093¶ 
-0.159 
0.087¶ 
OTS  0.028 
0.761¶ 
0.020 
0.830¶ 
-0.130 
0.164¶ 
1.863 
0.062‡ 
1.097 
0.273‡ 
2.577 
0.010‡ 
1.118 
0.264‡ 
0.100 
0.283¶ 
-0.220 
0.017¶ 
Pentagon 
copying 
-0.191 
0.039¶ 
-0.027 
0.771¶ 
-0.178 
0.056¶ 
0.763 
0.445‡ 
2.784 
0.005‡ 
2.290 
0.022‡ 
1.358 
0.175‡ 
-0.001 
0.992¶ 
-0.188 
0.043¶ 
 
Naming 
0.024 
0.795¶ 
0.021 
0.820¶ 
0.124 
0.184¶ 
0.456 
0.659‡ 
1.262 
0.207‡ 
0.564 
0.573‡ 
0.355 
0.723‡ 
0.115 
0.219¶ 
-0.080 
0.392¶ 
 
Language 
0.021 
0.826¶ 
0.151 
0.105¶ 
-0.160 
0.085¶ 
1.458 
0.145‡ 
2.558 
0.011‡ 
-0.221 
0.825‡ 
0.048 
0.962‡ 
0.138 
0.139¶ 
-0.160 
0.085¶ 
Language 
total 
0.035 
0.705¶ 
0.101 
0.277¶ 
-0.101 
0.278¶ 
1.470 
0.142‡ 
2.404 
0.016‡ 
0.120 
0.904‡ 
0.229 
0.819‡ 
0.164 
0.077¶ 
-0.136 
0.144¶ 
Cognitive 
complaint 
1.456 
0.156‡ 
0.469 
0.639‡ 
-0.791 
0.429‡ 
0.137 
0.711† 
0.985 
0.482† 
0.031 
0.860† 
0.0003 
0.986† 
-1.650 
0.099 
-3.200 
0.001 
 
MCI 
-1.368 
0.171‡ 
1.214 
0.225‡ 
-2.034 
0.042‡ 
2.168 
0.141† 
1.577 
0.283† 
5.889 
0.015† 
0.515 
0.218† 
-0.140 
0.889 
-2.317 
0.021 
TOTAL 
number 
NMS 
-0.019 
0.833¶ 
0.018 
0.842¶ 
0.026 
0.777¶ 
-1.48 
0.140‡ 
1.593 
0.111‡ 
0.911 
0.364§ 
0.238 
0.812‡ 
0.225 
0.012¶ 
0.482 
1.41E-
08¶ 
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Introduction
Interest in the role of epigenetic processes in common 
complex diseases continues to increase [1,2]. Epigenetics 
is a potentially major mechanism by which environmental 
factors can affect physiological function and disease risk. 
Research into epigenetics promises to reveal many of the 
causes that remain undiscovered after extensive investi­
gation of common genetic variation [3].
Epidemiological approaches can be used to identify 
whether epigenetic processes are involved in mediating 
the association between risk factors (environmental, 
genetic, lifestyle, socioeconomic and so on) and common 
complex disease [4,5]. For example, longitudinal cohort 
studies have been a cornerstone of observational epi­
demio logy for many years. Long­term follow­up of adult 
cohorts has identified important risk factors for cardio­
vascular disease, chronic bronchitis, and cancers, and 
follow­up of cohorts from birth or childhood has been 
equally successful at identifying the importance of early 
exposures (especially the childhood social environment) 
and developmental characteristics for adult health (for 
example, [6­10]). Longitudinal studies, particularly those 
that start in early life, can contribute to our understanding 
of how the epigenome changes over time, as a result of 
varying environmental exposures, and how disease 
pheno types evolve. Longitudinal studies are costly to 
instigate and maintain, and cross­sectional studies (a less 
expensive alternative study design) have more often been 
used to assess the relationship between exposures and 
the epigenome and/or the epigenome and disease. How­
ever, cross­sectional studies cannot capture the dynamic 
nature of epigenetic mechanisms [11], making it difficult 
to identify the influences of the environment and/or 
disease state (or sub­clinical features of disease) on the 
epigenome and thus establish the direction of causality. 
As a result of this, study designs that make use of multiple 
time points are being increasingly recognized as the most 
suitable to analyze the epigenetics of common complex 
diseases. Because longitudinal studies track the same 
cohort at multiple time points throughout their lifetime, 
enabling the temporal relationship between exposure and 
disease to be established, they are ideally placed for 
exploitation in epigenetic investigations.
Advances in genomic technologies have opened up the 
possibility of large­scale population­based assessment of 
epigenetic patterns to help understand their influence on 
disease. How should such studies be conducted to maxi­
mize their impact and what can epigenetics researchers 
learn from previous approaches to population­based 
studies? Here we focus on how epidemiological approaches, 
including the design of cohort studies, can help investi­
gate the role of epigenetic variation in common complex 
disease. Furthermore, the dynamic nature of epigenetic 
patterns means that they can be altered by disease­
related factors (a process called ‘reverse causation’) as 
well as a host of confounding factors (such as age, sex, 
socioeconomic position, diet, or smoking). Many relevant 
approaches have been developed in the context of both 
genetic and life course epidemiology that could be 
fruitfully applied to epigenetics; examples are methods 
for dealing with biases, confounding, and reverse causa­
tion and also longitudinal statistical modeling techniques 
[12,13]. We first assess what epigenetic markers have 
been measured within existing life course studies before 
Abstract
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how epigenetic patterns change over time and relate 
to changing exposure patterns and the development 
of disease. We highlight the challenges and 
opportunities in this approach.
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discussing how the epidemiologist’s toolkit can be 
applied to epigenomics.
epigenetic studies within longitudinal cohorts
Since 2010, 34 life course studies have included measure­
ments of DNA methylation, and just four of these have 
included analysis of epigenetic features at more than one 
time point (Table  1). In line with the vast majority of 
other epigenetic studies, the focus is on DNA methylation 
as this is the most straightforward form of epigenetic 
modification to measure, and the only currently feasible 
option in archived DNA samples. Prospective sample 
collection will permit the analysis of chromatin modifica­
tions and microRNA. Three of the studies analyzing 
more than one time point (Table 1) report findings relat­
ing specifically to age­related changes in childhood [14] 
or adulthood [15,16], and all three focus on gene­specific 
DNA methylation of a small panel of (different) loci and 
report differences that were modest in size (generally 
<5%). A further study considers changes in DNA methy­
la tion over a relatively short time period (28 to 180 days) 
in relation to air pollution exposure [17]. Although there 
was some indication of lower global DNA methylation in 
repetitive elements across the genome in this study [17] 
at 90 days of exposure, there was no evidence of a dose 
response, casting doubt on the biological importance of 
this association. In summary, very little has been done in 
this area.
Table 2 summarizes additional examples in which case­
control studies of DNA methylation have been nested 
within existing large­scale longitudinal cohorts; this 
approach has been applied so far exclusively in the 
context of cancer. Analyses in this instance have been 
limited to gene panels (generally established tumor sup­
pressor or oncogenes) and have been undertaken either 
(i)  to assess the utility of epigenetic signatures as early 
biomarkers of cancer risk [18­20] or (ii)  to consider the 
determinants of a perturbed methylation state (methy­
lator phenotype), which has been implicated in numerous 
cancers [21­25]. With improved knowledge of methyla­
tion variable regions associated with diseases other than 
cancer (for example, cardiovascular disease, dementia, 
and rheumatoid arthritis), the same approach could be 
adopted in the context of longitudinal cohort studies.
The paucity of DNA methylation measurements under­
taken in cohorts that have collected serial samples from 
the same individuals is clear, indicating that the potential 
richness of longitudinal data and sampling in these 
studies has yet to be fully exploited. Few studies have 
routinely collected serial samples from the same indivi­
duals at multiple points in the life course (for example, 
the Avon Longitudinal study of Parents and Children 
(ALSPAC) [26,27], and the Normative Aging Study 
[17,28­32]), but others are planning serial sampling in 
light of the interest in epigenetics (such as the Medical 
Research Council National Survey of Health and 
Develop ment [33] and the Southall And Brent REvisited 
(SABRE) cohort [34]). Given the temporal variation in 
epigenetic patterns, serial sampling of any longitudinal 
cohort would be advised where possible.
Of the studies published so far, the variety of tissues 
analyzed is limited mainly to easily accessible peripheral 
blood, cord blood or buccal cells, the studies are modest 
in size compared with those used for genetic research, 
and the range of different methods that have been used to 
quantify DNA methylation have led to an overall lack of 
comparability between studies. It is clear from these 
observations that more can be done with respect to the 
collection and analysis of biological samples from 
longitudinal cohorts so that they are optimal for 
epigenetic studies.
Attributes of longitudinal cohort studies
Ideally, longitudinal epigenetic studies should include 
extensive, prospectively collected data and biological 
samples at multiple time points across the life course. 
Many existing longitudinal cohort studies are population­
based, although some focus on a specific sub­group of 
the general population. For example, the SABRE cohort 
focuses on groups that are first or second generation 
migrants to the UK of non­European ethnicity to 
examine particular health issues, in this case the marked 
discordance in disease risk observed in migrant groups 
compared with Europeans living in the UK [34]. 
Longitudinal epigenetic studies can add value to existing 
resources, such as data from genome­wide association 
studies ­ for example, ALSPAC [26,27] and the Relation­
ship between Insulin Sensitivity and Cardiovascular 
disease (RISC) cohort [35]. Exposures commonly cap­
tured in longitudinal studies include lifestyle factors, such 
as smoking, alcohol intake, diet, and physical activity 
patterns, and also socioeconomic measures across the life 
course. Common phenotypes on which longitudinal 
studies tend to focus include physical and anthropometric 
measures, cognitive, cardiovascular, metabolic, respira­
tory, and musculoskeletal function, and a range of blood­
based intermediate biomarkers. Of particular value are 
birth cohorts with trans­generational and across­life 
samples from birth onwards, allowing an appraisal of 
epigenetic changes associated with in utero and early life 
exposures, a period when the epigenome is believed to be 
particularly plastic.
The epidemiological toolkit
Applying principles of life course epidemiology to 
epigenetic research
Research in life course epidemiology investigates develop­
mental, aging, and risk factor trajectories and how 
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dynamic relationships unfold over time, and takes into 
account potential confounding, mediating, or interactive 
effects of lifetime biological, psychological, and social 
risk factors [36]. This conceptual framework is relevant 
for epigeneticists investigating long­term associations 
that may be biased, confounded or due to reverse causa­
tion. Life course epidemiologists have investigated various 
different methods for modeling risk factor trajec tories 
(particularly growth trajectories) in relation to later 
health outcomes and have developed a novel structured 
approach [37] to distinguish critical, sensitive, and accu­
mu lation life course models [38]. They use a range of 
approaches for modeling repeat continuous and binary 
outcome measures, such generalized estimating equa­
tions or mixed models that consider correlated data such 
as repeat measures from the same individuals over time, 
and for modeling time to an event, such as survival and 
event history analysis. This toolkit is relevant to epi­
geneticists, whether studying lifetime environmental 
exposures that promote particular epigenetic signatures 
over time or how these signatures themselves may affect 
not just the level (intercept) of function (such as blood 
pressure) at a point in time but also its rate of change 
(slope) over time. Such statistical approaches have not 
been widely applied to epigenetic data, although exam­
ples can be found in Madrigano et al. [16,17], who illus­
trate the use of mixed models to analyze changes in 
methylation over time while accounting for the corre la­
tion among measurements within the same individual. 
Further discussion of this subject is provided below in 
the section on data analysis considerations.
Several research collaborations involving cohort studies, 
such as HALCyon (Healthy Aging across the Life Course) 
[39], FALCon (Function Across the Life Course) [40] and 
GEoCoDE (Genomic and Epigenomic Complex Disease 
Epidemiology) [41] have been formed. These have 
increased the sample size and power to investigate lifetime 
risk factors on longitudinal phenotypes and to test whether 
findings are replicated across cohorts in a systematic way, 
and they will be useful to epigenetics research. The 
collaborations have developed experience in data har mo­
ni zation to derive comparable phenotypes across the 
cohorts, and in cross­cohort methods (for example, [42]). 
Those running epigenetic studies may want to make use of 
these collaborations for similar reasons, and a coordinated 
approach is likely to advance the science and be appealing 
to funders. Coordinating the cohorts has led to more 
effective ways of gaining knowledge of the various datasets 
and metadata as well as facilitating data sharing and 
encouraging good practice in data management.
From genetic to epigenetic epidemiology
Incorporating epigenetic measures into epidemiological 
studies is often done in the context of genetic epidemiology 
resources. However, studying epigenetic factors  ­ which 
are, partly at least, phenotypic  ­ is more similar to 
conventional epidemiology than it is to genetic epidemi­
ology. Several aspects of germline genetic variation lead 
to special­case conditions that allow relaxation of usual 
epidemiological principles: reverse causation (disease 
influencing the variable being measured rather than vice 
versa) is clearly not an issue in genetic epidemiology, and 
confounding  ­ which often vitiates conventional epide­
miology  ­ generally relates only to ancestry in genetic 
epidemiology [43], and this can be accounted for by using 
principal components from genome­wide data as control 
variables. Germline genetic variation can be assessed on 
samples taken at any stage of life, does not change over 
time, and can be assayed with high precision and low 
measurement error. Effect sizes for the influence of 
common genetic variants on common complex diseases 
tend to be small, which means that very large sample 
sizes are required. Given these circumstances, the genetic 
epidemiology study design of choice became large case­
control studies, with the controls not being carefully 
selected to represent the source population ­ and some­
times (as in the case of the landmark Wellcome Trust 
Case Control Consortium (WTCCC) [44]) control 
groups shared for comparison with several disease groups. 
For example, in the WTCCC the common control groups 
consisted of blood donors (who are very unrepresentative 
in terms of factors that would be important confounders 
in conventional epidemiological studies, such as health­
related behaviors and social class) and participants in the 
1958 birth cohort  ­ all of the same age, which in some 
cases barely overlapped with the age of the cases.
However, such study designs are not appropriate for 
epigenetic epidemiology, as confounding, bias, and 
reverse causation are all serious problems when studying 
phenotypic exposures. It is important that the successes 
of genetic epidemiology are not translated into failures 
for epigenetic epidemiology [1,5,45]. Prospective studies 
are the ideal type of study, including documented 
exposure (epigenetic) measures collected before the 
outcomes and temporal changes, detailed assessment of 
confounding factors, and consideration of measurement 
error. Currently, the effect sizes of associations in epi­
genetic studies are poorly delineated, but it is likely that, 
unlike the situation in the early days of molecular genetic 
epidemiology, the problem will not be one of relatively 
few robust associations, but rather many real obser­
vational associations will exist and the issue will be the 
separation of causal associations from those generated by 
confounding and bias. Various methods that have been 
developed to strengthen causality in conventional epide­
miology ­ including collaborative analysis of multiple 
cohorts in which confounding structures differ [46], 
comparisons of plausible and implausible associations 
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[47,48], and the use of instrumental variables [47]  ­ can 
be applied to epigenetic epidemiology studies.
An instrumental variables method that uses germline 
genetic variants as the instruments ­ Mendelian randomi­
zation ­ is increasingly used to strengthen causality with 
respect to environmentally modifiable exposures for 
which genetic variants can serve as proxy measures 
[49­51]. Mendelian randomization can be extended to 
the investigation of epigenetic profiles as the potentially 
modifiable exposure. This method ­ ‘two step epigenetic 
Mendelian randomization’  ­ is currently under develop­
ment, and details can be found elsewhere [5,52].
A further complexity of epigenetic studies is the tissue­
specific nature of epigenetic patterns. Given that they are 
integrally involved in the process of cell and tissue 
differentiation, it is no surprise that epigenetic patterns 
differ between tissue sources. Genetic comparisons 
within and between studies can be made using a variety 
of sources of DNA to generate genotype data; however, 
this is not the case in an epigenetic context. Population­
based studies often have to rely on easily accessible DNA 
sources (such as blood, saliva, buccal cells; Table  1). 
These serve as a surrogate for the target tissue involved in 
the disease of interest, but there is inevitable hetero­
geneity in both specific cell type represented and sample 
processing, which may bias epigenetic measurement (see 
the section below on data analysis considerations). 
Despite these limitations, epigenetic epidemiological 
studies are emerging and include strategies such as 
Mendelian randomization approaches [53] or inter­tissue 
comparisons [15] to interrogate the functional relevance 
and casual nature of observations.
Inter-generational epigenetic studies
Family­based sampling of both siblings and multiple 
generations can have particular value in epigenetic 
studies. The fact that epigenetic states are often estab­
lished in early (in particular antenatal) development 
makes birth cohorts with recruitment and sample collec­
tion from pregnant women and sample collection on 
offspring from birth onwards of particular value [26,27]. 
There is considerable interest in the role of epigenetic 
mechanism in the developmental origins of adult disease, 
to which longitudinal cohort studies are making a 
valuable contribution [4,53­59].
Data analysis considerations
Most research undertaking longitudinal analysis of mole­
cular biomarker data assumes that there are predictable 
biological changes over time associated with a given 
exposure or disease process. However, in the context of 
epigenetic studies, change over time can be due to 
technical [60] or genetic factors [61], tissue type [62,63], 
changes with normal aging, and stochastic changes [64]. 
These sources of data ‘noise’ threaten the detection of the 
biological signal of interest. Thus, as is often the case, the 
first and most critical step to performing longitudinal 
DNA methylation analysis is careful study design and 
data collection with meticulous recording of technical 
factors and factors that vary between people. Given that 
data collection may occur months, years or even decades 
apart, the awareness and/or control of such sources of 
variability are paramount to making valid conclusions 
regarding within­individual changes over time as it may 
be impossible to account for these factors after the fact. 
Pre­processing of data is often necessary to generate 
comparable data from samples between and within 
individuals over time. International initiatives to address 
and reach consensus on such issues are in progress [65]. 
Equally important is that many of these methods seek to 
optimize the signal­to­noise ratio. These two considera­
tions are critical to generating valid and reproducible 
results. Prudent use of pre­processing that matches the 
study design and data, and experimentation with several 
different methods are strongly encouraged. In addition, 
the threat of time­varying artifacts masquerading as 
biological signal is constantly present in longitudinal 
studies. This possibility should be formally tested as an 
automatic addition to the primary study hypothesis.
An example of a ‘noise’ source that is just beginning to 
be understood is the role of genetic factors in determining 
the degree of variability in DNA methylation over time. 
This is suggested by familial clustering of DNA methy la­
tion variability over time [61]. From the perspective of 
individual loci, there is also evidence of CpG site­
dependent differential stability [15]. This indicates that 
loci should be carefully selected that demonstrate greater 
inter­ than intra­individual variation over time. The 
mecha nisms underlying this are unknown but could 
reasonably be related to overlying genetic architecture 
(for example, interaction with other epigenetic marks 
and possibly even the DNA itself ) or the cellular milieu, 
as suggested by tissue­specific difference in stability in 
the same loci [63]. With the success of next­generation 
sequencing and its falling costs, we can look forward to a 
clearer view of the effect of genetic factors on DNA 
methylation and time­dependent variability.
As alluded to earlier, the vast majority of longitudinal 
cohort studies that are in a position to consider including 
epigenetic assessment have used biological specimens 
collected from peripheral blood. Reliance on leukocyte 
DNA extracted from peripheral blood introduces a 
potential source of measurement error [66]. Given the 
labile nature of leukocyte subtype populations over time, 
this variation may make an important contribution to 
intra­individual changes in DNA methylation. For 
instance, shifts in leukocyte populations can occur as a 
result of normal development and aging, inflammation 
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from infectious, rheumatological, or oncological diseases, 
or normal response to medications (such as non­steroidal 
anti­inflammatory drugs). The most definitive solution is 
to isolate cell types (for example, through magnetic­
activated or fluorescence­activated cell sorting), so as to 
perform comparisons within relatively homogenous 
leukocyte populations. However, this is possible only 
with freshly collected samples; one of the advantages of 
prospective longitudinal studies is the potential to collect 
appropriate samples relevant for epigenetic studies.
When analysis of relatively homogeneous cell types was 
unavailable, Zhu and colleagues [67] used total and 
differ ential leukocyte count (from a sample drawn con­
current with the methylation sample) to control for this 
variation in regression models. These researchers found 
that the proportion of leukocyte cell types correlated 
with levels of LINE­1 methylation. Importantly though, 
statistical adjustment for this did not alter the association 
between LINE­1 and Alu methylation levels and 
individual characteristics (age, gender, smoking habits, 
alcohol intake, and body mass index). Candidate gene 
studies of methylation have reached similar conclusions 
[15,16]. This could mean that leukocyte populations 
contribute a negligible amount of variance relative to the 
specified model factors. Alternatively, it may be that 
controlling for leukocyte population in this manner 
inadequately captures the effect of this noise. The possi­
bility that using the direct measure of an unwanted 
variable in a regression equation may sub­optimally 
reduce noise was explored by Teschendorff and colleagues 
[60]. Using Illumina HumanMethylation27 BeadChip data, 
they proposed a variation of surrogate variable analysis in 
which confounders are modeled as statistically inde­
pendent components. Using these components instead of 
the original measures in regression analysis, they found a 
stronger association between methylation of Polycomb­
family gene loci and their phenotype of interest, age. From 
this, they concluded that the effect of confounders on the 
DNA methylation data was better represented by 
independent components than the original covariates.
Lastly, in cases where no information on cell counts is 
available, a potential solution may arise from the DNA 
methylation data itself. Such a possibility is presented by 
Houseman and colleagues through their software 
methylSpectrum [68]. The authors propose an algorithm 
to infer the contribution of different leukocyte sub­
populations to whole blood DNA methylation patterns. 
This software is not designed to examine changes over 
time and requires a suitable reference sample from which 
to make inferences, which would reasonably require 
multiple age­appropriate references in a longitudinal 
study setting.
In summary, we need formal comparisons of these 
methods in heterogeneous and homogeneous samples 
from the same specimen. International efforts to create 
reference epigenomes from homogeneous cell samples 
will be highly beneficial [65]. However, variation due to 
cellular and tissue heterogeneity is just one example of 
the wide breadth of issues regarding noise that require 
detailed and systematic study.
Modeling epigenetic change over time
There are several issues that need to be considered when 
analyzing epigenetic change over time, such as the unit of 
DNA methylation change under examination (Box 1) and 
the analytic technique. The unit of analysis must consider 
several issues. For example, how is DNA methylation 
measured? What is the question under investigation? Is 
the research focused on testing site­specific changes in 
DNA methylation related to exposures and/or outcomes 
or is it seeking to explore a network of gene regulation? 
What type of a priori information is available? How does 
this information contribute to understanding of error or 
covariance of methylation measurements? Are individuals 
compared using categorical or continuous variables?
Guided by the selected unit of DNA methylation change, 
we now turn to examples of modeling intra­individual 
variation over time that is due to disease and/or environ­
mental factors. The selection of an appropriate modeling 
technique has important implications for study power 
and calculations of statistical significance. We limit this 
discussion to longitudinal studies with three or more 
time points, as two time points can at most infer a differ­
ence rather than the nature of change. Much of this work 
is borrowed from other fields, particularly gene expres­
sion studies, and uses data­driven or knowledge­driven 
techniques, or combinations of both.
Several techniques use comparisons between two groups 
(such as controls versus cases) to determine differential 
time courses [69,70]. Some of these methods can be 
extended to comparisons between more than two groups 
(for example, [71]). An alternative to this individual­
based approach is to find time course patterns that distin­
guish one group of individuals from another (for example, 
[72,73]). Methods that capitalize on other biological 
knowledge (such as genomes, transcriptomes, or nucleo­
somes) may allow us to better infer the nature of 
methylation in the context of how functional regulation 
of the genome relates to exposures or disease processes. 
This is especially powerful to detect signals that are 
expected to be subtle but consistent among jointly regu­
lated loci [74]. An example is longitudinal gene set 
analysis [75] using annotations from databases such as 
Gene Ontology. The parallel analysis of different sources 
of high­throughput data has so far only been explored in 
cross­sectional methylation studies but could in theory 
be applied to longitudinal analysis. However, such longi­
tudinal analysis will require advanced multi­dimensional 
Ng et al. Genome Biology 2012, 13:246 
http://genomebiology.com/2012/13/6/246
Page 8 of 13
techniques (Box 2). These techniques require pre­
processed data that are relatively free of noise. Another 
approach may use data reduction techniques to extract 
meaningful features from data noise while simultaneously 
considering the time­varying nature of DNA methylation. 
For example, group­independent component analysis 
with temporal concatenation of microarray data would 
assume that there are common sites of epigenetic activity 
but that the course of change may be different for each 
individual. Most experience in this type of technique 
comes from the analysis of neuroimaging data, where the 
goal is to uncover areas of the brain that are activated 
similarly among individuals in an experimental group 
over time [76]. The translation of such ideas to molecular 
data, which often have far lower temporal resolution but 
higher ‘spatial’ resolution (gene loci as opposed to areas 
of the brain), would be a challenging but also potentially 
promising avenue.
The promise of epigenetic studies of longitudinal 
cohorts
Future longitudinal epigenetic studies will undoubtedly 
integrate greater levels of genomic, biologic and/or 
phenomic information. For example, our expanding know­
ledge of factors influencing chromatin architecture may 
soon allow the analysis of methylation marks within 
context of the broader chromatin state. Examples of such 
data are nucleosome mapping [77], histone modifications 
[78], and chromosome conformation capture [79]. The 
influence of the underlying and overlying chromatin 
archi tecture (interaction with protein, RNA, and DNA 
primary and secondary ‘structure’ [80]) on differential 
locus stability over time remains to be elucidated. Analy­
sis of DNA methylation is clearly only scratching the 
surface of the epigenetic information that regulates gene 
expression, but longitudinal cohort studies provide a 
tractable opportunity to contribute to our knowledge 
base in this area and, as our understanding of the wider 
epigenome improves, additional epigenetic features may 
also be added to such studies.
Increasingly, studies are pushing to provide a broader 
mechanistic picture of cellular function and regulation by 
juxtaposing data from two or more kinds of high­
throughput data [81,82]. So far, these data are often 
extracted from different materials or individuals (such as 
DNA methylation from whole blood and RNA from cell 
culture). This limits interpretation of functional rele­
vance. However, advances in biotechnology that reduce 
the amount of specimen required and increase automa­
tion, in conjunction with falling costs, are likely to over­
come this problem. Biobanked samples, such as plasma, 
DNA, and RNA from longitudinal cohorts, could make a 
valuable contribution to developments in this area. 
Furthermore, the development of nested recall studies for 
intensive phenotyping within established cohorts will 
greatly enhance research opportunities in this area.
As multi­dimensional datasets evolve and the ability to 
mine the information within them improves, it will be 
imperative that this information is made as accessible as 
possible to the wider scientific community. Although it is 
currently possible to access some information relating 
epigenetic data to common genetic variation and gene 
expression, providing an integrative approach, this is not 
available at multiple time points. Longitudinal studies 
can offer considerable added value in these settings and 
profiling using a comprehensive range of high­through­
put methods can be overlaid on a wealth of exposure and 
phenotypic data, allowing researchers to explore specific 
hypotheses in silico and thus helping to prioritize 
resources for more detailed investigations.
In summary, longitudinal cohorts can offer a great deal 
in the context of epigenetic epidemiology, including 
identification of the major determinants of epigenetic 
variation in populations and a better understanding of 
the relationship between genetic and epigenetic variation. 
They provide an unprecedented opportunity to increase 
our understanding of the dynamic nature of epigenetic 
patterns and how changes occur in response to a wide 
range of environmental, lifestyle, and behavioral factors. 
Population­based studies will improve our knowledge of 
the extent and topography of inter­individual variation in 
epigenetic patterns and permit assessment of effect sizes 
of shifts in epigenetic patterns on health­related 
Box 1: Potential units of change to examine epigenetic 
mechanisms
•	 A	single	gene	or	gene	region	of	interest
•	 Single	gene	loci	that	have	different	temporal	patterns	
between biological groups
•	 A	family	of	genes	of	known	biological	or	clinical	importance	
(such as those previously known to show exposure-related 
differential	methylation)
•	 A	group	of	functionally	related	genes	(for	example,	as	
identified by Gene Ontology or Kyoto Encyclopedia of Genes 
and Genomes (KEGG) terms)
•	 A	network	of	co-regulated	genes	(for	example,	using	
intersection with concurrent gene expression data or from 
previous literature)
•	 Genes	related	by	their	linear	proximity	on	the	DNA	strand	
(such	as	regional	grouping,	as	done	to	examine	differential	
methylation between and within individuals [70])
•	 Genes	related	to	the	overlying	chromatin	architecture	
(such as knowledge of nucleosome position or histone 
modifications)
•	 Genes	that	show	similar	patterns	of	change	(for	example,	
gene curve [71])
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outcomes. A wealth of statistical approaches can be 
borrowed and adapted from related fields and be applied 
to longitudinal epigenetic analysis ­ an area of bio­
statistics that is likely to grow exponentially as high­
throughput datasets become increasingly multi­dimen­
sional. Insights into the temporal relationship between 
changes in epigenetic patterns and functional and health­
related outcomes that can be gleaned from longitudinal 
studies will assist in defining causality. This, and other 
epidemiological methods to strengthen causal inference, 
will contribute to the identification of predictive epi­
genetic biomarkers and modifiable targets for intervention.
The ultimate goal of observational data generated in 
epidemiological investigations is to feed forward into 
clinical practice or public health. There is already 
evidence of translation of longitudinal biological data to 
clinical applications [83]. The incorporation of epigenetic 
biomarkers to enhance clinical tools for prediction and 
prognosis is beginning to emerge [5] (Table  2), and 
longitudinal cohorts will undoubtedly help in this domain.
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